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Abstract
Background
Monitoring to identify disease recurrence or progression is common, often with limited evidence to
support the tests used, subsequent decisions, frequency and duration of monitoring.
Aims
To develop methods for designing evidence-based monitoring strategies and estimating measurement
error, a key consideration in selecting monitoring tests.
Methods
To investigate studies of measurement error: frameworks were identified; design, analysis and re-
porting of studies were reviewed; a case study was analysed; and, simulation studies were performed
to evaluate varying sample size and outlier detection methods. To develop methods for designing
monitoring strategies the methods literature was reviewed and simulation models were developed and
validated.
Results
Biological variability studies are often poorly designed and reported. Studies are frequently small
and may not produce valid results; the required precision of estimates can inform the sample size.
Outlier detection can negatively bias variability estimates; methods should be used with caution,
with interpretation allowing for potential bias. Modelling monitoring data requires knowledge of the
natural history of disease, test performance and measurement error; such evaluation enables selection
of evidence-based monitoring strategies prior to full-scale investigation.
Conclusions
Poor monitoring tests can be identified early using small-scale studies and monitoring strategies should
be optimised prior to full evaluation.
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Chapter 1
Introduction
1.1 Evidence based monitoring
Does monitoring of patients improve patient care, and subsequently patient outcomes? What
evidence do we have to suggest that routine monitoring is beneficial to patients? With
increased knowledge, could we improve how we monitor patients?
Patient monitoring is often performed, at great cost, when the benefit of monitoring has not
been evaluated or evidence for monitoring is weak.1,2 When monitoring is formally assessed,
strategies should be evidence-based;3 however, strategies selected for assessment are not al-
ways developed using existing evidence.4 Monitoring strategies are complex interventions and
should be developed and evaluated accordingly.5
The aim of this thesis is to investigate optimal monitoring of progressive and recurrent disease.
This thesis focusses on two main areas: the design, analysis and reporting of biological
variability studies, which provide estimates of measurement error, and modelling to develop
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optimal monitoring strategies for further investigation, combing available evidence.
1.1.1 Definition of monitoring
Monitoring of the health of patients is defined here as: ‘scheduled repeated testing, where
pre-defined test results prompt a change in patient management’.6
When monitoring patients to identify disease progression or recurrence, to begin monitoring
patients must have previous disease that could potentially recur or early stage disease that
may progress. Selected patients are monitored using a strategy (test or tests used at a series
of monitoring points with a decision rule to declare a test result as positive or negative). A
decision rule is used at each monitoring point to identify if the result is positive or negative
(this may be assessing an image for indication of disease, comparing a test value to a defined
threshold or previous measures etc.). If the result is considered negative, monitoring will
continue at given time intervals until a positive result is achieved or a given amount of time
has passed. When a patient is considered positive, they are no longer monitored in the same
way, meaning a change in patient management (new treatment, more intense monitoring,
further testing etc.)7 see Figure 1.1. For a guide to the terminology used in this thesis see
Table 1.1.
1.1.2 Monitoring of disease progression and recurrence
Here, the focus is monitoring to identify progression or recurrence of disease, also referred to
as surveillance and watchful waiting. Patients would be managed using a monitoring strat-
egy after treatment for a recurrent condition or in the early stages of progressive disease. A
monitoring strategy involves repeated use of a test (or multiple tests) in these patients with
a specified rule for the test results that would be considered positive and that would lead to a
change in patient management. Examples of monitoring routinely performed in the UK are
cystoscopy for detecting recurrence of bladder cancer in patients who have previously had
tumours removed, with identification of further tumours resulting in subsequent surgery;8
2
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Table 1.1: Monitoring and variability terminology.
Term Explanation
Monitoring
Monitoring strategy A monitoring strategy specifies the monitoring test(s), frequency of monitoring,
total duration of monitoring and the decision rule used to identify a test result
as positive or negative.
Monitoring test The test used in a monitoring strategy.
Monitoring frequency The frequency of repeat testing in a monitoring strategy (not necessarily at
regular intervals).
Monitoring duration The total duration of use of a monitoring strategy, may potentially be until
disease progression or recurrence, or death.
Decision rule/monitoring rule The decision rule specifies which results from the monitoring test would be a
positive and a negative result. The decision rule may use only the last value
from the monitoring test or may rely on previous values also.
Threshold The threshold is a set level to measure test results against to identify positive
results.
‘track-shot’ rule A ‘track-shot’ rule uses multiple results for individuals and assesses these results
together to identify if a result is positive or negative.
‘snap-shot’ rule A ‘snap-shot’ rule uses a generic threshold for all individuals using the last
obtained monitoring test result to identify if a result is positive or negative.
Absolute change Changes in test values for an individual on the absolute scale, for example
values of 1 and 2 units show an absolute increase of 1 unit.
Relative change Changes in test values for an individual on the relative scale, for example values
of 1 and 2 units show a relative increase of 100%.
Patient management The management of a patient, for example monitoring, intensive monitoring,
treatment, invasive test to identify need for treatment etc.
Variability
Biological variability Biological variability is the variability in test measures between and within
individuals whilst in a stable disease state.
Pre-analytical variability Pre-analytical variability is the variability of a test measure due to differences in
the how samples have been obtained, stored and transported (prior to
evaluation of the sample).
Analytical variability (imprecision) Analytical variability is the variability of multiple assessments of a single sample
(same participant and observation point).
Within-individual variability Within-individual variability is the variability between test measures for a single
individual over time in a stable disease state.
Homeostatic setting point True value of the test for an individual.
Measurement error Measurement error is the variability in a test measure around the true value for
an individual, this is analytical and within-individual variability combined.
Between-individual variability Between-individual variability is the the variability in a test measure between
individuals.
Assessor variability Assessor variability is the variability in assessing the result of a test, this is most
often seen in imaging studies.
Inter reader variability Inter reader variability is the variability between readers in assessing a test
result, this is most often seen in imaging studies.
Intra reader variability Intra reader variability is the variability within readers (repeated reads by the
same reader) in assessing a test result, this is most often seen in imaging studies.
Evaluation
True positive Positive test result at a point when a patient is diseased.
False positive Positive test result at a point when a patient is not diseased.
True negative Negative test result at a point when a patient is not diseased.
False negative Negative test result at a point when a patient is diseased.
Sensitivity Proportion of diseased participants that have a positive test result at a test
point.
Specificity Proportion of non diseased participants that have a negative test result at a test
point.
Positive predictive value (PPV) Proportion of test positive participants that have a positive test result.
Negative predictive value (NPV) Proportion of test negative participants that have a negative test result.
Coefficient of variation (CV) Standard deviation of variability (at the analytical, within-individual and
between-individual levels) expressed as a ratio to the mean value.
Index of individuality (II) The ratio of analytical and within-individual variability compared to
between-individual variability. Indicates how much variability is within
measures for an individual compared to a group of people.
Reference change value (RCV) Change in a measure suggesting true change based on estimates of variability.
3
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Entry:
Patient has risk of disease
progression or recurrence
Monitoring strategy:
Monitoring test performed
and decision rule applied
(repeated at subsequent
monitoring points)
Strategy result:
Considered
positive
Management decision:
Consider change in pa-
tient management (new
treatment, intensive moni-
toring, further testing etc.)
Strategy result:
Considered
negative
Management decision:
No change in patient
management (con-
tinue monitoring)
next monitoring point
Figure 1.1: The general monitoring process.
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and, repeated blood tests to measure CD4+ cell counts in patients with HIV, to indicate pro-
gression of disease and allow antiretroviral treatment to be appropriately considered.9
There are many disease areas where monitoring is for treatment titration, with the purpose of
modifying doses. Whilst methods and theories relating to treatment titration are considered,
where appropriate, research in this area of monitoring is not directly applicable to the work
presented in this thesis. Examples of diseases where monitoring is for treatment titration are
hypertension10 and diabetes.11
Test and biomarkers with continuous measurements rather than binary or categorical are
considered in this thesis.
1.1.3 Monitoring data
Stevens and colleagues developed a general model for monitoring data. This model defines
Yit as the observed monitoring values and Uit as the ‘true’ underlying (‘latent’) value, which
can never be directly observed.
Uit = αi + βit and Yit = Uit + ωit,
where αi is the latent value at time 0, βit is the change in the latent value over time and ωit
is measurement error.12
1.1.4 Measurement error
The estimation of measurement error is a major theme of this thesis, as measurement error
was identified as a key component of monitoring data and vital when considering optimal
monitoring strategies. The design of studies and methods used to estimate test variability,
particularly biological variability studies, are investigated in this thesis.
5
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1.1.5 Biological variability
Studies of biological variability often estimate the partitioned variances of a test (at the ana-
lytical, within-individual and between-individual levels) allowing calculation of measurement
error.
Estimates of biological variability provide vital information when using tests for diagnosis and
monitoring.13 Essentially, biological variability estimates quantify the natural fluctuation in
test results which is useful when developing a monitoring strategy as true change (‘signal’)
can be detected over random and expected fluctuation (‘noise’).14 Biological variability is
defined as: ‘The natural variability in a laboratory parameter due to physiologic differences
among subjects and within the same subject over time.’ 15
The biological variability of a test can indicate the appropriate and optimal use for moni-
toring purposes; estimates suggest whether a test is best used with a threshold value for all
participants (‘snap-shot’ rule) or whether differences from previous values for each individual
should be considered (‘track-shot’ rule).9,16 Results of variability studies will also guide the
threshold values used (for the entire population or considering changes from previous values)
to define a positive test result, as these results suggest the magnitude of change implying a
real change in condition.16
1.1.6 Issues in the field
Issues when developing monitoring strategies are:
• Monitoring is performed as standard with many monitoring strategies not subjected to
formal evaluation.2
• Monitoring strategies (test frequencies, decision rules, thresholds and duration) used to
monitor patients with progressive and recurrent disease are rarely evidence based.2
• With limited information on variability, as is often the case, test frequencies are com-
monly based on routine care schedules and test thresholds are chosen arbitrarily.1
6
1.2. Design and evaluation of biological variability studies
• When monitoring strategies are evaluated using randomised controlled trials there is
limited evidence supporting the components of the strategies.4
Issues in studies of biological variability are:
• Estimates of biological variability are necessary for planning monitoring strategies;3 this
includes the design (specifically sample size), conduct, methods for analysis (including
outlier detection methods) and validity of analysis for studies estimating variability.
• Sources of estimates of biological variability may be important; current estimates from
test manufacturers are designed for the purpose of proving tests meet minimal quality
assurance standards and such studies often use spiked or calibrated samples (for example
Bargnoux et al17) this may not be appropriate when estimating variability to inform
monitoring of patients with potential disease progression or recurrence.
• Studies of biological variability may recruit healthy participants13,18 rather than those
with disease, the population of relevance for monitoring.
• For many tests and patient conditions there may be insufficient evidence for estimates
of biological variability used to plan monitoring strategies.
This lack of evidence for estimating test variability and designing monitoring strategies is
concerning not only due to the high cost of monitoring and studies evaluating monitoring
but the multiple opportunities monitoring has to benefit and harm patients. Strategies should
be optimised to ensure the greatest possible benefit to patients and evaluated.
1.2 Design and evaluation of biological variability studies
1.2.1 Aims of biological variability studies
The aim of biological variability studies is to quantify the inherent variability of test re-
sults.16
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1.2.2 Variability
When considering a standard laboratory based test there are four types of variability to esti-
mate; these are: pre-analytical, analytical, within-individual and between-individual variabil-
ity.16 Studies are often designed to assess analytical, within-individual and between-individual
level variability for a biomarker, for example estimated glomerular filtration rate (eGFR).19
Figure 1.2 shows these measures of variability around the mean value.
1.2.2.1 Pre-analytical variability
‘The pre-analytical phase entails all those actions that are necessary in order to obtain diag-
nostic specimens.’ 20 Pre-analytical variability is due to the differences in how subjects have
prepared for a sample to be taken and the process of taking the sample or performing the test.
The leading causes of pre-analytical variability (as reported in a review by Lippi et al)20 are:
patient preparation (fasting status, exercise and posture), blood drawing (misidentification,
insufficient volume, spurious haemolysis, contamination, venous stasis and blood collection
devices), sample handling (mixing), sample transportation (time, temperature and integrity)
and sample preparation (centrifugation and automation). Often measures are taken to keep
pre-analytical variability at a minimum,16 by keeping testing conditions consistent. The fac-
tors influencing pre-analytical variability vary from test to test; with different tests requiring
stability of different factors. Pre-analytical variability is not a focus of this thesis, and it is
assumed to be minimised.
1.2.2.2 Analytical variability
‘The analytical component of variation is derived from replicate analysis of subject samples.’ 16
Analytical variability is the variation of results from a single sample and is often assessed by
taking a sample and replicating the analysis of this sample.16 Analytical variability is also
known as imprecision and is: ‘the closeness of agreement between independent results of mea-
surements obtained under stipulated conditions.’ 21 To assess analytical variability the same
8
1.2. Design and evaluation of biological variability studies
9.
0
9.
5
10
.0
10
.5
11
.0
M
ea
su
re
m
en
t v
a
lu
e
Patient
C
9.
0
9.
5
10
.0
10
.5
11
.0
M
ea
su
re
m
en
t v
a
lu
e
Patient
C
9.
0
9.
5
10
.0
10
.5
11
.0
M
ea
su
re
m
en
t v
a
lu
e
Patient
C
7
8
9
10
11
12
13
M
ea
su
re
m
en
t v
a
lu
e
Patient
Pr
e−
an
al
yt
ica
l v
a
ria
tio
n
An
al
yt
ica
l v
a
ria
tio
n
W
ith
in
−i
nd
ivi
du
al
 v
a
ria
tio
n
Be
tw
e
e
n
−
in
di
vid
ua
l v
a
ria
tio
n 
   
ABCDE
F
ig
u
re
1.
2:
V
is
u
al
is
at
io
n
of
p
re
-a
n
al
y
ti
ca
l,
an
al
y
ti
ca
l,
w
it
h
in
-i
n
d
iv
id
u
al
an
d
b
et
w
ee
n
-i
n
d
iv
id
u
a
l
va
ri
a
b
il
it
y.
L
ef
t:
re
su
lt
s
fo
r
a
si
n
g
le
p
a
r-
ti
ci
p
an
t,
se
p
ar
at
el
y
sh
ow
in
g
p
re
-a
n
al
y
ti
ca
l
(t
op
),
an
al
y
ti
ca
l
(m
id
d
le
)
an
d
w
it
h
in
-i
n
d
iv
id
u
a
l
(b
o
tt
o
m
)
va
ri
a
b
il
it
y.
R
ig
h
t:
re
su
lt
s
fo
r
fi
ve
p
ar
ti
ci
p
an
ts
,
sh
ow
in
g
p
re
-a
n
al
y
ti
ca
l,
an
al
y
ti
ca
l,
w
it
h
in
-i
n
d
iv
id
u
al
an
d
b
et
w
ee
n
-i
n
d
iv
id
u
a
l
va
ri
a
b
il
it
y.
R
es
u
lt
s
sh
ow
a
h
y
p
o
th
et
ic
a
l
te
st
in
g
si
tu
at
io
n
w
h
er
e
th
e
tr
u
e
m
ea
n
va
lu
e
is
10
u
n
it
s,
va
lu
es
at
ea
ch
le
ve
l
of
va
ri
ab
il
it
y
fo
ll
ow
a
n
o
rm
a
l
d
is
tr
ib
u
ti
o
n
a
n
d
th
e
st
a
n
d
a
rd
d
ev
ia
ti
o
n
s
at
ea
ch
le
v
el
ar
e:
0.
5
u
n
it
s
fo
r
p
re
-a
n
al
y
ti
ca
l,
0.
1
u
n
it
s
fo
r
an
al
y
ti
ca
l,
0.
5
u
n
it
s
fo
r
w
it
h
in
-i
n
d
iv
id
u
a
l,
a
n
d
1
u
n
it
fo
r
b
et
w
ee
n
-i
n
d
iv
id
u
a
l
va
ri
ab
il
it
y.
Im
ag
e
sh
ow
s
va
lu
es
fo
r
5
p
at
ie
n
ts
w
it
h
4
m
ea
su
re
m
en
ts
ea
ch
,
as
se
ss
ed
4
ti
m
es
a
n
d
ea
ch
fr
o
m
4
d
iff
er
en
t
te
st
in
g
co
n
d
it
io
n
s.
9
Chapter 1. Introduction
sample is tested using the same testing procedure at the same time (analysis in duplicate)
and the difference in results at this level is assessed.16
1.2.2.3 Within-individual variability
Within-individual variability (also known as within-subject, within-person and intra-individual
variability) is the variability within test measures for an individual occurring due to normal
(and expected) variation in participants, for example variability may be detected in repeated
measures for an individual if measures are taken at different times of the day and a daily
rhythm exists; at different times of the month when a monthly rhythm exists; and, at dif-
ferent seasons when season is a factor.16 The test values for participants fluctuate for many
tests used in patient care without signifying a change in condition, and this is assessed by
taking multiple samples from participants over a short time period (when the disease state for
participants is expected to stay the same). Assessment of multiple measures for participants
allow this level of variability to be quantified.16
1.2.2.4 Between-individual variability
Between-individual variability (also known as between-subject, between-person and inter-
individual variation)22 is the variation between the central values for individuals. For some
tests individuals will have very similar results and for other tests very different results. Es-
timates of between-individual and within-individual variability allow us to identify if a test
is best used with a threshold to identify a positive or negative result for the population or
if the results for each individual should be considered separately with their own individual
threshold value.
1.2.2.5 Assessor variability
To evaluate the impact of different assessors on test results intra-inter reader studies are
used, often when assessing imaging tests. Individual readers will evaluate a result multiple
10
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times (intra-reader variability) and multiple readers will assess the same result (inter-reader
variability).23 For example, a study used readers to interpret the results of ultrasound scans to
measure bladder wall thickness, looking at the variability between and within readers.24
Assessor variability is not present when using most laboratory based tests as analytical pro-
cedures will provide the healthcare professional with a value of the test result. In the case
of assessing an image the process of obtaining a value (for example, measuring tumour size)
is variable, with variability occurring between and within assessors. The judgement required
in these tests will introduce additional variability.
1.2.2.6 Other sources of variability
Variability in test results can also be due to other factors. Other variability sources can be:
intra-inter assay variability,25 within and between batch variability26 or intra-inter laboratory
variability.27
1.3 Designing and evaluating monitoring strategies
1.3.1 Strategy design
Monitoring strategies are complex interventions. Each strategy has several components:
• monitoring test(s);
• monitoring rule–decision rule (for defining test positives);
• monitoring frequency;
• and, monitoring duration.
The review by Selby and colleagues4 identified less than 50% of monitoring trials assessed
gave evidence to support the frequency of monitoring and the intervention patients received
11
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after a positive result used in monitoring strategies; and less than 60% of trials gave evidence
to support the threshold used as part of the monitoring strategy.
1.3.1.1 Test(s)
The monitoring test or tests are chosen for their ability to identify the target condition in
patients with potential progressive or recurrent disease. The tests used are often chosen based
on accuracy estimates, usually for the purpose of diagnosis rather than monitoring or with
unclear evidence for the selection of the test.1,4
1.3.1.2 Monitoring rule
The monitoring rule (decision rule) is the most complex component of a monitoring strategy.
A simple decision rule would use a single threshold for all patients; those with a test result
exceeding the threshold would be positive and otherwise negative (‘snap-shot’ rule).9 A more
complex decision rule may have the threshold based on change from previous results for each
patient (‘track-shot’ rule), meaning an individual threshold for each participant.9 Decision
rules can also be designed to use not only test information but other factors (such as previous
results and medical history) with an algorithm to provide a positive or negative result.28
1.3.1.3 Monitoring frequency
The frequency of monitoring is how often monitoring tests are performed within a period,
for example two tests per year. The monitoring interval is the length of time between each
monitoring test. The frequency of monitoring can be the same for each patient for the
duration of monitoring or can be more complex. Monitoring may be performed more or less
frequently in the early or latter stages of monitoring or depending on previous results or
patient history, making the monitoring frequency specific to the individual.29
12
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Obtain estimates regarding disease progression or recurrence
and test performance (measurement error, accuracy, variability)
Simulate patient cohort modelling disease progression
and results of the monitoring test based on evidence
Evaluate the performance of alternative monitoring strate-
gies (different thresholds, test frequencies, decision rules)
Identify optimum strategies for further evaluation
Figure 1.3: Method for selection of monitoring strategies.
1.3.1.4 Monitoring duration
The duration of monitoring is dependent on the clinical situation. Monitoring may continue
indefinitely and usually for the duration of a trial, if a trial is assessing a monitoring strategy.
However, for some conditions it may be monitoring ceases after a certain period with no
positive results, or that if patients appear to be ‘low risk’ from previous results monitoring
can be stopped.8
1.3.2 Method for identifying monitoring strategies
The purpose of the work presented in this thesis is to provide guidance, considering the evi-
dence available, for selecting monitoring strategies for further evaluation, see Figure 1.3.
The approach used in this thesis follows from the method introduced by Stevens et al,12
see §1.1.3. Stevens and colleagues reviewed statistical models used for the control phase
of monitoring, including literature based methods, where parameter estimates are obtained
from reviewing the literature.
The model is used to simulate monitoring data for a cohort of patients and assess the per-
formance of monitoring strategies in this cohort by comparing the observed data (Yit) to the
13
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latent test value (Uit). The model uses the initial value for each individual (αi), the change
over time (βit), and the measurement error (ωit).
To use this approach, available information is collected regarding the progression or recurrence
of the disease monitored, and also information on test performance, relating to accuracy and
variability. Progression from an initial study starting point is estimated, the modelled latent
disease state of patients through time. Using information regarding test performance and
variability the observed results seen at monitoring points are estimated.
As both the latent underlying disease status of individuals and the monitoring test results that
would have been observed are estimated, the performance of various monitoring strategies
can be compared, with those appearing optimal highlighted for full evaluation in a trial, in
line with best practice.5
1.3.3 Assessing monitoring strategies
When assessing the ability of monitoring strategies, it may be desirable to assess patient
outcomes. However, the purpose of the work in this thesis is to present a method allowing
identification of optimal strategies for further evaluation in RCTs of monitoring.
1.3.3.1 Assessing test performance
In studies of diagnostic test accuracy, the test result is compared to the true disease status
(measured by a gold standard or reference test, or obtained by follow up of patients). If the
test result correctly detects the true disease status of a patient, this result is a true positive
(TP) if the test result is positive, or a true negative (TN) if the result is negative. If the
patient has a positive test result when the true disease status of the patient is no disease,
this is a false positive (FP) result. If a patient received a negative test result when the true
disease status of that patient is positive this is a false negative result (see Figure 1.4).
Basic measures of test performance are calculated using the number of patients with each
combination of test results and true disease status. Prevalence is the proportion of the
14
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True disease
status
+ −
Test result
+
−
TP FP
FN TN
Disease
Positive
Disease
Negative
Test
Positive
Test
Negative
Prevalence = (TP + FN)/(TP + FN + FP + TN)
Sensitivity = TP/(TP + FN)
Specificity = TN/(TN + FP)
PPV = TP/(TP + FP)
NPV = TN/(TN + FN)
Figure 1.4: Basic test accuracy measures.
population with the disease. Sensitivity is the proportion of patients with disease correctly
identified as positive by the test (TP) and specificity is the proportion of patients without
disease correctly identified as negative by the test (TN). The positive predictive value (PPV)
is the proportion of test positive patients that have the disease; and, the negative predictive
value (NPV) is the proportion of test negative patients that do not have the disease.
1.3.3.2 Assessing monitoring test performance
Usual test accuracy measures are more complex in monitoring studies as participants receive
multiple negative results and the disease status of participants is not constant (participants
develop disease). There are methods for calculating time-dependent sensitivity, specificity and
ROC curves, with these methods reviewed by Pepe and colleagues30 (see Chapter 7).
Adapted from the guidance Li and Gatsonis31 provide (see Chapter 7 for full details) the out-
comes chosen to assess monitoring strategies are: number of tests, positive predictive value
15
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and delay to diagnosis. The number of tests reflects the resource need of a strategy; the
positive predictive value shows the percentage of truly positive patients from those identified
as test positive; and, the delay to diagnosis reflects the harm to patients by the monitor-
ing strategy as it is the time between developing progressive or recurrent disease and the
monitoring strategy detecting disease. To allow these measures to be assessed objectively
the positive predictive value (PPV) was fixed at an acceptable level for the clinical question
and the number of tests and delay to diagnosis were compared. The threshold used in the
decision rule was adjusted to allow the PPV to be at the chosen level. The delay to diagnosis
estimate indicates the impact of false negatives and the false positives are controlled by fixing
the PPV.
1.3.4 Monitoring studies
Arguably the most robust study design to use when comparing patient health outcomes
between monitoring strategies (or comparing a monitoring strategy to routine care) is a
randomised controlled trial (RCT).4 In a typical RCT comparing a monitoring strategy to
standard care, patients are recruited and randomised to receive either the monitoring strategy
(in addition to routine care) or routine care only. Those receiving monitoring have the
monitoring test at specified time intervals and if they have a positive result the management
of their condition will change. If monitored patients have a negative test result, they continue
monitoring and are tested again at the next testing point.4 Patients in both randomisation
arms receive standard care and may have a change in management, see Figure 1.5.
RCTs evaluating monitoring may compare standard care with monitoring to standard care
alone; alternatively studies can compare two (or more) monitoring strategies (differing by test
used, test threshold or decision rule employed, frequency of monitoring etc.) or comparing
monitoring to immediate treatment.4
16
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1.3.5 Outcomes
As with trials of treatments, ideally trials of monitoring tests would evaluate differences in
patient outcomes across the arms. The review by Selby et al,4 showed for 49 trials reported
in 58 publications, patient outcomes were used in approximately half the trials assessed and
were generally patient mortality or the event of new or recurrent disease. Monitoring RCTs
may instead evaluate the difference in a process type outcome, such as the percentage of
patients having the condition detected. Process outcomes may be used rather than patient
outcomes as patient outcomes occur after a lengthy period of follow up, rarity of events or
other reasons. Trialists should ensure outcome assessment is not biased across randomisation
arms, such as evaluating positives detected using the monitoring test in one arm but an
alternative method in the other.4 The review by Selby and colleagues4 showed 17% of trials
had biased outcome assessment.
1.3.6 Impact on patients
Monitoring strategies are complex interventions, with the monitoring decision informing pa-
tient management. Whilst strategies can be evaluated by process measures, such as the
number of patients with identified disease, patient benefit is the true outcome of interest
which can only be measured with patient outcomes. From a recent review of monitoring
RCTs,4 in most trials the addition of monitoring was thought to lead to earlier treatment or
better selection of patients for treatment.
There are many ways tests can change the management of patients providing benefit and/or
harm. Ferrante di Ruffano et al32 identified ways the care pathway could be changed when
introducing diagnostic tests, and this has been modified for monitoring tests by Selby et
al.4 The items reported were: test delivery (test feasibility, procedure and frequency), test
result (interpretability, clinical validity, timing of test result, detection of long-term change),
management decision (added clinical value, timeframe of management decision, clinical con-
fidence) and treatment implementation (timing of treatment, efficacy and adherence). Due
to the complex relationship between monitoring and patient impact, full scale investigation
18
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in correctly powered trials with patient outcomes is optimal; and it is essential trials use the
evidence available to ensure the monitoring strategies are most beneficial.
Work by Selby and colleagues7 (adapted from Adriaensen et al33) shows the positive and
negative consequences of each type of test result on patients when monitoring a progressive
or recurrent condition. The positive consequences of monitoring are experienced by those
patients with true positive or true negative results; patients with true positive results benefit
from earlier treatment and patients with true negative results correctly avoiding treatment
or further testing. The patients with false positive and false negative results have undesirable
outcomes; patients with false negative results do not receive necessary treatment and have
the false confidence of a negative result, and patients with false positive results face the harm
of unnecessary treatment, further testing and overdiagnosis. All participants may benefit
from monitoring as their exposure to more invasive testing may be reduced; however, on the
contrary, monitoring tests may cause harm. There may also be psychological benefits and
harm from monitoring, see Figure 1.6.7,33
1.3.7 Relationship to screening
Monitoring of patients with progressive or recurrent disease is different to screening of the
asymptomatic population, as the disease prevalence in populations receiving testing in the
monitoring and screening situations is very different, and the participants without disease
will be different to healthy participants taking part in a screening programme. When using
tests for monitoring or screening purposes the specific use of such tests should be tailored
with the test variability information obtained using the appropriate population, and tests,
test frequencies, and decision rules specifically chosen.
There are similarities between monitoring and screening processes. With the methods for
screening being further developed, there are potential methods that can be adapted for use
in monitoring as appropriate.
19
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TP FP
FN TN
All
TP
+ Would have experienced clinical outcome but are
cured due to (earlier) detection and effective treat-
ment (A)
+ Would have been successfully treated anyway, but
quality of life is improved due to detection (at an
earlier stage of disease), ± less debilitating treat-
ment (B)
− Would have experienced clinical indications of dis-
ease at a later time point but clinical outcome not
improved and quality of life potentially decreased by
earlier detection and treatment (C)
FN
− Have the disease (or a progres-
sive precursor of the disease) but
have a negative monitoring test
resulting in a false feeling of secu-
rity, delay detection and delay of
effective treatment (D)
FP
− Do not have the disease, or any precursor, and
undergo unnecessary further investigation and treat-
ment (E)
− Have preclinical or early stage disease that would
not have progressed to clinically overt disease within
a ’reasonable’ timeframe (or could potentially have
regressed), resulting in overdiagnosis and unneces-
sary treatment and a longer period in a ’diseased’
state (F)
TN
+ Do not have the disease or preclin-
ical indicator of disease and are
reassured by the negative results
of a monitoring test that correctly
shows they do not have the disease
(G)
All
+ Experience benefit from the monitoring experience
either psychologically or due to less frequent or less
invasive testing (H)
− Experience direct harm from the monitoring test(s)
or from any confirmatory testing (I)
− Experience psychological impact from increased
anxiety or labelling effects (J)
Figure 1.6: Impact of monitoring on patients (from Selby et al,7 adapted from Adriaensen
and colleagues)33.
20
1.4. Research questions and thesis outline
1.4 Research questions and thesis outline
1.4.1 Research questions
How can optimal monitoring strategies be designed? What are the appropriate study designs
and methods for estimating variability of tests? In order to deliver on these main questions,
this thesis aims to answer the following questions:
• What are the current methods for assessing biological variability?
• How well are biological variability studies designed, analysed and reported?
• Can the design and analysis of biological variability studies be improved, specifically
sample size planning and outlier detection methods? Are the current methods for anal-
ysis of biological variability studies valid, considering sample size and outlier detection?
• What are the current methods for the design and analysis of monitoring strategies?
• Can modelling methods be used to predict the performance of monitoring strategies,
to identify optimal strategies to be evaluated in an RCT?
1.4.2 Thesis outline
The aim of this thesis is to investigate optimal monitoring of progressive and recurrent disease.
To achieve this aim the thesis looks broadly at two areas: the design, analysis and reporting
of biological variability studies, which provide estimates of measurement error, and the use
of modelling techniques to combine evidence and allow comparison of monitoring strategies,
so that optimal strategies can be used in further investigations.
1.4.2.1 Biological variability studies
Chapters 2 to 6 investigate biological variability studies by: reviewing the current methods
(Chapter 2), reviewing the current state of the field in terms of design, analysis and reporting
21
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(Chapter 3), providing critical evaluation and recommendations for these studies through
analysis of a case study (Chapter 4), providing guidance for sample size justification (Chapter
5), and evaluating the impact of outlier detection methods and subsequent removal of data
(Chapter 6). The validity of current methods is also evaluated considering different sample
sizes (Chapter 5) and outlier detection methods (Chapter 6).
Chapter 2 provides detailed explanation of the methods reviewed and used in Chapters 3
to 6. The purpose of this Chapter is to introduce concepts and terminology regarding the
design, analysis and reporting of biological variability studies.
Chapter 3 investigates biological variability studies by reviewing the literature across a range
of tests and test situations (laboratory, physiological and imaging tests). The purpose of
this review was to assess the design, analysis and reporting of biological variability studies.
Evaluation of studies identified in this review identified common weaknesses of studies, and
recommendations for reporting are proposed at the end of this Chapter.
Chapter 4 provides a detailed analysis of a biological variability study using a case study.
The aim of this chapter is to identify how the standard methods work using an example and
investigate the use of log-transformation and outlier detection methods.
Chapter 5 uses simulation to validate the confidence intervals for coefficients of variation (see
Chapter 2) provided by Burdick and Graybill34 and the variability of estimates from standard
analysis methods using different sample sizes. A tool was developed allowing researchers to
plan the sample size (number of participants, observations and assessments) based on the
precision of key estimates from biological variability studies. This Chapter provides guidance
for sample size when planning a biological variability study.
Chapter 6 uses simulation to investigate the results from biological variability studies when
(commonly used) outlier detection methods are used, with simulated data both including and
excluding outliers. The purpose of this Chapter is to understand how methods for outlier
detection impact the estimates of variability and the validity of these estimates. This Chapter
ends with recommendations for the use of outlier detection methods and interpretation of
studies using these methods.
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1.4.2.2 Designing monitoring strategies
Chapters 7 and 8 identify optimal evidence-based monitoring strategies for further assessment
explaining the methods and appropriate data required. Methods for monitoring strategy
design and related areas were reviewed (Chapter 7) and using the knowledge of test variability,
along with disease progression and test performance a model was developed allowing the
comparison of monitoring strategies (Chapter 8) in terms of test performance.
Chapter 7 provides an overview of the literature, with searches performed to identify the
current methods for the design of monitoring strategies and also methods from similar fields
(for example screening and biomarker development). The purpose of this review was to
identify appropriate methods for modelling monitoring strategies for progressive and recurrent
disease discussed.
Chapter 8 uses the methods identified in the review of monitoring and monitoring related
areas, to develop a model enabling the simulation of monitoring data. The purpose of this
model is to estimate the performance of strategies in terms of test performance (allowing
candidate strategies to be identified). The aim of this Chapter is to identify the data required
to develop a model to evaluate monitoring strategies, and assess and validate the model
itself.
Chapter 9 summarises the findings and concludes the thesis. A pathway of studies and
evidence required to develop a monitoring strategy is introduced and the implications for
practice discussed. This Chapter also suggests future work and discusses the limitations and
strengths of the thesis.
23

Chapter 2
Introduction to assessment of
biological variability: design,
analysis and reporting
Summary
Biological variability studies assess the between and within-individual variability of test data.
A review of biological variability studies was conducted and key methods were reported.
There are many alternative measures of variability with different terms favoured in each area
of research. Biological variability studies in laboratory medicine have a framework for design
and evaluation proposed by Fraser and Harris in 1989.35 Key papers focus on the analysis of
biological variability studies (usually ANOVA or equivalent methods) with little discussion
of the design of studies.
25
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2.1 Introduction
To assess biological variation of a test the variability within and between individuals needs
to be estimated after accounting for analytical variability,16 see Chapter 1. Estimates of
variability help place tests efficiently and optimally in the care pathway and indicate the
appropriate difference in test results required to change patient management.13 Knowledge
of variability allows the test results triggering a change in patient management to be reflective
of a change in the disease state of a patient rather than merely reflecting the usual variability
in multiple test measures.14
The levels of variability considered are: pre-analytical variability, analytical variability, within-
individual variability and between individual variability.
Pre-analytical variability is variability in a test due to the differences in how subjects have
prepared for a sample to be taken (for example, diet prior to sample being taken and time of
day) and the process of taking the sample or performing the test (for example, the equipment
used to perform a test and the person performing the test) and how this sample has been
treated prior to assessment (for example, in the case of laboratory based tests this may
be procedures for storing and transporting samples). Pre-analytical variability is usually
minimised where possible.16
Analytical variability is the variability of results from a single sample and is often assessed
by taking a sample and replicating the analysis of this sample.16 Analytical variability for
laboratory based tests is generally expressed by how well a laboratory process can replicate
results when using identical samples, but for other testing settings, such as imaging testing,
this process is different with variability in the assessment of an image being due to the
clinician tasked with reviewing the image. The analytical variation in imaging tests is often
assessed by the use of inter and intra reader studies. For physiological tests it is often not
possible to assess analytical variability.
Within-individual variability is the variability due to fluctuation in test results for an indi-
vidual with the underlying disease status of the individual remaining consistent for the time
26
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period assessed. Between-individual variability is the variability in test measures between
individuals in a population.16
Biological variation is a complex component of test evaluation and it is especially vital this
is accurately estimated when considering the repeated use of a test in a population to detect
disease progression or recurrence.13 Assessment of biological variability, prior to devising a
strategy of monitoring by repeated testing of individuals over time, is crucial to identify
optimal use of the test in the strategy (knowing if the test can be used with a constant
threshold for the whole population or if changes for each individual are more meaningful)
and to fully understand the impact of changes in test results for the multiple tests evaluated
for each participant by knowing the likely variability in results.13
To understand the scope of studies evaluating biological variability, the design, methods for
analysis, reporting and overall quality a review of studies of biological variation was conducted
(see Chapter 3), with the key methodological papers influencing this work identified and
summarised in this Chapter.
In many situations test data are not normally distributed and are log-transformed, the meth-
ods and results for this special case are considered in this Chapter.
2.2 Methods
A review of the design, analysis and reporting of biological variability studies was conducted.
To ensure the review covered a wide range of test areas there were many elements to the
search: searches for key terms were performed, hand searching through relevant journals,
identification of papers from a database of biological variability studies and searches specific
to three selected clinical areas. For full details of the search see Chapter 3. The searches
were developed to ensure that laboratory, physiological and imaging tests were identified in
the review.
Papers were included in the review if they reported a study where the purpose (primary or
secondary) was to assess the variability of measuring or evaluating test results in participants
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thought to be in a stable health state. Studies included were required to have multiple test
assessments for participants under the same conditions (testing and patient care). There was
no restriction placed on study participants for inclusion, with studies of healthy participants
and participants with disease included.
Multiple test assessment included repetition of part or all of the testing procedure; partici-
pants could be tested multiple times or a test could be assessed multiple times (for example,
clinicians assessing imaging results or retesting of stored samples). To obtain an estimate of
biological variability (‘The natural variability in a lab parameter due to physiologic differences
among subjects and within the same subject over time.’ 15), analytical variability needs to be
assessed and allowed for when measuring within-individual and between-individual variabil-
ity, so studies assessing analytical variability only were included. It was also required that
assessment was of participants or participant samples rather than control samples.
Whilst conducting the review, key methodological papers influencing the design, analysis and
reporting of the selected studies were identified and further texts were found from ‘snowball’
searches.36 The main findings from the methodological papers are reported here.
2.3 Results
The literature for designing, analysing and reporting variability studies is better defined in
laboratory science than for other areas of health care. This guidance is generally applicable
to any test providing a continuous value, although some tests do not lend themselves to the
assessment of analytical variability.
Studies of imaging tests have different methods for design, analysis and reporting as these
studies include the variability from having a reader interpret the image. The image may
provide a continuous value that can be used to guide patient care or it may provide a binary
result (presence or absence of disease).
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2.3.1 Design of biological variability studies
2.3.1.1 Studies of laboratory tests
In the area of clinical chemistry there are developed frameworks that are adhered to when
studying the variability of tests. These frameworks are often used with laboratory tests but
would be generally applicable to any test with a continuous outcome.
Fraser and Harris
The work of Fraser and Harris,35 published in 1989, provides a framework for the design of
biological variability studies conducted in the clinical chemistry laboratory setting. Fraser
and Harris35 state that studies with the aim of estimating biological variability should reduce
pre-analytical variation where possible with this including a strict testing protocol; this may
include tests being performed at the same time of the day, in the same place, by the same
person and at regular time periods in addition to the participant having prepared for the
test in the same way (diet and exercise) and consistent handling, transport and storage of
samples.
With regard to analysing the samples in the laboratory the favoured approach (introduced
by Cotlove and colleagues in 1971)37 is to allow all samples to be collected for the duration
of the study and then analyse all samples at the same time in duplicate.35 The benefit of
this approach is there is no variation due to the samples being analysed in different runs and
the analytical variation can be estimated as the samples are analysed in duplicate. If the
samples are not analysed in duplicate the analytical variance needs to be estimated using
quality control materials, stored samples or existing literature. Fraser and Harris warn that
this is not ideal, as the estimate of analytical variability: ‘may not accurately reflect the
true analytical variation achieved with the specimens from the subjects’.35 It is, however,
acknowledged that in some cases (such as when samples are unstable) analytical variability
will have to be assessed externally.35 Fraser and Harris35 also criticise the approach where
samples are analysed as they are collected, as this will incur between-run variation.
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Participant 1
Time 1
Time n2
Assessment 1
Assessment n3
Assessment 1
Assessment n3
Between-
individual
variability
Participant n1
Time 1
Within-
individual
variability
Time n2
Assessment 1
Assessment n3
Assessment 1
Analytical variability
Assessment n3
Figure 2.1: Biological variability study design.
In order to assess analytical, within-individual and between-individual variability, the design
often used in laboratory test experiments is to recruit n1 participants and take observations
from these participants at n2 time points, with each observation assessed n3 times,
35 see
Figure 2.1.
European Federation of Clinical Chemistry and Laboratory Medicine
The EFLM (European Federation of Clinical Chemistry and Laboratory Medicine) released
a consensus statement in 201538 following the conference held in Milan updating the guide-
lines created in Stockholm 15 years previously.39 This consensus statement offers three broad
approaches; the first concerns analytical performance and the impact of this on patient out-
comes; the second is based on estimating biological variation; and the final approach looks
at comparing analytical variability to performance goals known as ‘the-state-of-the-art’. The
authors advocate the use of the first and second model (individually and in combination)
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over the third as this does not consider impact on patients. There is also a move to make
the catalogued biological variability information more reliable.13
2.3.1.2 Studies of physiological tests
Non-laboratory based studies may be designed to recruit a group of patients and take repeated
measures for these patients without formal assessment of analytical variability. Indeed, for
some physiological measures it may not be possible to directly assess analytical variability, for
example spirometry and blood pressure testing. Use of these designs mean measurement error
is estimated when calculating the variability within participants, combining analytical and
within-individual variability. Laboratory studies may employ this design and calculate within-
individual variability by obtaining an estimate of analytical variability from an external
source. Simundic et al22 stress the importance of clarification when reported results showing
the combined analytical and within-individual variability.
2.3.1.3 Studies of imaging tests
Imaging tests can incur variability at the analytical, within and between-individual level,
but often the focus of the studies is the variability within and between readers, which is
not generally a concern for laboratory and physiological tests. For studies of intra and inter
reader variability of imaging or patient charts, a typical study design would be to recruit and
test each participant. Each result would then be independently assessed by multiple readers,
with a reader(s) assessing each result multiple times.23,40 Intra and inter reader studies often
have few readers.41 Repeat reading of images by readers may only be performed by a subset
of readers or even a single reader.23 In some studies stock images/records are repeatedly read
(for example To et al42). Readers may be chosen purposively to represent experienced and
inexperienced readers.40
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2.3.1.4 Populations investigated
The recommendation of Fraser and Harris,35 when assessing the variability of laboratory
based tests, is to only include apparently healthy participants in studies assessing biological
variability. The Milan consensus issued by the EFLM discussed how results can vary due to
the population and health care setting and participants being in a ‘steady disease state’.38
This issue is also considered by Aarsand et al13 when discussing the reliability of estimates
from biological variability studies.
For imaging and physiological tests no guidelines were identified suggesting the populations
to be tested but studies identified in the review (see Chapter 3) indicate participants with
disease were tested more often.
2.3.1.5 Sample size
There is limited guidance to inform the sample size, number of repeat measures, and timing
of measures when designing studies of test variability.
Studies of laboratory tests
Fraser and Harris35 use previous studies to support the view: ‘valid estimates of the compo-
nents of variation can be obtained from relatively small numbers of specimens collected from a
small group of subjects over a reasonably short period of time’.35 Subsequent work by Fraser16
states: ‘the number of subjects is a compromise between the large number that is the ideal
and the smaller number that can be handled in any good experimental design’.
Another approach for laboratory tests has been to evaluate the number of repeat samples
required (n) for an estimate to be within x% of the homeostatic setting point, which is n =(
1.96
(√
CV 2A+CV
2
I
x
))2
.16 The homeostatic setting point is the ‘true’ value for an individual.
This approach considers only the estimate of within-individual variability and focusses on
the number of repeat measures that would be required each time the test is performed. See
§2.3.2.4 for explanation of notation.
32
2.3. Results
More recently Røraas and colleagues43 assessed the power of biological variability studies
using simulation based on analysis using ANOVA, for varying numbers of individuals, sam-
ples, replicates and levels of analytical variability. The tables detailing the power of studies
are available to guide investigators to design biological variability studies with adequate
power.
Studies of physiological tests
In the medical testing setting studies of variability are often called reliability studies which
may be referred to as generalisability studies (G) and studies where the most reliable strategy
involving a decision making process is assessed, which are decision (D) studies.44 de Vet et al44
suggest that a sample size of 50 is appropriate for the measurement of variability reasoning
that this sample size will be adequate to fill a 2× 2 table and will allow a Bland-Altman plot
to be reasonably populated.
de Vet and colleagues44 discuss how statistical significance is not a component of devising the
sample size required to produce a reliability estimate, as it is the value of the estimate which
provides information about the ability of the measuring system rather than the difference from
zero. The importance of an adequate sample size is stressed as this will allow an adequate
95% confidence interval for the reliability parameter to be estimated with Streiner et al23 also
commenting on how sample size influences the accuracy of the reliability coefficient.
de Vet et al44 acknowledge that sample size guidance is difficult to locate and provide sample
size formula for intraclass correlation coefficients (ICCs) allowing the sample size (n) to be
calculated for a pre-specified CI. The formula is taken from Giraudeau and Mary:45
n =
8z21−α/2(1− ICC)2[1 + (n2 − 1)ICC]2
n2(n2 − 1)w2 ,
where n2 is the number of measures of each participant and w is the width of the 100(1−α)%
confidence interval for the ICC. See §2.3.2.4 for explanation of notation.
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Studies of imaging tests
When imaging studies produce a binary outcome, the measure commonly used is the Kappa
statistic (see §2.3.2.3). It is acknowledged that sample sizes for Kappa statistics need to
be larger as the data is categorical; however, sample size calculations for a Kappa statistic
are more difficult to perform as an estimate of Kappa and other distributional knowledge is
required.44
2.3.2 Analysis of biological variability studies
2.3.2.1 Preparing data for analysis
In studies of laboratory tests data is tested for normality and subjected to outlier detection
methods prior to analysis. For imaging and physiological studies no such practices were
identified.
Normality of data
For laboratory studies of biological variation, Fraser and Harris35 advocate the use of the
Shapiro-Wilk test for normality. This test is applied to results for each individual separately
and the data is transformed (log transformation) if the results for many individuals are not
normally distributed.35 Braga et al46 have offered further guidance introducing Kolmogorov-
Smirnov tests in addition to Shapiro-Wilk (see Box 2.1).
When using a model to evaluate three levels of variability, the model assumes normality of
the variability parameters at the analytical, within-individual and between-individual levels.
If this assumption is not held results from the model may not be valid. Simply assessing
the normality of the test measures may not be sufficient to investigate if the data meets the
assumptions of the model. Many of the outlier detection methods (see Chapter 6) rely on
the data to be normally distributed, hence the further requirement for normality prior to
assessing outliers.
It may also be desirable to convert to the log scale as when biological variability data are log-
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normally distributed, coefficients of variation (on the original scale) can easily be estimated
using the standard deviation of the log transformed data.47
For studies of physiological and imaging tests no guidance on normality checking and trans-
formation of data was identified.
Box 2.1: The Shapiro-Wilk test.
The Shapiro-Wilk test is the primary test used for assessing normality of data in studies
of laboratory test variability. The Shapiro-Wilk test uses analysis of variance to test for
normality, with the null hypothesis that data are normally distributed.48 Given a variable
y is ordered, such that y1 < y2 < . . . < yn the test-statistic for the Shapiro-Wilk test is:
W =
(
∑n
i=1 aiyi)
2∑n
i=1(yi − y¯)2
,
where y¯ is the mean value of the variable and ai = (a1, . . . , an) =
mTV −1
(mTV −1V −1m)1/2 . m =
(m1, . . . ,mn)
T are the expected values of ordered statistics and V is the corresponding
covariance matrix.49
Outliers
In the laboratory setting, it is recommended data are assessed for outlying results and these
should be removed prior to analysis. Most commonly, Cochran C test and Reed’s criterion are
used to identify data to be removed, as recommended in the Fraser-Harris Framework.16,35
The Cochran C test is used to assess variances within the duplicated results and if an outlier
is detected both results are removed; this test is used again to assess the variances of results
for each individual. Reed’s criterion is used to identify if the mean value for any individual
is an outlier.16 Other methods of outlier detection are used in the laboratory setting and are
further discussed (See Chapter 6).
In other areas of test evaluation an alternative view of outliers is taken. According to de
Vet et al outliers should not be deleted as errors do occur and may indicate difficulties with
measurement read outs or interpretation of scales.44
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2.3.2.2 General method for analysis of test variability studies
Across variability studies for laboratory, physiological and imaging tests the analysis allowing
the estimates of variability to be quantified is the same and comes from a model allowing the
variability at each level to be estimated, or equivalently analysis of variance, ANOVA.
The differences between studies of test types occur after this analysis has been performed.
Fraser and Harris35 provide guidance for the analysis of biological variability studies con-
ducted in the clinical chemistry laboratory setting. ANOVA is suggested as the method for
analysis providing estimates for each component of variance, which is equivalent to fitting
a linear regression model with only random effects when the number of observations within
participants is consistent for all participants and the number of assessments at each observa-
tion point is consistent for all observation points (a balanced design). ANOVA is performed
by the calculations shown in Table 2.1.
Table 2.1: ANOVA (adapted from Burdick and Graybill34).
DF SS MS EMS
Between participants G = n1 − 1 n2n3
∑
i(y¯i − y¯i)2 S2G θG = σ2A + n3σ2I + n2n3σ2G
Within participants I = (n2 − 1)n1 n3
∑
i
∑
j(y¯ij − y¯i)2 S2I θI = σ2A + n3σ2I
Within assessments A = (n3 − 1)n1n2
∑
i
∑
j
∑
k(y¯ijk − y¯ij)2 S2A θA = σ2A
Total T = n1n2n3 − 1
∑
i
∑
j
∑
k(y¯ijk − y¯)2
DF is degrees of freedom; SS is sum of squares; MS is mean squares; and EMS is expected mean squares
Where S2, the mean squares, is equal to the sum of squares divided by the degrees of freedom,
as is estimated by θ. In model notation this can be expressed as yijk = µ+αi+βij+ijk, where
i = 1, .., n1, j = 1, .., n2 and k = 1, .., n3, yijk is the test measure for the ith participant at the
jth time point and for the kth assessment, µ is the mean value of the measure, αi ∼ N(0, σ2G),
βij ∼ N(0, σ2I ) and ijk ∼ N(0, σ2A).
When using a linear regression model to estimate the variance parameters, the use of re-
stricted maximum likelihood estimation (which estimates the fixed and random effects in-
dependently) is preferred as the estimates are less biased compared to maximum likelihood
estimation methods, especially with small sample sizes.50 McNeish and Stapleton50 recom-
mend a minimum of ten observations per individual to estimate a variance parameter.
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Specialist ANOVA methods
Specifically referring to studies of laboratory tests, further work by Røraas et al51 has in-
vestigated the performance of the standard ANOVA method alongside ln-ANOVA and CV-
ANOVA methods. The ln-ANOVA method uses log transformed values and the method
CV-ANOVA normalises data for each individual (by dividing by the mean) prior to ANOVA
being performed. The ln-ANOVA method is often advocated as it easily allows estimation
of coefficients of variation (CV), see §2.3.2.4. The CV-ANOVA method is an alternative ap-
proach to obtaining CVs; however, it is not possible to estimate between-individual variability
with this method.51
2.3.2.3 Alternative methods for analysis of test variability studies
Bland-Altman method
The Bland-Altman method52 is primarily used when comparing two methods of measur-
ing the same outcome in the same individuals with the Bland-Altman method providing a
measure of agreement, and is often used for physiological measures. The method comprises
the calculation of the mean difference between the measures and 95% limits of agreement
around this estimate (d¯ ± 1.96σd), where σd is the standard deviation of the differences be-
tween measures for each individual, this is often displayed graphically also. When describing
this method, Bland and Altman provide detail regarding the estimation of repeatability of a
measure rather than comparison between two measures, suggesting ANOVA is used to pro-
vide an estimate of within-individual standard deviation which can then be used to compare
repeatability between measurement methods.
Bland and Altman advise that repeatability is evaluated and this is taken into account when
comparing methods of measurement. Bland and Altman also provide the repeatability co-
efficient (CR), which is calculated as 1.96
√
2σA+I , where σA+I is the calculated standard
deviation relating to measurement error. The repeatability coefficient is how close two read-
ings made using the same method will be for 95% of subjects (an absolute measure), with this
measure akin to the reference change value (RCV) but with variability expressed as standard
deviations and the within-individual variation estimate including analytical variation rather
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than estimated separately as measures are not performed in duplicate. This method is used
when assessing clinical measures.53
Kappa
Agreement within and between observers (or raters) is known as intra and inter rater vari-
ability. A basic way of expressing this level of agreement is percentage agreement, which is
the percentage of measurements showing agreement of the total number assessed. Cohen’s
Kappa extends this idea by allowing for agreement occurring by chance. Kappa is calculated
as:
κ =
po − pe
1.0− pe ,
where po is the proportion of cases where there is agreement and pe is the proportion of cases
where agreement would be expected by chance. The corresponding standard error for Kappa
is:
SE(κ) =
√
po(1− po)
n1(1.0− pe)2 ,
where n1 is the number of participants in the study. Cohen’s Kappa measures agreement by
providing a value between -1 and 1, with a value of 0 indicating chance agreement.54
Kappa is used in situations where the result of a test is categorical rather than a continuous
measurement as it is difficult to achieve complete agreement when a continuous measure is
used.
Capability measures
Outside of medicine, in the area of industrial management, there are measures of variability
for monitoring ongoing processes. Processes are monitored by taking repeated measures, and
controlled by comparing these to ‘capability measures’ calculated using variability estimates.
Precision to tolerance ratio (PTR) and signal to noise ratio (SNR) are capability measures.
PTR is calculated as
k
√
σ2A
USL−LSL , where USL and LSL are specification limits and k is equal to
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5.15 or 6 (this is the number of standard deviations between the ‘natural’ tolerance limits and
correspond to the central 99% or 99.73% of the ‘process’ respectively) and σ2A is the variance of
the measurement system. SNR is
√
2
σ2G
σ2A+I
, using the ratio of the process variance or between
individual variance (σ2G) to the measurement variance (σ
2
A+I). The SNR value indicates how
many categories can be reliably identified; SNR values of five and above mean monitoring is
recommended and SNR values of less than two indicate little benefit of monitoring. SNR and
PTR are plotted against each other, with 95% confidence intervals to account for uncertainty
of the estimates and these plots are used to assess the measurement system. Also used
are: intraclass correlation (ICC), a measure of the proportion of the total variation that is
attributed to the process, ρ =
σ2G
σ2G+σ
2
A+I
; and, process capability, Cp =
USL−LSL
6
√
σ2
G
σ2
A+I
, this is to
understand the ability of the process rather than the measurements.55
2.3.2.4 Reported measures from test variability studies
There are many different terms used to describe measures of test variability. These terms
refer to related concepts, and although some terms have precise definitions, in practice, they
are often used interchangeably. Streiner et al23 list some of the definitions used for variability
as: reliability, objectivity, reproducibility, stability, agreement, association, sensitivity, pre-
cision, accuracy, dependability, repeatability and consistency. The exact definitions of these
concepts are not defined here, but the statistical measures presented to describe variability
are discussed. Some measures of test variability are akin to those in other research areas but
may be specified differently.
Reported measures for studies of laboratory tests
Estimated standard deviations are used to set goals for analytical performance. Measures
include: coefficients of variation, reference change values and index of individuality.56 See
Table 2.2 for details of all measures reported in this section.
Coefficient of variation, or CV, is defined as σ/µ where σ is the standard deviation and µ is
the mean.16 Coefficients of variation are often expressed as percentages and allow measures
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to be interpreted in relation to the value of the mean. When calculating the coefficient of
variation at the analytical, within-individual and between-individual levels the corresponding
standard deviations are used and are divided by the overall (grand) mean to estimate the
CV.
The reference change value (RCV), also known as critical difference (CD), estimates the dif-
ference between two results for an individual that would indicate a real change above the ex-
pected random fluctuation in test measures.16 RCV is calculated using
√
2Z
√
(CV 2A + CV
2
I ),
where Z is selected from the normal distribution (usually 1.96) and CVA and CVI are the co-
efficients of variation at the analytical/reassessment and individual level respectively.16
The index of individuality (II), provides information regarding the best use of a test by quan-
tifying the ratio of variability at the analytical and within-individual levels to the between-
individual level, and is calculated using
√
(CV 2A + CV
2
I )/CVG where CVA, CVI and CVG are
coefficients of variation analytical, within and between individuals respectively. II is often
simplified to CVI/CVG, with the assumption that CVA << CVI .
16,22 Higher values indicate a
general threshold would be reasonable and lower values suggest changes from previous results
for an individual will more be meaningful.16,57
Also used is the index of analytical error, CVA/CVI . This measure is the ratio of analytical
variation to within-individual variation and is often used for setting analytical variability
goals.16
Total variance is the total variability in the data and is calculated by combining variances
at the analytical, within-individual and between-individual levels, σ2A +σ
2
I +σ
2
G.
46 This com-
bined variability can also be expressed as a standard deviation (σA+I+G or σTOT ) or as a
coefficient of variation (CVA+I+G or CVTOT ). Another combined variance is total error,
or measurement error, combing the analytical and within-individual variability. Total error
variance is calculated as: σ2A + σ
2
I . Again, total error can also be expressed as a standard
deviation (σA+I or σTE) or coefficient of variation (CVA+I or CVTE).
The index of heterogeneity (IH) is a measure of the heterogeneity of within-individual ob-
servations. IH measures the ratio of CVA+I to the theoretical CV and is calculated as:
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IH =
CVA+I√
2
n2−1
, where n2 is the number of observations for each individual.
46 Under the as-
sumption of no heterogeneity, the expected value is 1/
√
2n2. If the calculated IH is more
than twice the expected value, the IH indicates heterogeneity.46
The Validity Coefficient (VC) represents the difference between the measured value and the
true value, due to variability. V C =
√(
1 +
σ2I
n2σ2G
)−1
, where σI and σG are the standard
deviations at the within-individual and between-individual level respectively and n2 is the
number of observations from each individual.58
To demonstrate how the measures of variability differ in different situations estimates are
produced for four test scenarios: scenario A is a test with good analytical variability and
within-individual variability is much lower than between-individual variability; scenario B
is a test with the within-individual variability larger in comparison to between-individual
variability; scenario C is a test with poorer analytical variability; and scenario D is a test
with decreased between-individual variability, see Table 2.3. For further details of how these
measures can be employed for use in monitoring individuals see Chapter 7.
Studies of laboratory tests–log-normal data
Often in laboratory based studies data are considered to be log-normally distributed. Differ-
ent measures are reported when data follow a log-normal distribution.
When data requires log-transformation prior to analysis using ANOVA or modelling, the
estimated standard deviations are geometric CVs and these can be multiplied by 100 to be
expressed as a percentage.59 The exact geometric CV of values on the original scale (assum-
ing a log-normal distribution) can be estimated by
√
exp(σ2)− 1, where σ is the standard
deviation of the log transformed values, with
√
exp(σ2)− 1 × 100 to express CV as a per-
centage.59,60 This calculation of the coefficient of variation arises as standard deviations of
(natural) log transformed data represent a fraction standard deviation, the CV, and with
the equation expressed giving the exact relationship.59 An alternative way of using log trans-
formed data to provide an estimate of geometric CV is given by Kirkwood,61 as exp(σ) − 1
and with the CV expressed as a percentage using (exp(σ) − 1) × 100, where σ is again the
standard deviation of the log transformed values.
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When using log-normal data RCV limits are asymmetrical, meaning the positive and negative
difference are calculated separately. The percentage RCV limits when using log-normal data
are calculated using: RCVpos = [exp(Z×
√
2τ)−1]×100, and RCVneg = [exp(−Z×
√
2τ)−1]×
100 (where τ =
√
ln(CV 2A+I + 1), Z is selected from the normal distribution (usually 1.96)
and CVA+I is the coefficient of variation for the total imprecision, CVA+I =
√
CV 2A + CV
2
I ,
with CVA and CVI).
62,63
The measures for log-normal data for the four test scenarios are shown in Table 2.4.
Reported measures for studies of physiological tests
In general, reliability parameters are used to assess the ability of participants to be distin-
guished from each other and are forms of ICC. The reliability parameter is
R =
σ2G
σ2TOT
=
σ2G
σ2A+I + σ
2
G
,
where σ2TOT is the total variance of measures and σ
2
G is the ‘true’ variability between partic-
ipants. Here, σ2A+I is ‘measurement error’ which includes both within individual variability
and analytical variability, this would be obtained if the study design included only repeat
measures of a group of individuals and no assessment of analytical variability by repeated
assessment of measures. The reliability parameter takes values between 0 and 1, with a value
of 1 meaning the system is perfect at identifying individuals, and 0 meaning it is unreli-
able.
Reported measures for studies of imaging tests
ICC measures are further defined for studies considering the variance due to raters (identified
in inter-intra reader studies of imaging tests), these measures are further defined as ICCs for
agreement and consistency.
ICCagreement =
σ2G
σ2A + σ
2
I + σ
2
G
,
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where σ2A is residual variance, σ
2
I is the rater variance and σ
2
G is the between-individual
variance, and
ICCconsistency =
σ2A
σ2A + σ
2
G
,
where σ2A is the residual variance and σ
2
G is the variance of the ‘true’ scores of the partici-
pants.
For the consistency measure the rater variance is not considered; however, if interest is in
agreement between measures the variance due to raters is included.44
The reliability parameter can also be used when there are multiple (k) measures used to
generate an average,
R =
k2σ2G
kσ2A+I + k
2σ2G
.
A more reliable measure will always be achieved when based on the average of measurements
as the measurement error becomes smaller.44 Streiner et al advise that averaging of measures
is only used if this reflects practice.23
The relationship between the reliability parameter, R, and the standard error of measurement
(SEM) is: SEM = σ
√
1−R, where σ is the standard deviation of observed values.23 When
concerned with the variability of a measure itself it is of interest to assess the magnitude
of measurement error. For continuous outcomes the standard error of measurement error
and coefficients of variation are also often reported, and when comparing agreement between
tests the limits of agreement from the Bland-Altman method are used. When the outcome
is categorical (say a diagnosis) Cohen’s Kappa and weighted Kappa are often used to judge
agreement. There are no measurement error estimates for categorical outcomes; instead the
percentage of outcomes in agreement is usually used in some way.44 The use of ICCs and
ANOVA is advocated by Streiner et al rather than Bland-Altman and Kappa.23
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Table 2.2: Commonly reported variability measures.
Measure Formula
Commonly used in studies of laboratory tests
CV σ/µ
Reference change value (RCV)
√
2Z
√
(CV 2A + CV
2
I ),
where Z is selected from the normal distribution
Index of individuality (II)
√
(CV 2A + CV
2
I )/CVG
Index of analytical error CVA/CVI
Total variance σ2A + σ
2
I + σ
2
G
Index of heterogeneity (IH) CVA+I√
2
n2−1
Validity coefficient (VC)
√(
1 +
σ2I
n2σ2G
)−1
After log transformation
Exact geometric CV
√
exp(σ2)− 1
Alternative exact geometric CV exp(σ)− 1
Asymmetric RCV bounds exp(±Z ×√2τ)− 1,
where τ =
√
ln(CV 2A+I + 1)
Commonly used in studies of physiological and imaging tests
Reliability parameter (R)
σ2G
σ2A+I+σ
2
G
Reliability parameter with k measurements
k2σ2G
kσ2A+I+k
2σ2G
ICC agreement
σ2G
σ2A+σ
2
I+σ
2
G
ICC consistency
σ2A
σ2A+σ
2
G
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2.3.2.5 Use of confidence intervals
In the laboratory test setting, Fraser and Harris comment on the use of confidence intervals to
express uncertainty of estimates produced but caution these are often not considered due to
distributional assumptions.35 Røraas et al43 state that biological variability estimates should
be presented with confidence intervals to allow the uncertainty around the estimate to be un-
derstood. It is acknowledged that confidence intervals are rarely seen in biological variability
studies and as a consequence it is difficult to compare results across studies. This issue was
raised by Henderson64 with debate from Harris65 in 1993 in the Journal of Clinical Chemistry.
Henderson called for the consistent use of confidence intervals in the journal, arguing use was
commonplace in other fields of research, and requested this be made a requirement; however,
Harris was reluctant to employ this. At present the author guidelines for the Journal of
Clinical Chemistry66 state confidence intervals should be used ‘when appropriate’.
Røraas et al43 considered the standard biological variability study design with individuals
providing multiple samples and replicated analyses of these samples using ANOVA. Using
the formula introduced by Burdick and Graybill,34 Røraas et al provided confidence intervals
calculated for a varying numbers of individuals, samples, replicates and levels of analytical
variability. Researchers are encouraged to use the tables provided, demonstrating the width
of confidence intervals under certain designs, to estimate the width of the confidence interval
around an estimate. Røraas et al67 have subsequently investigated the ability of methods to
generate confidence intervals for estimates of within-individual biological variability. Burdick
and Graybill34 proposed methods to calculate approximate intervals for variance components
(see §2.3.2.5).
Burdick et al55 also comment on the use of confidence intervals, as for gauge reliability and
reproducibility studies, it is often not possible to calculate exact confidence intervals for esti-
mates of variability. Two alternatives are discussed, firstly, the modified large sample (MLS)
approach55 and, secondly, the computer intensive approach using generalised confidence in-
tervals. The authors warn intervals obtained from likelihood based methods (for example
REML models) are only valid for large samples and may not be appropriate.
46
2.3. Results
For other test types, the use of confidence intervals is commonplace but the issues with
obtaining exact confidence intervals for measures of variability remain. The default of many
computer packages is to display confidence intervals using an approximation via the delta
method.
Confidence intervals for variance components
These formulas are appropriate for any test type where estimates of variability at the ana-
lytical, within-individual and between-individual levels have been estimated.
Using the assumptions of the general model for data from biological variability studies: yijk =
µ+αi + βij + ijk, where µ is the mean value of the measure, αi ∼ N(0, σ2G), βij ∼ N(0, σ2I ),
ijk ∼ N(0, σ2A) and i = 1, . . . , n1, j = 1, . . . , n2 and k = 1, . . . , n3, n1S21/θ1, n2S22/θ1 and
n3S
2
3/θ1 are jointly independent chi-squared random variables, see ANOVA notation in Table
2.1. Using the formulas of Burdick and Graybill34 it is possible to calculate confidence inter-
vals calculated using the expected mean squares (as shown in Table 2.1). These equations have
also been coded in a shiny application allowing visualisation of the confidence intervals for
different estimates and sample sizes, https://alicesitch.shinyapps.io/bvs_cis/.
An exact two-sided confidence interval for analytical variation (σ2A), estimated by θA is given
by:
[
S2A
Fα:A,∞ ;
S2A
F1−α:A,∞
]
, with this converted to give the confidence interval for σA by taking
the square root of both the lower and upper bound.
To calculate a confidence interval for within-individual variation (σ2I ) the formula
[
S2I − S2A −
√
VIL
n3
,
S2I − S2A +
√
VIU
n3
]
is used and for between-individual variation (σ2G) the formula
[
S2G − S2I −
√
VGL
n2n3
,
S2G − S2I +
√
VGU
n2n3
]
is used where:
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VGL = GGS
4
G +H
2
IS
4
I +GGIS
2
GS
2
I
VGU = HGS
4
G +G
2
IS
4
I +HGIS
2
GS
2
I
VIL = GIS
4
I +H
2
AS
4
A +GIAS
2
IS
2
A
VIU = HIS
4
I +G
2
AS
4
A +HIAS
2
IS
2
A
GG = 1− 1
Fα:G,∞
GI = 1− 1
Fα:I,∞
GA = 1− 1
Fα:A,∞
HG =
1
F1−α:G,∞
− 1
HI =
1
F1−α:I,∞
− 1
HA =
1
F1−α:A,∞
− 1
GGI =
(Fα:G,I−1)2 −G2GFα:G,I −H2I
Fα:G,I
GIA =
(Fα:I,A−1)2 −G2IFα:I,A −H2A
Fα:I,A
HGI =
(1− F1−α:G,I)2 −H2GF 21−α:G,I −G2I
F1−α:G,I
HIA =
(1− F1−α:I,A)2 −H2IF 21−α:I,A −G2A
F1−α:I,A
.
Confidence intervals for coefficients of variation
Obtaining exact confidence intervals for coefficients of variation involves solving non-linear
equations. Assuming the coefficient of variation is positive, the lower bound of a confidence
interval can be obtained solving the following for β:
α/2 = FNCT (n− 1,
√
n/β)(X¯/(σ/
√
n)),
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where 1 − α represents the confidence level required, FNCT (n − 1,
√
n/β) is a non-central
t-distribution with n − 1 degrees of freedom and √n/β non-centrality parameter, X¯ is the
sample mean, σ is the sample standard deviation and n is the sample size. To obtain the
upper bound, the following equation must be solved for β:
1− α/2 = FNCT (n− 1,
√
n/β)(X¯/(σ/
√
n)).60,68
In addition to the computational complexities in obtaining exact confidence intervals for
coefficients of variation, this method can give confidence bounds of infinity. There are also
approximate methods for calculating confidence intervals for coefficients of variation, but the
issue of infinite upper bounds is more apparent for approximate methods.68 There is no closed
form solution for deriving confidence intervals for reference change values.51
Confidence intervals for coefficients of variation–log-normal data
When data are log-normal, the distribution of log transformed data (Yi) is normally dis-
tributed (Yi ∼ N(µ, σ2)) and a 1− α confidence interval for σ2 is [aL, aU ].
aL = (n− 1)σ2/(Fχ2(n− 1)−1(1− α/2)), and
aU = (n− 1)σ2/(Fχ2(n− 1)−1(α/2)),
where σ is the sample standard deviation of the log transformed data (Yi) and Fχ2(n− 1)(x)
is a cumulative distribution function of a central chi-squared distribution with n− 1 degrees
of freedom. This formula is equivalent to the formula for a confidence interval for σA provided
by Burdick and Graybill due to the χ2 distribution and F distribution being equivalent under
certain conditions.
Hence, to obtain a 1 − α confidence interval for the coefficient of variation for log-normal
data, the following is used:
[√
exp(aL)− 1,
√
exp(aU )− 1
]
.68
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2.3.2.6 Reporting of biological variability studies
Studies of laboratory tests
There are no guidelines for the reporting of laboratory biological variability data, unlike the
reporting of reference range estimates. Bartlett and colleagues,69 on behalf of the Biological
Variation Working Group of the European Federation of Clinical Chemistry and Laboratory
Medicine (EFCCLM) developed a checklist for the appraisal of existing and future publica-
tions of biological variability data.69 This checklist is developed from the idea of a minimum
dataset that must be provided to allow readers to accurately interpret results of biological
variability studies.70 The minimum dataset to be reported includes information on the: test,
population, study, analysed data and also suggests linking to a publication with further de-
tails and a rating of the study (in development).69,70 The checklist proposed has six domains:
title/abstract/keywords, introduction, data analysis, results and discussion, see Table 2.5.
Simundic et al suggest that consistent notation is used to avoid confusion when reporting
results from biological variability studies.22
Studies of physiological and imaging tests
For variability studies in other test areas there are reporting guidelines (GRRAS).40 These
guidelines include clear identification of the study type in the title; describing the testing
measurement or device, the population, rater population and study rationale; explanation of
the chosen sample size (number of subjects, raters and replicates), the sampling method, the
measurement and rating process; acknowledgement of independence; description of statistical
analyses; the results must state the number of raters, subjects and duplicates, describe the
raters and subjects and give ‘reliability and agreement’ measures with statistical uncertainty.
Further to these points, there should be discussion of the relevance of results and further
detailed results.
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Table 2.5: Biological variability study checklist. After Bartlett.69
Section and topic Item Evidenced
Title/abstract/keywords 1 The title should indicate that the content relates to a study of biological
variation, the subject of the study, the sample matrix, and the population
studied. Analyte (component being measured), the measurand/s (the
quantity or quantities to be measured, see Section 1.1), and state of
well-being of the subjects under study should be clearly and unambiguously
identified. Relevant coding systems might be employed, (e.g., LOINC,71
SNOMED,72 C-NPU.73)
Abstract 1.1 As a minimum it should contain the headline biological variation data, the
major characteristics of the population studied (numbers of subjects with
demographics), clearly identify the analyte and measurand/s studied [the
analyte quantities studied in a particular sample matrix, (e.g., concentration
of glucose in plasma)], the statistical approach taken, the duration of the
study and the geographical location of the study.
Introduction 2 Introduction should clearly identify the context and aims of the study and
cite any previous relevant studies of biological variability of the target
analyte. Recommended terminology to be adopted re description of
variability.22
Methods 3 Described in enough detail to facilitate transportability of the derived data
across populations and health care systems. The biological variation data
produced are effectively reference data and their applicability requires
delivery of appropriately described metadata to enable their use as such.
Analyte/measurand 3.1 The described study should clearly identify the target analyte and
measurand/s. Where available internationally agreed terminology and
codings should be utilised.
Subjects 3.2 The description of the subjects and population studied should be detailed
enough to enable transportability of the biological variation data. Minimum
data set should be present.70,74,75 This should include number of subjects
studied, age, gender, and state of well-being.
Measurement procedure 3.3 A clear description of the analytical methodology used should form part of
the metadata. This may be made available via an appropriate reference or
be presented within the publication. Deviation from standard operating
procedures, use of adaptations of published methods, and deviation from
manufacturers recommended methods in the case of commercially available
systems should be documented. Standardisation and traceability should be
clearly identified.
Length of study 3.4 Length of the study periods should be clearly identified.
aTests to determine the power of a study to identify heteroscedasticity need to be developed. If variances are not
homogenous derived estimates of biological variation cannot be trusted, and are not representative for the
population in which it is examined.
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Section and topic Item Evidenced
Sampling 3.5 Sampling protocols (e.g., subject preparation, sampling conditions) that
minimise pre-analytical variation should be adequately described to enable
transportability of the data.35 Numbers of samples taken should be
sufficient to deliver the required power to the study.35,43.
Samples 3.6 Recorded details should include the beginning and end date of the study
and timings of sampling. Sampling conditions and sample type should be
described in detail. Pre-analytical storage conditions of samples should be
described.
Conditions for analysis of samples 3.7 A description of conditions under which the samples were analysed.
Analytical protocols should be designed to minimise sources of analytical
variation (Optimal Conditions Precision).76
Data analysis 4 Data analysis techniques should be described. The power of the study to
identify indices of biological variation should be calculated and presenteda.43
Outlier analysis 4.1 Outliers should be excluded from the final analysis of the data. Test for
outliers should be applied to all levels of data (between replicate analysis,
between samples within subject, between subjects).35 The numbers of
outliers and reasons for their exclusion must be given.
Heterogeneity of variance 4.2 Subjects with outlying within subject variance should be rejected from
calculations used to determine an estimate of common true variance. The
numbers of outliers and reasons for their exclusion must be givena.
Statistical methods described and
appropriate
4.3 Statistical methods used should be appropriately identified, fit for purpose
and referenced. Data that do not conform to a normal distribution should
be appropriately transformed.35
Results 5 Unified terminology22 should be used and appropriately defined metadata
clearly presented to enable understanding and transportation of the data
through time and across health care systems.
Terminology 5.1 Terms and symbols should be used to describe biological variation should
conform standards identified by Simundic et al.22
Results clearly presented and
managed
5.2 Biological variation data, with derived indices, should be tabulated in a
format that enables extraction of the key data unambiguously associated
with a minimum data set to enable transportability of the data. Power of
the study and confidence limits around estimates of biological variation
should be presented.43 The results section should clearly identify the results
of outlier analysis undertaken and confirm homogeneity of the data sets. If
data are stratified the variables used to enable this should be clearly
characterised.
aTests to determine the power of a study to identify heteroscedasticity need to be developed. If variances are not
homogenous derived estimates of biological variation cannot be trusted, and are not representative for the
population in which it is examined.
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Section and topic Item Evidenced
Discussion 6 The discussion of the data should clearly include a focus on factors that
impact on the transportability of the data to other settings. Limitations and
strengths of the study should be addressed. If the data are used to set
analytical performance specifications, derive reference change values and
study individuality, the recommendations of Simundic et al. should be
followed.22
aTests to determine the power of a study to identify heteroscedasticity need to be developed. If variances are not
homogenous derived estimates of biological variation cannot be trusted, and are not representative for the
population in which it is examined.
2.4 Summary and conclusions
There are many summary measures of variability across various fields, some are analogous
and others expressed in different ways in different areas (such as coefficient of variation, where
the standard deviation is divided by the mean value and expressed as a percentage), but are
fundamentally expressing the same information to explain variability of tests. Simundic et
al22 called for standardisation of notation for variability measures reported from laboratory
studies but this could be extended to all studies of variability as the array of definitions used
is a source of confusion, making the results of studies inaccessible to those outside of the
field.
The design of studies of test variability is well documented for clinical laboratory based tests
with the Fraser and Harris framework.35 For other areas a paucity of literature concerning the
design of variability studies was identified. The framework of Fraser and Harris is lacking with
no advice given regarding sample size of variability studies. Røraas et al43 have developed
resources to help plan study sizes.
The methods for evaluating variability studies are again well defined for clinical laboratory
tests due to the framework of Fraser and Harris.35 However, some of the methods advocated
require evaluation, specifically the use of outlier detection methods and deletion of values prior
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to analysing data as this may impact variability estimates. In other areas the methods of
analysis appear to be more ad hoc with estimates of variability, such as ICCs, expressed.
The use of confidence intervals to express uncertainty of an estimate is an issue for biological
variability studies due to difficulties with calculation, although it is generally accepted con-
fidence intervals would be useful. Again, the work of Røraas et al43 provided investigators
with help generating confidence intervals. Confidence intervals are commonly used in the
medical field and would be reported as standard from ANOVA and multi-level modelling
analyses.
In order to understand the quality of biological variability studies, the review of studies will
address the areas of design, analysis and reporting with focus on specific elements that have
been highlighted as causing concern. These areas are sample size, data transformations,
outlier detection and the use of confidence intervals. The review will reveal the depth and
the scope of these issues in the current research (see Chapter 3).
To fully investigate the impact of the methods used to investigate biological variability, em-
pirical analyses will be performed to investigate these issues (see Chapter 4).
The issue of sample size specification is also considered further in Chapter 5 and the use of
outlier detection methods in Chapter 6.
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A review of biological variability
studies: design, analysis, and
reporting
This work has been partly presented in the following form:
Sitch, A, Mallett, S, Deeks, J. Biological variability studies: design, analysis and reporting.
4th Methods for Evaluating Medical Tests and Biomarkers (MEMTAB) Symposium,
Birmingham, UK. 19-20 July 2016.
Summary
Biological variability studies provide key information for using tests in patient care. These
studies are required to provide accurate information.13 A purposive search was conducted
to identify and review the design, methods and reporting of biological variability studies, to
identify key issues.
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Studies were difficult to find and the majority of those located were for laboratory tests,
with few studies of variability for imaging and physiological tests identified. The studies of
laboratory tests often used the same method for analysis, ANOVA or random effects linear
regression modelling, and outlier detection and deletion, as specified by Fraser and Harris.35
Sample size was not planned and/or reported in nearly all identified studies and the use of
confidence intervals to express uncertainty was rare.
This review identified the need for guidance when planning sample sizes for biological vari-
ability studies and calculating confidence intervals, and further investigation into the methods
used for outlier detection.
3.1 Introduction
As outlined in Chapter 2, for studies of laboratory tests a general framework for the design and
analysis of studies is advocated by Fraser and Harris.35 Røraas and colleagues have recently
provided guidance on sample size and expressing uncertainty of estimates from biological
variability studies.43 Also, Simundic et al22 have provided a guide for standardising notation
to aid understanding and Bartlett et al69 have developed a checklist for these studies (for
further information see Chapter 2). The Working Group on Biological Variation (WG-BV)
of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) have
been active in developing this field further.13,77
For studies of physiological and imaging tests, guidance on design was not identified and
methods for analyses varied as the types of variability estimated are often different (analytical
variability cannot be assessed using some tests and inter-intra reader variability is of interest
when studying an imaging test).
The purpose of this review is to understand and evaluate the state of the field by investigating
the design, analysis and reporting. This review will allow investigation into how well studies
adhere to the recommendations,69 where there is variation in methods used, and where there
is clear need for improvement.
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3.2 Aims and objectives
The aim of this review was to evaluate the design, analysis and reporting of biological vari-
ability studies. The study objectives were to identify:
• the current state of the field (aims of studies, test types and disease areas);
• how studies are designed;
• the methods used to analyse these studies;
• the quality of reporting;
• and, differences between studies assessing laboratory, imaging and physiological tests.
3.3 Methods
Several searches were used to identify published articles reporting test variability studies
(between November 2014 and May 2015). These searches were developed purposely to en-
sure different test types (laboratory based tests, imaging tests and physiological tests) were
included and the studies covered a range of clinical areas. The searches were not intended
to be fully comprehensive, but were designed to provide a representative sample of studies.
The identified studies were assessed for suitability in the review and key information was
extracted.
3.3.1 Searches used to identify studies reporting biological variability stud-
ies
The search strategy was developed adapting to the identified studies, to ensure a sufficient
number of studies were identified and these were representative. The first search was a broad
search; hand searching of specific journals was then used to ensure full coverage of these
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sources; the Westgard data base was utilised; and, specific searches in targeted clinical areas
were used.
3.3.1.1 Search A: Broad search–November 2014
• Key word search (bio* AND vari*) in title and/or abstract for the period 1st November
2013 to 31st October 2014.
The initial search was used to identify a broad range of studies. Using the results of this
search, searches were refined to identify appropriate studies of biological variability. Searches
were performed in PubMed in November 2014.
3.3.1.2 Search B: Hand search–January 2015
• All articles published in the journals Clinical Biochemistry (search B1), Radiology
(search B2) and Clinical Chemistry (search B3) during the period 1st January 2014 to
31st December 2014. Searches were performed in PubMed in January 2015.
This search looked at all articles for specific journals for a one year period. Journals were
targeted, informed by results from search A, and were chosen to include laboratory and
imaging studies.
3.3.1.3 Search C: Test specific searches–May 2015
Detailed searches for three different test types (imaging, laboratory and physiological) in
specific clinical areas:
• Search C1: Ultrasound imaging to assess bladder wall thickness in patients with incon-
tinence (exp Urinary Incontinence/ AND exp Ultrasonography).
• Search C2: Creatinine and Cystatin C measurements to estimate glomerular filtration
rate (GFR) in patients with chronic kidney disease (CKD) (exp Renal Insufficiency,
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Chronic/ AND exp Glomerular Filtration Rate/ AND (exp Cystatin C/ OR exp Cre-
atinine/).
• Search C3: Spirometry to measure forced expiratory volume (FEV) in patients with
chronic obstructive pulmonary disorder (COPD) (exp Pulmonary Disease, Chronic Ob-
structive/ AND exp Spirometry/ AND exp Forced Expiratory Volume/).
These particular tests and populations were considered due to ongoing work in these areas,
enabling knowledge of the literature and access to experts to develop the searches. Searches
were performed in PubMed in May 2015 with no restriction on the date of publication.
3.3.1.4 Search D: Westgard QC database–May 2015
Studies recorded in the Westgard QC database78 (an online resource giving biological variabil-
ity information for laboratory based tests collated from published studies18,79,80) published
from 1st January 2000 onwards. Accessed in 2015.
As studies have already been assessed prior to inclusion in the database and this is specifically
for laboratory tests, identifying studies only from this source would be limited.
3.3.1.5 Search E: Expert search
In addition to the studies identified by these searches, published articles identified by previous
and concurrent work meeting the criteria were included to enrich the sample. The test specific
searches (C1, C2 and C3) described did not manage to identify all known biological variability
studies in the specific clinical areas. Clinical experts provided further studies.
3.3.2 Eligibility criteria
Studies were included in the review if they met the following criteria:
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• Study aim: the purpose (primary or secondary) was to assess the variability of measur-
ing or evaluating test results in participants, in a stable health state over the period of
testing.
• Study test(s): include assessments of the test(s) for participants under the same con-
ditions.
• Study participants: there was no restriction placed on study participants, with studies
of healthy participants and participants with disease included. However, it was required
that assessment was of participants or participant samples rather than control/spiked
samples.
• Language: only studies reported in English were included in the review.
Studies were required to have multiple test assessment which included repetition of part or
all of the testing procedure; this could mean participants were tested multiple times or test
output/samples were assessed multiple times (for example, clinicians assessing imaging results
or retesting of stored samples). To obtain an estimate of biological variability (“The natural
variability in a lab parameter due to physiologic differences among subjects and within the
same subject over time.”15), analytical variability needs to be assessed and allowed for when
measuring within-individual and between-individual variability so studies assessing analytical
variability only were also included.
3.3.3 Review of selected studies and data extraction
Titles and abstracts were assessed for inclusion, full text was obtained for potentially eligible
articles and reviewed against the eligibility criteria. Details of the study design, methods of
analysis, and reporting were extracted and assessed by a single reviewer. The data extrac-
tion form was adapted from Bartlett’s checklist,69 including fields appropriate for studies of
physiological and imaging tests. Additional items were included for aspects of study design,
analysis and reporting.
The following information was extracted from the included studies:
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1. What are the aims of these studies and in which tests and test areas are they seen?
(a) Test type
(b) Study aim
(c) Situations assessed
2. How are studies assessing biological variability of tests designed?
(a) Participants included
(b) Sample size (any justification of the number of participants, observations per par-
ticipant and assessment of observations)
(c) Duration of study and time between repeated assessments
(d) Levels of variability assessed
(e) Reduction of pre-analytical variability
(f) Blinding
3. How are studies assessing biological variability of tests analysed?
(a) Methods for analyses (reported explicitly or judgement from results)
(b) Data transformation
(c) Outlier identification and exclusion
4. How are studies assessing biological variability of tests reported?
(a) Title identifies study as biological variability
(b) Clarity of reporting for study design and methods for analysis
(c) Biological variability estimates and the corresponding uncertainty
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3.4 Results
3.4.1 What is the current state of the field? What are the aims of these
studies and in which tests and test areas are they seen?
3.4.1.1 Studies identified
One-hundred-and-one studies were included in the review, see Figure 3.1. The Westgard
QC database contributed more studies to the review (n=57, 56%) than any other search,
see Table 3.1. Of the 101 studies, 75 (74%) were studies of clinical chemistry laboratory
tests, with 20 (20%) studies of imaging tests and 6 (6%) studies of physiological tests. The
tests evaluated in these studies varied, (including imaging to measure bladder wall thickness
and tumour size; spirometry to measure forced expiratory volume (FEV); and laboratory
tests measuring glomerular filtration rate (GFR), vitamin uptake, HbA1c, hepatic enzymes,
hormone levels and cardiac troponin), see Appendix A.
3.4.1.2 Study aims
Extracting the study aim gives insight into the main purpose of each study. Some studies
evaluated the variability of just one test (n=37, 37%) whereas others looked at multiple
tests, or multiple measurement types from a single test (n=64, 63%). Some studies (n=27,
27%) also evaluated tests in multiple populations (or subpopulations, defined by gender, age,
medication status etc.) or over different time ranges (n=11, 11%) and reported the results
separately for these situations. The aims of these studies varied also with some studies
looking at the variability of a test measure secondarily to evaluating the test for a different
property (n=25, 25%). The median number of testing situations (different measurement
type, population or time point) was 4 (Q1, Q3: 2, 7). One study estimated variability in 53
different test situations,82 see Box 3.1 for examples and Table 3.2.
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Records after du-
plicates removed
(n=4659)
Records identified through
PubMed database searchinga
(n=4704)
Additional records identified
through other sourcesb
(n=80)
Records screened
(n=4659)
Records excluded
(n=4509)
Full text articles as-
sessed for eligibility
(n=150)
Studies included in review
(n=101)
Full-text articles excluded,
with reasons (n=49)
• provides diagnosis rather than
test measure (n=7)
• uses non-participant/ spiked/
control samples (n=8)
• measures/ predicts participants
with non-stable disease/
measures progression (n=26)
• does not include repeated use
or interpretation of test (n=2)
• not a primary study (review or
opinion paper) (n=5)
• only assesses agreement
between tests (n=1)
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Figure 3.1: Flowchart studies included in biological variability review, from Moher81. asearch
A 1024 studies; B1 318 studies; B2 500 studies; B3 313 studies; C1 219 studies; C2 1578
studies; C3 752 studies. bsearch D 65 studies; search E 15 studies (see §3.3.1).
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Table 3.1: Identified biological variability studies by search.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Search*; n(%)
A 1 (5) 4 (5) 0 (0) 5 (5)
B1 0 (0) 2 (3) 0 (0) 2 (2)
B2 8 (40) 0 (0) 0 (0) 8 (8)
B3 0 (0) 5 (7) 0 (0) 5 (5)
C1 6 (30) 0 (0) 0 (0) 6 (6)
C2 0 (0) 5 (7) 0 (0) 5 (5)
C3 0 (0) 0 (0) 6 (100) 6 (6)
D 0 (0) 57 (76) 0 (0) 57 (56)
E 5 (25) 6 (8) 0 (0) 11 (11)
Year
Median 2012 2008 2006 2009
Q1, Q3 (2008, 2014) (2003, 2012) (2003, 2007) (2003, 2013)
Range [1994-2014] [1988-2014] [1996-2013] [1988-2014]
Journal; n(%)
Annals of Clinical
Biochemistry
0 (0) 6 (8) 0 (0) 6 (6)
Chest 0 (0) 0 (0) 2 (33) 2 (2)
Clinical Biochemistry 0 (0) 3 (4) 0 (0) 3 (3)
Clinical Chemistry 0 (0) 24 (32) 0 (0) 24 (24)
Clinical Chemistry and
Laboratory Medicine
0 (0) 21 (28) 0 (0) 21 (21)
Clinica Chimica Acta 0 (0) 2 (3) 0 (0) 2 (2)
European Journal of
Obstetrics, Gynaecology, &
Reproductive Biology
2 (10) 0 (0) 0 (0) 2 (2)
Kidney International 0 (0) 2 (3) 0 (0) 2 (2)
Radiology 8 (40) 0 (0) 0 (0) 8 (8)
Ultrasound Obstetrics
Gynaecology
2 (10) 0 (0) 0 (0) 2 (2)
World Journal of Urology 2 (10) 0 (0) 0 (0) 2 (2)
Other 6 (30) 17 (23) 4 (67) 27 (27)
*Four studies were identified by more than 1 search. See §3.3.1 for detail of searches.
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Differences between test types
Multiple tests were commonly evaluated across studies of each of the test types (imaging n=
14/20 (70%); laboratory n= 45/70 (60%); and physiological n=4/6 (67%)). More studies of
laboratory tests evaluated multiple populations (n=25/75, 33%) than for imaging (n=1/20,
5%) and physiological tests (n=1/6, 17%). Across all test types, studies showed analysis of
tests separate to estimating variability (imaging n= 9/20 (45%); laboratory n= 15/70 (20%);
and physiological n=1/6 (17%)).
The purpose of 16 (16%) studies was to assess inter and/or intra reader variability, these
studies were all studies of imaging tests, see Table 3.2. Some of these studies investigated
reassessment of images (for example a study of pelvic floor muscle contraction by ultrasonog-
raphy where ‘frozen images’ were reassessed)83 but in other imaging studies multiple images
were taken and assessed (for example a study investigating ultrasonography and Doppler
velocimetric assessment of the levator ani muscle used two investigators each performing the
imaging procedures)84.
Box 3.1: Multiple testing situations in identified biological variability studies.
Multiple tests and populations
Pediatric within-day biological variation and quality specifications for 38 biochemical
markers in the CALIPER Cohort, by Bailey et al82 looked at 53 different testing sit-
uations. This included 38 biochemical markers, for example Albumin, Glucose, and
Magnesium. Some of the biochemical markers were assessed separately for children in
different age bands, for example AST was assessed separately for children up to seven
years old, from seven years up to 12 years old and then from 12 years to 19 years old.
Multiple tests and time periods
Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I
in hemodialysis patients and healthy controls, by Aakre et al85 evaluated Cardiac troponin
T and Cardiac Troponin I for two distinct time ranges. The variability of the tests was
assessed by evaluating patients at 90 minute intervals over a 6 hour testing period and
weekly for a period of 10 weeks.
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Table 3.2: Aims of identified biological variability studies.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Single test evaluated; n(%) 6 (30) 30 (40) 2 (33) 37 (37)
Multiple tests evaluated; n(%) 14 (70) 45 (60) 4 (67) 64 (63)
Number of tests evaluated
Median (Q1, Q3) 4 (1, 6) 2 (1, 5) 5 (1, 11) 2 (1, 6)
Range [1-19] [1-38] [1-14] [1-38]
Multiple populations
evaluated; n(%)
1 (5) 25 (33) 1 (17) 27 (27)
Multiple time periods
evaluated; n(%)
1 (5) 8 (11) 2 (33) 11 (11)
Number of situations
evaluated
Median (Q1, Q3) 5 (1, 8) 4 (2, 7) 8 (2, 14) 4 (2, 7)
Range [1-19] [1-53] [1-30] [1-53]
Inter/intra rater variability;
n(%)
16 (80) 0 (0) 0 (0) 16 (16)
Test(s) evaluated separately
to variability; n(%)
9 (45) 15 (20) 1 (17) 25 (25)
3.4.2 How are studies assessing biological variability of tests designed?
3.4.2.1 Participants included
Biological variability estimates are required for the population that will receive the test. Vari-
ability estimates in healthy participants may be useful if using a test to screen or developing
test reference ranges; however estimates are required for diseased participants if a test is used
for monitoring progressive or recurrent disease.
The participants included in many of the studies were healthy (n=48, 48%). A further 21
(21%) studies assessed mixed populations (with some participants healthy and some dis-
eased), and 22 (22%) studies tested only diseased participants. The healthy status of these
populations was rarely confirmed (n=3, 3%), for example in a study assessing high-sensitivity
troponin T62 healthy individuals were verified through physical examination, MRI analysis
including adenosine perfusion or dobutamine stress, lung function testing, and blood sample
testing, see Table 3.3.
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Differences between test types
Assessment of healthy participants was more common in studies of laboratory tests (n=43/75,
57%) than imaging (n=4/20, 20%) and physiological tests (n=1/6 (17%)). Use of a mixed
population of healthy and diseased participants was seen across studies of all test types
(imaging n= 6/20 (30%); laboratory n= 14/70 (19%); and physiological n=2/6 (33%)), see
Table 3.3.
Table 3.3: Populations studied in identified biological variability studies.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Population; n(%)
Healthy population 4 (20) 43 (57) 1 (17) 48 (48)
Confirmed healthy population 0 (0) 3 (4) 0 (0) 3 (3)
Diseased population 6 (30) 12 (16) 3 (50) 21 (21)
Mixed healthy/diseased
population
6 (30) 14 (19) 2 (33) 22 (22)
Unknown population 4 (20) 6 (8) 0 (0) 10 (10)
3.4.2.2 Sample size
Study sample sizes require adequate consideration to ensure estimates produced are mean-
ingful. Sample size calculations were rarely performed in the identified biological variability
studies (n=1, 1%), with studies routinely omitting justification of the number of participants
included. The single study reporting a sample size justification used a previous study esti-
mate of variability and calculated the number of repeated measures required for each subject
to allow for small differences to be detected.86 The smallest studies had four participants87,88
and the largest had 7,101 participants.89 Many of the studies identified had few participants
(see Figure 3.2); the median number of participants was 24 (Q1, Q3: 15, 40). Of the 99
studies reporting a sample size, eight (8%) had more than 100 participants and two (2%)
had more than 1,000. Fourteen (14%) studies had 10 participants or fewer; 27 (27%) studies
had between 11 and 20 participants; and, 24 (24%) studies had between 21 and 30 partici-
pants. Studies with larger sample sizes utilised routinely collected data rather than following
a prospective plan for data collection, see Box 3.2.
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Figure 3.2: Histogram of study sample sizes in identified biological variability studies (ex-
cluding the 8 studies with sample size exceeding 100).
Many studies also looked at subgroups of participants or of the tests performed, and the
sample sizes for these analyses were smaller with some studies using data from only two
participants to provide estimates of variability (median=11; Q1, Q3: 7, 15). The median
number of observations (calculated for studies where there are multiple measures taken for
each person and the number of measures was reported) obtained from each participant to
allow an estimate of within-individual variability to be made was 5 (Q1, Q3: 3, 10) and
ranged from 2 to 40. The median number of assessments was 2 (Q1, Q3: 2, 3). For inter-
intra reader studies the median number of readers was 2 (Q1, Q3: 2, 2) and median number
of duplicate reads was 2 (Q1, Q3: 1, 2), with the common design using two readers for each
image and one reader duplicating all readings, see Table 3.4.
Differences between test types
The median total sample size was similar across studies of all test types (imaging n=26;
laboratory n=24; and physiological n=16), and for the number of repeats for each participant
(imaging n=2; laboratory n=5; and physiological n=5). The number of analyses for each
measure is only given for laboratory tests, as for physiological and imaging tests it is not
possible to assess variability at this level. All inter-intra reader studies were of imaging tests,
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see Table 3.4.
Box 3.2: Biological variability studies with large sample sizes–utilising existing data collec-
tion.
Variability of spirometry in chronic obstructive pulmonary disease: results from two clin-
ical trials, by Herpel et al89 used data collected from two clinical trials (the National
Emphysema Treatment Trial, NETT, and the Lung Health study, LHS). This study had
a large sample size of 7,101. Trial participants had two spirometry measurements taken
during baseline study investigations and the data from this was analysed to assess vari-
ability of spirometry in measuring FEV (forced expiratory volume) and FVC (forced vital
capacity) in this study.
Use of observed within-person variation of cardiac troponin in emergency department
patients for determination of biological variation and percentage and absolute reference
change values, by Simpson et al90 used repeat blood sample assessments of Cardiac Tro-
ponin (hs-cTnI) taken routinely for patients presenting in the emergency department
evaluated for acute coronary syndrome. The analysis of these data to estimate variabil-
ity was for the 283 individuals with two test results that did not have acute cardiac
disease at the time of testing in the emergency department.
3.4.2.3 Study duration and time between repeats
The duration of studies and the timing of repeats indicate the resources required for these
studies and the typical design. The median total study duration was 5 weeks (Q1, Q3: 2,
14), ranging from just a single day to five years. The median time between test repeats for
the studies was 1 week (Q1, Q3: 1, 4), with the most frequent repeats within a single day
and the least frequent six monthly, see Table 3.4.
Differences between test types
Studies of imaging tests were carried out over a shorter testing period (median of 0.5 weeks)
compared to laboratory and physiological tests (median of 7 weeks and 5 weeks respectively).
For the eight imaging studies where the time between repeats was reported the interval
(median of 1.5 weeks) was similar to using a laboratory or physiological test (median of 1
week for both test types), see Table 3.4.
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Table 3.4: Sample size and study duration in identified biological variability studies.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Sample size
Total sample size
calculation/justification provided;
n(%)
1 (5) 0 (0) 0 (0) 1 (1)
Total study sample size (n=20) (n=73) (n=6) (n=99)
Median (Q1, Q3) 26 (10, 52) 24 (4, 39) 16 (10, 30) 24 (15, 40)
Range [7-77] [4-1103] [9-7101] [4-7101]
Multiple measures per person (n=7) (n=66) (n=5) (n=77)
Median (Q1, Q3) 2 (2, 2) 5 (4, 10) 5 (3, 21) 5 (3, 10)
Range [2-6] [2-23] [2-40] [2-40]
Total number of analyses for
each measure
- (n=31) - (n=31)
Median (Q1, Q3) 2 (2, 3) 2 (2, 3)
Range [2-4] [2-4]
Subgroup study sample size (n=2) (n=31) (n=2) (n=35)
Median (Q1, Q3) 13 (7, 19) 12 (6, 15) 10 (10, 10) 11 (7, 15)
Range [7-19] [2-118] [10-10] [2-118]
Subgroup multiple measures
per person
(n=1) (n=29) (n=1) (n=31)
Median (Q1, Q3) 2 (2, 2) 5 (4, 6) 3 (3, 3) 5 (4, 6)
Range [2-2] [2-11] [3-3] [2-11]
Subgroup number of analyses
for each measure
- (n=14) - (n=14)
Median (Q1, Q3) 2 (2, 2) 2 (2, 2)
Range [2-3] [2-3]
Number of readers (n=16) - - (n=16)
Median (Q1, Q3) 2 (2, 2) 2 (2, 2)
Range [1-3] [1-3]
Number of duplicate reads (n=15) - - (n=15)
Median (Q1, Q3) 2 (1, 2) 2 (1, 2)
Range [1-3] [1-3]
Study duration
Total duration (weeks) (n=12) (n=69) (n=3) (n=84)
Median (Q1, Q3) 0.5 (0.1, 2) 7 (3, 20) 5 (1, 8) 5 (2, 14)
Range [0.1-4] [0.1-260] [1-8] [0.1-260]
Overall time between repeats
(weeks)
(n=8) (n=64) (n=2) (n=74)
Median (Q1, Q3) 1.5 (0.5, 3) 1 (1, 4) 1 (0.1, 2) 1 (1, 4)
Range [0.1-4] [0.1-26] [0-2] [0.1-26]
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3.4.2.4 Variability assessed
The design of studies allows assessment of different types of variability, this information
suggests the estimates researchers focus on. Most studies provided estimates of between-
individual variation (n=60, 59%) and within-individual variation (n=72, 71%). For labo-
ratory tests the estimated variability between and within individuals was also accompanied
by the assessment of analytical/reassessment variability in 35 (35%) studies. Sixteen (16%)
studies (all of imaging tests) explored within and between reader variability.
For laboratory based studies an estimate of analytical variability is required to enable the
calculation of between and within-individual variation. For studies not directly estimating
the analytical variation, an estimate of analytical/reassessment variation obtained from a
source external to the study (usually another study or published work) or from the analysis
of control samples, is used to calculate the other levels of variability, this was reported in 24
(24%) studies and a further 14 (14%) studies did not explicitly report this but it is suspected,
see Box 3.3. In addition to analytical, within-individual and between-individual variability,
few studies also attempted to assess the variability at other levels, such as between centre
variability, see Table 3.5.
Differences between test types
For studies of laboratory tests the variability at the analytical, within-individual and between-
individual levels were commonly considered. Of the studies evaluating physiological tests,
one (17%) evaluated variability at the within-individual level. Studies of imaging tests were
mainly inter-intra reader studies and investigated the variability between and/or within read-
ers, see Table 3.5.
3.4.2.5 Pre-analytical variability reduced prior to assessment
Pre-analytical variability was not a focus of this review but there is an assumption this is mini-
mal; many studies (n=85, 84%) reported having undertaken measures to reduce pre-analytical
variability. Most laboratory based studies reported using the same staff, instruments and con-
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Box 3.3: Biological variability studies: Analysis where CVA is estimated separately to main
variability study.
Controls
Biological variation of seminal parameters in healthy subjects, by Alvarez et al,91 looked
at the variability of seminal parameters in 20 healthy donors. However, to estimate ana-
lytical variation quality control materials were assessed.
Sub-samples
Weekly and 90-minute biological variations in cardiac troponin T and cardiac troponin I
in hemodialysis patients and healthy controls, by Aakre et al,85 assessed the variability of
cardiac troponin T and cardiac troponin I for 19 heamodialysis patients and 20 healthy
controls. When assessing analytical variation, however, only half of the samples were se-
lected to be analysed in duplicate in order for this to be estimated, with random selection
stratified by sex.
External estimate
Intra-individual variation in creatinine and cystatin C, by Bandaranayake et al,92 as-
sessed the variability of creatinine and cystatin C in 10 healthy participants. Estimates
of CVA obtained from external sources were stated and used to calculate other variability
estimates.
Analytical CV measured in study but external estimate used
Biological variation of myeloperoxidase, by Dednam et al,93 investigated 12 healthy indi-
viduals to understand the biological variability of myeloperoxidase, a marker of coronary
artery disease. Using samples for the 12 participants an estimate of CVA was produced
of 4%. The authors state the estimate was ‘unrealistically low’ and an estimate of 8.4%
obtained from an external source was used in all calculations.
ditions for sample collection in addition to storage of samples and transport. For other types
of studies, there was also reason to believe pre-analytical variation had been minimised (at
various points) by ensuring participants were prepared for the test in a consistent way and
using the same staff to carry out the test. Studies where measurements were not taken in
controlled circumstances were unable to demonstrate minimising pre-analytical variation (for
example, one study estimated biological variability using test measures obtained in intensive
care unit patients)94.
Differences between test types
Pre-analytical variability was often minimised across studies of all test types (imaging n=15/20
(75%); laboratory n=65/75 (87%); and physiological n=5/6 (83%)), see Table 3.5.
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Table 3.5: Variability levels assessed in identified biological variability studies.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Variability level assessed;
n(%)
Between individuals 0 (0) 60 (80) 0 (0) 60 (59)
Within individuals 1 (5) 70 (93) 1 (17) 72 (71)
Analytical/reassessment 1 (5) 34 (45) 0 (0) 35 (35)
Analytical/reassessment
evaluation external to study
0 (0) 24 (32) 0 (0) 24 (24)
Suspected
Analytical/reassessment
evaluation external to study
0 (0) 14 (19) 0 (0) 14 (14)
Within/between readers 16 (80) 0 (0) 0 (0) 16 (80)
Pre-analytical variation minimised 15 (75) 65 (87) 5 (83) 85 (84)
3.4.2.6 Blinding
Blinding is important when measuring quantities multiple times, especially for inter-intra
reader studies. Only seven (7%) studies reported blinding of some type. Studies achieved
blinding by keeping assessors and participants from knowing previously observed measures.
Although blinding is not explicitly reported in the majority of studies, it may be in many
studies, the design (with all samples being tested in a single batch at a later date) means the
analysis of samples was blinded.
Differences between test types
The majority of the studies (6/7, 86%) reporting blinding were inter-intra variability studies
using imaging tests. Blinding is integral to inter-intra variability studies as these studies
assess variability between and within readers and so information on the interpretation of
other readers and previous reads by the same reader would be detrimental to the study. For
studies of laboratory (n=0/75, 0%) and physiological tests (n=1/6, 17%) blinding was often
not reported and may not be as critical.
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3.4.3 How are studies assessing biological variability of tests analysed?
3.4.3.1 Methods for analysis
The primary method for analysis was extracted to understand the approaches used. Eighty-
eight (87%) studies appeared to use ANOVA or random effects modelling for the primary
analyses; for 40 studies (40%) the method was not explicitly expressed but the results sug-
gested ANOVA or random effects modelling. The framework introduced by Fraser and Har-
ris35 was referred to in the methods section by 32 (32%) studies and referenced by a total of
52 (51%) studies. Few studies used alternative methods, such as assessing change in a test
value over time or comparing methods of measurement, with the alternative methods Bland-
Altman (n=7, 7%), Kappa (n=1, 1%), other modelling (n=1, 1%) and other methods (n=10,
10%). Other methods were Chi-squared tests, t-tests, correlation coefficients, Kruskal-Wallis
tests and Mann-Whitney U tests, see Table 3.6.
Differences between test types
Across the test types, the use of ANOVA or random effects modelling was common; the
issue of assumed ANOVA or random effects modelling due to lack of clarity was common
across the test types also. All studies identified as following and referencing the Fraser-
Harris framework were evaluating laboratory tests. The use of Bland-Altman methods was
more common in studies of imaging (n=4/20, 20%) and physiological tests (n=2/6, 33%),
rather than laboratory tests (n=1/75, 1%). Kappa was used as the primary analysis for one
(5%) study of an imaging test, see Table 3.6.
3.4.3.2 Normality checking and data transformation
As data transformations may impact the results obtained, the methods for normality check-
ing were noted to understand how frequently this is performed, the methods used and the
transformation approach taken. The normality of obtained data was tested in 38 (38%)
studies, the methods used were: the Shapiro-Wilk test (n=12, 12%), Kolmogorov-Smirnov
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test (n=10, 10%) or visual inspection (n=4, 4%), others stated assessing normality but did
not specify a method (n=18, 18%). Twenty-two (22%) studies reported log transforming the
data, with no alternative transformations reported. Of the 22 studies that log transformed
the data, 17 (77%) reported testing for normality, see Table 3.6.
Differences between test types
Testing for normality was often seen in the laboratory based studies and was not as common
in the non-laboratory test studies (laboratory n=34/75 (45%); imaging n=3/20 (15%); and
physiological n=1/6 (17%). For the laboratory based studies, 21 studies (28%) reported log-
transforming the data, whereas only one (5%) imaging study and none of the identified (0%)
physiological test studies reported log-transformation of data, see Table 3.6.
3.4.3.3 Outlier detection and removal
As outlier detection and removal may impact variability estimates, details of outlier detection
and removal processes were identified to understand the frequency of use and the procedures.
Outliers were tested for in many of the studies identified (n=25, 25%), all were laboratory
based studies. The methods for detecting outliers were mainly Cochran’s C test and Reed’s
criterion (n=9, 9% and n=5, 5%), although in some studies the methods used were not
specified (n=6, 6%). Other outlier detection methods reported were ±3SD, Dixon’s Q test,
Grubbs’ test, Tukey’s IQR rule and visual inspection. Outliers were reported to have been
excluded in 27 (27%) studies, see Table 3.6. Of the 27 studies with outliers excluded, 4
studies did not report testing for outliers this could be due to ‘error’ data that was removed
without formal testing or these studies may have neglected to report the method used for
testing only reporting the consequential changes to the data.
Differences between test types
Testing for normality was often seen in the laboratory based studies; however, this process
was not reported in the studies of imaging and physiological tests (laboratory n=25/75 (33%);
imaging n=0/20 (0%); and physiological n=0/6 (0%). For the studies of laboratory tests,
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27 (36%) reported removing outliers, whereas no studies of imaging and physiological tests
reported outlier removal, see Table 3.6.
3.4.4 How are studies assessing biological variability of tests reported?
3.4.4.1 Title identifies study as biological variability
Following from the items in the Bartlett checklist,69 the titles of studies were assessed to
identify if they clearly labelled studies as biological variability studies. Of the studies identi-
fied by the search, 67 (66%) studies were clearly studies of biological variation from the title
of the article, see Table 3.7.
Differences between test types
Studies of laboratory tests were more likely to clearly identify as studies of biological vari-
ability from the title (n=61/75, 81%) compared to studies of imaging (n=5/20, 25%) and
physiological tests (n=1/6, 17%). This is likely due to the uniform terminology used in stud-
ies of laboratory tests which is not present for studies of imaging and physiological tests, see
Table 3.7.
3.4.4.2 Clarity of design and methods
The clarity of reporting of the design and methods in the identified studies was variable. Stud-
ies did not adequately describe the: population (n=10, 10%), duration of study (n=17, 17%),
method of measuring assessment variability (analytical variability) externally to the study or
from control/spiked samples (n=14, 14%), method for analyses (n=40, 40%), normality test-
ing procedure (n=31, 31%), outlier detection procedure (n=10, 10%), justification/rationale
for the sample size (n=100, 99%), number of repeats (n=39, 39%), timing of repeats (n=42,
42%), and number of assessments duplicated (n=4, 4%), see Table 3.7.
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Table 3.6: Analysis methods of studies in identified biological variability studies.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Primary analyses methods;
n(%)
ANOVA reported 2 (10) 33 (44) 2 (33) 37 (37)
RE reported 5 (25) 7 (9) 1 (17) 13 (13)
ANOVA/ RE assumed 6 (30) 33 (44) 1 (17) 40 (40)
Total ANOVA/RE 12 (60) 73 (97) 3 (50) 88 (87)
Bland-Altman 4 (20) 1 (1) 2 (33) 7 (7)
Kappa 1 (5) 0 (0) 0 (0) 1 (1)
ROC analysis 0 (0) 0 (0) 0 (0) 0 (0)
Other modelling 0 (0) 1 (1) 0 (0) 1 (1)
Other methods 6 (30) 2 (3) 2 (33) 10 (10)
Secondary analyses methods;
n(%)
Bland-Altman 1 (5) 5 (7) 0 (0) 6 (6)
Kappa 0 (0) 0 (0) 0 (0) 0 (0)
ROC analysis 3 (15) 2 (3) 0 (0) 5 (5)
Other modelling 4 (20) 15 (20) 1 (17) 20 (20)
Other methods 6 (30) 41 (55) 0 (0) 47 (47)
Fraser framework for
analyses; n(%)
Methods of analyses followed 0 (0) 52 (69) 0 (0) 52 (52)
Reference to framework 0 (0) 32 (43) 0 (0) 32 (32)
Transformation of data; n(%)
Assessment of normality 3 (15) 34 (45) 1 (17) 38 (38)
Shapiro-Wilks test 2 (10) 9 (12) 1 (17) 12 (12)
Kolmogorov-Smirnov test 2 (10) 8 (11) 0 (0) 10 (10)
Visual/plot of data assessment 0 (5) 3 (4) 0 (0) 4 (4)
Unclear method 0 (0) 18 (24) 0 (0) 18 (18)
Data transformed 1 (5) 21 (28) 0 (0) 22 (22)
Log transformation 1 (5) 21 (28) 0 (0) 22 (22)
Other transformation 0 (0) 0 (0) 0 (0) 0 (0)
Unclear transformation 0 (0) 0 (0) 0 (0) 0 (0)
Outlier detection; n(%)
Outliers tested 0 (0) 25 (33) 0 (0) 25 (25)
Cochran C test 0 (0) 9 (12) 0 (0) 9 (9)
Reed’s test 0 (0) 5 (7) 0 (0) 5 (5)
Other outlier test 0 (0) 13 (17) 0 (0) 13 (13)
Unclear method 0 (0) 6 (8) 0 (0) 6 (6)
Outliers removed 0 (0) 27 (36) 0 (0) 27 (27)
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Differences between test types
The population was not specified in more studies of imaging tests (n=4/20, 20%) compared to
laboratory and physiological test studies. The issue of not reporting sample size justification
was seen across all test types with only one imaging study reporting details of sample size.
Details of study design (number of repeats, timing of repeats, duration of study and methods
of analysis) were insufficiently reported in similar percentages of studies across the test types,
see Table 3.7. The issue of measuring analytical variability outside of the study was unique
to studies of laboratory tests, as was the lack of clarity when explaining the methods for
testing for normality and outlier detection.
3.4.4.3 Biological variability estimates and uncertainty
The most common estimates reported were coefficients of variation (CV): estimates of as-
sessment (analytical) variability (n=35, 35%), within-individual variability (n=72, 71%) and
between-individual variability (n=60, 60%). Some studies reported analytical (2, 2%), within-
individual (6, 6%) and between-individual variability (5, 5%) as standard deviations. Total
variability was not often reported in these studies, along with total error and total impreci-
sion. Four (4%) studies reported an exact CV after using log transformed data (methods for
exact geometric CV after log transformation,59,60 assuming the distribution was log-normal,
were used). The RCV (or repeatability coefficient) was reported for 48 (48%) studies, 42
(42%) studies reported a symmetric RCV and 7 (7%) reported a non-symmetric RCV inter-
val (one study reported both,62 see Box 3.4). Forty-four (44%) studies reported the index
of individuality (II) and 18 (18%) reported an ICC/reliability parameter. Estimates of per-
centage agreement, Kappa, AUROC, Bland-Altman limits, regression coefficients and other
general estimates were seen in some studies, and were mainly produced for secondary aims
or aims unrelated to assessing test variability, see Table 3.7.
The uncertainty around these estimates provided was rarely described with few studies (n=18,
18%) providing confidence intervals for any of the biological variability measures or describing
the uncertainty in any other way (n=2, 2%), comparison to the reference range and caution
when interpreting the results. Some of the studies reviewed were considered to have reported
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Table 3.7: Reporting of identified biological variability studies.
Test type
Imaging Laboratory Physiological All
N 20 75 6 101
Identification; n(%)
Biological variation study clear
from title
5 (25) 61 (81) 1 (17) 67 (66)
Poor clarity (unclear or
insufficient detail); n(%)
Population 4 (20) 6 (8) 0 (0) 10 (10)
Sample size 19 (95) 75 (100) 6 (100) 100 (99)
Number of participants 0 (0) 2 (3) 0 (0) 2 (2)
Number of repeats 5 (25) 30 (40) 4 (67) 39 (39)
Timing of repeats 14 (70) 25 (33) 3 (50) 42 (42)
Number of assessments duplicated 1 (5) 3 (4) 0 (0) 4 (4)
Duration of study 8 (40) 6 (8) 3 (50) 17 (17)
Variability of measure of
assessment external to study
0 (0) 14 (19) 0 (0) 14 (14)
Methods for analyses 6 (30) 33 (44) 1 (17) 40 (40)
Normality procedure 0 (0) 31 (41) 0 (0) 31 (31)
Outlier procedure 0 (0) 10 (13) 0 (0) 10 (10)
Estimates; n(%)
Assessment (analytical) variability
CV
1 (5) 34 (45) 0 (0) 35 (35)
Within-individual variability CV 1 (5) 70 (93) 1 (17) 72 (71)
Between-individual variability CV 0 (0) 60 (80) 0 (0) 60 (59)
Assessment (analytical) variability
SD
0 (0) 2 (3) 0 (0) 2 (2)
Within-individual variability SD 0 (0) 5 (7) 1 (17) 6 (6)
Between-individual variability SD 0 (0) 5 (7) 0 (0) 5 (5)
Exact CV 0 (0) 4 (5) 0 (0) 4 (4)
RCV/repeatability coefficient 0 (0) 48 (64) 0 (0) 48 (48)
Symmetric RCV 0 (0) 42 (56) 0 (0) 42 (42)
Non-symmetric RCV 0 (0) 7 (9) 0 (0) 7 (7)
II 0 (0) 44 (59) 0 (0) 44 (44)
ICC/reliability parameter 10 (50) 6 (8) 2 (33) 1 (18)
Percentage agreement 0 (0) 0 (0) 1 (17) 1 (1)
Kappa 1 (5) 0 (0) 0 (0) 1 (1)
AUROC 1 (5) 1 (1) 0 (0) 2 (2)
Bland-Altman limits 3 (15) 2 (3) 2 (17) 7 (7)
Uncertainty; n(%)
Confidence intervals 12 (60) 4 (5) 2 (33) 18 (18)
Other measure of uncertainty 0 (0) 2 (3) 0 (0) 2 (2)
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Box 3.4: Biological variability studies: symmetric and non-symmetric RCVs.
Biological variation and reference change value of high-sensitivity troponin T in Healthy
Individuals during short and intermediate follow up periods, by Frankenstein et al,62
presented both symmetric and non-symmetric reference change values, for normal and
log-normal data respectively. For the estimate of hourly hsTnT using the E 170 assay
the RCV% for normal data was ±47 and for log-normal data was 64, -39.
the results well and are shown as exemplars, see Box 3.5.
Differences between test types
Estimates of CV were almost exclusively reported in studies of laboratory tests, with one
(5%) study of an imaging test and one (17%) study of a physiological test reporting the CVs.
RCVs and IIs were only reported in studies of laboratory tests. ICC measures were used in
10 (50%) studies of imaging tests, 2 (33%) studies of physiological tests and 6 studies (8%)
of laboratory tests. The use of confidence intervals was seen more frequently in studies of
imaging tests (n=12, 60%) and physiological tests (n=2, 33%) compared with laboratory
tests (n=4, 5%), see Table 3.7.
Box 3.5: Biological variability studies: reporting exemplars.
Clarity of external analytical CV estimate
Intra-individual variation in creatinine and cystatin C, by Bandaranayake et al,92 assessed
the variability of creatinine and cystatin C in 10 healthy participants, with variability
estimates calculated using CVA obtained from external sources. This study clearly ex-
pressed external estimates of CVA would be used in the materials and methods section
of the article and stated the estimates of CVA for both creatinine and cystatin C. Many
other studies do not explicitly inform readers that external estimates of CVA are used
and do not give the value of the CVA estimate.
Use of confidence intervals
Within-subject biological variation of glucose and HbA1c in healthy persons and in type
1 diabetes patients, by Carlsen et al,95 was one of the few studies reviewed that pro-
vided any indication of the precision of the estimates generated by the study. This study
reported 95% confidence intervals, generated using the methods of Burdick and Gray-
bill.34 Demonstrating precision of estimates is vital to allow the estimates presented to
be appropriately interpreted and used further.
It is also noted, many of the studies published in laboratory clinical medicine journals were
very short articles, and the low word count available may contribute to lack of clarity.
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3.4.5 What are the differences between studies assessing biological vari-
ability of laboratory, imaging and physiological tests?
There were few studies assessing physiological (n=6, 6%) and imaging test (n=20, 20%)
identified by the review, with the majority of studies (n=75, 74%) assessing laboratory tests.
Biological variability studies appear to be defined for laboratory based studies (n=61/75,
81%) but not for imaging and physiological test studies, (n=5/20 (25%) and n=1/6 (17%)
refer to biological variation in the study title respectively). In the previous sections detailed
comparisons between test types were made; key issues from these analyses are presented
here.
Many of the studies evaluating laboratory based tests assessed only healthy participants
(n=43/75, 57%), and this was less common for physiological and imaging tests (n=5/26,
19%).
With 52 of the 74 (69%) studies assessing laboratory tests referencing or following the frame-
work of design and analysis introduced by Fraser and Harris, the majority of laboratory test
studies used similar study designs and methods. Many of the studies assessing laboratory
tests, tested to identify non-normality of data (n=34/75, 45%) and outliers (n=25/75, 33%),
whereas this was not as common in the non-laboratory test studies (n=4/26 (15%) and 0/26,
(0%) for normality checking and outlier detection respectively). Sample sizes were generally
small, with only a few exceptions.
The quality of reporting appeared similar across the studies of different test types. Biologi-
cal variability studies of laboratory tests reported CVs (n=73/75, 93%), RCVs (and n=48,
64%) and II (n=44, 59%). The studies assessing non-laboratory tests mostly reported ICCs
(n=12/26, 46%) and other measures (percentage agreement, Kappa, AUROC and Bland-
Altman limits), only one study (n=1/26, 4%) reported CVA and two studies (n=2/26, 8%)
reported CVI . Giving an estimate of uncertainty by producing confidence intervals was very
rare in the laboratory test studies (n=4/75, 5%) but more common in imaging and physio-
logical test studies (n=14/26, 54%).
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3.5 Discussion
3.5.1 What is the current state of the field? What are the aims of these
studies and in which tests and test areas are they seen?
It was not easy to identify studies of biological variability, suggesting these studies are not
often performed and/or published. A paucity of biological variability studies would be con-
cerning given the importance of these studies, not just for planning monitoring strategies for
patients with potential disease progression and recurrence but also for selecting tests to be
evaluated for accuracy, or conversely identifying tests that are not fit for purpose and should
not be further investigated.
The review mainly identified studies investigating the variability of clinical laboratory tests.
This may suggest studies of biological variability are more common in this area or it may
be the searches used identified more studies of clinical laboratory tests than imaging and
physiological tests.
Most studies did not aim to assess the variability of a single test situation but multiple tests,
testing populations, measurements from tests, or time points.
3.5.2 How are studies assessing biological variability of tests designed?
The populations assessed in most of the identified studies were partly or fully formed of
healthy individuals. This practice is problematic as test performance and variability may be
different in non-healthy/diseased populations, in whom the tests will be used for diagnostic
and monitoring purposes, compared to healthy populations. However, knowledge of variabil-
ity of tests in healthy populations may be beneficial for screening and developing reference
ranges.
Sample size justification was found to be absent in almost all studies identified; this is likely
due to limited funding and the burden of repeated testing on participants, meaning only a
small sample can be achieved. The recent work of Røraas and colleagues43 may help improve
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the planning of sample sizes for studies in the future and additional guidance may also be
required to enable researchers to appropriately plan studies.
The relatively short duration of studies and fast rate of retesting is to be expected as measures
should be taken over a stable period of disease. The small number of repeats generally seen
in these biological variability studies is also likely linked to the burden on patients and the
need to test within a stable period of disease. Guidance on the number of repeats necessary
is required to help researchers plan these studies.
The levels of variability assessed were mainly within-individual variability and between-
individual variability. The studies where analytical variability was estimated using control
samples or an estimate from a separate source was used are concerning as this estimate of
variability may not be appropriate. Encouragingly, reduction of pre-analytical variability
prior to test assessment was seen in many of the studies.
Blinding is not explicitly reported in the majority of laboratory based studies, this is po-
tentially due to blinding of assessors (laboratory workers) being assumed as the analysis of
samples is performed separately without the input of clinicians or participants. The issue
of blinding is much more important in the imaging test studies, especially those where inter
and intra rater reliability is assessed as ideally observers would be blinded to the true condi-
tion of the participant and also to the measurement(s) obtained from the other observer(s).
Blinding has perhaps been used in more of these studies but poor reporting means this is not
clear.
3.5.3 How are studies assessing biological variability of tests analysed?
Methods for analyses were mainly ANOVA and random effects models. However, for some
studies the methods were not clear and it was assumed ANOVA or random effects modelling
methods had been used, based on the results reported. For the biological variability studies
of laboratory tests the ANOVA and random effects modelling methods are likely used as the
majority of studies followed the methods of Fraser and Harris;35 studies of other test types
more often used alternative methods.
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The practice of transforming data and, identifying and removing outliers was used in many
of the studies identified; again this is likely due to the framework of Fraser and Harris35 and
was mainly seen in studies of laboratory tests.
Due to the framework, it is assumed some studies of laboratory tests may have transformed
the data, or at least tested the normality of the data, but not reported this explicitly; whereas,
this is less likely for imaging and physiological test studies. Some studies may also be log
transforming data as this simplifies calculations (see Chapter 2), rather than for distribu-
tional benefits. It is also anticipated (due to the framework) that although some studies do
not directly report the identification of outliers and consequent removal this has been con-
sidered; however, the non-laboratory test studies may not consider outliers when analysing
the data.
3.5.4 How are studies assessing biological variability of tests reported?
Studies of laboratory tests may have been identified more easily as the clinical laboratory
community have defined terminology for these studies. Identification of biological variability
studies was difficult, and the established database for laboratory tests provided most of the
studies in the review. Correct terminology and labelling of these studies would make it easier
for biological variability studies to be identified.
The clarity of design and methods for analysis was variable for the identified studies with
studies lacking detail of: justification of sample size, number of measurements and timing of
repeats and the methods for analysis. In some cases the detail regarding timing and frequency
of measures is missing due to the ad hoc nature of taking measurements, for example the
studies taking advantage of routinely collected data meaning measurements are made as and
when standard practice dictates. In general, all aspects of reporting for these studies could
be improved. The Bartlett checklist69 and the exemplars given here will hopefully provide
authors with guidance to improve the reporting of these studies. It is also noted many of the
studies published in laboratory clinical medicine journals were very short articles, and the
low word count available may contribute to lack of clarity.
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Often biological variability estimates are not given with corresponding uncertainty estimates.
Again the work of Røraas and colleagues43 will hopefully give researchers guidance and lead
to improvements.
3.5.5 What are the differences between studies assessing biological vari-
ability of laboratory, imaging and physiological tests?
There are clear differences between the studies of biological variability for laboratory tests
compared with imaging and physiological tests. The laboratory tests have a set framework,
whereas the other test types vary more. The imaging studies are also different as the purpose
is often to explore inter and intra reader variability. Studies of different test types lend
themselves to assessment of different levels of variability; some test types do not allow for
assessment of analytical variability.
Issues with not justifying sample size and lack of clarity for reporting were seen in studies
of all test types; however, studies of physiological and imaging tests more often reported
confidence intervals for estimates.
Testing for outliers was identified as a common procedure in studies of laboratory tests but
not for studies of physiological and imaging tests.
3.5.6 Limitations
This review was not a systematic review. There will be studies of biological variability not
captured by this review and it is likely the searches used identified studies of better quality
(due to the journals chosen for the targeted searches and selection of studies that have been
previously assessed for inclusion in the Westgard QC database). Only articles written in
English were included in the review and a single reviewer extracted information from the
studies. The review only considered published work, which again may be of better quality
than unpublished work. There is no way of knowing if the searches developed capture all
studies meeting the criteria.
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The criteria for inclusion in the review meant that studies using calibrated and spiked samples
were not included. These studies may be beneficial in early test development and evaluation
stages but cannot be used to estimate test variability for patients. The searches used were
limited and could be further developed to detect a broader range of studies.
The purpose of this review was to identify methodology issues for biological variability studies
with articles identified to understand these issues rather than provide an exhaustive sample
of studies.
3.5.7 Further work
This review could be strengthened by improved searches, possibly including key estimates
such as CV, II, RCV and ICC. This review has highlighted the need for guidance in certain
areas. Some of these areas (sample size, uncertainty of estimates and general reporting)
have already been identified and there is guidance for researchers.22,43,77 As the sample size
issue is vital, additional work in this area would be beneficial. Also, the impact of data
transformations and outlier identification and removal requires further investigation.
3.6 Conclusions
Due to a lack of specific search terms for biological variability studies, studies were difficult to
detect. Search terms should be developed for these studies and test developers, researchers
and funders need to be aware of the need for variability estimates and the importance of
biological variability studies.
The design, methods of analysis and clarity of reporting for biological variability studies
can be improved. Primarily, methods for sample size calculation are required as this was
identified as a major deficit of the identified studies. In addition to the work of Røraas et
al,43 guidance is required for sample size justification. Further work investigating sample size
for biological variability studies has been conducted, see Chapter 5. The population assessed
in these studies needs to be chosen considering the likely use of the test. Studies should be
86
3.6. Conclusions
designed to evaluate all levels of variability and any subgroups should be pre-specified, also
considering sample size.
The practice of outlier detection and deletion, and also data transformation is apparent. The
impact of data transformation and outlier detection requires investigation, as these processes
may be eliminating the variability the studies are aiming to estimate. These procedures were
investigated by carrying out empirical analyses, see Chapter 4, and also the impact of these
methods, see Chapter 6.
The Fraser-Harris framework requires updating. The design of studies evaluating variability
should be fully considered, specifically the sample size (especially if using subgroup analyses),
populations evaluated and levels of variability assessed. The methods for analysis should not
be so prescriptive, allowing assessment of normality and outliers in a tailored way for each
study rather than following a method that may not be appropriate.
The reporting of biological variability studies needs to be detailed and transparent. With
the adoption of the Bartlett checklist,69 this improvement can be achieved. The onus for
detailed and transparent reporting should also be with journals, with the word limits for
reporting allowing the necessary detail. It should be required that estimates are reported
with confidence intervals.
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Chapter 4
Analysis of biological variability
studies: a case study evaluating
glomerular filtration rate (GFR)
This work has, in part, been submitted for publication:
Rowe C, Sitch A, Barratt J, Brettell E, Cockwell P, Dalton N, Deeks J, Eaglestone G,
Pellatt-Higgins T, Kalra P, Khunti K, Loud F, Morris F, Ottridge R, Stevens P, Sharpe C,
Sutton A, Taal M, Lamb E. Biological variation of measured and estimated glomerular
filtration rate (GFR) in patients with chronic kidney disease: the eGFR-C Study. Kidney
International (in press).
Summary
This chapter presents an analysis of markers used in a study of glomerular filtration rate of
patients with chronic kidney disease (CKD), the eGFR-C study. The methods for analysing
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biological variability were described in Chapter 2.
Analysis of the eGFR-C study data using the methods identified in the review of biological
variability studies (see Chapters 2 and 3), highlighted the differences when using normality
checks and transformation, outlier detection and removal, and the use of ‘exact’ measures
and asymmetric reference change values.
There were differences in results when data were analysed with and without transformation–
with some results after log transformation requiring alternative methods. When outliers were
detected and removed the estimates of variability at each level decreased, especially at the
within and between-individual levels.
4.1 Introduction
Glomerular filtration rate (GFR) is the primary method of detecting chronic kidney dis-
ease (CKD) with the reference standard method for measuring GFR being iohexol clear-
ance,19 a method which is time consuming and unreasonable to undertake for the purposes
of disease detection, staging and monitoring of progression. There are also methods for
estimating GFR. Estimated GFR, or eGFR, can be calculated using equations requiring
characteristics of the patient (age, gender and ethnicity) along with serum creatinine and
cystatin C levels (MDRDcreatinine,
96 CKD-EPIcreatinine,
97 CKD-EPICystatin C,
98 and CKD-
EPICystatin C creatinine
98). Estimated GFR is often used in clinical practice as the measures
required to calculate eGFR using the equations are easier to obtain.
The eGFR-C study19 is a prospective longitudinal study designed to investigate the accuracy
of the various eGFR equations for the purposes of diagnosis and monitoring of patients with
CKD. The eGFR-C study also has a sub-study component where the biological variation of
reference (iohexol) GFR, creatinine, and cystatin C (along with the eGFR measures calculated
from their use) is assessed, in a population known to have CKD.
Methods for the design and analysis of biological variability studies are sparse with many
laboratory based studies using the framework introduced by Fraser and Harris in 1989.35
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A review of biological variability studies, see Chapter 3, showed studies of laboratory tests
generally adhered to the same methods for analysis; with procedures for evaluating normality
of data with data transformations if required, outlier detection with data deletion if necessary
and one way analysis of variance techniques used to estimate variability at each level, generally
expressed as coefficients of variation (CV) and reference change values (RCV). Using the
standard methods for assessing biological variability, data obtained from the eGFR-C sub-
study can be analysed to not only produce estimates for the iohexol, creatinine and Cystatin
C measures but sensitivity analyses allow the standard methods to be assessed using this
example; specifically the impact of data transformation and outlier detection were explored
with the impact of this methodology evaluated.
4.2 Aims and objectives
There were two primary aims. Firstly, to present a standard analysis of the eGFR-C study
and obtain biological variability estimates. Secondly, the impact of certain elements of the
standard analysis procedure were further evaluated, namely: data transformation and outlier
detection. The method for sample size justification was investigated also.
4.3 Methods
For full details of the eGFR-C study see the published protocol by Lamb et al.19
4.3.1 Eligibility criteria
To be eligible to enter the study, participants were required to be:
• aged 18 years or older;
• in stage 3 CKD (GFR 30-59 mL/min/1.73 m2), diagnosed using eGFR (with at least
two consecutive test results in this range at least 90 days apart and the most recent
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test in the last 12 months);
• and, treated in primary or secondary care.
4.3.2 Study design
In one study centre, twenty people with stage 3 CKD were recruited to have four iohexol
reference measures of GFR along with creatinine and Cystatin C at weekly intervals. In
practice, the creatinine and Cystatin C measures were used to estimate GFR using the four
estimating equations. Measurements for each individual were taken at the same time of the
day (morning), the same day of the week and after participants had consumed only a light
breakfast, see Figure 4.1
Participant 1
Time 1
Time 2
Time 3
Time 4
Assessment 1
Assessment 2
Assessment 1
Assessment 2
Assessment 1
Assessment 2
Assessment 1
Assessment 2
Participant 20
Time 1
Time 2
Time 3
Time 4
Assessment 1
Assessment 2
Assessment 1
Assessment 2
Assessment 1
Assessment 2
Assessment 1
Assessment 2
Figure 4.1: eGFR-C biological variability sub-study design.
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4.3.3 Sample size
The sample size for the eGFR-C study uses an estimate of precision for within-individual
CV. CVI was estimated to be 10%. With twenty participants recruited and tested on four
occasions an approximate 95% confidence interval for CVI has limits ±2% absolute. This
calculation assumes data are log-normally distributed and uses a Chi-squared distribution
for the calculation of the confidence interval for CVI .
4.4 Analysis
The analyses will follow the framework introduced by Fraser and Harris,35 see Box 4.1 and
Chapter 2 for further detail. Analyses will also be conducted to investigate the impact
of certain elements of the methodology, specifically data transformation and outlier detec-
tion.
Box 4.1: Fraser Harris framework.
Normality
• Data is checked for normality using the Shapiro Wilk test, with the test used to
evaluate the distribution of all data points and the distribution of measurements
for each individual separately.
• If the data is non-normal for all measurements or most individuals separately, data
transformation should be considered.
Outliers
• Firstly Cochran’s C test is used to identify outlying measures at the level of dupli-
cate assessments with those identified removed.
• Secondly, Cochran’s C test is used to identify outliers at the within-individual level,
with individuals detected having the extreme duplicate measures removed.
• Thirdly, Reed’s test is used to identify outlying individual means with all measures
for detected individuals removed.
Pre-analytical variability was kept to a minimum by standardising test procedures and was
not considered when evaluating the results. Analytical variability, within-individual vari-
ability and between-individual variability were assessed by allowing for multiple observations
within individual and multiple assessments of each observation. A linear mixed model was
fitted. The model was a null model with random effects for individuals and observation points
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within each individual. All analyses used the ‘xtmixed’ command in Stata version 15, with
restricted estimation of maximum likelihood (REML).
The variability estimates at each level were expressed as coefficients of variation (CV), refer-
ence change values (RCV), index of individuality (II) and interclass cluster correlation (ICC).
Estimates were presented with corresponding 95% confidence intervals (calculated using the
methods of Budick and Graybill),34 where applicable.
4.4.1 Sensitivity analyses
To evaluate the standard methods for analysis of laboratory tests a series of sensitivity anal-
yses were performed, assessing the impact of the methods for normality testing and data
transformation, outlier detection and removal, and reporting of CVs. Combinations of the
following analyses were investigated:
• non-transformed and transformed data;
• no outlier detection, Fraser-Harris method for outlier detection and, Cochran C test
and Reed’s criterion for outlier detection (see §6.3.2);
• and, reporting of CVs and RCVs for log-transformed data.
The Fraser-Harris method uses the Cochran C test and Reed’s criterion for detection of
outliers, see Box 4.1. The Cochran C test requires all measurements (for an individual) to
be removed if detected as an outlier when assessing variances for individuals. The method
introduced by Fraser and Harris suggested that only a set of outlying duplicate results for
detected individuals be removed. The Cochran C test also requires repeated use after deleting
identified values until no additional outliers are detected,99 which is not specified by the
Fraser-Harris method.
Additionally, the method for calculation of geometric CV following log transformation was
investigated using a ‘raw’ calculation of geometric CV(%) (σ × 100) and ‘exact’ calculations
of CV (formula for exact geometric CV(%):
√
(exp(σ2)− 1)× 100,59,60 and alternative exact
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geometric CV(%): (exp(σ)−1)×100)61. The calculation of symmetric and asymmetric RCVs
was also considered (RCVpos = [exp(Z ×
√
2τ)− 1]× 100, and RCVneg = [exp(−Z ×
√
2τ)−
1] × 100, where τ =
√
(ln(CV 2A+I + 1)), Z is selected from the normal distribution (usually
1.96) and CVA+I the total imprecision CVA+I =
√
(CV 2A + CV
2
I ))
62,63, see Chapter 2.
4.5 Results
4.5.1 Study population and completeness of data
Twenty participants were recruited; ten were male and ten female. The median (Q1, Q3)
age (years) was 71 (64, 75) and the median (Q1, Q3) BMI (kg/m2) was 28.2 (25.0, 30.2). All
participants were of White/Caucasian ethnicity (see Table 4.1).
Table 4.1: Characteristics of patients recruited to eGFR-C biological variability sub-study.
Characteristic Summary
N 20
Gender (male); n (%) 10 (50)
Age (years); median (Q1, Q3) 71 (64, 75)
BMI (kg/m2); median (Q1, Q3) 28.2 (25, 30.2)
Of the twenty participants, 19 obtained results in duplicate at all four weekly assessments for
all measures, giving eight measures per test per participant. One participant did not attend
the fourth week of testing and only had six available results for each test measure (duplicate
assessments at three time points). The total available data were 158 measurements from 20
patients for each measure.
All data were considered prior to analysis. For the iohexol measure, clinical colleagues ob-
served eight measurements (four duplicated results for four patients) were the result of the
dose not being fully administered or being subcutaneously administered; these eight mea-
surements were removed.
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4.5.2 Analyses using standard laboratory based biological variability meth-
ods
4.5.2.1 Normality testing and data transformation
Firstly data was assessed for normality. Shapiro-Wilk tests suggested iohexol, creatinine
and Cystatin C data were not normally distributed (p-values 0.0004, 0.0010 and 0.0117
respectively, see Table 4.2). When performing tests on the data for each individual separately,
for the iohexol measures only one individual had a significant p-value at the 5% level and
for creatinine and Cystatin C data two individuals had significant p-values at the 5% level,
indicating non-normality.
After log transformation, the p-value from the Shapiro-Wilk test for iohexol measures was
0.1123, suggesting no evidence of non-normality; however, for the log transformed creatinine
and Cystatin C values the Shapiro-Wilk test p-values are 0.0106 and 0.0003 respectively,
suggesting the log transformed data are not normally distributed. When performing tests
on the log transformed data for each individual separately, for the iohexol and Cystatin C
measures, the test for one individual produced a significant p-value at the 5% level and for
the creatinine data tests for two individuals produced significant p-values at the 5% level,
indicating non-normality.
From visual inspection of histograms (see Figure 4.2) there was little difference between the
distribution of the original values and the log transformed data. As the normality of all
data was marginally improved and there is a benefit regarding the calculation when using log
transformed data (calculation of geometric CVs, see Chapter 2 for more details), use of log
transformed data was the preferred approach for these analyses. This approach was supported
by clinical chemist colleagues and was considered typical decision making for analysis of this
type of study.
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Figure 4.2: Histogram of original and log transformed measures.
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4.5.2.2 Outlier detection and data exclusion
Using the log-transformed data and the method for outlier detection suggested by Fraser and
Harris, for the iohexol, creatinine and Cystatin C analyses eight, four and six measurements
were removed respectively, see Table 4.3.
Table 4.3: Analysis of the eGFR-C biological variability study–outlier detection using the
Fraser-Harris method.
Outlier Detection Iohexol Creatinine Cystatin C
Measurements 142 154 152
Participants 20 20 20
Mean (SD) 3.9 (0.2) 4.8 (0.2) 0.5 (0.2)
Median (IQR) 3.9 (3.7, 4.0) 4.8 (4.7, 5.0) 0.5 (0.4, 0.6)
Cochran C duplicates
Measurements 6 4 6
Duplicates 3 2 3
Participants 3 2 3
Cochran C individuals
Measurements 2 0 0
Duplicates 1 0 0
Participants 1 0 0
Reed’s test
Measurements 0 0 0
Duplicates 0 0 0
Participants 0 0 0
Total outliers 8 4 6
For the iohexol analysis, six measurements were removed after the first use of the Cochran
C test (at the level of duplicate measurements within individuals) and two measurements for
the second use of the Cochran C test (at the level of individuals within the whole group).
The analysis of creatinine removed four measurements after the first use of the Cochran C
test; analysis of Cystatin values removed six measurements after the first use of the Cochran
C test. For creatinine and Cystatin C analyses, the second use of the Cochran C test led to
no outlier detection. For all measures, Reed’s test revealed no outliers for exclusion.
4.5.2.3 Analysis of variance
The analysis of iohexol results following the use of the Fraser-Harris method allowed the
exact geometric coefficients of variation (expressed as percentage) and corresponding 95%
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confidence intervals to be calculated. The coefficient of variation at the analytical level, CVA
was 2.22 (95% CI: 1.92, 2.63); at the within-individual level, CVI was 6.67 (5.60, 8.20); and
at the between-individual level, CVG was 16.61 (12.43, 24.53). Positive and negative RCV
bounds were calculated, and are again expressed as percentages; the positive RCV bound was
21.49 and the negative was -17.69, the index of individuality was 0.42, see Table 4.4.
Table 4.4: Analysis of the eGFR-C biological variability study–results using the Fraser-Harris
method.
Test Iohexol Creatinine Cystatin C
Measurements 142 154 152
Participant 20 20 20
Raw geometric CVsa
CVA 2.22 (1.92, 2.63) 0.66 (0.57, 0.78) 0.56 (0.48, 0.66)
CVI 6.66 (5.59, 8.19) 4.34 (3.68, 5.30) 3.99 (3.38, 4.86)
CVG 16.61 (12.43, 24.53) 19.79 (14.98, 29.00) 18.86 (14.28, 27.63)
CVTOT 18.04 (14.27, 25.53) 20.28 (15.62, 29.34) 19.29 (14.84, 27.92)
Exact geometric
CVsb
CVA (95% CI) 2.22 (1.92, 2.63) 0.66 (0.57, 0.78) 0.56 (0.48, 0.66)
CVI (95% CI) 6.67 (5.60, 8.20) 4.35 (3.68, 5.30) 3.99 (3.38, 4.87)
CVG (95% CI) 16.73 (12.48, 24.91) 19.99 (15.07, 29.62) 19.03 (14.36, 28.17)
CVTOT (95% CI) 18.18 (14.34, 25.95) 20.49 (15.71, 29.98) 19.47 (14.92, 28.48)
Alternative
geometric CVsc
CVA (95% CI) 2.25 (1.94, 2.66) 0.67 (0.58, 0.79) 0.56 (0.48, 0.66)
CVI (95% CI) 6.89 (5.75, 8.53) 4.44 (3.75, 5.44) 4.07 (3.44, 4.98)
CVG (95% CI) 18.07 (13.23, 27.80) 21.89 (16.17, 33.65) 20.76 (15.35, 31.82)
CVTOT (95% CI) 19.77 (15.34, 29.09) 22.48 (16.90, 34.09) 21.27 (16.00, 32.21)
IId 0.42/0.42/0.40 0.22/0.22/0.21 0.21/0.21/0.20
RCV positived 21.47/21.49/22.22 12.95/12.95/13.25 11.81/11.81/12.06
RCV negatived -17.67/-17.69/-18.18 -11.46/-11.47/-11.70 -10.56/-10.56/-10.76
SDA (95% CI) 0.022 (0.019, 0.026) 0.007 (0.006, 0.008) 0.006 (0.005, 0.007)
SDI (95% CI) 0.067 (0.056, 0.082) 0.043 (0.037, 0.053) 0.040 (0.034, 0.049)
SDG (95% CI) 0.166 (0.124, 0.245) 0.193 (0.146, 0.283) 0.189 (0.143, 0.276)
SDTOT (95% CI) 0.180 (0.143, 0.255) 0.198 (0.152, 0.286) 0.193 (0.148, 0.279)
ICCA 0.015 0.001 0.001
ICCI 0.137 0.046 0.043
ICCG 0.848 0.953 0.956
All CV and RCV values as expressed as percentages. aσ × 100; b√(exp(σ2)− 1)× 100;
c(exp(σ)− 1)× 100; d calculated using raw CV/ exact geometric CV/ alternative geometric
CVs. 95% confidence intervals were calculated using methods of Burdick and Graybill.34
When analysing the creatinine results using the Fraser-Harris method, CVA, CVI and CVG
were 0.66 (0.57, 0.78), 4.35 (3.68, 5.30) and 19.79 (14.98, 29.00) respectively. The positive
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and negative RCV bounds were 12.95 and -11.47, and II was 0.22. Finally for Cystatin C, the
analysis using the Fraser-Harris method provided estimates of CVA, CVI and CVG of 0.56
(0.48, 0.66), 3.99 (3.38, 4.87) and 18.86 (14.28, 27.63) respectively. The positive and negative
RCV bounds were 11.81 and -10.56, and II was 0.21.
4.5.3 Sample size
The sample size calculation was based on precision of the estimate of CVI . The estimate of
CVI was 10% whereas estimates obtained were lower and the confidence intervals for these
estimates were within the absolute ±2% targeted.
4.5.4 Sensitivity analyses to investigate the impact of methods of analysing
standard laboratory based biological variability methods
4.5.4.1 Normality testing and data transformation
When using the transformed and non-transformed data, outliers detected and excluded were
the same measurements for analyses of iohexol and creatinine for both the Fraser-Harris
method (eight iohexol measurements removed and four creatinine measurements removed)
and complete outlier detection (12 iohexol measurements removed and four creatinine mea-
surements removed), see appendix Table B.1 and Table B.2. Outlier detection for Cystatin
C differed when using log transformed and non-transformed data; when analysing the log-
transformed data fewer measurements were removed for both the Fraser-Harris method (six
compared with eight) and complete outlier detection (six compared with 22), see appendix
Table B.3.
Analyses of log-transformed data generally gave higher CV estimates compared with non-
transformed data, with the exceptions of iohexol CVG and creatinine CVA, see Table 4.5-Table
4.7. It should be noted estimates obtained after log-transformation are geometric CVs.
The reference change values from the analyses of log transformed data are asymmetric (dif-
101
Chapter 4. Analysis of biological variability studies
T
a
b
le
4
.5
:
A
n
a
ly
sis
o
f
th
e
eG
F
R
-C
b
iological
variab
ility
stu
d
y
–resu
lts
of
Ioh
ex
ol
an
aly
ses.
N
o
t
tra
n
sfo
rm
e
d
T
ra
n
sfo
rm
e
d
O
u
tlie
r
D
e
te
c
tio
n
N
o
n
e
F
ra
se
r-H
a
rris
m
e
th
o
d
C
o
ch
ra
n
C
te
st
&
R
e
e
d
’s
C
rite
rio
n
N
o
n
e
F
ra
se
r-H
a
rris
m
e
th
o
d
C
o
ch
ra
n
C
te
st
&
R
e
e
d
’s
C
rite
rio
n
D
a
ta
rem
ov
ed
0
/
1
5
0
8
/
1
5
0
1
2
/
1
5
0
0
/
1
5
0
8
/
1
5
0
1
2
/
1
5
0
R
aw
C
V
s
a
C
V
A
(9
5
%
C
I)
2
.1
6
2
.0
5
1
.8
5
2
.3
9
(2
.0
7
,
2
.8
2
)
2
.2
2
(1
.9
2
,
2
.6
3
)
1
.9
9
(1
.7
3
,
2
.3
6
)
C
V
I
(9
5
%
C
I)
6
.3
4
6
.1
3
5
.4
7
6
.9
1
(5
.7
9
,
8
.4
9
)
6
.6
6
(5
.5
9
,
8
.1
9
)
5
.9
4
(4
.9
8
,
7
.3
0
)
C
V
G
(9
5
%
C
I)
1
7
.0
5
1
7
.3
3
1
7
.6
8
1
6
.3
0
(1
2
.1
7
,
2
4
.1
1
)
1
6
.6
1
(1
2
.4
3
,
2
4
.5
3
)
1
7
.0
3
(1
2
.7
9
,
2
5
.0
8
)
C
V
T
O
T
(9
5
%
C
I)
1
8
.3
1
1
8
.5
0
1
8
.5
9
1
7
.8
7
(1
4
.1
9
,
2
5
.2
1
)
1
8
.0
4
(1
4
.2
7
,
2
5
.5
3
)
1
8
.1
5
(1
4
.2
4
,
2
5
.8
6
)
E
x
a
ct
g
eo
m
etric
C
V
s
b
C
V
A
(9
5
%
C
I)
2
.3
9
(2
.0
7
,
2
.8
2
)
2
.2
2
(1
.9
2
,
2
.6
3
)
1
.9
9
(1
.7
3
,
2
.3
6
)
C
V
I
(9
5
%
C
I)
6
.9
2
(5
.8
0
,
8
.5
1
)
6
.6
7
(5
.6
0
,
8
.2
0
)
5
.9
4
(4
.9
9
,
7
.3
1
)
C
V
G
(9
5
%
C
I)
1
6
.4
1
(1
2
.2
2
,
2
4
.4
6
)
1
6
.7
3
(1
2
.4
8
,
2
4
.9
1
)
1
7
.1
5
(1
2
.8
5
,
2
5
.4
8
)
C
V
T
O
T
(9
5
%
C
I)
1
8
.0
1
(1
4
.2
6
,
2
5
.6
1
)
1
8
.1
8
(1
4
.3
4
,
2
5
.9
5
)
1
8
.3
0
(1
4
.3
1
,
2
6
.3
0
)
A
ltern
a
tiv
e
g
eo
m
etric
C
V
s
c
C
V
A
(9
5
%
C
I)
2
.4
1
(2
.0
9
,
2
.8
6
)
2
.2
5
(1
.9
4
,
2
.6
6
)
2
.0
1
(1
.7
4
,
2
.3
8
)
C
V
I
(9
5
%
C
I)
7
.1
5
(5
.9
6
,
8
.8
6
)
6
.8
9
(5
.7
5
,
8
.5
3
)
6
.1
2
(5
.1
1
,
7
.5
7
)
C
V
G
(9
5
%
C
I)
1
7
.7
1
(1
2
.9
4
,
2
7
.2
6
)
1
8
.0
7
(1
3
.2
3
,
2
7
.8
0
)
1
8
.5
7
(1
3
.6
5
,
2
8
.5
1
)
C
V
T
O
T
(9
5
%
C
I)
1
9
.5
6
(1
5
.2
5
,
2
8
.6
7
)
1
9
.7
7
(1
5
.3
4
,
2
9
.0
9
)
1
9
.9
0
(1
5
.3
1
,
2
9
.5
1
)
I
I
d
0
.3
9
0
.3
7
0
.3
3
0
.4
5
/
0
.4
5
/
0
.4
3
0
.4
2
/
0
.4
2
/
0
.4
0
0
.3
7
/
0
.3
7
/
0
.3
5
R
C
V
p
ositiv
e
d
2
2
.4
2
/
2
2
.4
5
/
2
3
.2
4
2
1
.4
7
/
2
1
.4
9
/
2
2
.2
2
1
8
.9
4
/
1
8
.9
6
/
1
9
.5
2
R
C
V
n
eg
a
tiv
e
d
-1
8
.3
1
/
-1
8
.3
3
/
-1
8
.8
5
-1
7
.6
7
/
-1
7
.6
9
/
-1
8
.1
8
-1
5
.9
2
/
-1
5
.9
4
/
-1
6
.3
3
R
C
V
1
8
.5
0
1
7
.9
1
1
5
.9
9
S
D
A
(9
5
%
C
I)
1
.0
3
1
(0
.8
9
3
,
1
.2
1
9
)
0
.9
7
4
(0
.8
4
4
,
1
.1
5
3
)
0
.8
8
4
(0
.7
6
5
,
1
.0
4
6
)
0
.0
2
4
(0
.0
2
1
,
0
.0
2
8
)
0
.0
2
2
(0
.0
1
9
,
0
.0
2
6
)
0
.0
2
0
(0
.0
1
7
,
0
.0
2
4
)
S
D
I
(9
5
%
C
I)
3
.0
1
9
(2
.5
3
2
,
3
.7
0
9
)
2
.6
1
5
(2
.1
9
4
,
3
.2
1
3
)
2
.6
1
5
(2
.1
9
4
,
3
.2
1
3
)
0
.0
6
9
(0
.0
5
8
,
0
.0
8
5
)
0
.0
6
7
(0
.0
5
6
,
0
.0
8
2
)
0
.0
5
9
(0
.0
5
0
,
0
.0
7
3
)
S
D
G
(9
5
%
C
I)
8
.1
4
6
(6
.1
0
9
,
1
2
.0
1
1
)
8
.4
5
6
(6
.3
6
9
,
1
2
.4
3
2
)
8
.4
5
6
(6
.3
6
9
,
1
2
.4
3
2
)
0
.1
5
9
(0
.1
1
8
,
0
.2
3
5
)
0
.1
6
2
(0
.1
2
1
,
0
.2
3
9
)
0
.1
7
0
(0
.1
2
8
,
0
.2
5
1
)
S
D
T
O
T
(9
5
%
C
I)
8
.7
4
8
(6
.8
8
9
,
1
2
.4
3
1
)
8
.8
9
5
(6
.9
4
1
,
1
2
.7
3
8
)
8
.4
5
6
(6
.3
6
9
,
1
2
.4
3
2
)
0
.1
7
5
(0
.1
3
9
,
0
.2
4
6
)
0
.1
7
6
(0
.1
4
0
,
0
.2
4
9
)
0
.1
8
1
(0
.1
4
2
,
0
.2
5
9
)
I
C
C
A
0
.0
1
4
0
.0
1
2
0
.0
1
0
0
.0
1
8
0
.0
1
5
0
.0
1
3
I
C
C
I
0
.1
1
9
0
.1
1
0
0
.0
8
6
0
.1
4
9
0
.1
3
7
0
.1
0
7
I
C
C
G
0
.8
6
7
0
.8
7
8
0
.9
0
4
0
.8
3
3
0
.8
4
8
0
.8
8
1
A
ll
C
V
a
n
d
R
C
V
va
lu
es
a
s
ex
p
ressed
a
s
p
ercen
ta
g
es.
a
σ×
1
0
0
fo
r
lo
g
tra
n
sfo
rm
ed
d
a
ta
;
b √
(ex
p
(σ
2)−
1
)×
1
0
0
;
c(ex
p
(σ
)−
1
)×
1
0
0
;
d
ca
lcu
la
ted
u
sin
g
raw
C
V
/
ex
a
ct
g
eo
m
etric
C
V
/
a
ltern
a
tiv
e
g
eo
m
etric
C
V
s.
9
5
%
co
n
fi
d
en
ce
in
terva
ls
w
ere
ca
lcu
la
ted
u
sin
g
m
eth
o
d
s
o
f
B
u
rd
ick
a
n
d
G
ray
b
ill 3
4
w
ith
n
o
C
Is
p
rov
id
ed
fo
r
n
o
n
-tra
n
sfo
rm
ed
d
a
ta
.
S
h
a
d
ed
co
lu
m
n
sh
ow
s
sta
n
d
a
rd
d
a
ta
a
n
a
ly
sis.
102
4.5. Results
T
ab
le
4.
6:
A
n
al
y
si
s
of
th
e
eG
F
R
-C
b
io
lo
gi
ca
l
va
ri
ab
il
it
y
st
u
d
y
–
re
su
lt
s
o
f
C
re
a
ti
n
in
e
a
n
a
ly
se
s.
N
o
t
tr
a
n
sf
o
rm
e
d
T
ra
n
sf
o
rm
e
d
O
u
tl
ie
r
D
e
te
c
ti
o
n
N
o
n
e
F
ra
se
r-
H
a
rr
is
m
e
th
o
d
/
C
o
ch
ra
n
C
te
st
&
R
e
e
d
’s
C
ri
te
ri
o
n
N
o
n
e
F
ra
se
r-
H
a
rr
is
m
e
th
o
d
/
C
o
ch
ra
n
C
te
st
&
R
e
e
d
’s
C
ri
te
ri
o
n
D
a
ta
re
m
ov
ed
0
/
1
5
8
4
/
1
5
8
0
/
1
5
8
4
/
1
5
R
aw
C
V
sa
C
V
A
(9
5
%
C
I)
0
.7
0
0
.7
1
0
.6
6
(0
.5
7
,
0
.7
8
)
0
.6
6
(0
.5
7
,
0
.7
8
)
C
V
I
(9
5
%
C
I)
4
.3
2
4
.3
3
4
.3
1
(3
.6
5
,
5
.2
6
)
4
.3
4
(3
.6
8
,
5
.3
0
)
C
V
G
(9
5
%
C
I)
1
9
.8
6
1
9
.7
1
1
9
.9
2
(1
5
.0
8
,
2
9
.1
8
)
1
9
.7
9
(1
4
.9
8
,
2
9
.0
0
)
C
V
T
O
T
(9
5
%
C
I)
2
0
.3
4
2
0
.1
9
2
0
.3
9
(1
5
.7
0
,
2
9
.5
1
)
2
0
.2
8
(1
5
.6
2
,
2
9
.3
4
)
E
x
a
ct
g
eo
m
et
ri
c
C
V
sb
C
V
A
(9
5
%
C
I)
0
.6
6
(0
.5
7
,
0
.7
8
)
0
.6
6
(0
.5
7
,
0
.7
8
)
C
V
I
(9
5
%
C
I)
4
.3
1
(3
.6
5
,
5
.2
6
)
4
.3
5
(3
.6
8
,
5
.3
0
)
C
V
G
(9
5
%
C
I)
2
0
.1
2
(1
5
.1
7
,
2
9
.8
1
)
1
9
.9
9
(1
5
.0
7
,
2
9
.6
2
)
C
V
T
O
T
(9
5
%
C
I)
2
0
.6
0
(1
5
.7
9
,
3
0
.1
6
)
2
0
.4
9
(1
5
.7
1
,
2
9
.9
8
)
A
lt
er
n
a
ti
v
e
g
eo
m
et
ri
c
C
V
sc
C
V
A
(9
5
%
C
I)
0
.6
6
(0
.5
7
,
0
.7
8
)
0
.6
7
(0
.5
8
,
0
.7
9
)
C
V
I
(9
5
%
C
I)
4
.4
1
(3
.7
2
,
5
.4
0
)
4
.4
4
(3
.7
5
,
5
.4
4
)
C
V
G
(9
5
%
C
I)
2
2
.0
4
(1
6
.2
8
,
3
3
.8
8
)
2
1
.8
9
(1
6
.1
7
,
3
3
.6
5
)
C
V
T
O
T
(9
5
%
C
I)
2
2
.6
2
(1
7
.0
0
,
3
4
.3
2
)
2
2
.4
8
(1
6
.9
0
,
3
4
.0
9
)
I
I
d
0
.2
2
0
.2
2
0
.2
2
/
0
.2
2
/
0
.2
0
0
.2
2
/
0
.2
2
/
0
.2
1
R
C
V
p
o
si
ti
v
ed
1
2
.8
4
/
1
2
.8
5
/
1
3
.1
4
1
2
.9
5
/
1
2
.9
5
/
1
3
.2
5
R
C
V
n
eg
a
ti
v
ed
-1
1
.3
8
/
-1
1
.3
9
/
-1
1
.6
1
-1
1
.4
6
/
-1
1
.4
7
/
-1
1
.7
0
R
C
V
1
2
.1
4
1
2
.1
6
S
D
A
(9
5
%
C
I)
0
.8
9
7
(0
.7
7
7
,
1
.0
6
1
)
0
.9
0
1
(0
.7
8
0
,
1
.0
6
6
)
0
.0
0
7
(0
.0
0
6
,
0
.0
0
8
)
0
.0
0
7
(0
.0
0
6
,
0
.0
0
8
)
S
D
I
(9
5
%
C
I)
5
.5
1
0
(4
.6
6
4
,
6
.7
2
2
)
5
.5
1
2
(4
.6
6
6
,
6
.7
2
5
)
0
.0
4
3
(0
.0
3
7
,
0
.0
5
3
)
0
.0
4
3
(0
.0
3
7
,
0
.0
5
3
)
S
D
G
(9
5
%
C
I)
2
5
.3
0
7
(1
9
.1
5
9
,
3
7
.0
7
8
)
2
5
.0
8
8
(1
8
.9
9
2
,
3
6
.7
6
1
)
0
.1
9
9
(0
.1
5
1
,
0
.2
9
2
)
0
.1
9
8
(0
.1
5
0
,
0
.2
9
0
)
S
D
T
O
T
(9
5
%
C
I)
2
5
.9
1
5
(1
9
.9
5
6
,
3
7
.4
9
9
)
2
5
.7
0
3
(1
9
.7
9
6
,
3
7
.1
8
5
)
0
.2
0
4
(0
.1
5
7
,
0
.2
9
5
)
0
.2
0
3
(0
.1
5
6
,
0
.2
9
3
)
I
C
C
A
0
.0
0
1
0
.0
0
1
0
.0
0
1
0
.0
0
1
I
C
C
I
0
.0
4
5
0
.0
4
7
0
.0
4
7
0
.0
4
6
I
C
C
G
0
.9
5
4
0
.9
5
1
0
.9
5
2
0
.9
5
3
A
ll
C
V
a
n
d
R
C
V
va
lu
es
a
s
ex
p
re
ss
ed
a
s
p
er
ce
n
ta
g
es
.
a
σ
×
1
0
0
fo
r
lo
g
tr
a
n
sf
o
rm
ed
d
a
ta
;
b
√ (e
x
p
(σ
2
)
−
1
)
×
1
0
0
;
c
(e
x
p
(σ
)
−
1
)
×
1
0
0
;
d
ca
lc
u
la
te
d
u
si
n
g
ra
w
C
V
/
ex
a
ct
g
eo
m
et
ri
c
C
V
/
a
lt
er
n
a
ti
v
e
g
eo
m
et
ri
c
C
V
s.
9
5
%
co
n
fi
d
en
ce
in
te
rv
a
ls
w
er
e
ca
lc
u
la
te
d
u
si
n
g
m
et
h
o
d
s
o
f
B
u
rd
ic
k
a
n
d
G
ra
y
b
il
l3
4
w
it
h
n
o
C
Is
p
ro
v
id
ed
fo
r
n
o
n
-t
ra
n
sf
o
rm
ed
d
a
ta
.
S
h
a
d
ed
co
lu
m
n
sh
ow
s
st
a
n
d
a
rd
d
a
ta
a
n
a
ly
si
s.
103
Chapter 4. Analysis of biological variability studies
T
a
b
le
4
.7
:
A
n
a
ly
sis
o
f
th
e
eG
F
R
-C
b
iological
variab
ility
stu
d
y
–resu
lts
of
C
y
statin
C
an
aly
ses.
N
o
t
tra
n
sfo
rm
e
d
T
ra
n
sfo
rm
e
d
O
u
tlie
r
D
e
te
c
tio
n
N
o
n
e
F
ra
se
r-H
a
rris
m
e
th
o
d
C
o
ch
ra
n
C
te
st
&
R
e
e
d
’s
C
rite
rio
n
N
o
n
e
F
ra
se
r-H
a
rris
m
e
th
o
d
/
C
o
ch
ra
n
C
te
st
&
R
e
e
d
’s
C
rite
rio
n
D
a
ta
rem
ov
ed
0
/
1
5
8
8
/
1
5
8
2
2
/
1
5
8
0
/
1
5
8
6
/
1
5
8
R
aw
C
V
s
a
C
V
A
(9
5
%
C
I)
0
.5
6
0
.5
2
0
.5
3
0
.6
0
(0
.5
2
,
0
.7
1
)
0
.5
6
(0
.4
8
,
0
.6
6
)
C
V
I
(9
5
%
C
I)
4
.1
1
3
.6
9
3
.3
2
3
.9
8
(3
.3
7
,
4
.8
5
)
3
.9
9
(3
.3
8
,
4
.8
6
)
C
V
G
(9
5
%
C
I)
1
8
.0
5
1
7
.9
5
1
8
.2
4
1
8
.8
2
(1
4
.2
5
,
2
7
.5
6
)
1
8
.8
6
(1
4
.2
8
,
2
7
.6
3
)
C
V
T
O
T
(9
5
%
C
I)
1
8
.5
2
1
8
.3
3
1
8
.5
5
1
9
.2
4
(1
4
.8
1
,
2
7
.8
6
)
1
9
.2
9
(1
4
.8
4
,
2
7
.9
2
)
E
x
a
ct
g
eo
m
etric
C
V
s
b
C
V
A
(9
5
%
C
I)
0
.6
0
(0
.5
2
,
0
.7
1
)
0
.5
6
(0
.4
8
,
0
.6
6
)
C
V
I
(9
5
%
C
I)
3
.9
8
(3
.3
7
,
4
.8
6
)
3
.9
9
(3
.3
8
,
4
.8
7
)
C
V
G
(9
5
%
C
I)
1
8
.9
8
(1
4
.3
2
,
2
8
.0
9
)
1
9
.0
3
(1
4
.3
6
,
2
8
.1
7
)
C
V
T
O
T
(9
5
%
C
I)
1
9
.4
2
(1
4
.8
9
,
2
8
.4
1
)
1
9
.4
7
(1
4
.9
2
,
2
8
.4
8
)
G
eo
m
etric
C
V
s
c
C
V
A
(9
5
%
C
I)
0
.6
0
(0
.5
2
,
0
.7
1
)
0
.5
6
(0
.4
8
,
0
.6
6
)
C
V
I
(9
5
%
C
I)
4
.0
6
(3
.4
3
,
4
.9
7
)
4
.0
7
(3
.4
4
,
4
.9
8
)
C
V
G
(9
5
%
C
I)
2
0
.7
0
(1
5
.3
1
,
3
1
.7
4
)
2
0
.7
6
(1
5
.3
5
,
3
1
.8
2
)
C
V
T
O
T
(9
5
%
C
I)
2
1
.2
2
(1
5
.9
6
,
3
2
.1
2
)
2
1
.2
7
(1
6
.0
0
,
3
2
.2
1
)
I
I
d
0
.2
3
0
.2
1
0
.1
8
0
.2
1
/
0
.2
1
/
0
.2
0
0
.2
1
/
0
.2
1
/
0
.2
0
R
C
V
p
o
sitiv
e
d
1
1
.7
9
/
1
1
.8
0
/
1
2
.0
4
1
1
.8
1
/
1
1
.8
1
/
1
2
.0
6
R
C
V
n
eg
a
tiv
e
d
-1
0
.5
5
/
-1
0
.5
5
/
-1
0
.7
5
-1
0
.5
6
/
-1
0
.5
6
/
-1
0
.7
6
R
C
V
1
1
.4
9
1
0
.3
4
9
.3
3
S
D
A
(9
5
%
C
I)
0
.0
0
9
(0
.0
0
8
,
0
.0
1
1
)
0
.0
0
9
(0
.0
0
8
,
0
.0
1
0
)
0
.0
0
9
(0
.0
0
8
,
0
.0
1
0
)
0
.0
0
6
(0
.0
0
5
,
0
.0
0
7
)
0
.0
0
6
(0
.0
0
5
,
0
.0
0
7
)
S
D
I
(9
5
%
C
I)
0
.0
6
9
(0
.0
5
9
,
0
.0
8
4
)
0
.0
6
2
(0
.0
5
2
,
0
.0
7
6
)
0
.0
5
5
(0
.0
4
6
,
0
.0
6
7
)
0
.0
4
0
(0
.0
3
4
,
0
.0
4
9
)
0
.0
4
0
(0
.0
3
4
,
0
.0
4
9
)
S
D
G
(9
5
%
C
I)
0
.3
0
3
(0
.2
3
0
,
0
.4
4
5
)
0
.3
0
1
(0
.2
2
8
,
0
.4
4
1
)
0
.3
0
0
(0
.2
2
7
,
0
.4
3
9
)
0
.1
8
8
(0
.1
4
2
,
0
.2
7
6
)
0
.1
8
4
(0
.1
3
9
,
0
.2
6
9
)
S
D
T
O
T
(9
5
%
C
I)
0
.3
1
1
(0
.2
4
0
,
0
.4
5
0
)
0
.3
0
7
(0
.2
3
6
,
0
.4
4
5
)
0
.3
0
5
(0
.2
3
4
,
0
.4
4
3
)
0
.1
9
2
(0
.1
4
8
,
0
.2
7
9
)
0
.1
8
8
(0
.1
4
5
,
0
.2
7
2
)
I
C
C
A
0
.0
0
1
0
.0
0
1
0
.0
0
1
0
.0
0
1
0
.0
0
1
I
C
C
I
0
.0
4
9
0
.0
4
1
0
.0
3
2
0
.0
4
3
0
.0
4
3
I
C
C
G
0
.9
5
0
0
.9
5
9
0
.9
6
7
0
.9
5
6
0
.9
5
6
A
ll
C
V
a
n
d
R
C
V
va
lu
es
a
s
ex
p
ressed
a
s
p
ercen
ta
g
es.
a
σ×
1
0
0
fo
r
lo
g
tra
n
sfo
rm
ed
d
a
ta
;
b √
(ex
p
(σ
2)−
1
)×
1
0
0
;
c(ex
p
(σ
)−
1
)×
1
0
0
;
d
ca
lcu
la
ted
u
sin
g
raw
C
V
/
ex
a
ct
g
eo
m
etric
C
V
/
a
ltern
a
tiv
e
g
eo
m
etric
C
V
s.
9
5
%
co
n
fi
d
en
ce
in
terva
ls
w
ere
ca
lcu
la
ted
u
sin
g
m
eth
o
d
s
o
f
B
u
rd
ick
a
n
d
G
ray
b
ill 3
4
w
ith
n
o
C
Is
p
rov
id
ed
fo
r
n
o
n
-tra
n
sfo
rm
ed
d
a
ta
.
S
h
a
d
ed
co
lu
m
n
sh
ow
s
sta
n
d
a
rd
d
a
ta
a
n
a
ly
sis.
104
4.5. Results
ferent values indicate a true change depending on positive or negative change between mea-
sures);62,63 whereas, RCVs calculated from the analyses of non-transformed data give a single
value for changes in either the positive or negative direction. The RCVs calculated using the
log transformed data appeared conservative compared to the non-transformed data (log-
transformed and non-transformed data using Fraser-Harris method: iohexol -17.69, 21.49
and ±17.91; creatinine -11.47, 12.95 ±12.16; Cystatin C -10.56, 11.81 and ±10.34).
The index of individuality was stable across analyses of log-transformed and non-transformed
data for creatinine and Cystatin C. For the analyses of iohexol the IIs estimated showed
greater change when calculated from the log transformed and non-transformed data (Fraser-
Harris method: 0.42 and 0.37 respectively).
4.5.4.2 Outlier detection and data exclusion
All outlier testing methods led to the exclusion of data when analysing the three measures.
For iohexol, complete outlier detection deleted more measurements (12 measurements for
full detection and eight for Fraser-Harris method) due to the Cochran C test leading to the
removal of all data for the identified individual, see appendix Table B.1. When identifying
outliers in the creatinine data, the outlier detection methods identified the same four mea-
surements, see Appendix B Table B.2. Identification of outliers in the Cystatin C data led
to deletion of the same six measurements when using the Fraser-Harris and complete outlier
detection methods on the transformed data; however, for the non-transformed Cystatin C
data, additional measurements were identified using the complete outlier detection method
(22 compared with eight measurements, see appendix Table B.3). The additional measure-
ments were detected when using the Cochran C test for individuals (the complete outlier
detection method identified all eight measurements to be removed for an individual and a
further eight were removed when another individual was identified using Cochran C testing
of individuals for a second time on the remaining data). See Figure 4.3.
Comparison of analyses of data after different outlier detection approaches were used sug-
gested that estimates of CVA and CVI decrease as more data were excluded, with results
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Iohexol
30 40 50 60 70 80
Log Iohexol
3.4 3.6 3.8 4.0 4.2 4.4
Creatinine
80 100 120 140 160 180 200
Log Creatinine
4.2 4.4 4.6 4.8 5.0 5.2 5.4
Cystatin C
1.0 1.2 1.4 1.6 1.8 2.0 2.2 2.4
Log Cystatin C
0.0 0.2 0.4 0.6 0.8 1.0
Values
Removed by full and FH method
Removed by full method
Figure 4.3: Beeswarm plot of data and removed data.
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appearing similar when fewer outliers were detected. Comparing estimates of CVG showed
increases with outlier detection for the analysis of iohexol and Cystatin C (see Table 4.5
and Table 4.7) but decreases for creatinine. Similar trends were seen when analysing the
non-transformed data.
The reference change value bounds decreased with more stringent outlier detection when
analysing the iohexol data. The RCVs for creatinine and Cystatin C appeared similar when
using different outlier detection methods, and the RCV values for the non-transformed data
decreased with stricter outlier detection methods for the analysis of iohexol and Cystatin
C. For the analyses of the non-transformed creatinine data the RCVs remained stable with
different methods of outlier detection.
The index of individuality reduced with increased outlier detection for the analyses of log
transformed iohexol data but remained stable for the analysis of log transformed creatinine
and Cystatin C data. The IIs estimated when analysing non-transformed data decreased as
outlier detection increased for iohexol and Cystatin C measures but for creatinine remained
similar.
4.6 Discussion
4.6.1 Sample size
The sample size calculation used in this study focused on the estimate of within-individual
coefficient of variation only, using the number of participants and observation points to assess
precision. The method used for this was simplistic, as the duplicated measures within each
observation point were not factored into the calculation. The method of using confidence
intervals for a given level of precision is appropriate but further guidance is required to
ensure this is correct and the precision of additional estimates are considered. A tool to enable
researchers to easily use these methods to plan the sample size of studies is required.
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4.6.2 Normality and data transformation
The results of analysing the values recorded for iohexol, creatinine and Cystatin C tests
showed estimates were slightly different when using log transformed and non-transformed
data. As the estimates generated from these analyses have shown differences depending on
whether non-transformed data or transformed data was used, and the interpretation of these
estimates differ, it is vital that studies of biological variation report any transformations per-
formed and consider if data is normally distributed prior to transformation and log-normally
distributed after log-transformation.
From investigating published biological variability studies (see Chapter 3) it seems log-
transformation may be used to allow simplification of calculations primarily and the avail-
ability of formulae for calculating confidence intervals for estimates. The true need for trans-
formation of data is often not given.
When using a model to evaluate three levels of variability, the model takes the form of
yijk = µ + αi + βij + ijk, where µ is the mean value of the measure, αi ∼ N(0, σ2G),
βij ∼ N(0, σ2I ), ijk ∼ N(0, σ2A) and i = 1, . . . , n1, j = 1, . . . , n2 and k = 1, . . . , n3. The
number of participants is n1, the number of observations for each participant is n2 and the
number of replicate assessments of each observation for each participant is n3. The analytical,
within-individual and between-individual variability, expressed as standard deviations are σA,
σI and σG. This model assumes normality of the variability parameters at the analytical,
within-individual and between-individual levels. If this assumption is not held results from
the model may not be valid. Simply assessing the normality of the test measures may not be
sufficient to investigate if the data meets the assumptions of the model. Many of the outlier
detection methods (see §6.3.2) rely on the data to be normally distributed, hence the further
requirement for normality prior to assessing outliers.
When using normality tests on small samples the tests have limited power; and, with larger
samples the results of normality tests may be significant, indicating non-normality, when
deviations from the normal distribution are small and alternative approaches (non-parametric
testing or transformation) cause limited differences to the results obtained.100
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Further work is required to investigate issues arising when biological variability data are not
normally distributed or log-normally distributed.
4.6.3 Outlier detection and removal
The results of the analyses of iohexol, creatinine and Cystatin C measures showed estimates
were different when outliers are detected and removed. In situations with increased out-
lier detection estimates of variability were generally reduced, meaning these methods were
potentially providing optimistic estimates of variability. The risk in using outlier detection
methods is that valid data is removed rather than data ‘errors’ and the consequence is reduced
estimates of variability.
The results also showed different types of outlier detection led to different results. The method
of Fraser and Harris can be interpreted in different ways leading to differing numbers of
outliers detected which can change the results of biological variability studies. The exact use
of outlier detection methods need to be carefully explained, if these methods are considered
appropriate. It is not clear what the impact of outlier detection is and the most appropriate
method to use in biological variability studies.
The Cochran C test is not a perfect test to use even if outlier detection is appropriate and
necessary. ’t Lam99 discusses the disadvantages of the Cochran C test: requiring a balanced
design; use of the test requires reading of critical values from tables and, the test is not a
two-sided test as it uses critical values to identify large variances but does not identify small
variances.
4.6.4 Limitations
This chapter displays the analysis of only one data set where the distribution of data and
outliers did not appear to have great impact on the analyses performed. For other data sets
the difference in analyses could be greater and this requires further investigation.
Differences in results were seen across the analyses but it is difficult to know what magnitude
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would be meaningful. CVs are often the reported results of biological variability studies but
it may be that estimates of RCV are more meaningful and researchers should be mindful of
the precision of this estimate when planning studies.
4.7 Conclusion and recommendations
The methods for analysing biological variability studies can impact on results, this could
be using: log-transformed or non-transformed data, different outlier detection methods or
different methods of calculation of geometric coefficients of variation. The methods for eval-
uating biological variability studies require updating and researchers need to be made aware
of the methods for analysing these types of studies and the differences in interpretation of
results when geometric coefficients of variation are calculated. Only with clear and trans-
parent reporting can the analyses of biological variability studies be used to inform further
research.
It needs to be clearly reported if the data has been analysed using log-transformed data or
data on the original scale. The decision to transform data should be made given the distribu-
tion of study data and prior knowledge of the measure, with these decisions and considerations
reported. Researchers should also clearly report which method has been used to give CV es-
timates when using log-transformed data. The benefits of using the log-transformed data are
simplification of the calculation of CV and the ability to calculate confidence intervals for
these CVs.
Using outlier detection methods may lead to the identification and deletion of legitimate
test measurements and consequently may decrease the estimates of variability. The impact
of outlier detection methods on variability estimates in biological variability studies needs
further investigation with the methods for identifying outliers compared.
More guidance is required for planning sample sizes for biological variability studies taking
account of the variability at all levels assessed, which can be done with the appropriate
confidence interval calculations. It would also be beneficial to have guidance for sample size
110
4.7. Conclusion and recommendations
based on the precision of measures in addition to CVs, such as RCVs. A tool for calculating
the precision of estimates for given sample sizes would allow researchers to easily incorporate
these calculation when planning studies.
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Chapter 5
Sample size guidance and
justification for studies of biological
variation
This work has been partly presented in the following form:
Sitch, A, Mallett, S, Deeks, J. Sample size guidance and justification for studies of
biological variation. EuroMedLab–22nd IFCC-EFLM European Congress of Clinical
Chemistry and Laboratory Medicine, Athens, Greece. 11-15 June 2017.
Summary
Biological variability studies aim to measure variability in a biomarker both between and
within individuals, allowing the potential for a biomarker to diagnose and monitor disease to
be assessed. Sample sizes for these studies state the numbers of participants (n1), observations
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per participant (n2) and repeat assessments of each observation (n3). Little guidance exists
to compute these values.
Simulation of biological variability data and subsequent analysis allows potential results to
be observed for more common measures of variability including the coefficient of variation
(CV), reference change values (RCV), and index of individuality (II). Using simulation and
observing the results can help researchers plan sample size (the application is available at
https://alicesitch.shinyapps.io/bvs_simulation/).
Results of simulations showed greater numbers of participants increased the precision of
estimated analytical, within and between-individual variability; increasing the number of
observations per participant increases the precision of estimates of analytical and within
individual variability; and, increasing the number of assessments of observations per partici-
pants increases precision of only analytical variability. If the desired precision of variability
components are known, values for n1, n2 and n3 can be determined.
5.1 Introduction
Biological variability studies look to estimate variability by assessing participants whilst in a
stable disease state. Multiple participants are tested at multiple time points, and each obser-
vation for each participant is assessed multiple times.35 Recruitment of multiple participants
allows the variability between participants to be assessed; multiple measures for each partici-
pant allows within-individual variability to be assessed; and, the multiple assessment of each
measure from each participant allows assessment of analytical variability.16 Pre-analytical
variability is minimised by keeping test procedures constant and is not evaluated.16
Analysis of variability is by ANOVA or random effects modelling. Estimates of variability
are often expressed as coefficients of variation (CVs), identified in the review of biological
variability studies (Chapter 3). Additional estimates provided are index of individuality (II)
and reference change value (RCV), for further details see Chapters 2 and 3.
From the review presented in Chapter 3, few studies of biological variability justified the
114
5.1. Introduction
sample size used. Few studies gave any indication of the uncertainty of the estimates produced
with confidence intervals rarely presented. The Fraser and Harris35 guide for the design and
analysis of biological variability studies does not cover sample size justification, stating only
that: ‘valid estimates of the components of variation can be obtained from relatively small
numbers of specimens collected from a small group of subjects over a reasonably short period
of time’.35
Røraas et al43 have provided guidance for both sample size justification and the use of con-
fidence intervals for estimates from biological variability studies. Their work was based on
a simulation study using the standard ANOVA or random effects modelling approach to
analyse biological variability data, whilst varying the analytical variability, number of repli-
cates, number of samples, and number of individuals, and looked at the effect of varying
these study aspects on the confidence interval width for the estimate of within-individual
variability. Tables provided enable planning of appropriate sample size and estimation of
confidence intervals for within-individual variability estimates. Confidence intervals were
calculated using the formula introduced by Burdick and Graybill,34 see Chapter 2.
McNeish and Stapleton50 reviewed ‘rules of thumb’ for the number of clusters to fit multilevel
models and achieve unbiased estimates. The authors acknowledge a ‘a specific sample size
cannot be pinpointed’ with guidance ranging. Kreft101 suggested 30 clusters with 30 data
points within each cluster; Snijders and Bosker102 suggested 20 clusters were necessary and
multilevel models should not be used if fewer than 10 clusters are present;103 and, Hox104 sug-
gested 50 clusters with 10 data points in each cluster was necessary for multilevel modelling,
with this increased to 100 clusters with 10 datapoints in each if variance parameters were
estimated. McNeish and Stapleton50 used simulation to suggest a minimum of ten clusters
to estimate a variance parameter and 50 clusters to estimate the standard error of a variance
parameter. A generic multilevel model was used (also with the estimate of fixed effects)
with only two levels of data. This example was not tailored to biological variability data
but for more general analysis accounting for clustering of data. The validity of multilevel
modelling to obtain estimates of variability with small numbers of participants, observations
and assessments is unknown.
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The work presented in this chapter aims to use simulation to assess the validity of the
methods used to produce variability estimates for varying sample sizes and provide guidance
to demonstrate the impact of sample size on the precision of various estimates from biological
variability studies (including estimates where precision cannot easily be derived, such as CV
for non-transformed data, RCV and II). For estimates where estimated confidence intervals
can be derived (CV estimates when data is log-normally distributed and log transformed) the
simulation will be used to validate these methods. Researchers will be provided with a tool
to enable planning and justification of sample size. This tool will not only provide precision
of estimates of within-individual variability but also for analytical and between-individual
variability, and the subsequent measures generated in biological variability studies.
5.2 Aims and objectives
The aims of this study were:
• primarily, to assess the validity and precision of estimates produced when varying sam-
ple size for normal and log-normal data;
• secondarily, to investigate the difference in estimates for a given sample size when
changing the variability at the analytical, within-individual and between-individual
level.
The simulated scenarios were evaluated by assessing:
• bias, accuracy and coverage of the methods used for analysis when estimating standard
deviations;
• and, a range of estimates from biological variability studies (standard deviations, CVs,
II, RCV).
This analysis allowed the validity of methods to estimate variability and calculate confidence
intervals when varying sample size to be assessed, and provides researchers with likely esti-
mates from planned studies so sample size can be modified to achieve the required precision.
116
5.3. Methods
An application was developed enabling sample sizes for biological variability studies to be
planned and justified prior to recruitment of participants. In addition an application was
developed to calculate confidence intervals given specified variability estimates and sample
sizes, using analytical methods where possible.
5.3 Methods
The model simulated data for a given sample size (number of participants, observations
and assessments) and test performance (between-individual, within-individual and analytical
variability). After simulating the data, standard analyses were performed to estimate the
between-individual, within-individual and analytical variability. The simulation and analysis
was repeated 1,000 times with the results from the multiple runs analysed to assess the bias,
accuracy and coverage of the estimated standard deviations and the precision of estimates
of biological variability (standard deviations, CVs, II, RCV). This was repeated for differ-
ent sample sizes, test performance values and normal and log-normal data. For estimates
where approximate confidence intervals can be calculated using the methods of Burdick and
Graybill34 these were compared to the results obtained using simulation.
See Table 5.1 for a guide to the notation used when describing the method.
5.3.1 Number of simulations
With 1,000 simulations the 95% confidence interval for coverage, assuming an estimate of
95% would range from 93.46% to 96.27%. One thousand data simulations were used for each
scenario to allow precision of estimates but also efficiency of computing, which would be
required for researchers to use the tool when planning studies. A simulation of 10,000 data
sets was used with the base-case scenario and results were similar when compared to those
generated when using 1,000 data sets.
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Table 5.1: Notation description for biological variability study sample size simulation method.
Description Notation
Simulation inputs
Sample size
Number of participants n1
Number of observations per participants n2
Number of assessments per observation per participants n3
Test estimates
Mean test value µ
Analytical variability (standard deviation) σA
Within-individual variability (standard deviation) σI
Between-individual variability (standard deviation) σG
Log transformed analytical variability (standard deviation) σ∗A
Log transformed within-individual variability (standard deviation) σ∗I
Log transformed between-individual variability (standard deviation) σ∗G
Simulation and results
Sample size function
Data simulation and analysis
Simulated test value for each assessment of each observation for each
participant
yijk
Mean test value µ
Between-individual variability; model parameter αi ∼ N(0, σ2G) αi
Within-individual variability; model parameter βij ∼ N(0, σ2I ) βij
Analytical variability; model parameter ijk ∼ N(0, σ2A) ijk
Participant number; i = 1, . . . , n1 i
Observation number; j = 1, . . . , n2 j
Assessment number; k = 1, . . . , n3 k
Estimates
Estimated analytical variability (standard deviation) σˆA
Estimated within-individual variability (standard deviation) σˆI
Estimated between-individual variability (standard deviation) σˆG
Estimated analytical coefficient of variation CVA
Estimated within-individual coefficient of variation CVI
Estimated between-individual coefficient of variation CVG
Estimated index of individuality II
Estimated reference change value RCV
Estimated positive reference change value RCVpos
Estimated negative reference change value RCVneg
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5.3.2 Input values
The simulation required details of the sample size of the biological variability study: the
number of participants (n1), the number of observations for each participant (n2) and the
number of replicate assessments of each observation for each participant (n3). Also required
were estimates of the mean value of the test (µ) and the analytical, within-individual and
between-individual variability, expressed as coefficients of variation (CVA, CVI and CVG) or
standard deviations (σA, σI and σG).
A previous review of biological variability studies (see Chapter 3) showed the median (Q1,
Q3) number of individuals in biological variability studies (n1) was 25 (15, 40); for the number
of observations per participant (n2) this was 5 (3, 10); and, for the number of assessments
per observation point 2 (2, 3). From the same review estimates of CVA, CVI and CVG were
extracted with the median (Q1, Q3) of 3.5 (1.4, 6.3), 10.0 (5.0, 18.5) and 26.3 (14.0, 43.9)
respectively.
5.3.3 Data simulation
5.3.3.1 Basic simulation model with normally distributed errors
Test data were simulated to follow the model yijk = µ+ αi + βij + ijk, where µ is the mean
value of the measure, αi ∼ N(0, σ2G), βij ∼ N(0, σ2I ), ijk ∼ N(0, σ2A) and i = 1, . . . , n1,
j = 1, . . . , n2 and k = 1, . . . , n3, see Figure 5.1. This was equivalent to the model proposed
by Røraas et al.43
This gave n1×n2×n3 observations; n3 assessments of n2 observations for n1 participants. A
histogram of the simulated measures and plot of the simulated measures by participant can
be seen in Figure 5.2.
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Figure 5.2: Histogram (left) and plot (right) of simulated biological variability data with
normally distributed variability (n1 = 20, n2 = 4, n3 = 2, CVG = 20%, CVI = 10% and
CVA = 5%). Duplicate assessments within observation points shown by points with the same
colour.
5.3.3.2 Log-normal data simulation model
An alternative simulation of log-normal data was performed. Data were simulated following
the model yijk = µ × αi × βij × ijk, thus ln(yijk) = ln(µ) + ln(αi) + ln(βij) + ln(ijk) and
ln(αi) ∼ N(0, σ2G), ln(βij) ∼ N(0, σ2I ), ln(ijk) ∼ N(0, σ2A) and i = 1, . . . , n1, j = 1, . . . , n2
and k = 1, . . . , n3. This gave n1×n2×n3 observations; n3 assessments of n2 observations for
n1 participants. Figure 5.3 shows the distribution of the measurements on the original and
log scale.
5.3.3.3 Detailed specification of the log-normal data
The analytical, within-individual and between-individual standard deviations of the log trans-
formed data are σA, σI and σG respectively. The analytical, within-individual and between-
individual standard deviations of the data on the original scale are σ∗A, σ
∗
I and σ
∗
G.
A log-normal variable y has standard deviation σ∗ and mean µ∗σ, and when log trans-
formed has a normal distribution such that ln(y) ∼ N(µσ, σ2). The mean of log trans-
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Figure 5.3: Histograms (left) and plots (right) of simulated biological variability data
(n1 = 20, n2 = 4, n3 = 2, CVG = 20%, CVI = 10% and CVA = 5%) with log-normal dis-
tributed variability (left shows original data and right shows log transformed data). Duplicate
assessments within observation points shown by points with the same colour.
formed log-normally distributed data (µσ) is ln
 µ∗σ√
1+σ
∗2
µ∗2σ
 and the standard deviation (σ)
is
√
ln
(
1 + σ
∗2
µ∗2σ
)
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The simulation provided exact geometric estimates of CVA, CVI and CVG. This was achieved
by simulating the log transformed data to satisfy σ =
√
ln(CV 2 + 1), so the exact CV is equal
to
√
exp(σ2)− 1.59,60 Log-normal data was simulated using the R function ‘lnorm’, meaning
zero-cell corrections were not necessary.
The mean value of the measure on the original scale is y¯ijk = µ × α¯i × β¯ij × ¯ijk (hence
µ =
y¯ijk
α¯i×β¯ij×¯ijk ) and the mean value of the measure on the log scale is ln(y¯ijk). For the
purpose of the simulation the value of ln(µ) was set to equal 10 units. As CV estimates are
geometric for this simulation, the value of the mean is independent.
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5.3.4 Analysis
5.3.4.1 Normally distributed data
The generated test data (yijk) was analysed using a linear model with random effects for
participants and observation points within participants. yijk = µ + αi + βij + ijk, where
i = 1, . . . , n1, j = 1, . . . , n2 and k = 1, . . . , n3, yijk is the test measure for the ith participant
at the jth time point and for the kth assessment, µ is the mean value of the measure,
αi ∼ N(0, σ2G), βij ∼ N(0, σ2I ) and ijk ∼ N(0, σ2A).
Fitting the model allowed estimates of σA, σI and σG to be obtained, σˆA, σˆI and σˆG. In
addition to standard deviations, other measures of variability were produced (coefficient of
variation (CV), index of individuality (II) and reference change values (RCV)) using the
estimates from the model.
5.3.4.2 Log-normal data
Analyses were performed using the same model but after log transforming the data.
5.3.5 Results for each simulation
Standard deviations were estimated after fitting the random effects model to each simulated
data set, at the analytical (σˆA), within-individual (σˆI) and between-individual (σˆG) level.
Coefficients of variation (CV), index of individuality (II) and reference change values (RCV)
were calculated. CVA =
σˆA
µ , CVI =
σˆI
µ , CVG =
σˆG
µ , II =
√
CV 2A+CV
2
I
CVG
and RCV =
√
2 ×
1.96 ×
√
CV 2A + CV
2
I . For the analyses of the log transformed data, exact geometric CVs
were calculated using
√
exp(σˆ2)− 1.59,60 Corresponding 95% confidence intervals for the
standard deviations and CVs for the log-transformed data were calculated using the equations
presented by Burdick and Graybill,34 and asymmetric RCV, where RCVpos = exp(1.96 ×
√
2τ)− 1, and RCVneg = exp(−1.96×
√
2τ)− 1, where τ =
√
ln(CV 2A+I + 1), 1.96 is selected
from the normal distribution and CVA+I is the coefficient of variation for the total imprecision,
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CVA+I =
√
CV 2A + CV
2
I
62,63, as described in Chapter 2.
The application also provides estimates of geometric CVs using exp(σˆ)−161 and intracluster
correlation coefficients (ICCs), however, these estimates are not presented here.
5.3.6 Repeated data simulations and analyses
Standard simulation performance measures were used to evaluate the ability of the methods
to estimate the standard deviations for differing sample sizes and test performance. These
measures were suggested by Burton et al,106 see Table 5.2. As the amount of bias considered
problematic is not know (Burton et al106 state this has been estimated between 12SE(βˆ) and
2SE(βˆ)) the bias is also considered as a percentage of the estimate (percentage bias) and as a
percentage of the empirical standard error of the estimate from the simulations (standardised
percentage bias). Burton and colleagues advocate the use of the standardised percentage bias
as it: ‘can be more informative, as the consequence of the size of the uncertainty’.106
Table 5.2: Performance measures to assess biological variability sample size simulation results.
Evaluation criteria Formula
Bias
Bias δ = ¯ˆσ − σ
Percentage bias
(
δ
σ
)× 100
Standardised bias
(
δ
SE(σˆ)
)
× 100
Accuracy
Mean squared error δ2 + SE(σˆ)2
Coverage
The proportion of times the 100(1− α)% confidence interval includes σ
Average 100(1− α)% confidence interval length
σ is the true value of the standard deviation.
σˆ is the estimated σ for each simulation.
¯ˆσ is the sum of the σˆ divided by the number of replicate simulations performed (the mean).
SE(σˆ) is the empirical standard error of the estimate for all simulations (the SD across simulated estimates).
For each of the estimates, the mean, median, 25th percentile (Q1), 75th percentile (Q3),
minimum and maximum value were calculated to summarise results. The 2.5th and 97.5th
percentiles are available in the application also.
All analyses were performed using the statistical software R with the seed set at the start
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of each scenario. Each scenario differs due to the sample size and data drawn from different
distributions. For analyses varying sample size, data simulations are not paired. For analyses
of the same sample size varying σA, σI or σG the results are for paired analyses changing
only the specified component. All models were fitted using restricted estimation of maximum
likelihood (REML).
5.3.7 Simulation inputs
5.3.7.1 Base-case
Base-case parameters were kept constant with n1 = 20, n2 = 4, n3 = 2, σA = 0.5 (CVA =
5%), σI = 1 (CVI = 10%) and σG = 2 (CVG = 20%), chosen to reflect standard measures
seen in the review of biological variability studies, see Chapter 3.
5.3.7.2 Varying sample size
The input parameters were varied to reflect the range of sample sizes seen in the review of
biological variability studies (see Chapter 3), with the number of participants ranging from
5 to 100 (5, 10, 20, 30, 40, 60, 100); the number of observations ranging from 2 to 20 (2,
4, 6, 8, 12, 20); and, the number of assessments ranging from 2 to 10 (2, 3, 4, 6, 10). The
log-normal simulation maintained the same CV estimates but the standard deviations used
were slightly different to ensure the CV values remained the same.
Sensitivity analyses were performed increasing the variability of the test measures to σA = 1
(CVA = 10%), σI = 2 (CVI = 20%) and σG = 4 (CVG = 40%).
5.3.7.3 Varying test performance
The variability measures were chosen to reflect likely test performance also, with values
(across all simulations) for σA varying from 0.125 to 1.25 (CVA 1.25%, 2.5%, 3.75%, 5%,
6.25%, 7.5%, 8.75%, 10%, 11.25%, 12.5%); values for σI varying from 0.5 to 2.5 (CVI 5%,
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7.5%, 10%, 12.5%, 15%, 17.5%, 20%, 22.5%, 25%); values for σG varying from 1 to 5 (CVG
10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%), reflecting the values of CV reported
and assuming a mean test value of 10 units. Variability measures were used in simulations
ensuring σA ≤ σI ≤ σG.
Sensitivity analyses were performed increasing the sample size to n1 = 40, n2 = 10 and
n3 = 3.
5.4 Results
An application was developed (allowing these simulations to be performed) to simulate dif-
ferent biological variability study scenarios, giving an indication of the precision of estimates.
This application can be found at https://alicesitch.shinyapps.io/bvs_simulation/.
An application was also developed allowing confidence intervals to be calculated for estimates
of standard deviation at the analytical, within-individual and between-individual levels, and
can be found at https://alicesitch.shinyapps.io/bvs_cis/.
All CVs and RCVs are displayed as percentages.
5.4.1 Number of participants, observations and assessments
5.4.1.1 Analysis of normally distributed data
Bias
For σA, σI and σG the bias appeared to be negative for all simulated situations except for
some scenarios using larger sample sizes, see Table 5.3. With only five participants, four
observations and two assessments the percentage bias–bias as a percentage of the true value–
was -0.564, -1.834 and -7.250 at the analytical, within-individual and between individual
levels respectively; the standardised percentage bias–the bias expressed as a percentage of the
standard error of the estimate–was -3.698, -8.783 and -20.212. When increasing the number
of participants to 20, the percentage bias was smaller at the analytical, within-individual and
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between-individual levels (-0.175, -0.332 and -1.529); with 100 participants the percentage
bias decreased further (+0.072, -0.127, -0.012). The bias was less than 2% for all situations
with at least 20 participants. With increases in the number of participants (n1) the bias
for σA, σI and σG decreased; with increases in the number of observations (n2) the bias for
σA and σI decreased; and for increases in the number of assessments (n3) the bias for σA
decreased.
Confidence intervals
As the number of participants, observations and assessments increased the mean width of
the Burdick and Graybill34 95% confidence intervals for estimated CVA, CVI and CVG all
reduced in width. The coverage of 95% confidence intervals for estimates of σA, σI and σG
was consistently close to 95%, with two of the scenarios providing coverage estimates for σG
at the lower bound of what was expected given the number of simulations, see Table 5.4
and Figure 5.4. For some of the smaller sample sizes 95% confidence intervals could not be
calculated (when n1 = 5, 10 and n2 = 2). Comparison of the results from the simulated data
to the bounds produced by the Burdick and Graybill confidence intervals (see Figure 5.5)
suggest the lower bound is underestimated.
Estimates of standard deviations and coefficients of variation
The median estimate of σA, σI and σG, and CVA, CVI and CVG appeared consistent for
each number of participants, observations and assessments. For increases in the number of
participants (n1) the range of estimates for σA, σI and σG (and therefore CVA, CVI and CVG)
decreased with estimates from the 1,000 replications closer to the true value. For increases
in the number of observations (n2) the range of estimates for σA and σI (and CVA and CVI)
decreased; however for all numbers of observations, the range of estimates of σG (and CVG)
were constant. For increases in the number of assessments, the range of estimates of σA (and
CVA) decreased only; the estimates of σI and σG (CVI and CVG) were similar, see Figures
5.5 and 5.6 and Appendix C Table C.1 and Table C.2.
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Figure 5.4: Coverage estimates from biological variability data simulations varying sample
size: coverage of SDA (left column), SDI (middle column) and SDG (right column) estimates
when varying number of participants (n1, top row); number of observations per participant
(n2, middle row); and, number of replicate assessments per observation per participant (n3,
bottom row). 95% coverage is shown by horizontal line. Estimates shown in red are for the
baseline strategy. 95% confidence intervals were calculated using the methods of Burdick and
Graybill.34 Confidence intervals could not be calculated for all scenarios, see Table 5.4.
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5.4. Results
Estimates of index of individuality and reference change value
The median estimates of II and RCV were consistent and accurate for all numbers of par-
ticipants, observations and assessments. As the number of participants and observations
increased (n1 and n2), the range of estimates for both II and RCV decreased. With fewer
participants (n1 = 5) II was overestimated. With increased number of assessments, there was
little change in the range of estimates of II and RCV, see Figure 5.7 and Appendix C Table
C.3.
5.4.1.2 Analysis of log-normal data
When simulating log-normal data the CVs shown are exact geometric CVs and all CVs and
RCVs are displayed as percentages.
When analysing the simulated log-normal data the bias in results along with the coverage
was comparable with the normal data simulation. The log-normal data simulation yielded
similar trends in estimated standard deviations, CVs, RCVs and IIs for increased sample
sizes.
Confidence intervals were calculated for the estimates of CV directly using the equations
of Burdick and Graybill.34 These confidence intervals were appropriate compared to the
simulated results and estimates of coverage were mainly within the expected range (coverage
for one scenario when estimating CVG was 93.4%), see figure 5.8.
The range of values from the 1,000 simulations were less varied for the log-normal simulation
than the normal data simulation, see Appendix C Tables C.4 to C.9 and Figures C.1 and
C.3.
5.4.2 Analytical, within-individual and between-individual variability
Results for scenarios are similar as only the chosen variability estimate is changed in the
simulation; analyses are paired.
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Figure 5.5: SD estimates from biological variability data simulations varying sample size:
SDA (left column), SDI (middle column) and SDG (right column) estimates when varying
number of participants (n1, top row); number of observations per participant (n2, middle
row); and, number of replicate assessments per observation per participant (n3, bottom row).
Median is shown by horizontal line, Q1 and Q3 shown by extremes of box; and minimum and
maximum values shown by arrows. Estimates shown in red are for the baseline strategy. The
dashed line reflects the true SD and the dotted lines are the 95% confidence intervals around
the true value of the estimate for the given sample size, using the methods of Burdick and
Graybill.34
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Figure 5.6: CV estimates biological variability data simulations varying sample size: CVA
(left column), CVI (middle column) and CVG (right column) estimates when varying number
of participants (n1, top row); number of observations per participant (n2, middle row); and,
number of replicate assessments per observation per participant (n3, bottom row). Median is
shown by horizontal line, Q1 and Q3 shown by extremes of box; and minimum and maximum
values shown by arrows. Estimates shown in red are for the baseline strategy. The dashed
line reflects the true CV.
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Figure 5.7: II and RCV estimates from biological variability data simulations varying sample
size: II (left column) and RCV (right column) estimates when varying number of participants
(n1, top row); number of observations per participant (n2, middle row); and, number of
replicate assessments per observation per participant (n3, bottom row). Median is shown by
horizontal line, Q1 and Q3 shown by extremes of box; and minimum and maximum values
shown by arrows. Estimates shown in red are for the baseline strategy. The dashed line
reflects the true II or RCV. *Maximum value not shown.
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Figure 5.8: Log-normal biological variability sample size simulation: CV estimates from
biological variability data simulations varying sample size: CVA (left column), CVI (middle
column) and CVG (right column) estimates when varying number of participants (n1, top
row); number of observations per participant (n2, middle row); and, number of replicate
assessments per observation per participant (n3, bottom row). Median is shown by horizontal
line, Q1 and Q3 shown by extremes of box; and minimum and maximum values shown by
arrows. Estimates shown in red are for the baseline strategy. The dashed line reflects the
true CV and the dotted lines are the 95% confidence intervals around the true value of the
estimate for the given sample size, using the methods of Burdick and Graybill.34
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Bias
For σA, σI and σG the bias was negative for all simulated situations, see Table 5.5. The bias
was less than 2% for each estimated standard deviation for most scenarios; for three of the
simulated scenarios the bias was greater than 2%: 1) σA = 0.5, σI = 1.75 and σG = 2; 2)
σA = 0.5, σI = 2 and σG = 2; and 3) σA = 0.5, σI = 1 and σG = 1. With increased analytical
variability (CVA) the bias for σI increased; with increased within-individual variability (CVI)
the bias for σA and σI increased; and for increased between-individual variability (CVG) the
bias for σG increased.
Confidence intervals
As the analytical variability (CVA) increased the mean width of 95% confidence intervals for
σA, σI and σG increased; as the within-individual variability (CVI) increased the width of 95%
confidence intervals for σI and σG increased (with the width of 95% confidence intervals for
σA unchanged); and for increases in between-individual variability (CVG) the mean width of
the 95% confidence intervals for only σG increased in width (with the width of 95% confidence
intervals for σA and σI were constant). The coverage of 95% confidence intervals for estimates
of σA, σI and σG was close to 95% and greater than the expected lower bound given the
number of simulations, see Table 5.6 and Figure 5.9. For some of the larger variability
estimates 95% confidence intervals could not be calculated. Again, comparison of the results
from the simulated data to the bounds produced by the Burdick and Graybill confidence
intervals (see Figure 5.10) suggest the lower bound is underestimated.
Estimates of standard deviations and coefficients of variation
The median estimate of σA, σI and σG and CVA, CVI and CVG changed as expected for each
level of test variability. For increases in analytical variation (CVA) the range of estimates for
σA and σI (and therefore CVA, and CVI) increased, with the range of estimates for σG (CVG)
consistent. For increases in within-individual variation (CVI) the range of estimates for σI and
σG (and CVI and CVG) increased; however for all values of within-individual variation, the
range of estimates of σA (and CVA) appeared constant. For increases in between-individual
variation, the range of estimates of σG (and CVG) increased, with the estimates for σA and
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Figure 5.9: Coverage estimates from biological variability data simulations varying SDA, SDI
and SDG: coverage of SDA (left column), SDI (middle column) and SDG (right column)
estimates when varying value of SDA (top row); value of SDI (middle row); and, value of
SDG (bottom row). 95% coverage is shown by horizontal line. Estimates shown in red are for
the baseline strategy. 95% confidence intervals were calculated using the methods of Burdick
and Graybill.34 Confidence intervals could not be calculated for all scenarios, see Table 5.6.
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σI (CVA and CVI) constant, see Figures 5.10 and 5.11 and Appendix C Tables C.10 and
C.11.
Estimates of index of individuality and reference change value
The median estimates of II and RCV were consistent and accurate for all test variation values.
As the analytical variation increased, there was little change in the range of estimates for both
II and RCV. As the within-individual variation increased, the range of estimates for both
II and RCV increased. The range of estimates for II, decreased with increases in between-
individual variability; whereas the range of estimates for RCV increased with increases in
between-individual variability, see Figure 5.12 and Appendix C Table C.12.
5.4.2.1 Analysis of log-normal data
Again similar trends were seen when simulating log-normal data and changing the estimates
of variability. See Figures C.4 to C.7 and Tables C.13 to C.18.
5.4.3 Sensitivity analyses
When increasing the base case number of participants in the simulation (n1 = 40, n2 = 10 and
n3 = 3) and the base case test variability (σA = 1, σI = 2 and σG = 4) the observed trends
remained the same. For simulations with the base case number of participants, observa-
tions and assessments increased, the range of results decreased from the original simulation,
see Appendix C Tables C.19 to C.28. When the base case reflected a test with increased
variability the range of results increased, see Appendix C Tables C.29 to C.38.
5.5 Discussion
The trends seen when varying factors of the simulation (number of participants, observa-
tions and assessments, and test variability at the analytical, within-individual and between-
individual level) are intuitive but allow planning given the specific purpose of the study and
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Figure 5.10: SD estimates from biological variability data simulations varying test variability:
SDA (left column), SDI (middle column) and SDG (right column) estimates when varying
value of SDA (top row); value of SDI (middle row); and, value of SDG (bottom row).
Median is shown by horizontal line, Q1 and Q3 shown by extremes of box; and minimum and
maximum values shown by arrows. Estimates shown in red are for the baseline strategy. The
dashed line reflects the true SD and the dotted lines are the 95% confidence intervals around
the true value of the estimate for the given sample size, using the methods of Burdick and
Graybill.34
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Figure 5.11: CV estimates from biological variability data simulations varying test variability:
CVA (left column), CVI (middle column) and CVG (right column) estimates when varying
value of CVA (top row); value of CVI (middle row); and, value of CVG (bottom row). Me-
dian is shown by horizontal line, Q1 and Q3 shown by extremes of box; and minimum and
maximum values shown by arrows. Estimates shown in red are for the baseline strategy. The
dashed line reflects the true CV.
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Figure 5.12: II and RCV estimates from biological variability data simulations varying test
variability: II (left column) and RCV (right column) estimates when varying value of CVA
(top row); value of CVI (middle row); and, value of CVG (bottom row). Median is shown by
horizontal line, Q1 and Q3 shown by extremes of box; and minimum and maximum values
shown by arrows. Estimates shown in red are for the baseline strategy. The dashed line
reflects the true II or RCV.
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the estimate required, with resource used to give precision of a specific estimate. The nega-
tive bias (underestimation) of the variance parameters was expected with the small sample
size.50,107 The bias was less than 2% for scenarios with at least 20 participants. For studies
with fewer than 20 participants (of which many were identified, see Chapter 3) the bias may
have a large enough impact on results; results from small studies may not be valid and should
be interpreted with caution.
The Burdick and Graybill method for calculating confidence intervals performed well with
coverage estimates in the expected range for most simulated scenarios. Comparison of re-
sults from simulations to estimates of confidence intervals using the equation suggest the
lower bound of the interval is consistently underestimated for all sample sizes and variability
estimates investigated. This is perhaps due the restriction on the lower bound (the standard
deviation cannot take a negative value).
Increases in the number of participants increased precision of all estimates of variability;
whereas increases in the number of observations increased precision of estimates of variability
at the analytical and within-individual level only, and increasing the number of assessments
increased precision of analytical variability estimates only.
The index of individuality (II) includes the coefficient of variation (CV) at the analytical,
within-individual and between-individual level with each contributing to the estimate ob-
tained. However, as analytical variation is small this has little impact on the estimate of
II. If interest is in the estimate of II, precision of the estimates of variability at the within-
individual and between-individual level should be prioritised by increasing the sample size
via increasing the number of participants and observations for each participant.
The measure of reference change value (RCV) includes the variability estimates at the ana-
lytical and within-individual levels. Again, the variability at the analytical level is generally
small and the level of precision of the variability at the analytical level has little impact on
the estimate of RCV. Increasing the number of observations per participant will increase the
precision of the estimate of within-individual variability and analytical variability. Interest-
ingly, increases in the number of participants increases the precision of RCV also as increases
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in the number of participants helps increase the precision of estimates of variability at the
analytical, within-individual and between-individual levels.
5.5.1 Limitations
The simulation method used assumes test data are normally distributed or log-normally
distributed. Any data that are not distributed in this way may require transformation prior
to analysis as the methods used assume this distribution. The sample size tool, like standard
sample size calculation tools, requires estimates of variability which may be unknown.
Simulation results are shown for the combinations of variability and sample size that have
been selected to demonstrate trends based on the sample sizes and results seen in the review
of biological variability studies (see Chapter 3). The results displayed may not reflect results
for all combinations of variability and sample size, which would need to be considered prior
to planning a study.
Both the normal and log-normal simulation methods used assume the errors have no bias.
This was a necessary assumption, allowing the comparison of input values to estimated results
given the methods used.
When simulating data for more extreme scenarios (large sample sizes and large variability)
the random-effects model failed to converge for a minority of the 1,000 simulations and the
result was forced without convergence.
5.6 Conclusions
When sample sizes of at least 20 participants (with repeated observations and assessments)
are used the methods to generate estimates of analytical, within-individual and between-
individual variability appear valid, with small negative bias. With fewer than 20 participants
the bias may impact results and results from studies should be interpreted with caution.
The methods to generate 95% confidence intervals for biological variability estimates were
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valid.
The use of the specified tool allows simulation of biological variability studies using different
sample sizes, for various estimates of variability. From analysing the simulated data and ob-
serving the range of results obtained the appropriate sample size required to ensure precision
of a given estimate can be inferred.
Increasing the number of participants appears to benefit the precision of all estimates of vari-
ability (analytical, within-individual and between-individual) and this subsequently improves
the precision of estimates of commonly reported measures of biological variability of CVA,
CVI and CVG, and also II and RCV.
Increasing the number of observations for each participant has a positive impact on the
precision of estimates of analytical and within-individual variability; this improves precision
of the estimates of II and RCV also, but not to the magnitude of increasing the number
of participants. Increasing the number of assessments of observations for each individual
increases precision of estimates of analytical variability; this improves precision of CVA but
has little impact on measures of II and RCV.
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Chapter 6
The impact of outlier detection and
removal on studies of biological
variability
This work has been partly presented in the following form:
Sitch A, Mallett S, Deeks J. The impact of outlier detection and removal on studies of
biological variability (BV). Methods for Evaluation of medical prediction Models, Tests And
Biomarkers (MEMTAB), Utrecht, Netherlands. 2-3 July 2018.
Summary
Outlier detection methods are frequently used in the analysis of laboratory based studies of
biological variability. The methods for detecting outliers to be removed from a data set prior
to evaluation vary. Some methods account for the structure of data (multiple assessments of
multiple observations of multiple participants) by comparing variances, and others look at all
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data points evaluating differences in measurements in terms of the range, interquartile range
or standard deviation with comparison to fixed values or critical values based on distributional
assumptions.
Simulation was used to compare the results of analyses using different methods to identify
outliers, with these data points removed prior to analysis.
The simulation showed that when outlier detection is used (when data were log-normally
distributed and had been log-transformed) and identified values are removed the resulting
estimates of analytical, within-individual and between-individual variability are underesti-
mated. The bias in these estimates was greatest when using a detection strategy involving
the Cochran C test and Tukey’s IQR rule. When data were simulated to include outlying
measurements, different outlier detection methods worked best depending on the number of
outliers present. The nature of outliers must be understood before an appropriate method
can be identified.
6.1 Introduction
In biological variability studies of laboratory tests, it is considered best practice to use meth-
ods to identify outliers.13 Identified data are removed prior to obtaining estimates of vari-
ability. Outliers can have a large impact on estimates of variability, especially in small data
sets.108 The methods commonly used are Cochran C test, Reed’s criterion, Dixon’s test,
Grubbs’s test, the Tukey IQR rule and checking values are within three standard deviations,
see Chapter 3. These methods detect data as outlying by assessing the variance of values in
subsets, or evaluating the range, interquartile range or standard deviation with comparison
to fixed values or critical values based on distributional assumptions
Aguinis et al109 offered an extensive review of outlier detection methods defining, identifying
and handling outliers. This review considered 14 outlier definitions, 39 outlier identification
methods and 20 approaches to handling outliers. Outlier definitions leave three main types
of outliers to be considered; ‘error outliers’, ‘interesting outliers’ and ‘influential outliers’.
148
6.1. Introduction
‘Error outliers’ are inaccurate data points; ‘interesting outliers’ are data points outside of
the usual range but offer key information; and, ‘influential outliers’ are data points affecting
model fitting and prediction. The authors offer decision making trees depending on the type
of outliers you are looking to identify and the analysis used. The recommendations are: for
‘error outliers’ remove the data and carefully report this; for ‘interesting outliers’ further
study is appropriate; and, for ‘influential outliers’ analyses should be performed and reported
with and without these outlying measures.
By recommending testing for outliers when analysing biological variability studies35,69 there
is a danger of identifying and removing test values which are plausible (potential interesting
and/or influential outliers) rather than only erroneous data (‘error outliers’), which would be
appropriate and in most circumstances could be identified using basic data descriptions and
clinical knowledge. Outlier detection and removal is performed as researchers believe this
process is beneficial with the estimates obtained after analysis a better reflection of the truth
than if the ‘outlying’ data were to remain.13 However, the practice of detecting and removing
outliers may lead to underestimated variability.
The Cochran C test is criticised for only applying to data with equal groups (balanced design)
and not being two-sided (only large variances are identified).99 Methods relying on detecting
differences from the mean in terms of standard deviations are criticised as the mean and the
standard deviation can be strongly influenced by outliers, they require normality of the data
and perform poorly in small samples.110
A variety of methods are used to identify outliers in biological variability studies, see Chapter
3, with combinations of outlier detection methods used also. Some tests and testing strategies
are specific to the study design and account for the clustering of data, identifying outliers at
each level, and others simply look at the range of the data in comparison to distributional
assumptions. The aim is to understand the impact of using outlier detection methods on
the analysis of biological variability studies comparing no outlier detection and removal to
different methods of outlier detection and removal.
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6.2 Aims and objectives
The aim of this work is to understand and evaluate the impact of outlier detection and
removal on obtaining accurate estimates for biological variability studies. The difference
between methods was evaluated, considering data without outliers and data with ‘error’
outliers.
The main research questions were:
• What are the differences between outlier detection methods when simulating data with-
out outliers? How many data points are unnecessarily and inappropriately removed with
each method and what is the consequence?
• What are the differences between outlier detection methods when simulating data with
‘error’ outliers? How many data points are correctly removed and how many are un-
necessarily removed in addition to these for each method, and what is the consequence?
The specific objectives were to:
• investigate the difference in the number of measurements detected and removed (cor-
rectly and incorrectly) using different methods;
• understand the impact of outlier detection methods on the estimated standard devia-
tions;
• and, evaluate the impact of outlier detection methods on estimates of CV, II and RCV.
The methods of outlier detection evaluated were the Cochran C test, Reed’s criterion, the
Fraser-Harris method,35 the Tukey IQR rule, Dixon’s Q test, Grubbs’s test and restricting
the data to be within three standard deviations of the mean. These methods were identified
when reviewing biological variabilty studies, see Chapter 3.
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6.3 Methods
Biological variability data was simulated and tests for outliers were then used. The detected
outliers were removed and the remaining data were analysed.
6.3.1 Data simulation
6.3.1.1 No outlying data simulation
Log-normally distributed data were simulated. Data were simulated following the model
yijk = µ × αi × βij × εijk, thus ln(yijk) = ln(µ) + ln(αi) + ln(βij) + ln(εijk). Data were
simulated where ln(αi) ∼ N(0, σ2G), ln(βij) ∼ N(0, σ2I ), ln(εijk) ∼ N(0, σ2A) and i = 1, . . . , n1,
j = 1, . . . , n2 and k = 1, . . . , n3.
The simulation was performed with the sample size of 20 participants (n1), four observa-
tion points per participant (n2), and two assessments of each observation (n3). Variabil-
ity estimates were fixed at CVA = 5%, CVI = 10%, and CVG = 20%, and sensitivity
analyses were performed for a ‘poor performing’ test with CVA = 7.5%, CVI = 15%, and
CVG = 30% (increasing each CV separately) and increasing the sample size (n1 = 40, n2 = 4
and n3 = 2).
See Chapter 5 (§5.3.3.3) for further details on the data simulation.
6.3.1.2 Outlying data simulation
Data were also simulated with a percentage of measurements randomly changed by a factor
of 10 or two (multiplied or divided) to give the effect of outliers due to a missed digit or lab
error. Simulations were performed with 0.5%, 1% and 2% of data replaced (using a ceiling
function to give 0.5%=1 measurement; 1%=2 measurements; and, 2%=4 measurements) and
using the multipliers of 10 and two separately.
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6.3.2 Outlier detection methods
A review of studies of biological variability (see Chapter 3) identified the reported methods
for detecting outliers used in these analyses. The following methods were considered:
• no outlier detection;
• Cochran C test;
• Cochran C test partial;
• Fraser-Harris method (Cochran C test and Reed’s criterion for means);
• Reed’s criterion for means;
• Reed’s criterion for measurements;
• Tukey IQR rule;
• Dixon’s Q test;
• Grubbs’s test;
• and, ± 3SD.
6.3.2.1 Cochran C test
Cochran C test for outliers is used in two ways for the purpose of biological variability
data. Firstly the method is used to identify excessive variances for duplicate results within
observations for an individual; and, secondly to identify excessive variances for measurements
for individuals between participants.16
Cochran C test compares the variance of a subgroup of data points to the sum of variances
across all subgroups (subgroups can be duplicate results or observations within individuals).
This ratio of variances is then compared to a critical value (obtained using Fisher’s F ratio).
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If the critical value is exceeded the values within the subgroup generating the largest variance
are deleted and the process is repeated until no variances exceed the critical value.99
Cochran C test for outliers compares the variance within subgroups to the sum of variances
for all subgroups within the larger group. Cochran C values are calculated using:
Cj =
σ2j∑N
i=1 σ
2
i
where there are n assessments within N subgroups. Cochran C values are calculated using
the ratio of the variance of measures within each subgroup and the sum of the variances
across all subgroups.99
For the first assessment, identifying outliers within duplicate assessments, for each individual
σ2j is the variance of the jth pair of observations and is divided by the sum of the variances for
all duplicates for that individual.16 For the second use of the Cochran C test, the variance of
measures for each individual is divided by the sum of variances for all individuals to calculate
the Cochran C value (for this the mean of duplicate assessments is used).
After calculating Cochran C values these are compared to a critical value defined by:
CUL =
[
1 +
(N − 1)
Fc(α/N, (n− 1), (N − 1)(n− 1))
]−1
,
where Fc is the critical value from Fisher’s F ratio. If the Cochran C value is greater than
the critical value the data for the subgroup with Cochran C value exceeding the critical value
is excluded. Strict use of the Cochran C method would mean exclusion of both duplicates
in the first use of the test and all values for an individual in the second use of the test. The
procedure of calculating Cochran C values is repeated and results evaluated until no values
exceed the critical value.99
Partial use of the Cochran C test uses the test only once at each level to identify outliers, as
stated by Fraser and Harris,35 rather than being used repeatedly until no further outliers are
detected. The test statistic was calculated using the R command ‘C.test’.
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6.3.2.2 Reed’s criterion
Reed’s criterion assesses the difference between the largest and next largest and smallest and
next smallest measurements, with these extreme values deleted if the difference is greater
than one-third of the range of the data.16
Say there are a set of measurements x1, . . . , xn where these measurements are arranged in
increasing order, so x1 < x2 < . . . < xn−1 < xn. To assess if the minimum and maximum
values are outliers, the criterion is:
x2 − x1 > 1
3
(xn − x1)
xn − xn−1 > 1
3
(xn − x1).
Reed’s criterion can also be applied to the mean values for each participant. For each par-
ticipant, the mean of their measures is calculated. Say there are n1 participants yielding n1
mean values. These are x¯1, . . . , x¯n where these means are arranged in increasing order, so
x¯1 < x¯2 < . . . < x¯n1−1 < x¯n1 . To assess if the minimum and maximum means are outliers,
the criterion is:
x¯2 − x1 > 1
3
(x¯n − x¯1)
x¯n − xn−1 > 1
3
(x¯n − x1).
If a mean for a participant is detected as an outlier, all values for that participant are
removed.
6.3.2.3 Fraser-Harris method
Outlier detection and removal is advocated in the framework outlined by Fraser and Harris.35
The suggested method involves the use of the Cochran C test firstly, to identify outliers at
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the level of duplicate measurements and observations within individuals, followed by Reed’s
criterion using the mean test value for each individual.16,35
The use of the Cochran C test as explained by Fraser and Harris appears to be conservative
in the second use of the test with only the set of duplicate measures appearing to contribute
to the large variance being removed (partial use of the test) rather than all measurements
for that individual.35
6.3.2.4 Tukey IQR rule
Tukey defined data as outlying if the data did not fall into a region defined using interquartile
ranges. Values were considered to be outliers if they were less than the 25th percentile minus
1.5 times the interquartile range (the difference between the 75th and 25th percentile); or, if
values were greater than the 75th percentile plus 1.5 times the interquartile range.111
If values did not fall into the following region (x) they were declared outliers:
25th percentile− (1.5× IQR) ≤ x ≤ 75th percentile + (1.5× IQR).
6.3.2.5 Dixon’s Q test
Dixon’s Q test was designed to identify a single outlier. The data points are ranked and the
differences between consecutive measurements are calculated. These differences are compared
to the range of all data to generate Q. The value of Q is then compared to a critical value
(depending on the number of measurements and the confidence level); with the extreme value
detected as an outlier and deleted if Q is greater than the critical value.112
Say there are a set of measurements x1, . . . , xn and these are arranged in increasing order, so
x1 < x2 < . . . < xn−1 < xn. To assess if x1 is an outlier Q is calculated as:
Q =
x2 − x1
xn − x1 ,
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providing the ratio of the difference between neighbouring measurements and the range of
the dataset. The calculated Q value is compared to a critical value obtained from tables
(depending on the confidence level and the number of measurements). If Q is greater than the
critical value an outlier has been detected and should be removed from the data set.112
Simulations used the 95% level and defaulted to the maximum number of values available
if the data set contained more using the inbuilt function in R ‘qdixon’. See Table 6.1 for
extract from the Q tables.
Table 6.1: Dixon’s Q tables.
Number of values: 3 4 5 6 7 8 9 10
Q90%: 0.941 0.765 0.642 0.560 0.507 0.468 0.437 0.412
Q95%: 0.970 0.829 0.710 0.625 0.568 0.526 0.493 0.466
Q99%: 0.994 0.926 0.821 0.740 0.680 0.634 0.598 0.568
6.3.2.6 Grubbs’s test
Grubbs’s test again aims to identify a single outlier. Grubbs’s test calculates the difference
between values and the sample mean in terms of the sample standard deviation. These
values are then compared to a critical value (derived from the t distribution), with differences
exceeding this critical value declared outliers and removed.113
Grubbs’s test identifies the maximum difference between a measure (xi) and the sample mean
(x¯) in terms of the sample standard deviation (σ). The test statistic is calculated as:
G =
max|xi − x¯|
σ
.
When conducting a two-sided test the critical value the G statistic is compared to is calculated
as:
n− 1√
n
√
(tα/2n,n−2)2
n− 2 + (tα/2n,n−2)2
,
where n is the sample size and tα/2n,n−2 denotes the critical value from the t distribution
with n − 2 degrees of freedom and significance level of α/2n. The calculated value of G is
compared to the critical value and if G exceeds this value the measure is identified as an
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outlier and should be deleted.113
6.3.2.7 ± 3SD
The simplest outlier detection method calculates the sample standard deviation and values
are declared as outliers and removed if they are not within three standard deviations of the
mean.
Note that methods other than the Cochran C test and the Fraser Harris method do not
account for the clustering of the data in biological variability studies.
6.3.3 Data analysis
As the simulated data were log-normally distributed, data were firstly log transformed and
outlier detection was performed on the log transformed scale. All identified outliers were
removed and a random effects model was fitted to the remaining data; this was a null model
with random effects allowing for assessments within observations and observations within
participants. ln(yijk) = ln(µ) + ln(αi) + ln(βij) + ln(εijk), where i = 1, . . . , n1, j = 1, . . . , n2
and k = 1, . . . , n3, yijk is the test measure for the ith participant at the jth time point and for
the kth assessment, µ is the mean value of the measure, ln(αi) ∼ N(0, σ2G), ln(βij) ∼ N(0, σ2I )
and ln(εijk) ∼ N(0, σ2A).
Fitting the model allowed estimates (σˆA, σˆI and σˆG) of σA, σI and σG to be obtained. The
coefficient of variation (CV), index of individuality (II) and reference change values (RCV)
were additionally produced using estimates from the model.
Exact geometric CVs were calculated using
√
exp(σˆ2)− 159,60 (assuming log-normally dis-
tributed data) and used to calculate II, RCV, and asymmetric RCV, where RCVpos =
exp(1.96 × √2τ) − 1, and RCVneg = exp(−1.96 ×
√
2τ) − 1, where τ =
√
ln(CV 2A+I + 1)
(1.96 is selected from the normal distribution and CVA+I is the coefficient of variation for
the total imprecision, CVA+I =
√
CV 2A + CV
2
I .
62,63 Asymmetric CVs are more appropriate
estimates of RCV when using log-normal data.
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6.3.4 Repeated simulations
Each data simulation, outlier detection method and corresponding analyses were performed
5,000 times. The number of simulations was chosen based on the estimate of coverage; with
5,000 randomly generated data sets an estimate of coverage of 95% (for each of the standard
deviation estimates obtained) would have a confidence interval ranging from 94.359% to
95.588%.
For each outlier strategy the number of measurements identified as outliers and the number
of individuals with outliers removed for each simulated data set was obtained.
Standard simulation performance measures were used to evaluate the ability of the methods
to estimate the standard deviations using different outlier identification procedures and re-
moving identified outliers from the data set. These measures were as suggested by Burton et
al,106 see Chapter 5 Table 5.2.
Additionally, for each of the calculated results the mean, median, 25th percentile (Q1), 75th
percentile (Q3), minimum and maximum value were calculated to summarise results.
All analyses were performed using the statistical software R with the seed set at the start of
each scenario (unique for each scenario). The same simulated data were used and analysed
for each of the outlier strategies, meaning the analysis is paired for each of the 5,000 randomly
generated data sets. All models were fitted using restricted estimation of maximum likelihood
(REML).
6.4 Results
All displayed results give CVs and RCVs as percentages.
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6.4.1 Simulation without outliers
6.4.1.1 Outliers detected and removed
Outlier detection strategies including the Cochran C test identified the most outliers; the
median number of measurements removed in each data set was two when using just the
Cochran C test and four when using the Cochran C test with Reed’s criterion for means.
The full use of the Cochran C test alone identified a maximum of 30 measurements and
partial use identified a maximum of 14 measurements; when pairing with Reed’s criterion
for means (Fraser-Harris method) this increased to a maximum of 20. Reed’s criterion on
mean values for individuals resulted in a median of zero measurements removed but the
maximum number of measurements removed was 16. See Table 6.2 and Figure 6.1 for further
details.
Tukey’s IQR rule identified a median of zero outliers for the 5,000 simulated data sets, but
identified a maximum of 19 measurements in one of the simulated data sets. Grubbs’s test
and the ± 3SD rule identified a maximum of one and seven measurements, respectively;
however, the median number identified and removed was zero. Use of Reed’s criterion for all
measurements and Dixon’s Q test did not identify any outliers to be deleted.
Table 6.2: Outliers removed by each detection method for the 5,000 simulations. Maximum
number of measurements removed is 160 and maximum number of individuals removed is 20.
Outlier strategy Measurements removed Individuals with
measurements removed
median (Q1, Q3) [minimum, maximum]
n % n %
Cochran C test 2 (0, 4)[0, 30] 1 (0, 3)[0, 19] 1 (0, 2)[0, 8] 5 (0, 10)[0, 40]
Cochran C test partial 2 (0, 4)[0, 14] 1 (0, 3)[0, 9] 1 (0, 2)[0, 7] 5 (0, 10)[0, 35]
Fraser-Harris method 4 (2, 8)[0, 20] 3 (1, 5)[0, 13] 1 (1, 2)[0, 7] 5 (5, 10)[0, 35]
Reed’s criterion for means 0 (0, 8)[0, 16] 0 (0, 5)[0, 10] 0 (0, 1)[0, 2] 0 (0, 5)[0, 10]
Reed’s criterion for measurements 0 (0, 0)[0, 0] 0 (0, 0)[0, 0] 0 (0, 0)[0, 0] 0 (0, 0)[0, 0]
Tukey IQR rule 0 (0, 2)[0, 19] 0 (0, 1)[0, 12] 0 (0, 1)[0, 5] 0 (0, 5)[0, 25]
Dixon’s Q test 0 (0, 0)[0, 0] 0 (0, 0)[0, 0] 0 (0, 0)[0, 0] 0 (0, 0)[0, 0]
Grubbs’s test 0 (0, 0)[0, 1] 0 (0, 0)[0, 1] 0 (0, 0)[0, 1] 0 (0, 0)[0, 5]
± 3SD 0 (0, 0)[0, 7] 0 (0, 0)[0, 4] 0 (0, 0)[0, 2] 0 (0, 0)[0, 10]
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Figure 6.1: Histograms showing the number of measurements removed across the 5,000 sim-
ulations when using each outlier detection strategy.
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6.4.1.2 Ability of methods to estimate standard deviations
The bias in estimating the analytical standard deviation was larger for the methods including
the Cochran C test, with increased negative bias compared to the data with no outlier
detection (percentage bias for analytical, within-individual and between-individual SD was
-0.256, -0.365 and -1.608 respectively). The negative bias, even for the no outlier detection
method was expected due to small sample bias (see Chapter 5).50,107 Estimates of within-
individual SD showed increased bias for the methods including the Cochran C test, especially
the Fraser-Harris method (percentage bias for analytical, within-individual and between-
individual SD was -2.126, -0.529 and -3.641 respectively). Use of Reed’s criterion for means
(percentage bias for analytical, within-individual and between-individual SD was -0.290, -
0.492 and -3.679 respectively) increased bias, particularly at the between-individual level;
and, use of the Tukey IQR rule (percentage bias for analytical, within-individual and between-
individual SD was -0.496, -1.549 and -4.305 respectively) increased bias at all levels.
Coverage for estimates of analytical SD was lower when using an outlier detection strategy
including the Cochran C test (decrease from 95.2% to 93.5%-94.0%) with the estimates of
coverage for the Cochran C test analyses below the limit expected given 95% coverage based
on the number of simulations used. Coverage estimates for within-individual SD were also
lower with full use of the Cochran C test. When evaluating the estimate of between-individual
SD the bias increased when using outlier strategies including Reed’s criterion for means and
for full use of the Cochran C tests, see Tables 6.3 and 6.4.
Results when using Tukey’s IQR rule showed increased bias for all estimates of SD and
decreased coverage for estimates of within-individual and between-individual variability. In-
creases in bias were seen for all estimates of SD when using Grubbs’s test and ± 3SD also,
but with the magnitude of the difference to no outlier detection compared with Tukey’s IQR
rule being less.
For the strategies using Reed’s Criterion for measurements and Dixon’s Q test no outliers
were removed so performance was the same as when using no outlier detection.
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6.4. Results
6.4.1.3 Ability of methods to estimate CVs
When using outlier detection strategies including the Cochran C test prior to analysis the
median CVA was 4.89%-4.91% compared with 4.99% for the no outlier detection method,
with the true value of 5%. Reed’s criterion for means, Tukey’s IQR rule, Grubbs’s test
and the ± 3SD rule provided median estimates of CVA of 4.98%, 4.97%, 4.98% and 4.98%
respectively.
For the estimate of CVI , the full Cochran C test strategy had a median value of 9.90%
whereas the no outlier strategy had a median estimate of 9.94%; the true value was 10%.
The Tukey IQR rule and the ± 3SD rule yielded median estimates of CVI of 9.83% and 9.91%
respectively.
When evaluating estimates of CVG, the true value was 20%. The median estimate when
using no outlier detection was 19.58%, this was similar when using strategies including the
Cochran C test only (full and partial use) but for strategies including Reed’s criterion for
means, the median estimates produced were 19.15%. The Tukey IQR rule gave the worst
estimate of 19.00%. When using the ± 3SD rule the median estimate was 19.48%. Results
when using Grubbs’s test and the Cochran C tests were similar to when no outlier removal
was performed.
All estimates for strategies using only Reed’s criterion for all measurements and Dixon’s Q
test remained the same as for using no outlier detection. See Tables 6.5 and 6.6, and Figure
6.2.
6.4.1.4 Ability of methods to estimate IIs and RCVs
The median result when estimating II using no outlier detection was 0.57; the true value
was 0.56. Strategies including the Cochran C test provided a similar median estimate of II
(0.56-0.58; slightly overestimated (II=0.58) when using the Fraser-Harris method and Reed’s
criterion for means). The Tukey IQR outlier method also slightly overestimated II (II=0.58).
All other methods gave very similar results to the analysis when no outlier detection was
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Figure 6.2: Estimates of CVs when using different outlier detection strategies. Beanplots
to show distribution; median is shown by bold line and the dashed line reflects the value
estimated when no outliers are removed.
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used (II=0.57).
The RCV value for this simulation was 30.99%. The median RCV was estimated at 30.86%
when no outlier detection was used and this reduced to 30.65%-30.74% when using strategies
including Cochran C test. The lowest median estimate was 30.53% when using the Tukey
IQR rule. Use of the ± 3SD rule yielded a slight difference in median RCV estimate of
30.76%, see Table 6.7 and Figure 6.3.
Similar results were seen when evaluating the asymmetric RCVs with the lower and upper
bound slightly further underestimated, compared to using no outlier detection method, when
using the strategies including the Cochran C test and ± 3SD rule; and the underestimation
exaggerated further when using the Tukey IQR rule, see Table 6.8 and Figure 6.4.
6.4.1.5 Sensitivity analysis–simulation of test with ‘poor performance’
The simulation of data for a test with increased variability showed the same pattern of results
as seen in the original simulation. The outlier strategies detecting the most measurements
to be removed remained consistent; with slightly fewer measurements removed compared
to the analysis of the original data simulation. The absolute bias estimates were generally
larger with bias increased (underestimation) for analytical and within-individual estimates of
variability when using methods including the Cochran C test, and for estimates of variability
at all levels when using methods including the Tukey IQR rule and the ± 3SD rule. Coverage
again decreased for estimates of analytical and within-individual SD when using strategies
including the Cochran C test. Median estimates of CVA and CVI were underestimated
when using strategies including the Cochran C test and estimates of CVI and CVG were
underestimated when using Tukey IQR rule and ± 3SD rule. See Appendix D Tables D.1-
D.28.
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0.5 1.0 1.5 2.0
+/− 3SD
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Reed’s criterion for measurements
Reed’s criterion for means
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Cochran C test partial
Cochran C test
No outlier detection
Estimated II
0.3 0.7
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+/− 3SD
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No outlier detection
Estimated RCV (%)
Figure 6.3: Estimates of II and RCV when using different outlier detection strategies. Bean-
plots to show distribution; median is shown by bold line and the dashed line reflects the value
estimated when no outliers are removed.
168
6.4. Results
−35 −30 −25 −20
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
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Reed’s criterion for means
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Cochran C test
No outlier detection
Estimated RCV negative (%)
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No outlier detection
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Figure 6.4: Estimates of asymmetric RCV when using different outlier detection strategies.
Beanplots to show distribution; median is shown by bold line and the dashed line reflects the
value estimated when no outliers are removed.
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6.4.1.6 Sensitivity analysis–simulation of data with increased sample size
When increasing the number of participants, the results when using the different outlier
detection strategies followed the same pattern. The number of measurements removed was
increased, as would be assumed given an increased sample size, and there were more measure-
ments identified by the same strategies (strategies including the Cochran C test, Tukey IQR
rule and ± 3SD). The bias in results was consistent, with methods including the Cochran
C test having increased negative bias for estimates of analytical and within-individual vari-
ability and bias for all estimates was poorer for the strategies including Tukey IQR rule
and ± 3SD. Estimates of bias generally were increased for analytical variability and de-
creased for within-individual and between-individual variability. Coverage for the estimate
of analytical SD when using methods including the Cochran C test remained low; with the
coverage when estimating within-individual variability still lower than when no outliers were
removed but closer to 95% than in the base case simulations. Coverage for the estimate of
between-individual SD when using the Tukey IQR rule appeared notably lower also. The
effect on median CV estimates was similar to other data simulations. See Appendix D Tables
D.29-D.35.
6.4.2 Simulation of outlying data
For full results of simulations including outlying data see Appendix D Tables D.36-D.71.
6.4.2.1 Outliers detected and removed
The Cochran C test (full and partial), the Fraser-Harris method and the Tukey IQR rule
identified all outliers in the simulation for all scenarios but with the exclusion of many more
non-outliers. Reed’s criterion for means performed poorly, not identifying all outliers and
removing many valid measurements. Dixon’s Q test, Grubbs’s test and Reed’s criterion for
measurements worked appropriately with only a single outlier but could not identify outliers
when more than one was present. The ± 3SD rule performed well, especially when the
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magnitude of the difference for outliers was smaller and there was only one outlier, see Table
6.9 for full results.
6.4.2.2 Ability of methods to estimate standard deviations
Estimates of bias for the standard deviations showed when no outliers detection was used, for
all outlier simulation scenarios, the analytical SD was overestimated and the within-individual
and between-individual SDs were underestimated.
When the data included only one outlier (magnitude 2 and 10), Reed’s criterion for means
performed poorly (overestimating σA and underestimating σI and σG). Results for outlier
detection strategies including the Cochran C test and the Tukey IQR rule underestimated
the standard deviations at all levels, compared with results using Reed’s criterion for mea-
surements, Dixon’s test, Grubbs’s test and ± 3SD (methods that correctly identified only the
outlier).
When more than one outlier was simulated and the magnitude was two, the methods of
Reed’s criterion for means and measurements, Dixon’s test and Grubbs’s test performed
poorly (overestimating σA and underestimating σI and σG); strategies including the Cochran
C test and the Tukey IQR rule did not perform as well as ± 3SD. When simulating data
with multiple outliers and with the increase magnitude (10) the ± 3SD rule also performed
poorly.
171
C
h
ap
ter
6.
T
h
e
im
p
act
o
f
ou
tlier
d
etection
an
d
rem
oval
on
stu
d
ies
of
b
iological
variab
ility
Table 6.9: Outlier detection methods with outlier simulation–outliers removed by each detection method. Maximum number of measurements
is 160, maximum number of individuals is 20 and maximum number of outliers removed is 0.5%=1, 1%=2 and 2%=4.
Outlier strategy Observations removed Individuals with Outliers removed
measurements removed
median (Q1, Q3) [minimum, maximum]
n % n % n %
Scenario: 0.5% and magnitude 2
Cochran C test 4 (2, 6)[2, 30] 3 (1, 4)[1, 19] 2 (1, 3)[1, 7] 10 (5, 15)[5, 35] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Cochran C test partial 4 (2, 6)[2, 12] 3 (1, 4)[1, 8] 2 (1, 3)[1, 6] 10 (5, 15)[5, 30] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Fraser-Harris method 4 (4, 10)[2, 24] 3 (3, 6)[1, 15] 2 (2, 3)[1, 7] 10 (10, 15)[5, 35] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Reed’s criterion for means 8 (0, 8)[0, 16] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 5 (0, 5)[0, 10] 1 (0, 1)[0, 1] 100 (0, 100)[0, 100]
Reed’s criterion for measurements 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Tukey IQR rule 1 (1, 3)[1, 20] 1 (1, 2)[1, 13] 1 (1, 2)[1, 7] 5 (5, 10)[5, 35] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Dixon’s Q test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Grubbs’s test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
± 3SD 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Scenario: 1% and magnitude 2
Cochran C test 6 (4, 8)[4, 32] 4 (3, 5)[3, 20] 3 (2, 4)[2, 8] 15 (10, 20)[10, 40] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Cochran C test partial 6 (4, 8)[4, 16] 4 (3, 5)[3, 10] 3 (2, 4)[2, 8] 15 (10, 20)[10, 40] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Fraser-Harris method 6 (4, 12)[4, 24] 4 (3, 8)[3, 15] 3 (2, 4)[2, 8] 15 (10, 20)[10, 40] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Reed’s criterion for means 8 (0, 8)[0, 16] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 50 (0, 50)[0, 100]
Reed’s criterion for measurements 1 (0, 1)[0, 2] 1 (0, 1)[0, 1] 1 (0, 1)[0, 2] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 50 (0, 50)[0, 100]
Tukey IQR rule 2 (2, 4)[2, 21] 1 (1, 3)[1, 13] 2 (2, 3)[2, 8] 10 (10, 15)[10, 40] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Dixon’s Q test 1 (0, 1)[0, 1] 1 (0, 1)[0, 1] 1 (0, 1)[0, 1] 5 (0, 5)[0, 5] 1 (0, 1)[0, 1] 50 (0, 50)[0, 50]
Grubbs’s test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 50 (50, 50)[50, 50]
± 3SD 2 (2, 2)[2, 2] 1 (1, 1)[1, 1] 2 (2, 2)[2, 2] 10 (10, 10)[10, 10] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
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Outlier strategy Observations removed Individuals with Outliers removed
measurements removed
median (Q1, Q3) [minimum, maximum]
n % n % n %
Scenario: 2% and magnitude 2
Cochran C test 10 (8, 14)[8, 38] 6 (5, 9)[5, 24] 5 (4, 5)[4, 9] 25 (20, 25)[20, 45] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Cochran C test partial 10 (8, 10)[8, 18] 6 (5, 6)[5, 11] 5 (4, 5)[4, 9] 25 (20, 25)[20, 45] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Fraser-Harris method 10 (8, 16)[8, 26] 6 (5, 10)[5, 16] 5 (4, 6)[4, 10] 25 (20, 30)[20, 50] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Reed’s criterion for means 8 (0, 8)[0, 16] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 25 (0, 25)[0, 50]
Reed’s criterion for measurements 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 5)[0, 5] 0 (0, 1)[0, 1] 0 (0, 25)[0, 25]
Tukey IQR rule 4 (4, 6)[4, 23] 3 (3, 4)[3, 14] 4 (4, 5)[4, 9] 20 (20, 25)[20, 45] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Dixon’s Q test 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 5)[0, 5] 0 (0, 1)[0, 1] 0 (0, 25)[0, 25]
Grubbs’s test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 25 (25, 25)[25, 25]
± 3SD 4 (4, 4)[4, 4] 3 (3, 3)[3, 3] 4 (4, 4)[4, 4] 20 (20, 20)[20, 20] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Scenario: 0.5% and magnitude 10
Cochran C test 4 (2, 6)[2, 28] 3 (1, 4)[1, 18] 2 (1, 3)[1, 7] 10 (5, 15)[5, 35] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Cochran C test partial 4 (2, 6)[2, 14] 3 (1, 4)[1, 9] 2 (1, 3)[1, 7] 10 (5, 15)[5, 35] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Fraser-Harris method 4 (4, 10)[2, 22] 3 (3, 6)[1, 14] 2 (1, 3)[1, 8] 10 (5, 15)[5, 40] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Reed’s criterion for means 8 (0, 8)[0, 8] 5 (0, 5)[0, 5] 1 (0, 1)[0, 1] 5 (0, 5)[0, 5] 1 (0, 1)[0, 1] 100 (0, 100)[0, 100]
Reed’s criterion for measurements 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Tukey IQR rule 1 (1, 3)[1, 22] 1 (1, 2)[1, 14] 1 (1, 2)[1, 7] 5 (5, 10)[5, 35] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Dixon’s Q test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
Grubbs’s test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
± 3SD 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 100 (100, 100)[100, 100]
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Outlier strategy Observations removed Individuals with Outliers removed
measurements removed
median (Q1, Q3) [minimum, maximum]
n % n % n %
Scenario: 1% and magnitude 10
Cochran C test 6 (4, 8)[4, 28] 4 (3, 5)[3, 18] 3 (2, 4)[2, 9] 15 (10, 20)[10, 45] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Cochran C test partial 6 (4, 8)[4, 18] 4 (3, 5)[3, 11] 3 (2, 4)[2, 9] 15 (10, 20)[10, 45] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Fraser-Harris method 6 (4, 12)[4, 26] 4 (3, 8)[3, 16] 3 (2, 4)[2, 9] 15 (10, 20)[10, 45] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Reed’s criterion for means 8 (0, 8)[0, 16] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 50 (0, 50)[0, 100]
Reed’s criterion for measurements 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 5)[0, 5] 0 (0, 1)[0, 1] 0 (0, 50)[0, 50]
Tukey IQR rule 2 (2, 4)[2, 21] 1 (1, 3)[1, 13] 2 (2, 3)[2, 7] 10 (10, 15)[10, 35] 2 (2, 2)[2, 2] 100 (100, 100)[100, 100]
Dixon’s Q test 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 1)[0, 1] 0 (0, 5)[0, 5] 0 (0, 1)[0, 1] 0 (0, 50)[0, 50]
Grubbs’s test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 50 (50, 50)[50, 50]
± 3SD 2 (1, 2)[1, 2] 1 (1, 1)[1, 1] 2 (1, 2)[1, 2] 10 (5, 10)[5, 10] 2 (1, 2)[1, 2] 100 (50, 100)[50, 100]
Scenario: 2% and magnitude 10
Cochran C test 10 (8, 14)[8, 44] 6 (5, 9)[5, 28] 5 (4, 5)[4, 10] 25 (20, 25)[20, 50] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Cochran C test partial 10 (8, 10)[8, 20] 6 (5, 6)[5, 13] 5 (4, 5)[4, 10] 25 (20, 25)[20, 50] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Fraser-Harris method 10 (8, 16)[8, 28] 6 (5, 10)[5, 18] 5 (4, 6)[4, 10] 25 (20, 30)[20, 50] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Reed’s criterion for means 8 (0, 8)[0, 16] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 5 (0, 5)[0, 10] 1 (0, 1)[0, 2] 25 (0, 25)[0, 50]
Reed’s criterion for measurements 0 (0, 0)[0, 1] 0 (0, 0)[0, 1] 0 (0, 0)[0, 1] 0 (0, 0)[0, 5] 0 (0, 0)[0, 1] 0 (0, 0)[0, 25]
Tukey IQR rule 4 (4, 6)[4, 21] 3 (3, 4)[3, 13] 4 (4, 5)[4, 9] 20 (20, 25)[20, 45] 4 (4, 4)[4, 4] 100 (100, 100)[100, 100]
Dixon’s Q test 0 (0, 0)[0, 1] 0 (0, 0)[0, 1] 0 (0, 0)[0, 1] 0 (0, 0)[0, 5] 0 (0, 0)[0, 1] 0 (0, 0)[0, 25]
Grubbs’s test 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 1 (1, 1)[1, 1] 5 (5, 5)[5, 5] 1 (1, 1)[1, 1] 25 (25, 25)[25, 25]
± 3SD 2 (2, 3)[1, 4] 1 (1, 2)[1, 3] 2 (2, 3)[1, 4] 10 (10, 15)[5, 20] 2 (2, 3)[1, 4] 50 (50, 75)[25, 100]
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6.4.2.3 Ability of methods to estimate CVs
With no outlier detection methods used the analysis of the data from the outlier simulations
overestimated CVA, and underestimated CVI and CVG. When simulating a single outlier,
estimates of CVA were reasonable for all outlier exclusion methods, except for Reed’s criterion
for means. When using Reed’s criterion for means the median CVA was still close to the true
value but for some simulations CVA was overestimated.
For the simulations of more than one outlier with magnitude two, the estimates of CVA were
overestimated when using Reed’s criterion for means and measurements, Dixon’s test and
Grubbs’s test. Estimates of CVA were appropriate for strategies including the Cochran C
test, the Tukey IQR rule and ± 3SD.
When simulating data with outlier(s) of magnitude 10, there was a general increase in the
variability of estimates of CVs. For the 1% outlier simulation, the methods of Reed’s criterion
for means and measurements, Dixon’s test and Grubbs’s test were poor. The median estimate
of CVA when using ± 3SD was slightly increased also. When the outliers were increased to 2%
the same strategies performed poorly, and the estimates were further overestimated.
When analysing estimates of CVI and CVG there was a similar pattern for the outlier detection
strategies performing poorly, but with underestimation, and this was not as extreme as for
CVA. See Figures 6.5-6.10.
6.4.2.4 Ability of methods to estimate IIs and RCVs
The II and RCV estimates were extreme, compared to the true values, when analysing the
simulated data with outliers using no outlier detection (II: 3.41 to > 104; lower bound RCV
(%): -87.13 to -100.00; and, upper bound RCV (%): 677.30 to > 104). Estimates when
simulating data with only one outlier (regardless of magnitude) were inflated using Reed’s
criterion for means (II=0.68/0.64; lower bound RCV (%):-28.01/-27.59; and, upper bound
RCV (%): 38.91/38.10). When estimating II and RCV with simulations with more outliers,
the methods of Reed’s criterion for means and measurements, Dixon’s and Grubbs’s test
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Figure 6.5: Outlier detection methods with outlier simulation (magnitude 2)–analytical CV.
Beanplots to show distribution. Vertical lines indicate values at the 2.5th percentile, 25th
percentile, median, 75th percentile and 97.5th percentile of estimates when simulating data
without outliers. The true value of CV is 5%. * shows estimates continue beyond the range
displayed.
176
6.4. Results
2 5 10 20 50 100 200 500 1000
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
Reed’s criterion for measurements
Reed’s criterion for means
Fraser−Harris method
Cochran C test partial
Cochran C test
No outlier detection
Magnitude 10 & 0.5%
Estimated analytical CV (%)
2 5 10 20 50 100 200 500 1000
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
Reed’s criterion for measurements
Reed’s criterion for means
Fraser−Harris method
Cochran C test partial
Cochran C test
No outlier detection
Magnitude 10 & 1%
Estimated analytical CV (%)
2 5 10 20 50 100 200 500 1000
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
Reed’s criterion for measurements
Reed’s criterion for means
Fraser−Harris method
Cochran C test partial
Cochran C test
No outlier detection
Magnitude 10 & 2%
Estimated analytical CV (%)
Figure 6.6: Outlier detection methods with outlier simulation (magnitude 10)–analytical CV.
Beanplots to show distribution. Vertical lines indicate values at the 2.5th percentile, 25th
percentile, median, 75th percentile and 97.5th percentile of estimates when simulating data
without outliers. The true value of CV is 5%. * shows estimates continue beyond the range
displayed.
177
Chapter 6. The impact of outlier detection and removal on studies of biological variability
2 5 10 20 50 100 200 500 1000
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
Reed’s criterion for measurements
Reed’s criterion for means
Fraser−Harris method
Cochran C test partial
Cochran C test
No outlier detection
Magnitude 2 & 0.5%
Estimated within−individual CV (%)
2 5 10 20 50 100 200 500 1000
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
Reed’s criterion for measurements
Reed’s criterion for means
Fraser−Harris method
Cochran C test partial
Cochran C test
No outlier detection
Magnitude 2 & 1%
Estimated within−individual CV (%)
2 5 10 20 50 100 200 500 1000
+/− 3SD
Grubbs’s test
Dixon’s Q test
Tukey IQR rule
Reed’s criterion for measurements
Reed’s criterion for means
Fraser−Harris method
Cochran C test partial
Cochran C test
No outlier detection
Magnitude 2 & 2%
Estimated within−individual CV (%)
Figure 6.7: Outlier detection methods with outlier simulation (magnitude 2)–within-
individual CV. Beanplots to show distribution. Vertical lines indicate values at the 2.5th
percentile, 25th percentile, median, 75th percentile and 97.5th percentile of estimates when
simulating data without outliers. The true value of CV is 10%. * shows estimates continue
beyond the range displayed.
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Figure 6.8: Outlier detection methods with outlier simulation (magnitude 10)–within-
individual CV. Beanplots to show distribution. Vertical lines indicate values at the 2.5th
percentile, 25th percentile, median, 75th percentile and 97.5th percentile of estimates when
simulating data without outliers. The true value of CV is 10%. * shows estimates continue
beyond the range displayed.
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Figure 6.9: Outlier detection methods with outlier simulation (magnitude 2)–between-
individual CV. Beanplots to show distribution. Vertical lines indicate values at the 2.5th
percentile, 25th percentile, median, 75th percentile and 97.5th percentile of estimates when
simulating data without outliers. The true value of CV is 20%. * shows estimates continue
beyond the range displayed.
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Figure 6.10: Outlier detection methods with outlier simulation (magnitude 10)–between-
individual CV. Beanplots to show distribution. Vertical lines indicate values at the 2.5th
percentile, 25th percentile, median, 75th percentile and 97.5th percentile of estimates when
simulating data without outliers. The true value of CV is 20%. * shows estimates continue
beyond the range displayed.
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produced extreme results (II and RCV upper bound (%) estimates > 104 and RCV lower
bound (%) estimates of -100); for the high outlier magnitude simulation ± 3SD also pro-
duced extreme results (II: 6.94; lower bound RCV (%): -93.85; and, upper bound RCV (%):
1526.72).
6.4.3 Comparison of outlier detection methods
The Cochran C test, Cochran C test partial, Fraser-Harris method and Tukey IQR rule
introduced negative bias to estimates of variability when outliers were simulated and not
simulated; when outliers were simulated estimated standard deviations were similar to analy-
ses of data when outliers were not simulated. When using Reed’s criterion for means, Reed’s
criterion for measurements, Dixon’s test and Grubbs’s test the bias was small when analysing
data with no outliers but with the outlier simulation (or more than one outlier simulated) the
methods failed to identify outliers and the bias was large. The ± 3SD method gave reasonable
estimates with small bias for the no outlier simulation and most of the outlier scenarios, the
bias only increased for the most extreme outlier scenario, see Figure 6.11.
When estimating the analytical standard deviation using the Cochran C test, Cochran C
test partial and the Fraser-Harris method the bias was negative (approximately -2%) when
no outliers were simulated and for all outlier simulation scenarios; there was less bias (ap-
proximately -1%) when using the Tukey IQR rule. When estimating the within-individual
standard deviation the Tukey IQR rule gave the most negatively bias results for all scenarios
(no outliers and all outlier simulations); results when using the Cochran C test, Cochran C
test partial and the Fraser-Harris method were less biased. When estimating the between-
individual standard deviation, bias was larger when using the Fraser-Harris method and
Tukey IQR rule for the no outlier and all outlier scenarios; estimates when using Cochran C
test and Cochran C test partial were close to results using no outlier detection for the data
with no outliers simulated.
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Figure 6.11: Comparison of average percentage bias for analytical, within-individual and
between-individual standard deviations between outlier detection methods. Dotted line indi-
cates the average percentage bias when using no outlier detection methods for the data with
no outliers. Crosses indicate the average percentage bias for the scenarios with outliers of
magnitude 2 (salmon) and magnitude 10 (teal). Red points indicate the average percentage
bias for each outlier detection method when analysing data with no outliers.
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6.5 Discussion
The analyses using the different outlier detection methods showed, in many cases, none of
the log-normally distributed data were considered outlying, leading to no changes to the data
and the same results obtained from analysis. The methods of outlier detection using the
Cochran C test and Reed’s criterion for means caused data to be detected as outlying more
often and subsequently the results for this analysis reflected an increase in (negative) bias
when estimating analytical and within-individual variation. The Tukey IQR rule, Grubbs’s
test and ± 3SD method led to outlier detection also, with increases in the bias of variability
results (particularly when using the Tukey IQR method). Strategies including the Cochran
C test led to reduced estimates of CVA and CVI ; and strategies using the Tukey IQR rule
led to decreased CVI and CVG estimates. For all strategies estimates of II were similar with
slightly increased results when using the Tukey IQR rule and the RCV bound estimates were
closer to zero for methods including the Cochran C test, Tukey IQR rule and ± 3SD rule.
The negative bias (underestimation) of the variance parameters was expected with the small
sample size.50,107
This simulation showed some of the outlier detection methods used may incorrectly identify
data as outlying and these data were inappropriately removed prior to analysis. These outlier
detection methods are based on reducing the variability within and between groups and the
range of data, with the more extreme data points removed. After detecting data as outlying
these data were then removed resulting in reduced variability shown by the increased negative
bias in the variability results after using outlier detection techniques; some estimated standard
deviations at the analytical level had -2% bias; at the within-individual level had -1% bias;
and, at the between-individual level -4% bias, which has the potential to impact results and
how tests are used. Different techniques affected different levels of bias with the Cochran C
test changing the results for analytical and within-individual variability, as the test focussed
on variability within the duplicate assessments and the groups; and, Reed’s criterion for
means and the Tukey IQR test had biggest impact on the estimate of variability at the
between-individual level.
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6.5. Discussion
The outlier simulation showed methods that identify a single outlier or a minimum and/or
maximum outlier worked well when only one outlier was present. Other methods detected
more data to be excluded than the just the outlying measurements. Given the magnitude
of the difference in the outlying data compared with the unaltered data, the outlying mea-
surements could easily have been detected using descriptive data summaries or plots of the
data. It is important for researchers in this area to understand how these outlier detection
methods work and for these methods to be used in an appropriate way, tailored to the data
set. Outlier detection methods should not be used as standard but only if there is reason
to believe extreme data are present with the nature of these outliers understood and the
appropriate action identified. The ± 3SD rule worked well, only providing invalid results for
the most extreme outlier simulation.
Separate estimates of CVA, CVI and CVG were more robust to incorrect outlier removal than
estimates of II and RCV which use combinations of CVA, CVI and CVG. For the analyses
where outliers were simulated, the results showed increased CVA as the outliers introduced
were ‘error outliers which would increase variability at the analytical level.
Outlier detection methods were used following transformation of data. In this artificial sim-
ulation of log-normal data, this approach is known to be required. As many of the outlier
methods rely on normality of data, this approach should allow optimal use of these methods.
There is guidance for the use of outlier detection and data transformation that may lead
to outlier detection and removal prior to transformation.46 If this strategy is used, outlier
detection methods may perform poorly in comparison to the results shown.
The Birmingham Quality group, part of the National External Quality Assessment Scheme
(NEQAS), monitor the results across UK labs when assessing control material. When re-
porting the results of monitoring assessments, NEQAS rank the data and the 2.5th to 97.5th
percentile range is reported,114 similar to the methods relying on data ranges evaluated.
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6.5.1 Limitations
Data were simulated from a log-normal distribution which may not be truly reflective of
biological variability data seen in practice. The first stage of simulations used data that
were normally distributed after transformation and because of this outlier detection was not
necessary as the data were simulated without outlying data. This element of the study only
allows understanding of the consequences of using different outlier detection methods on data
that are normally distributed. To understand the potential performance of outlier detection
strategies, simulations were performed with outliers introduced.
This artificial generation of outliers may not be reflective of the type of outlying data seen in
biological variability studies. The simulation used added ‘error’ outliers. These values were
random with no link to observation points or individuals. Further work could investigate the
impact of outliers with trend relating to individuals and/or observation points.
A limited number of scenarios were used to investigate the performance of outlier detec-
tion methods. Sensitivity analyses were used, varying the sample size and test variability
estimates; however, the ability of these methods may vary with study design and test per-
formance. The combined effect of small sample size (see Chapter 5) and outlier detection
methods has not been fully investigated.
6.6 Conclusions
In the situation when data are known to be incorrect (an ‘error’ outlier) because of im-
plausible values, be it due to an error in performing the test, storing a sample or recording
a result, then these data should be discarded and with remaining values used for analysis
and the process for removing data carefully reported. However, if data are plausible, the
removal of such data should be treated with extreme caution as these outlying data may be
informative (an ‘interesting’ or ‘influential’ outlier). These types of outliers require further
consideration.
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6.6. Conclusions
The analysis presented has shown often used methods of outlier detection (particularly the
methods advocated by Fraser-Harris) can lead to bias in the results of biological variabil-
ity studies by underestimating the variability which may impact how tests are used, hence
studies using these methods should be interpreted with caution. Also, the analysis of data
including outliers showed different methods performed better depending on the number of
outlying measurements and the magnitude of the difference between the outlying data and
the rest of the data. Different methods of outlier detection may be selected based on the
number of outliers considered. The ± 3SD rule worked well, only providing invalid results for
the most extreme outlier simulation and introducing less bias than the other methods able
to appropriately eliminate outliers (Cochran C test, Cochran C test partial, Fraser-Harris
method and Tukey IQR rule) at the analytical, within-individual and between-individual
level.
It is recommended the data obtained in biological variability studies is viewed prior to using
outlier detection methods, with these methods only employed if visualisation of the data
shows cause to investigate. It is also recommended if outlier detection methods are used and
this leads to the removal of data, the analysis is performed on both the original and modified
data and any differences are commented on or both sets of results are displayed. If an outlier
detection method is required, the ± 3SD rule is recommended.
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Chapter 7
A review of monitoring-related
methodology literature
This work has been partly presented in the following form:
Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe
C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes
J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter
P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme
C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S,
Trainor S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin
N, McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D.
Methods for the evaluation of biomarkers in patients with kidney and liver diseases:
multicentre research programme including ELUCIDATE RCT. Chapter 5: A review of
monitoring-related methodology literature. Programme Grants for Applied Research 2018.
189
Chapter 7. A review of monitoring-related methodology literature
Summary
The review of monitoring and monitoring related literature yielded few methods directly
applicable to monitoring of progressive or recurrent disease.
Many of the methods identified are in the related areas of screening, biomarker development
and monitoring for treatment titration purposes. Work in screening may be adapted to
identify appropriate monitoring frequency and applications of the signal to noise approach
for choosing decision rules and thresholds.
Biases identified in areas related to monitoring also need to be considered when using tests
to monitor progression and recurrence of disease.
7.1 Introduction
The purpose of this work is to identify methods for the analysis of data collected from the
monitoring of progressive and recurrent conditions and the design of monitoring strategies
for subsequent evaluation. There are also related areas that may have methods for analysis
and design that can be adapted to be applicable for monitoring of progressive and recurrent
conditions.
Research in the area of monitoring has concentrated on treatment titration. Whilst the pro-
cesses involved in monitoring treatment differ from monitoring patients with potential for
progressive or recurrent disease, the general structure of the data is the same and there are
lessons to be learnt from the research that has been done. There is some methods literature in
the area of screening and, whilst screening is carried out in asymptomatic individuals rather
than patients known to have disease that may progress or recur, there are obvious parallels
between screening and monitoring. These methods are not currently used when planning
screening strategies, with economic evaluations preferred to inform processes, however work
is currently ongoing to improve the selection of screening strategies.115 The literature on ref-
erence change values and statistical process controls may also contribute to the development
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of methods for monitoring of progressive and recurrent disease.
7.2 Aims and objectives
The aim of this review was to understand the current methods available to design monitoring
strategies. To investigate methods in monitoring and related areas searches were developed
to identify papers developing and evaluating monitoring and screening strategies, introducing
time dependent measures of test performance, explaining methods to evaluate measurement
change from test variability and health economic approaches to developing testing proto-
cols.
7.3 Methods
Methodological information related to monitoring was firstly sought from the first edition of
the book ‘Evidence-based medical monitoring’, edited by Paul Glasziou, Les Irwig and Jeffrey
Aronson. Key textwords related to monitoring methodology were identified and purposive
searches of MEDLINE were undertaken from 2000 to 2010 (searches conducted on 26 March
2010). Reference tracking and citation tracking using Science Citation Index were used to
identify additional relevant literature.
A variety of searches were performed to identify relevant literature using various combinations
of the following text words:
(i) monitor*;
(ii) measure* or biomarker* or marker*;
(iii) serial or repeat* or periodic or longitudinal or trajectory*;
(iv) recurrence or progression;
(v) rule* or threshold* or trigger;
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(vi) statistical process control or control chart* or reference change value or critical differ-
ence;
(vii) screen* with frequenc* or intensit* or interval*.
The searches retrieved 2,578 papers for review. These papers were screened by a single
reviewer, and only papers reported in the English Language were considered. After reviewing
72 articles were included initially. Summaries from biomarker development papers identified
by the search are not presented here. Full details have been published.116
The papers selected for review were summarised and full details can be seen in Appendix E
E Table E.1.
7.4 Results
Limited methodological literature was identified providing guidance for the design of studies
to evaluate monitoring tests. Work has focussed more on analytic techniques to assist with
the design of monitoring strategies; primarily through analysis of existing data in order to
make recommendations on monitoring frequency or decision rules, or simulation work, with
both approaches specific to the disease area researched.
The identified literature can be categorised as:
• Development and evaluation of monitoring strategies
– Linear mixed effects models and estimation of signal to noise ratio;
– Joint modelling of longitudinal and outcome data;
– Non-linear mixed models;
– Alternative modelling approaches;
– Simulation studies;
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– Analysis of cohort data;
• Screening;
• Time-dependent ROC curves;
• Differentiating measurement change from measurement variability;
• Health economic approaches
– Decision analytic models;
– Real options approaches.
7.4.1 Development and evaluation of monitoring strategies
The literature in the area of monitoring focussed on modelling approaches (linear mixed mod-
elling, joint modelling and non-linear modelling). The review of the literature also identified
simulation studies and work on the evaluation of monitoring strategies.
Most identified papers provided methods (or examples of methods being applied) to assess
monitoring data via linear mixed modelling, signal to noise ratio analysis and joint modelling.
Articles considering design of monitoring strategies were rare and tended to consider test
frequency rather than decision rules and test thresholds. See Table 7.1.
Table 7.1: Focus of monitoring papers.
Concept Number of papers
Design
Test frequency 89,11,29,31,117–120
Test thresholds 29,117
Decision rules 49,29,119,120
Other 4121–125
Analysis
General data structure 212,124
Linear mixed effects modelling/SNR 149–12,14,117,118,123,126–131
Joint modelling 1029,31,119,132–138
Review of methods 212,132
Other 7124,125,130,131,138–140
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7.4.1.1 Linear mixed effects models and estimation of signal to noise ratio
General description of models
Stevens et al12 reviewed statistical models used for the control phase of monitoring and
explained how models can be fitted to observed monitoring data providing details of maximum
likelihood methods, moment-based methods and literature based methods, where parameter
estimates are obtained from reviewing the literature. They introduced a generic model for
monitoring data, defining Yit as the observed monitoring values including assay noise and
variability, and Uit as the ‘true’ underlying and unobserved values. Uit = αi + βit and
Yit = Uit + ωit where αi is the true value at time 0, βit is the change in the true value over
time and ωit is random error,
12 see Chapter 1.
Stevens et al12 discussed the analytical methods required to give the proportion of positive
tests that are truly positive, normality is assumed allowing the marginal and joint distribution
of observed and unobserved values to be used. With more complex models (correlation
structures and distributional assumptions) analytical methods become more difficult to use
and simulation may be favourable. The intercept and gradient can be simulated using their
modelled distributions allowing the unobserved underlying values to be generated. The error
term can be simulated also and combined with the underlying values to give the observed
values. Calculations are then made by comparing the underlying true values with the observed
values.
Signal and noise
Glasziou and colleagues121 questioned the need for randomised controlled trials of monitoring
under certain circumstances, instead promoting understanding the background variation and
evaluating the signal to noise ratio when assessing treatment effects. They suggested large
estimated treatment effects would be required to demonstrate an effect.
Modelling methods are used with repeated test data in the hope of distinguishing ‘signal’
from ‘noise’. The ‘noise’ is normal fluctuation in test results for patients (caused by the
measurement variability of the test) and the ‘signal’ is a change in test results signifying a
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Box 7.1: Signal and noise monitoring examples.
Thompson and Pocock126 presented their findings following the analysis of repeated serum
cholesterol measurements on 14,600 men and women. Their work focussed on the impact
of within-individual variability on screening and monitoring. Using the cholesterol data
a single observed measurement did not reflect the true underlying measure. Thompson
and Pocock showed how the probability of a measure being classed as ‘high’ varied with
the true underlying value, and whether the classification was based on a single measure
or the mean value of multiple measures. The use of multiple measures was shown to
improve classification. The authors identified regression to the mean when analysing
multiple measures and variability in the measures for untreated individuals over time
leading them to doubt whether repeated measures would be able to identify the benefit
of treatment. The authors state the use of repeated measures could be ‘very discouraging’
for some patients.
Buclin et al9 defined two decision rules that could be used to guide the treatment of pa-
tients with HIV infection with antiretroviral treatment based on CD4 cell measurements
using a review of longitudinal analyses of CD4 cell trajectories. The first decision rule was
a ‘snap-shot rule’, dependent on a single CD4 measure, and the other was a ‘track-shot
rule, where multiple CD4 measures are required. The devised rules were tested using
clinical data, to minimise false findings, and recommendations were made regarding the
frequency of testing.
Bell and colleagues122 developed a framework to identify when monitoring of initial re-
sponse to treatment would be beneficial using data from RCTs. The findings showed
monitoring of initial response to treatment would only be useful when there is variation
in treatment effect between patients and not all treated patients achieved results at the
therapeutic level targeted.
Other examples of the use of mixed modelling and signal to noise ratio estimation, to
understand when it is appropriate to monitor response to treatment, thresholds or moni-
toring frequency were: monitoring of cholesterol,14,122,127 bone mineral density,123 blood
pressure,10,117,128,129 lipids,118 and diabetes.11
true change in disease state, see Box 7.1 for examples of using these models.
7.4.1.2 Joint modelling of longitudinal and outcome data
Joint latent class models
When fitting a joint latent class model subjects are split into a finite number of latent sub-
groups. The trajectory of biomarker measurements and the risk of event are specific to each
latent class, with the model allowing for the dependency of biomarker values and risk of
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event. A multinomial logistic regression model is used to assign subjects to subgroups. A lin-
ear mixed model is used to model repeated biomarker measurements given the assigned latent
class of the subject; and, a survival model is used to model the time-to-event, again given the
latent class of the subject. The model is fitted using maximum likelihood estimation.132
Examples of the use of joint latent class models can be seen in work by Proust-Lima and
Taylor133 and Li and Gatsonis,31 both applied to monitoring with prostate specific antigen
(PSA) prostate cancer recurrence, see Box 7.2.
Box 7.2: Joint latent class models example.
Proust-Lima and Taylor133 discussed the derivation of a posterior probability of recur-
rence from a joint class linear model to identify a ‘dynamic prognostic tool of recurrence’.
The posterior probability obtained from the joint latent class model gives the probability
of an event occurring between time s and time s + t (where the subject is event free at
time s). Estimating the probability of an event after a certain time requires fitting sur-
vival models to subjects at each time estimated with only covariates available at time s.
As biomarker data are often discrete, imputation techniques are used to allow predictions
of an event to be obtained at multiple time points. Proust-Lima et al also discussed the
validation of predictive tools and the lack of consensus in this area.
Li and Gatsonis31 used a joint latent class model to develop a strategy that modifies
monitoring intervals. Li and Gatsonis used a two-stage approach when fitting the joint
latent class model, where the model used to identify latent classes was fitted separately.
Bayesian Information Criteria was used to select the number of classes. The two-stage
approach has the advantage of being less computationally intensive. The uncertainty of
latent class assignment was evaluated using multiple imputation assuming latent class
was missing completely at random. For prospective studies the two-stage procedure is
repeated as new information is collected (measures, events and study end). Li and Gat-
sonis demonstrated the method using simulated PSA measurements for 150 patients with
prostate cancer with testing to identify recurrence. Predictions from the model inform
a utility function which was used to identify the appropriate monitoring intervals for
each patient. The expected value of the utility function used is U˜t = aP (event at time t)
where a is a negative value if the event occurs and zero otherwise. The optimal monitor-
ing interval can be identified for individuals or groups of patients; the authors advocated
optimising by latent class as these intervals can then be adapted for new patients.
Bayesian hierarchical change-point models
Bayesian hierarchical change-point models model the trajectory of test results prior to, at
the time of and after the onset of disease simultaneously. Models also allow for the within-
individual correlation, as individuals have multiple test measurements, between-subject vari-
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ation in trajectories and the random change-point. A piecewise or segmented linear model is
used where the parameters of the model are the trajectory of test results prior to the change-
point, the test result value at the time of the change point, the time of the change-point and
the trajectory of results after the change-point; each of the parameters is a random effect
within the model. Non-informative prior distributions are used for the parameters in the
model134,135 see Box 7.3.
Box 7.3: Bayesian hierarchical change-point models examples.
Slate and Turnbull134 demonstrated the use of Bayesian hierarchical change-point mod-
els analysing PSA data. The authors state the advantages of using Bayesian hierarchical
change-point models are ‘borrowing of strength’ when estimating parameters specific to
individuals whilst also accounting for the correlation of measures and, by obtaining poste-
rior distributions using Gibbs sampling, the model can give the probability an individual
has reached the change-point.
Bellera et al135 stated additional advantages of this type of modelling are the ability to
provide precise estimates compared with simpler models, the parameters used by the
model are all of clinical importance, estimates of test measurement variability can be
estimated as a function of test result value, and the model is flexible. Bellera and col-
leagues, however, commented that the model can be influenced by the timing of and the
number of test measurements for individuals with the potential for this to cause bias, as
participants with more results will provide more information for the model and partici-
pants with more test results may be different to those with fewer test results. Subsequent
work by Bellera et al119 used an empirical simulation approach (see Section 7.4.1.5 for
further detail).
Inoue et al136 combined longitudinal PSA measurements from three different studies us-
ing a non-linear Bayesian hierarchical model. At the individual level a non-linear model
was used to model PSA over time and the hierarchical model component then accounted
for the variability between studies.
7.4.1.3 Non-linear mixed models
Non-linear mixed models allow more flexibility in modelling as linearity of the parameters
is not necessary which may be appropriate for modelling longitudinal test data in some
conditions. Multiple measures for each individual can also be accounted for by non-linear
mixed models with the incorporation of random effects, see Box 7.4 for examples.
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Box 7.4: Non-linear models examples.
Subtil and Rabilloud137 used a non-linear mixed model to evaluate PSA measures to
identify recurrence of prostate cancer after initial treatment. To model the trajectory
of PSA measures a non-linear exponential decay growth model was used. This model
contained parameters for the intercept of PSA trajectory and the trajectories before
and after recurrence, with the parameters included as random effects. The model was
empirically derived and was used to model the exponential increase in PSA occurring at
the time of recurrence. The non-linear model was preferred to the change-point model,
in this case, as the non-linear model was thought to be more flexible and allowed for
exponential increase of PSA measures after recurrence. Subtil and Rabilloud discussed
the potential issues introduced by data showing random fluctuation in PSA measures
and suggested using the student t-distribution and a Dirichlet process assumption to
both reduce the weighting of outlying PSA measures used in the model and allow the
distribution of the random effects to be non-normal.
Taylor et al138 demonstrated a modelling approach, again in the area of PSA monitoring
after treatment for prostate cancer. The approach used a model for cure, a model of PSA
measures and a model of clinical events. For the modelling of serial PSA measurements a
non-linear hierarchical model, similar to the model used by Subtil and Rabilloud,137 was
used.
7.4.1.4 Alternative modelling approaches
Alternative modelling approaches were used by Thie´baut et al130 and Wolbers et al131 in the
area of CD4 cell monitoring to understand when to initiate treatment for patients with HIV,
see Box 7.5. These approaches combined piecewise linear models with Cox models.
7.4.1.5 Simulation studies
With knowledge of the progression of disease and the variability of the test used to monitor
the disease, data can be simulated allowing the evaluation and comparison of decision rules
and testing frequency, see Box 7.6.
The approaches outlined by So¨le´tormos et al120 and Bellera et al29 used the biomarker values
with measurement error excluded as the underlying disease state without any link between
biomarker values and true disease state, as measured by the gold standard. The ability of
decision rules were assessed without accounting for the meaning of the underlying biomarker
values in terms of disease state.
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Box 7.5: Alternative modelling approaches examples.
Thie´baut et al130 modelled time to an AIDS event or death after the initiation of highly
active antiretroviral therapy for patients with HIV, using a two-stage approach. Mea-
sures of CD4 cell count and HIV RNA were firstly modelled using a piecewise linear mixed
model with a slope estimated from the initiation of treatment until two months and from
two months after treatment onwards. This model was used to account for measurement
error and avoid making further assumptions of the observed measures. The results of
this model were then used as time dependent covariates in a Cox proportional hazards
model.
Wolbers et al131 modelled the survival of patients with HIV after the initiation of com-
bination antiretroviral therapy with emphasis on the prognostic value of CD4 cell count
change prior to beginning treatment. For patients with two or more CD4 cell measure-
ments, a slope was estimated using linear mixed effects modelling (sensitivity analyses
also use joint modelling of CD4 measures and separate estimates for each patient) with
the value of the slope then used as a prognostic factor in a Cox proportional hazards
survival model, modelling time from initiation of combination antiretroviral therapy to
AIDS event or death.
7.4.1.6 Analysis of cohort data
Existing longitudinal data sets can allow comparison of monitoring approaches. In some
disease areas data sets from multiple cohort studies exist and it is possible to combine the
data and analyse the pooled group of patients. With information on the patients within the
cohort studies it is possible to use the combined data as a proxy for trial data and compare
potential monitoring strategies or components of strategies, see Box 7.7 for details.
7.4.1.7 Evaluation of monitoring strategies
Measuring the performance of a monitoring strategy is different, and more complex, compared
to testing at a single time point, due to repeated testing and the potential for patients to
change disease state.
DeLong et al139 discussed the sensitivity and specificity of a monitoring strategy in the
situation where patients were permitted to change disease state between monitoring test
applications and patients with disease are removed from the sample after their first result
whilst diseased, as the purpose of the test would be to detect the onset of disease. DeLong and
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Box 7.6: Simulation studies examples.
So¨le´tormos et al120 used simulation to compare rules used for monitoring of cancer anti-
gen 15.3 (CA15.3) and carcinoembryonic antigen (CEA) to identify metastatic breast
cancer. The approach simulated observed monitoring results for individuals with pro-
gression and those in a stable state. Simulations were produced using 48 permutations
of background variation value and cutoff/starting concentration value; 12 permutations
of background analytical and biological variation, and progression rate given concentra-
tions start in the middle of a reference interval; and, 12 permutations of background
variation value and progression rate, given concentrations start above the criteria cutoff.
Previously established criteria were then compared using the simulated data. So¨le´tormos
and colleagues stated there is great potential for using simulation to compare progression
criteria, although the approach demonstrated used only specific values of starting con-
centration, analytical and biological variation, and progression rate. The results showed
the extremes of the abilities of the guidelines rather than how these would perform in the
population they would be used to monitor, and, furthermore, only established guidelines
were tested.
Bellera et al29 used an empirical simulation approach to estimate the sensitivity and
specificity of a decision rule stating three consecutive rises in PSA measure should con-
stitute a positive result indicating possible recurrence of prostate cancer. Firstly, Bellera
and colleagues used Bayesian hierarchical change-point modelling (for further detail see
Section 7.4.1.2) to analyse longitudinal PSA measures for a cohort of patients. The re-
sult of this modelling process was considered the true underlying trend in PSA and the
modelling also provides an estimate of the variability of PSA measurements, allowing
empirical simulation of observed results. Sensitivity and specificity were then estimated
by comparing the simulated results with the modelling results. The authors stated an
advantage of this approach to be the flexibility in evaluating decision rules based on
consecutive increases or decreases in results as the performance of decision rules can be
evaluated for different frequencies of observations, underlying progression and variability.
The limitations of this study were that the process requires a longitudinal data set for
analysis that may not be available for all situations, only decision rules based on trends
(increases and decreases) are investigated, and this approach would not be appropriate
in cases where increases (or decreases) in the test measures are expected and the objec-
tive of monitoring is to identify progression at the point of a clinical event rather than
distinguishing stable disease from non-stable disease.
colleagues used partial likelihood to estimate test performance summaries. Other approaches
of estimating time-dependent sensitivity and specificity for ROC curve analysis are described
in Section 7.4.3.
Li and Gatsonis31 provided guidance on the evaluation of monitoring strategies, specifying
the reporting of:
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Box 7.7: Pooled analyses examples.
The When To Start Consortium124 used data from multiple cohort studies to investigate
when to start combination antiretroviral treatment for patients with HIV-1. Treatment
was started either when the CD4 cell count of a patient was at a higher value (threshold
1) or treatment would not be given until the patient reached a lower CD4 cell count
(threshold 2). As there was limited evidence comparing the use of the two strategies
analysis of cohort studies was sought. The data available to the research team consisted
of cohort studies prior to and after the use of combination antiretroviral therapy. Kaplan-
Meier estimates of the probability of progression to AIDS or death based on time from
initiation of treatment and starting CD4 cell count were obtained using the data from
treated patients. Simple hazard ratios of AIDS and death were also calculated using
Cox regression, with a more complex method involving imputation also used (method
introduced by Cole et al140) allowing for lead time bias–extra time from initiation of
treatment to AIDS or death due to patients receiving treatment earlier–and unseen events
for those not receiving treatment until reaching a lower CD4 cell count (threshold 2).
The data collected prior to the use of combination antiretroviral treatment was used to
estimate the distribution of time from reaching threshold 1 to worsening to reach threshold
2. The probability of progressing to AIDS or death before having a CD4 cell count low
enough to reach threshold 2 was modelled also. Progression rates were compared and
random effects models used to estimate the decrease in CD4 cell count for the period
prior to antiretroviral therapy and for the period where antiretroviral therapy was used.
Ahdieh-Grant et al125 used the cohort approach, again, as a proxy for a trial looking
to identify the appropriate CD4 cell level at which to begin antiretroviral treatment
for patients with HIV. The authors draw attention to the disadvantage of using data
obtained by cohort studies as there is no randomisation. Ahdieh-Grant and colleagues
also discussed the issue of lead time bias, which they accounted for by splitting the
time to progression to AIDS into time from CD4 cell count being in a certain range to
beginning antiretroviral treatment and beginning antiretroviral treatment to the onset
of AIDS. Time to event analysis was used to analyse the cohort data, comparing the
patients starting antiretroviral treatment at high and low CD4 cell count levels.
(i) the total number of tests required for each patient;
(ii) the difference in how early the new strategy can detect an event compared to the
comparator strategy;
(iii) the detection rate (events detected by monitoring/events) and error rate (symptomatic
detected events/events);
(iv) the cost of monitoring examination and any required confirmatory tests;
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(v) and, the percentage of monitoring detected length
PMLD =
monitoring detected time− time at change point
time at symptomatic event− time at change point × 100,
where the time at change point is the time the biomarker begins to change (a proxy for
the time of event).
7.4.2 Screening
The aim of screening is to benefit patients by detecting disease prior to the onset of symptoms
as is the case with monitoring. Figure 7.1 describes the development of disease and the
screening process. The detectable pre-clinical stage of disease is the time when screening
may detect asymptomatic disease; this is also known as the sojourn time. The delay time is
the period of the sojourn time when the screening has not detected disease and lead time is
the period of sojourn time after screening has detected disease. The greater the lead time,
the greater the potential benefit of screening.
Walter and Day141 discussed the biases that need to be considered when analysing screening
data. Firstly, the population that participate in screening may vary from the population that
do not participate in screening, as they may be at higher or lower risk of having the disease
the screening process aims to detect. This is likely to be less of an issue for monitoring
populations, although it is conceivable that there will be differences between those who do
participate in monitoring and those who either drop out (perceiving themselves to be at low
risk of the event in question) or who demand some form of treatment (perceiving themselves
to be at high risk of the event in question). Other biases that may affect monitoring studies
include length-biased sampling and lead time bias. Length-bias sampling occurs as patients
with more aggressive disease will be in the pre-clinical phase of disease where screening will
detect disease (sojourn time) for a shorter length of time than those with less-aggressive
disease. Screening is most likely to detect cases with a longer sojourn time, hence cases
of less-aggressive disease which will likely have a better prognosis. Lead time bias is when
survival times for screened cases appear to be greater than survival times for cases identified
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Figure 7.1: Process of screening patients (after Walter and Day141).
by different means when there is no difference in survival; the only difference is cases identified
by screening are detected earlier.
Work has focussed on estimating the duration of the pre-clinical stage of disease (Walter
and Day,141 Day and Walter142 and Etzioni and Shen143), which enabled further work into
the optimal frequency of screening (Zelen144, Lee and Zelen,145 Frame and Frame146 and
Lee et al147). Others have considered how to set the optimal decision rule for a screening
strategy using a new test when the length of the sojourn period is not known (McIntosh and
colleagues148 and McIntosh and Urban149), see Boxes 7.8 to 7.10.
7.4.3 Time-dependent ROC curves
When a test gives a binary result (positive or negative) the performance of the test is usually
assessed by calculating the sensitivity and specificity. When the result of a test is a continuous
value the performance of the test is evaluated for various cut offs by calculating the sensitivity
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Box 7.8: Estimating the duration of the pre-clinical stage of disease.
Walter and Day141 presented a method that uses the prevalence of disease at the time
of screening and the incidence of disease in the time between screening visits to estimate
a distribution for the time in a pre-clinical state and the sensitivity of screening. The
benefit of this approach is length biased sampling is accounted for. Walter and Day
discussed the effect of screening on the incidence rate of a population. The authors
assumed that prior to screening commencing the incidence rate will remain at a constant
level. After a screening test has taken place the incidence rate reduces and initially the
majority of new cases of disease will consist of individuals that have a false negative
result from the previous screening test. Until the next screening point the incident
rate will then gradually increase. Fewer cases will be seen at each successive screening
point, with the incidence rate between screening points also being lower as screening
continues. If screening were to stop the incidence rate would gradually increase to the
level prior to screening. Using these observations Walter and Day derived an expression
for the incidence at time t given the previous false negative results of the population and
the sojourn time, and from this the distribution of lead time can be obtained. Later,
Day and Walter142 published further detail of these expressions which allowed lead time
distributions to be estimated for screening strategies other than the strategy used when
the data set was collected. The authors used these expressions in analysing the Health
Insurance Plan of Greater New York (HIP) study of breast cancer where approximately
62,000 women were randomised to be offered screening or receive no screening.141,142
Etzioni and Shen143 developed the work of Walter and Day141 by using the false negative
rate, as this varies with the sojourn time, to estimate the asymptomatic period of cancer.
Estimates were produced using non-parametric methods with the EM algorithm utilised.
and specificity of the test at each possible result value and plotting sensitivity against 1-
specificity, a receiver operating characteristic (ROC) plot. The ROC plot and the areas
under the curve produced can then be used to assess the performance of the test and identify
optimal thresholds for the use of the test in practice. When allowing for time in ROC analysis,
time-dependent ROC methods are used.
Pepe and colleagues30 undertook a review of time-dependent ROC curves. The definition of
sensitivity of a test is dependent on the time when the test is performed. As it is assumed
diseased cases will present with positive test values early in the testing process it is thought
sensitivity will decrease with time. Pepe et al also discussed cumulative sensitivity, which
would provide the sensitivity for a test for an interval of time, and how this can be derived.
The false positive fraction, or 1- specificity, is problematic to define as the disease status of
individuals can change over time making it difficult to classify individuals as diseased or non-
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Box 7.9: Optimal screening frequency.
Zelen144 expanded the ideas of Day and Walter142 to calculate the optimal frequency of
screening. Zelen described the three health states of screening; patient free of disease, pa-
tient with pre-clinical disease and patient with clinically diagnosed disease. The screening
period in which a patient enters the pre-clinical disease phase was then used in deriving
the incidence and the probability of being in the pre-clinical disease phase at time t. The
benefit of Zelen’s approach over Day and Walter’s approach is the effect of cases present
at the initial screening point is accounted for. To use the derived expressions to identify
optimal screening frequencies Zelen used a weighted utility function assigning different
weights to cases observed at the first screening point, subsequent screening points and
between screening points (cases not identified by screening). A different weight was used
for the initial screening point as the initial screening point will be most affected by length
biased sampling. Using the assigned weights an equation was given to calculate the op-
timal frequency of screening observations. Zelen also provided a proof of equal time
between screening only being optimal if the sensitivity of the screening test is equal to 1.
Lee and Zelen145 developed the work on optimal screening schedules by Zelen144 and
proposed threshold and sensitivity methods to dictate appropriate screening times. The
threshold method required screening to be undertaken at time points such that the proba-
bility of being in the pre-clinical detectable state is at a pre-assigned level. The sensitivity
method defines the screening schedule based on the ratio of the number of cases the screen
is expected to detect to the number of cases that will be detected over the specified dura-
tion of screening. However, Frame and Frame146 argued the risk of disease should not be
a factor in evaluating appropriate screening frequencies. Instead, Frame and Frame ad-
vocated determining screening schedules based on knowledge of the progression of disease
and the sensitivity of the screening test used and gave a mathematical expression for the
error of a screening strategy (the proportion of cases of pre-clinical disease not identified
by screening, E), E = (1−S)WF , based on the relationship between the sensitivity of the
screening test (S), the sojourn time (W ) and the frequency of screening (F ).
Lee and colleagues147 further developed the methods of Lee and Zelen145 by incorpo-
rating mortality into the model for selecting optimal screening frequency strategies. To
predict the difference in mortality for different screening strategies the model used the
idea of stage-shift with the key assumption that survival is improved for cases identified
by screening as they are detected in at an early stage of disease compared with cases
identified by usual care. The model predicting mortality assumes the natural history of
disease is progressive and benefits of early detection are due to stage-shift in diagnosis.
diseased, especially in situations where all individuals will have an event at some point. One
approach is to choose a time point specific to the context assessed and individuals are treated
as non-diseased if they are free of the event at the specified time (the static false positive
fraction). Another approach is to allow the false positive fraction to vary with the time
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Box 7.10: Optimal decision rules for novel tests.
McIntosh and colleagues148 and McIntosh and Urban149 provided a method for deciding
the optimal decision rule for a screening strategy when using a new test, when the length
of the sojourn period is not known. An algorithm using parametric empirical Bayes (PEB)
theory was discussed. Test values from healthy individuals collected over time were used
to estimate total, between-individual and within-individual variance and the trajectory
of test values. Using the estimates of trajectory and allowing for heterogeneity in the
population to be screened the PEB algorithm can produce person specific thresholds to
maintain a specified false negative rate (FNR) to be used at the next screening point.
The authors state the use of the PEB algorithm to generate person specific thresholds
allows earlier detection of disease without increasing the burden on healthy individuals.
since the test was performed (the dynamic false positive fraction). When using the dynamic
false positive fraction test performance may be misleading as a positive result will be falsely
positive shortly before an individual develops disease. For tests with continuous results time-
dependent ROC curves compare individuals with and without disease at each time point.
If using the dynamic false positive fraction ROC curves are difficult to interpret due to the
non-diseased group changing over time (see Boxes 7.11 and 7.12 for examples).
7.4.4 Differentiating measurement change from measurement variability
The variability of repeated test measures for an individual can be broken down into three
components: pre-analytical variability, analytical variability and individual variability.16,56
The coefficient of variation (CV) is calculated by dividing the standard deviation by the
mean and is commonly used in place of standard deviations as this allows for a reference
change value (RCV) to be calculated to reflect percentage changes rather than absolute
changes. Given the values of analytical and within-individual variation, a difference between
two results greater than the RCV suggests a real change in condition.155 For further detail
see Chapter 2.
Statistical process control methods (first developed by Shewhart) are often used in manu-
facturing and can be used for medical applications when a process can be measured directly
or via a biomarker. Statistical process control procedures measure variability across time,
where variability can be split into common cause and special cause variability (or assignable
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Box 7.11: Sensitivity and specificity.
Cai et al150 presented equivalent time dependent definitions of sensitivity and 1- speci-
ficity, but with the emphasis on the time of an event occurring, defining sensitivity and
1- specificity to be functions of time relative to the time of disease or time of an event.
The authors stated most research in the area assumed the test and assessment of disease
status are carried out simultaneously raising the issue of the predictive accuracy of a test
dependent on the time it is carried out in comparison to the onset of disease, assuming an
increase in accuracy if the test is used closer to the time of an event. Cai and colleagues
also fitted semi-parametric models using longitudinal test data to separately estimate
sensitivity and 1- specificity.
Zheng and Heagerty151 discussed sensitivity and specificity for time-dependent ROC anal-
ysis as functions of both the time of testing and the time of event. Zheng and Heagerty
also discussed the difference between estimating incident and prevalent ROC curves, re-
stricting their work to incident ROC curves.
Subtil et al152 discussed how incident sensitivity requires a test to be performed a given
number of days prior to the onset of disease and offers a way of taking the variation of
time between individuals receiving a test and developing disease into account. Subtil and
colleagues introduced a Bayesian method to allow for the interval-censored measurements.
Results of using this method compared with the method without adjustment suggested
the ‘crude’ method underestimates sensitivity.
Parker and DeLong153 provided a method to convert estimates of sensitivity and speci-
ficity for monitoring tests for ROC curve analysis. The estimates of sensitivity and
specificity used are those introduced by DeLong et al,139 which were derived using par-
tial likelihood estimation under the assumption that diseased participants can have at
most one test result when in the diseased state.
cause variability). Special cause variability is akin to signal and signifies true change in the
disease state of an individual. Common cause variability, as noise, reflects random variability
in measures.155
X-bar charts are used to display measurements over time for an individual. If a process is
stable, measurements are expected to fluctuate around the mean, and the standard deviation
of observed measures is expected to be constant over time. Estimates of the mean (µ) and
standard deviation (σ) can be taken from stable processes, with an unbiased estimate of
the standard deviation obtained using a moving range (the difference between consecutive
measures) and dividing the mean of the moving range estimates by a constant (d2 = 1.128).
Estimates of the mean and standard deviation of a stable process can then be used to identify
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Box 7.12: Modelling to produce time-dependent ROC curves.
Slate and Turnbull134 reviewed methods used to analyse repeated test data when the test
is used to screen or monitor the onset of disease in a population. These methods are used
to estimate the ROC curve for each test and the resulting ROC curves are compared.
The review discussed the use of time dependent Cox proportional hazards modelling, joint
modelling of longitudinal test data and time of diagnosis, Weibull methods to model two
time events, random effects models and integrated Onstein-Uhlnbeck (IOU) stochastic
processes, multi-state models and Markov models, and change-point models.
Zheng and Heagerty151 discussed a semi-parametric regression approach used to estimate
ROC curves and an approach based on asymptotic distribution theory, which will allows
covariates to change the distributional shape of test results.
Etzioni et al154 introduced and demonstrated two methods for modelling the effect of lead
time on the ROC curve. The first approach required modelling of longitudinal test data
and then using parameter estimates from the model the ROC curve can be estimated
at varying time points. The second approach directly modelled the ROC curve as a
function of covariates including time of the test relative to the time of diagnosis. Etzioni
and colleagues discussed how the methods can be adapted to compare two tests. The first
method required separate fitting of models using data for the two tests with comparison of
the derived ROC curves after; whereas, the approach of modelling the ROC curve directly
more easily allowed for comparison of tests. Other advantages of the direct modelling
approach were: fewer distributional assumptions with the method using the ranking of
data points, robustness and flexibility and ease of implementation.
control limits.
The control limits can be identified using many criteria and should be modified depending on
the situation; it may be target values are safety driven. Moving range charts and exponentially
weighted moving average charts (moving averages are calculated with greater weight given
to the most recent observations) are also used in similar ways. The variability of a process
can be quantified using the capability index, the difference between the upper and lower limit
divided by 6σ. The off-target ratio, ST = (µ − T )/σ where T is the target value, measures
how far the process is from the specified target value in terms of standard deviations. Process
control charts use the assumption of independent normally distributed outcomes and generally
require at least 20-25 observations.155
See examples in Boxes 7.13 and 7.14, and issues with these methods in Box 7.15.
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Box 7.13: Methods accounting for test variability.
So¨le´tormos et al28 used a rule based on an RCV in a computer model for monitoring of
progression to metastatic breast cancer with cancer antigen 15.3 (CA15.3), carcinoem-
bryonic antigen (CEA) and tissue polypeptide antigen (TPA).
Smellie57 questioned the use of the 5% significance level when evaluating differences be-
tween results, as 10% or higher levels may be more appropriate in some situations.
Petersen156 commented on how the use of RCV only considers the type I statistical error
rate and not power, which is linked to the magnitude of the change in values for an in-
dividual. Petersen et al157 discussed the importance of distinguishing between reference
intervals and decision limits.
Klee158 reviewed methods for setting analytical performance goals; these methods include
the use of guides produced by regulations and external assessment, biological variation
limits, needs of clinicians, subsequent testing and medical decision models. Klee identified
differences in the performance limits identified by the different approaches.
7.4.5 Health economic approaches
7.4.5.1 Decision analytic models
Decision analytic modelling evaluates the cost, outcomes and cost effectiveness of interven-
tions. In the case of repeated testing appropriate techniques need to be used for this evalua-
tion, see Box 7.16.
7.4.5.2 Real options approaches
Palmer and Smith169 introduced real options approaches, inspired by methods used in fi-
nancial markets, which aim to include the uncertainty around the use of a new technology
along with health economic evaluation. The approach uses the potential to delay introducing
a new technology (akin to a change in management) and the irreversibility of using a new
technology. Analyses factor in deferring using a technology and the better evidence that may
be available after deferral using expected value of perfect information methods (EVPI), see
Box 7.17.
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Box 7.14: Statistical process control and statistical rules for interpretation of sequential tests.
Tennant et al159 reviewed studies where patients were monitored using statistical process
control methods and compare the use of statistical control methods with currently used
rules and guidelines. Clinical areas found to use process control methods were: peak flow
measurements for patients with asthma, blood pressure measurements for patients with
hypertension and serum creatinine measurements for patients after undergoing a kidney
transplant.
Thor et al160 also reviewed studies using statistical control processes to monitor patients
and highlight the disadvantages of using these methods. Thor and colleagues discussed
that in some studies methods had been employed where there was a clear lack of under-
standing. The authors also commented on issues with auto-correlated measures, collection
of data and application of the methods.
Gavit et al161 discussed a slightly different approach to process control in change point
analysis. Change point analysis uses cumulative sum charts of the difference between the
mean value and the recorded value. Change points were then analysed as bootstrapping
methods are used to generate a confidence interval for the change point. The change
point method can also be used to identify differences in variability. An advantage of
the change point method is the ability to analyse non-normal data due to the lack of
distributional assumptions. Gavit and colleagues also claimed the change point method
is able to identify subtle changes that would not be picked up by control charts.
7.5 Summary and conclusions
This review revealed limited methodological literature around the design of monitoring strate-
gies. Work has focussed primarily on analysis of data where subsequently recommendations
of monitoring frequency or decision rules could be made or simulation work performed, with
both approaches being specific to the disease area researched. The area of screening has
developed methods with the focus being identifying the optimal frequency of screening which
could be used for designing monitoring strategies. There was some work on the design of
biomarker development studies which could potentially be adapted to allow for the evalua-
tion of a monitoring strategy using previously collected specimens. It appeared thresholds
are often developed by analysis of the variability of the test being used, identified by the
literature describing signal to noise ratio, biomarker development studies, statistical process
control and reference change values.
The study by Buclin et al9 showed an approach where decision rules were devised by a review
210
7.5. Summary and conclusions
Box 7.15: Issues for methods using test variability.
Omar et al162 discussed how useful reference change values are. Omar and colleagues
commented on issues regarding the timing of observations, as the CVI can increase as the
interval between tests increases, and auto-correlation of serial measurements. Omar and
colleagues also discussed that within-individual variability is commonly the largest com-
ponent of RCV and how estimates of CVI are usually available in the literature. Omar et
al also explained the issues with these studies as estimates of CVI are often for healthy
participants and this may not reflect the variability of participants in stable disease.
Biosca et al163 reported a study of biological variability to identify the appropriate RCV
to use for long-term monitoring of renal post-transplantation. The research group had
already conducted a biological variation study to determine the RCV values required for
short-term monitoring. These studies showed little difference between RCVs required
for short and long term monitoring; however, the RCVs obtained from studies using an
appropriate population were very different to those detected using healthy participants.
A review of the accuracy and prognostic literature of cardiac natriuretic hormone (CNH)
assays by Clerico and Emdin164 highlighted differences in analytical sensitivity across
studies carried out in differing populations. The results of accuracy measures were diffi-
cult to compare due to different gold-standards.
Box 7.16: Decision analytic models examples.
Karnon et al165 reviewed models for measuring the cost effectiveness of screening regimes
for breast, cervical and colorectal cancer. The review covered approaches including: deci-
sion trees, Markov models, MIcrosimulation for SCreening ANalysis (MISCAN), discrete
event simulation (DES) and more complex approaches, such as the Baker166 and Parmi-
giani167 approaches.
Sutton et al168 introduced comprehensive decision modelling, a combination of evidence
synthesis and decision modelling, to integrate the analysis of diagnostic test performance
and cost-effectiveness.
of the literature and then using an obtained data set and analysis of signal and noise the
rules were refined to minimise false results. Following this, recommendations of the decision
rule and frequency of monitoring could be made. Takahashi et al,117 Takahashi et al118
and Oke et al11 also used signal and noise methods when analysing data and subsequently
recommendations can be made for future monitoring strategies.
A number of applications of the signal and noise approach9–11,14,117,118,121–123,126–129 were
identified, largely in the area of treatment titration. The limitations of this approach for
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Box 7.17: Real options approaches examples.
Driffield and Smith170 further explained how these methods can be used to understand
the benefit of ‘watchful waiting’ with some monitoring of disease progression rather than
immediate treatment. The method was demonstrated using the example of the manage-
ment of abdominal aortic aneurysms. Meyer and Rees171 further developed the approach
by allowing the incorporation of patient aversion by using a Poisson process.
Shechter et al172 used a real options approach with a Markov decision model incorpo-
rated to identify the optimal time to cease monitoring and begin treatment. Shechter and
colleagues also presented an example, looking at treatment for patients with HIV, of the
errors made when the development of future technologies is not taken into consideration.
Whynes173 introduced a similar approach looking at identifying the optimal time to move
from monitoring to treatment considering the problem as a cost-minimisation exercise.
Lasserre et al174 used this type of method to investigate when to begin antiretroviral
treatments in patients with HIV-infection.
monitoring disease progression or recurrence are that rules and thresholds are devised purely
by analysing the variability of test measures and the minimisation of false findings rather
than detection of disease at the earliest point possible and the impact on patients.
The simulation approach proposed by Li and Gatsonis31 uses a joint latent class model which
combines predictions from the model along with a utility function to identify optimal moni-
toring frequencies. The results of a simulation study reported by Li and Gatsonis appeared
promising; however, the approach has not been widely adopted perhaps due to the complex
nature of the model. Other simulation approaches may also have potential under certain
circumstances, particularly if measurement error, and a link between biomarker values and
true disease state can be included.
The biases that are well documented in the screening literature are applicable to the area of
monitoring also. Length-time bias and lead time bias should be considered when analysing
monitoring data and when designing monitoring studies. There is also the issue of post-
screening noise which is again important to take into consideration when evaluating a moni-
toring strategy; the time point at which monitored and non-monitored patients are compared
should be selected to minimise the issue of incidence after the final testing point and should
also consider the number of likely events. Harm to patients is vitally important in screening
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and monitoring as this harm may be at several time points and this must be thought of when
designing strategies.
A further consideration for the analysis of monitoring data concerns the number of test mea-
surements and the timing of test measurements:135 people with more results will contribute
more data to the model but they may be very different to those with fewer results. Measure-
ment error and particularly biological variability also requires consideration. Studies have
shown that reference change values from biological variability studies of healthy participants
are not necessarily reflective of the true RCV for a diseased population. As methods to
derive test thresholds used in monitoring rely heavily on the variability of test results it is
important that estimates from biological variability studies are accurate. Also, the quality of
studies undertaken when developing new biomarkers is not always rigorous; however, there is
literature concerning the design of these studies and the evaluation of quality of these studies
that may in time improve quality.
7.5.1 Limitations
This review was not systematic, meaning this search will not have identified all methods
papers relevant to the area of monitoring. The searches were performed in 2010, so new
methods may have been published and missed. To limit missing new developments the
literature has been evaluated as it becomes available (published articles and conferences) and
included if relevant, and sources working in screening have been able to provide information
regarding current practice.115
7.5.2 Application to thesis: methods used
A simulation approach using the general model of Stevens and colleagues12 was used in
subsequent work (see Chapter 8) to investigate optimal monitoring strategies (decision rule,
threshold and duration of monitoring) for a trial evaluating a monitoring test.
A simulation approach was chosen as data were required to fit the unique situation of the
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corresponding trial (see Chapters 1 and 8). This approach used a model with a random
intercept and a random slope. Simulation of the latent test values and observed test values
allowed multiple candidate strategies to be compared, evaluating all aspects of the monitoring
strategy (test frequency, decision rule, test threshold) simultaneously. Simulation approaches
had been used to compare monitoring strategies, as identified in this review. The approach
used in this thesis allowed the latent and observed values to be modelled, taking account of
the measurement error of the test. The importance of measurement error estimates used in
the developed model were investigated through sensitivity analyses, but the analyses were
driven by differences in potential patient outcomes rather than simply controlling the false
findings, as used in other monitoring studies. The chosen approach also allowed the link
between true disease state and the biomarker to be modelled and fully incorporated.
For the evaluation of monitoring strategies, the criteria introduced by Li and Gatsonis31 was
modified.
The methods identified for screening were considered but not utilised fully as they only al-
lowed optimisation of individual components of the monitoring strategy. The biases identified
in the screening literature were taken into account when developing the monitoring model
and analysing the data. The issues raised by Bellera et al135 regarding the difference in par-
ticipants contributing large and small amounts of data to models was also considered when
analysing the data from the trial.
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Simulating monitoring data and
evaluating monitoring strategies
This work has been partly presented in the following form:
Selby PJ, Banks RE, Gregory W, Hewison J, Rosenberg W, Altman DG, Deeks JJ, McCabe
C, Parkes J, Sturgeon C, Thompson D, Twiddy M, Bestall J, Bedlington J, Hale T, Dinnes
J, Jones M, Lewington A, Messenger MP, Napp V, Sitch A, Tanwar S, Vasudev NS, Baxter
P, Bell S, Cairns DA, Calder N, Corrigan N, Del Galdo F, Heudtlass P, Hornigold N, Hulme
C, Hutchinson M, Lippiatt C, Livingstone T, Longo R, Potton M, Roberts S, Sim S, Trainor
S, Welberry Smith M, Neuberger J, Thorburn D, Richardson P, Christie J, Sheerin N,
McKane W, Gibbs P, Edwards A, Soomro N, Adeyoju A, Stewart GD, Hrouda D. Methods
for the evaluation of biomarkers in patients with kidney and liver diseases: multicentre
research programme including ELUCIDATE RCT. Chapter 7: Simulating monitoring data
and evaluating monitoring strategies. Programme Grants for Applied Research (2018).
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Summary
There is a need to develop monitoring strategies based on evidence of effectiveness in the
monitored population.2 An example was presented using the Enhanced Liver Fibrosis (ELF)
biomarker in managing patients with known liver fibrosis, specifically the ELUCIDATE
trial.
Existing data and expert opinion were used to estimate the progression of disease and the
performance of repeat testing. Knowledge of the true disease status in addition to the ob-
served test results for a cohort of simulated patients allowed various monitoring strategies to
be implemented and evaluated. The modelled data was validated by comparing to data from
the trial.
The monitoring strategy utilising a prediction from a linear regression model in the decision
rule and the monitoring strategy using a simple threshold decision rule performed similarly
well. The results of sensitivity analysis showed the importance of accurate data to inform
the simulation. Monitoring data can be simulated and strategies compared given adequate
knowledge of disease progression and test performance. The simulated data compared well
to the trial data.
8.1 Introduction
Although patient monitoring is a fundamental function of healthcare, incurring consider-
able cost to health care providers, the underlying methodology of monitoring is under re-
searched2,175 and there is an increased need for monitoring strategies to be systematically
developed incorporating known likely progression of disease and the performance of the mon-
itoring test to be used. Dinnes et al reviewed the evidence base for prostate specific antigen
(PSA) monitoring to identify recurrence of prostate cancer.1,176 The review identified the
lack of a systematic approach in developing a monitoring strategy, with monitoring intervals
based on standard follow-up schedules and limited evidence of consensus for the thresholds
used to initiate treatment.1
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Stevens et al12 discussed various statistical models of the transition between the maintenance
and re-established control phases of monitoring (the process of detecting when a disease is
out of control leading to a change in management, for example treatment or more intensive
monitoring) and identified a general statistical model for the evolution of monitoring data
over time outlining possible sources of variation.12 This general statistical model proposes the
form of monitoring data based upon the observed values of sequential monitoring tests, the
values of measurement error and other sources of variability, and the true disease state, which
can be modelled based on epidemiological evidence but never observed, see §1.3.2.
This general model along with existing data, and evidence gathered from the literature, can
be used to simulate monitoring data and allow the evaluation of strategies for a given target
condition. The potential effect of monitoring strategies can then be evaluated and ranked,
prior to full-scale investigation.5
The example presented investigates the use of the Enhanced Liver Fibrosis (ELF) biomarker
in monitoring patients with known liver fibrosis. This modelling work was done alongside a
prospective multicentre randomised trial (the Enhanced Liver fibrosis (ELF) test to Uncover
Cirrhosis as an Indication for Diagnosis and Action for Treatable Events (ELUCIDATE)
trial177). The ELUCIDATE trial evaluates ELF for the early detection of progression from
liver fibrosis to liver cirrhosis compared to routine care, with the aim of enabling earlier treat-
ment and potentially improved patient outcomes. Participants with known liver fibrosis and
meeting a minimum ELF level at registration were recruited to the study and randomised to
receive either standard care or standard care and monitoring with the biomarker Enhanced
Liver Fibrosis (ELF). In the ELUCIDATE trial the ELF biomarker was used to detect pro-
gression in patients with liver disease so patients could be managed appropriately to prevent
complications of cirrhosis. Participants randomised to the monitoring arm received an ELF
test every six months and had a positive monitoring test if the result was 9.5 or above.
Those with a positive monitoring test received a change in patient management and those
with a negative result went forward to the next monitoring point with their management un-
changed, see Figure 8.1. As the monitoring trial was performed simultaneously, this provided
the opportunity to use information to inform the model building and allowed validation of
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the model, by comparing the simulated data to the real study data. Designing a monitoring
strategy using all available evidence should be performed prior to the conduct of a monitoring
study evaluating the strategy.
8.2 Aims and objectives
The aims of the study were to:
• develop a model for simulating and evaluating monitoring data.
• use these data to identify the optimal monitoring strategy, from candidate monitoring
strategies, for patients known to have liver fibrosis receiving repeated testing using the
biomarker ELF. Candidate strategies were selected and evaluated to:
– compare the alternative frequencies of monitoring (6 month or 12 month intervals).
– evaluate the benefit of using targeted retesting compared to no retesting.
– compare decision rules (positive results based on crossing a threshold determined
by a single value (snapshot simple threshold rule), and track-shot rules based on
absolute or relative increases from first test value, absolute or relative increases
from last test value and prediction from a linear regression model).
• assess the validity of the model by comparing the estimated performance of the strate-
gies, using the simulation, to results from the trial.
8.3 Methods
The method used to simulate data followed the model introduced by Stevens et al.12 The
process involved simulating the ‘true’ underlying and unobserved data and, including mea-
surement error to generate the observed data.
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• A model was used to generate the underlying and unobserved disease progression (giv-
ing ‘latent’ biomarker values), incorporating estimates of disease progression and the
variability of these estimates, for a cohort of simulated individuals.
• Observed test result values were generated using the latent disease progression values
and estimates of test performance.
• Selected monitoring strategies were then evaluated and compared, using both the ob-
served test values and the true disease status.
Explanation of the notation used in the model can be seen in Table 8.1.
Table 8.1: Monitoring simulation model notation.
Description Notation
Individual number i
Number of initially simulated individuals n
Time across fibrosis stages t
Fibrosis progression rate pi
Mean fibrosis progression rate µp
Standard deviation of fibrosis progression rate σp
Fibrosis stage s
Starting fibrosis stage Si
ELF value each stage of fibrosis Es
Mean ELF value at each fibrosis stage µs
Standard deviation of ELF value at each fibrosis stage σs
Observed mean ELF value at each fibrosis stage µYs
Observed standard deviation of ELF value at each fibrosis stage σYs
ELF at the beginning of each fibrosis stage Eis
Gradient of ELF progression βis
Latent ‘true’ ELF Uit
Measurement error ωit
Standard deviation of measurement error σA+I
Observed ELF Yit
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8.3.1 Simulation of true disease progression
The model simulated true disease progression, generating a random slope and random inter-
cept in terms of fibrosis stage for each patient.
8.3.1.1 Fibrosis progression–random slope
The rate at which each individual patient progresses through the fibrosis stages was assumed
to be constant, throughout the stages of fibrosis. The progression rates between patients
varied; this was assumed to be normally distributed, pi ∼ N(µp, σ2p), where i = 1, . . . , n and
n is the number of simulated individuals; µp is the mean and σp is the standard deviation of
fibrosis progression rate. Fibrosis progression rate was restricted to only positive values, by
fixing pi at 0.01 if pi ≤ 0, meaning only increases in fibrosis stage were simulated; however,
as the increase is just 0.01 fibrosis units per year this effectively means these patients are in
a stable fibrosis state. The data source used to provide an estimate of fibrosis progression is
given in §8.3.3.1.
8.3.1.2 Fibrosis stage at entry–random intercept
Patients recruited to a trial would be in varying stages of disease at entry. Using data on the
likely distribution of fibrosis stage for a population with known liver fibrosis, a multinomial
distribution was used to simulate a starting stage for each individual Si. The data source
used to provide an estimate of fibrosis stage at entry is given in §8.3.3.2.
8.3.1.3 ELF value link to fibrosis stage
For each stage of fibrosis, the distribution of latent ELF values within fibrosis stage was
assumed to follow a normal distribution, Es ∼ N(µs, σ2s), where s is the fibrosis stage and
s = 0, . . . . , 4; µs is the mean value of ELF at each fibrosis stage and σs is the standard
deviation of ELF at each fibrosis stage. The data source used to provide estimates for the
ELF link to fibrosis stage is given in §8.3.3.4.
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8.3.1.4 ELF progression between fibrosis stages
The model used fibrosis stage as a continuous value. To generate ELF values for each patient
at all stages of fibrosis, ELF progression between consecutive integer fibrosis stages was
assumed to be linear. It was assumed that patients would have ELF values at the same point
of the normal distribution for each fibrosis stage (patients would remain a given number of
standard deviations from the mean). To randomly select the point of the normal distribution
that patients would follow, a value from the standard normal distribution was generated
for each patient (zi). The ELF value for each participant, at each stage of fibrosis was
Eis = µs + (ziσs), see Figure 8.2 (left).
8.3.1.5 ELF progression–random slope
The ELF values at the beginning of each fibrosis stage for each individual (Eis) and the rate
each simulated participant progressed through fibrosis (pi), were combined to calculate the
increase in ELF per year. The gradient of ELF progression was βis = (Ei,s+1 − Ei,s) pi, for
s = 0, . . . , 3. The gradient of ELF progression after stage 4 was assumed to be the same as
the gradient between stages 3 and 4, βi3 = βi4. βis is the random slope in terms of ELF
progression. The latent ELF progression values for each stage and all time points from the
onset of fibrosis was:
Uit =

Eij0 + βi0xt for time in stage 0
Eij1 + βi1xt for time in stage 1
Eij2 + βi2xt for time in stage 2
Eij3 + βi3xt for time in stage 3
Eij4 + βi4xt for time in stage 4
where t is time across all stages. This allowed the simulation of life time progression data for
a cohort of patients; see Figure 8.2 (centre). ELF values were truncated at 0 if a negative
value was simulated.
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8.3.1.6 ELF value at entry–random intercept
The simulation was conducted to prevent patients from inclusion if they would be confirmed
as having cirrhosis, or at a point of fibrosis they would not have reached in their lifetime due
to their simulated progression rate. A maximum value was used to restrict the time patients
had liver fibrosis and cirrhosis.
The time at registration for each participant was a randomly selected time point from the
time period when the individual was in their generated fibrosis stage at study entry. If the
participant was in stage 4 of fibrosis at entry, a random value from the interval of stage 4
starting to a point two years after was selected. The maximum time participants could have
fibrosis was 20 years, see Table 8.2
In the ELUCIDATE trial, a registration ELF test was given to each patient to assess eligibility.
The first ELF test included in the trial data was taken at the point of randomisation. The
start of the trial was assumed to occur three months after registration.
Table 8.2: Trial consideration estimates used in monitoring simulation modelling.
Description Estimate used in simulation modelling
Maximum time in cirrhosis
before trial entry
To avoid simulating patients that are in advanced cirrhosis, the maxi-
mum amount of time a patient has been cirrhotic for is set to 2 years.
Maximum time in fibrosis
before entry to the trial
To avoid patients being simulated at a point of disease they would not
have reached given their fibrosis progression rate the maximum amount
of time a patient has had fibrosis for at the time of entering the trial is
set at 20 years.
Time between registration
and randomisation
The time between registration ELF test and randomisation ELF test
was estimated to be 3 months.
Trial duration The duration of the trial used in all simulations was 5 years.
Time between test and
retest measures
The time between a patient having a test and retest (if the original test
was in the target range) was estimated to be 1 week.
8.3.1.7 Random slope and random intercept model in terms of ELF
The underlying disease progression for the simulated individuals, Uit, was used for the time
period starting at study entry and continuing for the duration of the trial (5 years was used)
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for simulated patients with an eligible registration ELF test value (see §8.3.2.2), see Figure
8.2 (right).
8.3.2 Simulation of observed values
The latent underlying ELF measurements were converted to observed ELF measures by the
addition of measurement error.
8.3.2.1 Measurement error
The measurement error at each observation point (ωit) was formed of within-individual vari-
ation and analytical variation. Measurement error was assumed to be normally distributed
with a mean of zero, ωit ∼ N(0, σ2A+I). The observed ELF measurement at any given time
(Yit) was the underlying measurement plus the measurement error Yit = Uit + ωit. Values
were adjusted to equal 0 if a negative observed ELF value was simulated. The data sources
used to provide an estimate of ELF measurement error are given in §8.3.3.3.
8.3.2.2 Entry criteria
In order to fulfil trial entry criteria the observed ELF measurement at registration had to
be greater than or equal to the pre-set value of 8.4. An example of simulated observed ELF
measures can be seen in Figure 8.3.
8.3.3 Data sources
The data sources used to estimate fibrosis progression rate, fibrosis stage at trial entry,
measurement error and ELF value link to fibrosis stage are described below and also in Table
8.3.
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Figure 8.3: Observed ELF measures from monitoring data simulation.
8.3.3.1 Fibrosis progression rate
An estimate of the rate of fibrosis progression, based on data for 1,157 patients179 with chronic
hepatitis C followed up for over 40 years, was obtained from Poynard et al. When consulting
clinical experts it was suggested the estimate provided by Poynard et al179 was identified in
a population that was not comparable with that of the ELUCIDATE study (participants in
the Poynard study were thought to have less severe disease). The estimate from Poynard et
al was used primarily in the simulation model with an adjusted estimate (doubled) used for
sensitivity analyses. Estimates of fibrosis progression were measured using the METAVIR
system, assumed to approximate Scheuer fibrosis units per year, where Scheuer scores range
from 0 to 4 and measure severity of liver disease with stage 0 showing no fibrosis and 4
showing liver cirrhosis.178
8.3.3.2 Fibrosis stage at entry
A cross-sectional data set with ELF results and Scheuer fibrosis scores following liver biopsy
for 921 patients180 was used to identify the distribution of fibrosis stages in the cohort. This
data set contained fibrosis scores from histology and ELF values for participants.
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8.3.3.3 Measurement error
To estimate the error associated with each observed ELF test value, three data sources were
considered. Firstly, a longitudinal data set with repeat ELF measurements (baseline and at 3
months) for 220 patients182 was subjected to analysis of variance to identify variability at the
individual level. Without repeated analyses of test observations for individuals, this variabil-
ity was the combined analytical and within-individual variability (σ2A+I). The manufacturer
also provided information on the measurement error of the ELF test (σ2A+I).
181 Details of
the analysis and design of this study were unclear but it was understood that repeated mea-
surement of a small sample of healthy volunteers were used. Due to discrepancies between
the estimates from the two sources, data was obtained directly from the ELUCIDATE trial.
Analysis of variance was used to obtain an estimate of the analytical and individual level
variability for the registration and randomisation ELF values for the first 112 eligible partic-
ipants; this estimate was used in the simulation model.
8.3.3.4 ELF value link to fibrosis stage
The cross-sectional data set180 (including ELF values and fibrosis units from histology for 921
patients) was used to provide an estimate of the observed ELF value for patients at each level
of fibrosis with a corresponding measure of variability (σYs is the observed standard deviation
at each stage of fibrosis). To estimate the latent and unobserved standard deviation of ELF
values at each fibrosis stage (the between individual variation, σ2s), the measurement error
(σ2A+I) that would have been included in these observed measures was accounted for. As
the latent ELF variability (σ2s) and the measurement error (σ
2
A+I) are independent in the
simulation, σ2Ys = σ
2
s + σ
2
A+I , so σs =
√
σ2Ys − σ2A+I .
To estimate the latent and unobserved mean ELF value at each stage of fibrosis the observed
estimates were assumed to give the mean value for the midpoint of the corresponding fibrosis
stage.
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8.3.4 Implementation of a monitoring strategy
The effect of implementing different monitoring strategies was predicted using simulated
observed values of ELF. The specified monitoring strategy (decision rule, use of retesting and
frequency of testing) changed the simulated observed values that would be measured and
how the value or values for each individual would be interpreted.
8.3.4.1 Monitoring strategies
Simple decision rule (strategy A)
The simplest decision rule was based on a single value threshold (snap-shot rule). The
threshold value was specified and any observed value over this threshold indicated a positive
result for that participant at that time point.
Retesting (strategy B)
Patients with an initial test value within 1 ELF unit of the threshold value were subjected to
retesting, an additional test would be carried out one week after the standard test. When a
patient required retesting, the mean of the original test and the retest result was calculated
and this value was subjected to the decision rules to identify positive participants. Patients
with a value above the upper limit of the range were classed as positive on the initial test
without further testing and patients below the limit of the retesting range were classed as
negative using just the initial test. The retesting component could be used with any of the
alternative decision rules.
Frequency of monitoring (strategy C)
The frequency of monitoring was varied by increasing the interval between monitoring tests,
from six months to twelve months. Varying the frequency of monitoring could be used in
conjunction with any of the alternative decision rules explained.
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Alternative decision rules
Decision rules incorporating previous test results as well as the current result (track-shot
rules) to identify positive patients were also considered. Absolute and relative increases from
randomisation ELF or from the last recorded ELF measure were investigated. A rule using
predictions from a linear regression model fitted using all available observed data points was
also considered.
Decisions rules based on absolute and relative increases and the linear regression method
required at least two observations to declare a participant as positive. A simple threshold
rule was used to identify participants at the first monitoring point.
Absolute increase from start value (strategy D)–A result was considered positive when
the absolute difference between the test value and the first recorded value for the patient was
greater than the threshold.
Absolute increase from last observed value (strategy E)–A result was considered
positive when the absolute difference between the test value and the last observed test value
for that patient was greater than the threshold.
Relative increase from start value (strategy F)–A result was considered positive when
the relative difference between the test value and the first recorded test value for the patient
was greater than the threshold.
Relative increase from last observed value (strategy G)–A result was considered
positive when the relative difference between the test value and the last observed test value
for that patient was greater than the threshold.
Linear regression (strategy H)–The linear regression decision rule involved fitting a lin-
ear regression model to the data for each participant at each time point, using all available
measures for that participant. The prediction from the model was then used to identify
the patient as test positive or negative. A result was considered positive when the predic-
tion (at that monitoring time point) from the linear regression model was greater than the
threshold.
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8.3.5 Evaluation of a monitoring strategy
To evaluate each strategy, the decision made from implementing the monitoring strategy
using the simulated observed values and the corresponding latent values was assessed. With
knowledge of the true underlying disease state of each participant, the performance of a
variety of monitoring strategies was evaluated. These measures were adapted from the criteria
introduced by Li and Gastonis.31
8.3.5.1 Comparison of observed results with the underlying disease state
Participants had a positive or negative test result based on the simulated observed data and
the decision rule used. The test result was then found to be either true or false depending
on the underlying disease state. The purpose of the ELF test was to identify when patients
entered compensated cirrhosis, stage 4. As it may be beneficial to identify patients a short
period of time prior to entering compensated cirrhosis, participants were classed as ‘diseased’
three months prior to this time point.
If, at a testing point, a participant was ‘diseased’, a positive result would be a true positive
and a negative result would be a false negative. If, at a testing point, the patient was not
diseased, a negative result would be a true negative and a positive result would be a false
positive. As a positive result (true or false) caused a change in management and cessation of
monitoring, patients with a positive result do not have a test result at subsequent monitoring
times. Figure 8.4 illustrates how a strategy with a simple threshold decision rule can be
evaluated.
8.3.5.2 Measuring the performance of a monitoring strategy
The performance of a monitoring strategy was assessed at each monitoring point by calcu-
lating the number of patients at each monitoring test visit, and the number of true positive,
false positive, true negative and false negative test results.
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Figure 8.4: Implementing a monitoring strategy using simulated data.
The criteria used to asses strategies across all time points (adapted from the criteria intro-
duced by Li and Gastonis.31) were:
• the number of tests carried out across the duration of the strategy–to represent resource
use;
• the positive predictive value (PPV)–to investigate how likely it was for an individual
with a positive result to be diseased;
• and, the time between the onset of compensated cirrhosis and a patient having a positive
test result–to measure the potential patient outcome.
When comparing strategies the number of tests per person for the duration of monitoring,
PPV (for all tests over the duration of monitoring) and percentage of patients with ‘delayed
diagnosis’ (delay from onset of disease to diagnosis of over 12 months) were used to measure
performance. To allow for comparisons to be made between strategies where only two of the
three measures of performance ranged, thresholds used by monitoring strategies were varied
to obtain a PPV of 25%. A PPV of 25% was chosen as this would be an acceptable PPV in
practice.183
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With the PPV kept constant, differences in the percentage of patients with delay to diagnosis
of 12 months or more and the number of tests can be compared and appropriate strategies
selected. The delay to diagnosis estimate indicates the impact of false negatives and the false
positives are controlled by fixing the PPV.
8.3.5.3 Evaluation of strategies
The strategy evaluated first was the simple threshold strategy with observations every six
months and no retest component (reference strategy). Alternative strategies were evaluated
where individual components of the reference strategy were varied: the frequency of moni-
toring, the decision rule and whether a retest value was used. The same simulated data were
used when evaluating strategies A to H, to allow a direct comparison.
Sensitivity analyses
Sensitivity analyses were carried out to estimate the effect of inaccurate information regarding
test performance and progression of liver disease. Estimates of between-individual variability,
measurement error and fibrosis progression rate were altered (halved and doubled) and the
reference strategy (strategy A) was evaluated with all aspects of the strategy kept constant
(including the threshold value). Analyses were performed with the threshold varied to give
PPV of 25% using data with altered estimates also. Further sensitivity analyses were un-
dertaken in which the fibrosis progression rate was adjusted based on expert opinion, these
were analyses of: strategies A to H as for the main analysis (with PPV held at 25%), and
the reference strategy using varied estimates to generate monitoring data.
Validation of the ELUCIDATE trial data
To assess the accuracy of the model, the mean and standard deviation of randomisation
ELF values were calculated and compared for the ELUCIDATE and simulated data sets.
Analysis of variance was used to assess between-individual and within-individual variability
of ELF values recorded for patients in the trial and the simulated results. Multilevel models
(accounting for the repeated observations for patients) were fitted, both with and without
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estimating a random slope, using the simulated observed values and observed values from the
ELUCIDATE trial (for participants with two or more ELF measures post registration) and
the results from these models were compared. In the ELUCIDATE trial ELF measurements
were not taken in the majority of cases after the participant had an ELF result of 9.5 or above.
To allow for this the ELUCIDATE and simulated data sets were modified so that each patient
with an ELF measure of 9.5 or above did not have any subsequent measures.
Sample size
Simulations were based on a cohort of 20,000 patients to give adequate precision. With 20,000
test results, if one of the performance measures gave an estimate of 15% a corresponding 95%
confidence interval would range from 14.5% to 15.5%; for an estimate of 1.5% a 95% confidence
interval would range from 1.3% to 1.7%.
8.4 Results
The same simulated data were used when evaluating strategies A to H, to facilitate direct
comparisons. For the simulated cohort of 20,000 patients, 5,314 (26.6%) would develop
cirrhosis.
8.4.1 Reference monitoring strategy (strategy A)
Table 8.4 shows the performance of the reference monitoring strategy at each testing time
point. For the reference monitoring strategy (simple threshold, observations six-monthly and
no retest component), the threshold required to maintain the PPV at 25% was an ELF value
of 10.715. This was identified using an iterative process of modifying the threshold used in
the simulation. The sensitivity and PPV calculated for the strategy were highest at the initial
observation point and the percentage of tests with a positive result was also larger, due to
cases being identified from a prevalent population at the initial testing point. The percentage
of false negative results generally rises as the strategy continues in time. Over the duration
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of the monitoring strategy 7.64 tests per person (152,724 tests in total) were performed and
6.10% of all patients had delay to diagnosis.
8.4.2 Comparing strategies with changes to individual components to the
reference strategy
Figure 8.5 and Table 8.5 show the performance of various monitoring strategies. Results of
each strategy by observation point can be found in Appendix F Tables F.1 to F.7.
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Figure 8.5: Performance of various monitoring strategies on simulated monitoring data with
PPV of 25%. A is the simple threshold strategy; B is the retest strategy; C is the decreased
monitoring frequency strategy; D is the absolute increase from initial value strategy; E is the
absolute increase from last value strategy; F is the relative increase from initial value strategy;
G is the relative increase from last value strategy; H is the linear regression strategy.
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8.4.2.1 Inferior strategies
The retest strategy (strategy B) and the strategies with decision rules based on absolute
and relative increases from the first and last recorded value (strategies D, E, F and G) were
inferior to the reference strategy, requiring more tests and causing more patients who had
progressed to liver cirrhosis to experience a delay to diagnosis, whilst achieving the same
PPV.
The main effect of the retest strategy was to increase the number of tests performed (increase
of 3.30 tests per person), with also a small increase in the percentage of patients with delay
to diagnosis of 12 months or more (absolute increase of 0.40 percentage points). Whereas,
the strategies with decision rules based on absolute and relative increases from an initial
value showed only small increases in the number of tests required (increases of 0.14 and
0.18 tests per person respectively) but larger increases in the percentage of patients with
delay to diagnosis of 12 months or more (absolute increases of 1.58% and 2.05% respectively)
compared with the reference strategy. The absolute and relative increase from last recorded
value decision rules both increased the number of tests required (by 0.98 and 1.18 per person,
respectively) and increased the percentage of patients with delay to diagnosis of 12 months
or more (to 10.42% and 11.09%).
8.4.2.2 ‘Trade-off’ strategies
The reduced monitoring frequency strategy (strategy C) showed a ‘trade-off’ between delay
to diagnosis and the number of tests required when compared with the results of the reference
strategy. The number of tests required decreased by 3.30 tests per person and the percentage
of patients with delay to diagnosis of 12 months or more increased by 0.15 percentage points
(absolute increase) compared with the reference strategy.
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8.4.2.3 Superior strategies
The reference strategy was found to be inferior to the linear regression strategy. The linear
regression strategy used fewer tests (decrease of 0.12 tests per person) and had a lower
percentage of patients with delay to diagnosis of 12 months or more (absolute decrease of
0.47%) when compared to the reference strategy.
8.4.3 Sensitivity analyses
8.4.3.1 Comparing results from the reference strategy when varying estimates
of test performance and disease progression
Table 8.6 demonstrates the effect on the reference strategy of increasing (doubling) or de-
creasing (halving) parameter estimates (measurement error, between-individual variability
and fibrosis progression rate). Results for each monitoring time point using these alternate
estimates can be seen in Appendix F Tables F.8 to F.19. Analyses were performed with the
estimates varied to understand the impact of incorrect data on the simulation; these scenarios
were also analysed with the thresholds manipulated to give a PPV of 25%.
Improved estimates of test performance (decreased measurement error and decreased between-
individual variability) both improved PPV (absolute increases of 4.6% and 8.6% respectively)
and increased the number of tests required (increases of 0.73 and 0.91 tests per person) with
decreased measurement error also increasing the percentage of patients with delay to diagno-
sis (absolute increase of 1.30%). Both increased and decreased between-individual variability
reduced the percentage of patients with delay to diagnosis (absolute decrease of 0.72% and
2.12% respectively). An increased rate of fibrosis progression led to both increased PPV (ab-
solute increase of 4.2%) and percentage of patients with delay to diagnosis (absolute increase
of 1.52%) but decreased the number of tests required (decrease of 0.64 tests per person).
The largest difference in PPV was achieved by increasing the between-individual variability
(absolute decrease of 8.8%); the largest difference in number of tests required was achieved by
increasing measurement error (decrease of 1.84 tests per person); and the largest difference
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in the percentage of patients with delay to diagnosis was achieved by decreasing between-
individual variability (absolute decrease of 2.12%).
Analyses were performed with the thresholds calibrated to give PPV of 25%. The biggest
difference in delay to diagnosis of 12 months or more was changing between-individual vari-
ability. The biggest difference in the number of tests per person was caused by changing the
fibrosis progression rate.
8.4.3.2 Adjusted fibrosis progression rate
Results of evaluating strategies based on data with the adjusted estimate of fibrosis progres-
sion can be seen in Appendix F Tables F.20 to F.41 and Figure F.1. Results for strategies,
comparing to the reference strategy, appeared similar to results when using the unadjusted
estimate.
8.4.4 Comparison to ELUCIDATE data
The ELUCIDATE data contained 705 observations taken from 420 participants randomised
to the ELF monitoring arm of the trial. After removing measurements following an ELF value
of 9.5 or above for each individual (akin to the trial setting), the simulated data set contained
66,320 observations for 20,000 participants and the simulated data set with adjusted fibrosis
progression included 59,000 observations for 20,000 participants.
Analysis of the ELF value at the point of randomisation for each of the data sets showed
similar results–mean (SD) for the ELUCIDATE data was 9.57 (1.21); for the simulated data
9.71 (1.15); and for the simulated data with adjusted fibrosis progression 9.83 (1.20)–with the
mean value being slightly lower for the ELUCIDATE data than the two simulated data sets.
The between-individual standard deviation was higher for the ELUCIDATE data than for the
simulated data sets (0.93 for the ELUCIDATE data compared with 0.76 for the simulated data
and 0.82 for the simulated data with adjusted fibrosis progression). The within-individual
standard deviation was similar for the ELUCIDATE data and both simulated data sets (0.53
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for the ELUCIDATE data and, 0.51 and 0.52 for the simulated and simulated with adjusted
fibrosis progression data sets respectively). Results of analysis of randomisation ELF and
analysis of variance on ELF at all recorded time points can be seen in Table 8.7.
Table 8.7: Comparison of monitoring simulation to trial data–results of analysis of randomi-
sation ELF and analysis of variance for ELF measurements at all time points.
ELUCIDATE data Simulated data Simulated data with
adjusted fibrosis
progression
Randomisation point ELF
ELF mean (SD) 9.57 (1.21) 9.71 (1.15) 9.83 (1.20)
Analysis of variance
Between-individual SD 0.93 0.76 0.82
Within-individual SD 0.53 0.51 0.52
The ELUCIDATE data modelled consisted of 429 observations from 153 participants, with
each participant having a minimum of 2 and a maximum of 6 ELF observations and the
average number of observations per person was 2.8. The number of observation points used
from the simulation model was therefore capped to give a similar mean number of observations
per person to the value seen in the ELUCIDATE data. Allowing more observations per
person would introduce bias as patients with slower progressing disease will have more ELF
measurements prior to having a test result of 9.5 or above. The bias seen here relates to
comments made by Bellera et al135 when analysing monitoring data, with those patients
contributing the most monitoring observations generally in a more stable disease state and
potentially different to those contributing few monitoring observation points, see Chapter
7.
The model fitted to simulated data used 26,429 observation points for 9,608 simulated partici-
pants and the simulated data with adjusted fibrosis progression rate used 23,972 observations
for 8,779 simulated participants. For the simulated data sets the mean number of observa-
tions was 2.8 for the original data set with unadjusted fibrosis progression and 2.7 for the data
set with adjusted fibrosis progression. Results of modelling the ELUCIDATE data, simulated
data and adjusted fibrosis progression estimate simulated data can be seen in Tables 8.8 and
8.9.
Modelling of the ELUCIDATE data estimated the increase in ELF per year was 0.31 (95% CI
242
8.4. Results
Table 8.8: Results of multilevel model of repeated ELF measures from ELUCIDATE trial
and monitoring simulation.
Estimate 95% Confidence Interval P-value
ELUCIDATE ELF
Time since randomisation (years) 0.31 (0.22, 0.39) < 0.001
Constant 8.73 (8.63, 8.82) < 0.001
Between-individual SD 0.43 (0.36, 0.51)
Within-individual SD 0.48 (0.44, 0.52)
Simulated ELF
Time since randomisation (years) 0.24 (0.23, 0.26) < 0.001
Constant 8.84 (8.83, 8.85) < 0.001
Between-individual SD 0.42 (0.41, 0.43)
Within-individual SD 0.47 (0.46, 0.47)
Simulated ELF with adjusted fibrosis progression
Time since randomisation (years) 0.28 (0.27, 0.30) < 0.001
Constant 8.86 (8.84, 8.87) < 0.001
Between-individual SD 0.42 (0.41, 0.43)
Within-individual SD 0.46 (0.46, 0.47)
Table 8.9: Results of multilevel model (with random slope estimated) of repeated ELF mea-
sures from ELUCIDATE trial and monitoring simulation.
Estimate 95% Confidence Interval P-value
ELUCIDATE ELF
Time since randomisation (years) 0.38 (0.28, 0.49) < 0.001
Constant 8.71 (8.62, 8.80) < 0.001
Between-individual SD 0.41 (0.34, 0.49)
Within-individual SD 0.43 (0.38, 0.47)
Random slope 0.34 (0.23, 0.51)
Simulated ELF
Time since randomisation (years) 0.32 (0.30, 0.34) < 0.001
Constant 8.83 (8.82, 8.84) < 0.001
Between-individual SD 0.39 (0.38, 0.40)
Within-individual SD 0.42 (0.41, 0.42)
Random slope 0.46 (0.44, 0.48)
Simulated ELF with adjusted fibrosis progression
Time since randomisation (years) 0.36 (0.35, 0.38) < 0.001
Constant 8.84 (8.83, 8.86) < 0.001
Between-individual SD 0.38 (0.37, 0.39)
Within-individual SD 0.41 (0.41, 0.42)
Random slope 0.46 (0.44, 0.48)
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(0.22, 0.39); p-value < 0.001). Modelling of the simulated data showed the increase in ELF
per year to be comparable at 0.24 (95% CI (0.23, 0.26); p-value < 0.001) and for the simulated
data with adjusted fibrosis progression the increase in ELF per year was 0.28 (95% CI (0.27,
0.30); p-value < 0.001). When allowing for the random slope the estimate of increase in
ELF per year from the ELUCIDATE data was 0.38 (95% CI (0.28, 0.49); p-value< 0.001);
from the model this was 0.32 (95% CI (0.30, 0.34); p-value< 0.001) and from the model with
increased fibrosis progression this was 0.36 (95% CI (0.35, 0.38); p-value< 0.001).
Findings from the simulated data were broadly comparable with the trial. Comparison of the
cirrhosis outcomes for the simulated data and ELUCIDATE data (monitoring arm) showed a
higher percentage of positive results (70.7%/74.4% vs 64.2%) in the simulated data compared
with the ELF arm of the trial. The percentage of positive results in the standard care arm
was lower (4.5%). However, the percentage of diagnoses of cirrhosis after the first testing
time point were greater for the trial than the simulated data (18.7%/18.3% vs 29.9%), see
Table 8.10.
Table 8.10: Comparison of outcomes for trial and simulated data.
Outcome RCT RCT Model Model
monitoring standard care Unadjusted Adjusted
Fibrosis progression Fibrosis progression
Diagnosis of cirrhosis
during trial 281/438 (64.2%) 20/440 (4.5%) 14132/20000 (70.7%) 14876/20000 (74.4%)
Diagnosis of cirrhosis
after 1st measurement 84/438 (29.9%) 20/440 (4.5%) 3740/20000 (18.7%) 3655/20000 (18.3%)
8.5 Discussion
8.5.1 Reference strategy
At the initial testing point a monitoring strategy will be identifying cases from a prevalent
population where a large proportion of patients will have high ELF values. At subsequent
time points those with a previous positive result will not be tested and the tested population
will contain cirrhotic patients that were falsely negative at the previous testing point or
have developed cirrhosis since the last testing point (incident cases), hence the difference in
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results at the initial monitoring time point compared with others. The percentage of false
negative results generally increased with each time point as patients with low ELF trajectory
have reached compensated cirrhosis but as they have a low ELF value for their disease stage
they are required to progress further to have a positive test result using the simple threshold
decision rule. The increasing percentage of false negative results as the testing points advance
suggests the simple threshold should be reduced at later time points to account for the patients
that have false negative results using the original threshold.
8.5.2 Comparing strategies with changes to individual components to the
reference strategy
8.5.2.1 Inferior strategies
It was anticipated that the strategy with retesting would result in an increase in the number
of tests per person required compared to the reference strategy (due to the increase in tests at
each observation point) but the percentage of patients with delay to diagnosis increased also.
Due to the measurement error of both the initial and retest results some patients would have
been positive on their initial test (as with the reference strategy) but using the mean of the
initial and retest means they have a negative result. The slight increase in time to diagnosis
when using a retest strategy will have a small effect on the percentage of participants with
delay to diagnosis also.
The strategies using absolute and relative increase from last recorded value decision rules were
notably worse than the strategies using absolute and relative changes from the initial recorded
value. When using a decision rule based on detecting a magnitude of change between one
value and another, the two values used to calculate the change will both have measurement
error. Comparisons with the initial value will consider increases in ELF across the entire
monitoring period rather than increases since the previous monitoring point only. Differences
from the initial value rather than the last value were better for detecting true change over
measurement error (signal from noise).
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The simple threshold strategy outperformed the strategies comparing current to previous
values. This is linked to the index of individuality (II), the ratio of within-individual and
between-individual variation. If a test has a high II value, where an individual can have results
spanning a wide range of the possible results for a group of people, comparison to constant
thresholds will be more meaningful than for tests with low II values, where an individual
will have tests results spanning only part of the possible range of results and comparisons to
previous results will be more beneficial.35 Modelling results showed the measurement error
and between-individual variability to be similar which would lead to a large II, see Table
8.8.
8.5.2.2 ‘Trade-off’ strategies
The reduced test frequency strategy showed a large decrease in the number of tests per person
used for a small increase in the percentage of people with delay to diagnosis. It may be that
for a substantial decrease in the number of tests required, and therefore the resource used, the
slight potential for increased harm to patients (through later diagnosis) is acceptable.
8.5.2.3 Superior strategies
The linear regression strategy was the only strategy tested that showed a reduction in both
the number of tests required and the percentage of patients with delay to diagnosis. By fitting
a regression model using all previous observations for an individual and obtaining a prediction
from this, the linear regression method utilised all available data and some allowance was
made for the fluctuation in results due to measurement error. The linear regression strategy,
however, only resulted in small benefits compared with the reference strategy. This modest
improvement in monitoring strategy performance may not merit the extra complexity involved
when using the linear regression method.
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8.5.3 Estimates of test performance and disease progression (sensitivity
analyses)
The results obtained when varying estimates in the simulation model and evaluating the
reference strategy highlight the importance of accurate data. The increases and decreases
in estimates of test performance (measurement error and between-individual variability) and
fibrosis progression rate affected the three measures of performance in different ways.
8.5.3.1 Measurement error and between-individual variability
The measurement error of a test affects the number of false positive test results, with larger
measurement error resulting in more false positive results and smaller measurement error re-
sulting in fewer false positive results. Between-individual variability will affect the underlying
ELF values possible at each fibrosis stage. Providing ELF is related to fibrosis stage, if the
between-individual variability is smaller it will be easier to correctly identify fibrosis stage
from ELF resulting in fewer false positive results and more true positive results.
With fewer false positives and more true positives, PPV will increase, the number of tests
required will increase as the reduction in false positives means the number of patients cor-
rectly staying in the monitoring programme will increase. With reduced measurement error
the observed values reflect more closely the underlying disease state of each patient, if the
threshold does not adequately account for this patients will need to progress for longer to
have a test value over the threshold indicating a positive result. When the between-individual
variability is reduced, due to the increase in true positive results the percentage of patients
with delay to diagnosis will decrease.
8.5.3.2 Comparison of simulated and trial data
Analysis of the simulated and trial data showed similar results; indicating the model may
reflect patient progression well. The monitoring arm of the trial detected cirrhosis in 64.2%
of patients compared with just 4.5% in the standard care arm and the model predicted this
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would be 70.7%. Such a difference in detection suggests the false positive rate is high with
the strategy used in the trial. Had there been sufficient time this modelling exercise could
have been used to modify the strategy.
8.5.3.3 Fibrosis progression rate
Fibrosis progression rate will affect the number of diseased patients. With an increased
fibrosis progression rate more patients will have compensated cirrhosis, which will lead to an
increase in PPV. With increased fibrosis progression rate patients have positive results earlier
in the strategy and the strategy will require fewer tests to be performed. If patients have
increased fibrosis progression rate more patients will have been in cirrhosis for more than 12
months meaning more patients can be undetected for over 12 months.
8.5.4 Comparison of modelled data to ELUCIDATE
The fibrosis progression rate, adjusted (increased) due to clinical opinion, seemed reason-
able compared to the ELUCIDATE data. The estimates of between and within-individual
standard deviations for the simulated data were similar to the ELUCIDATE data. The
comparison of individuals detected as positive was higher in the simulated data, but the pro-
portion of patients identified after the first testing point was underestimated in the simulated
data, suggesting a decreased severity of disease at entry in the trial.
Overall, the simulated data compared well with the ELUCIDATE data, showing the possi-
bilities of modelling to design a monitoring strategy prior to evaluating in a trial.
8.5.5 Limitations
8.5.5.1 Data sources
The estimates from data sources used to inform the simulation model will have a large impact
on the results of the simulation model. The suitability of data was assessed, by consultation
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with clinical colleagues, and where necessary estimates were adjusted for sensitivity analyses.
However, as the model was dependent on the information it used, the quality and suitability of
data used will always be a limitation. Just one cross-sectional study provided information on
both the link between ELF values and fibrosis stage and the distribution of fibrosis stages at
entry to the trial. When looking to identify an estimate of measurement error several sources
were identified with the estimates from each found to be vastly different. The data used
to obtain the estimate of measurement error did not allow within-individual and analytical
variation to be estimated separately meaning an estimate of total imprecision was used and
applied at each time point. The data linking ELF to fibrosis stage defined fibrosis stage by
biopsy. Even though biopsy is the reference standard for staging fibrosis, biopsy is known to
not be accurate in some cases.
The ELUCIDATE trial data used to assess the simulation model was not completely ap-
propriate as the dataset contained repeated observations from 153 participants with many
participants having only two observations; more observations per person would allow the
model to better estimate the error terms and the changes over time. ELF measurements only
being taken until the point of a measurement being classed as positive also hinders the ability
of the data to estimate the true progression of ELF over time as those with higher ELF val-
ues (and possibly more developed cirrhosis) cease to have ELF recorded and so progression
beyond this ELF value cannot be assessed. Patients with lower ELF measures (below 9.5)
continued monitoring meaning they had more measures, and therefore contributed more data
to the model; however they were potentially very different to those with fewer measures, who
were likely in a worse health state.
8.5.5.2 Assumptions
A limitation of the simulation model is the number of assumptions required. Some of the
estimates used to generate the monitoring data, such as fibrosis progression rate and mea-
surement error, can be varied in magnitude and the results assessed to identify the impact of
using data of insufficient quality or suitability in the model. However, there were assumptions
in the development of the model that were not explored.
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The model assumes fibrosis progression is constant and requires patients to have positive
fibrosis progression. The model assumed linear increases in ELF between fibrosis stages,
normally distributed ELF within fibrosis stage and constant fibrosis progression rate. The
error associated with each observation was assumed to be normally distributed and a simple
error term was used. The measurement error used in the simulation may be simplistic as it
is randomly chosen from a distribution that is constant across individuals and time, and not
linked to the magnitude of the ELF value. As no alternative data or substantiated opinion
was available to enable modelling of these factors in any other way, these assumptions were
necessary for the development of the model. Longitudinal data sets with ELF values and
biopsy recorded in addition to data from a biological variability study of ELF would be
required to test these assumptions.
8.5.5.3 Trial considerations
Several criteria were required to allow the simulation model to generate data for a trial
(described in Table 8.2). Whilst these criteria were included to avoid anomalies and were
based on clinical advice, there is no data to support them.
8.5.6 Further work
A greater variety of strategies could be evaluated with multiple components assessed simul-
taneously. More complex decision rules and frequencies could be explored, for example a
simple threshold decision rule where the threshold remains the same across patients but
varies by time point within a monitoring strategy or changing the frequency of testing to be
non-constant.
It may be possible for the simulation model to be adapted to account for usual care (and
variation in usual care). If usual care could be modelled, it may be possible to compare the
use of monitoring strategies (in addition to usual care) to usual care alone and with further
simulation work estimate differences in patient outcomes between the approaches.
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The model can be used to show lifetime progression for a time-matched cohort of patients
with fibrosis (if the data is simulated with all patients starting at the onset of liver fibrosis).
These data may be beneficial to the assessment of how a strategy would perform in practice
rather than specifically in the trial setting as this would provide information on how newly
diagnosed patients would benefit from monitoring.
Well-designed studies of biological variability would mean accurate estimates of variability
(see Chapters 3 and 5) could be used in the model enabling more accurate monitoring data
to be generated and analysed.
8.6 Conclusions
Simulation can be used to obtain monitoring data for candidate monitoring strategies and to
enable an appropriate strategy to be selected for full scale evaluation.
To generate monitoring data there has to be available evidence on the natural history of the
disease and the performance of the monitoring test (measurement error and test accuracy)–
this evidence can be from existing data sets, reviewing the literature or potentially expert
opinion. If the data informing the simulation model is inaccurate the results obtained from
evaluation of strategies will not reflect the truth. Inaccurate estimates will affect results in
a complex way. The results of sensitivity analyses highlighted the importance of accurate
estimates of test performance and progression. See Chapters 2 to 5 for reviews of methods
and studies, analysis and studies of sample size for biological variability studies.
Comparison of the trial data and the simulated data provided similar results. Bias in mon-
itoring data, particularly concerning the number of recorded results, should be considered
when analysing as those contributing more monitoring data points are generally different to
those contributing few (see Chapter 7).
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Chapter 9
Discussion and Conclusions
Monitoring of disease progression and recurrence is frequently used by healthcare providers in
the management of patients with little or no evidence of effectiveness.2 The evidence required
to know how and when a test can be used to monitor disease progression and recurrence is
often poorly understood and neglected.1
The overarching questions addressed in this thesis were:
• How can optimal monitoring strategies be designed?
• What are the appropriate study designs and methods for estimating variability of tests?
To investigate estimating test variability the design, analysis and quality of reporting of stud-
ies was assessed to understand test behaviour in a monitoring setting. Results of these studies
help researchers understand how tests can be best used to monitor patients, informing deci-
sion rules for identifying test positives. To investigate how to optimise monitoring strategies,
work focussed on how monitoring strategies can be designed and evaluated prior to full scale
253
Chapter 9. Discussion and Conclusions
evaluation in a randomised controlled trial. The purpose of this work was to optimise all
aspects of the monitoring strategy (the decision rule, threshold for a positive test, frequency
of monitoring and duration of monitoring) considering both the performance of monitoring
strategies and the impact on patient outcomes. The aim was to combine knowledge of dis-
ease progression and the ability of the monitoring test to optimise a monitoring strategy that
could then be used in a randomised controlled trial.
9.1 Overview of thesis
9.1.1 Research questions
This thesis looked broadly at two areas: the design, analysis and reporting of biological
variability studies, which provide estimates of measurement error, and the use of modelling
techniques to combine evidence and allow comparison of monitoring strategies, so that opti-
mal strategies can be used in further investigations.
How can optimal monitoring strategies be designed? What are the appropriate study designs
and methods for estimating variability of tests? In order to deliver on these main questions,
this thesis aimed to answer the following questions:
• What are the current methods for assessing biological variability?
• How well are biological variability studies designed, analysed and reported?
• Can the design and analysis of biological variability studies be improved, specifically
sample size planning and outlier detection methods? Are the current methods for anal-
ysis of biological variability studies valid, considering sample size and outlier detection?
• What are the current methods for the design and analysis of monitoring strategies?
• Can modelling methods be used to predict the performance of monitoring strategies,
to identify optimal strategies to be evaluated in an RCT?
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The first Chapter provided an overview of the issues with non-evidence based monitoring
strategies being commonly used in practice. This Chapter provided background detail on
biological variability, the standard study design and associated study designs. The broad
concepts for developing a monitoring strategy and full evaluation of a monitoring strategy
were also introduced. The eGFR-C and the ELUCIDATE studies were introduced in Chapter
1 as they were case studies used in subsequent Chapters of the thesis. This Chapter defined
the scope of the thesis and specified the main aims.
The second Chapter focussed on biological variability and introduced the key ideas to as-
sessing biological variability. This Chapter considered the design, analysis and reporting of
studies to evaluate biological variability using literature from a variety of areas, not just
laboratory sciences.
The third Chapter was a review of the current state of biological variability studies. This
review identified studies of biological variability across test areas (laboratory, physiological
and imaging) and assessed the design, analysis and reporting of these studies.
The fourth Chapter showed analysis of a biological variability case study conducted as part of
the eGFR-C study. The analysis of these data was performed in several ways to understand
the impact of the various methods identified in Chapters 2 and 3 (transformation of data and
outlier detection).
The fifth Chapter focussed on sample size for biological variability studies. Using simulation,
biological variability data were generated and the standard methods were used to analyse
these data. This simulation process allows researchers to understand the validity of results
and the potential results they may generate from studies given their chosen sample size.
The sixth Chapter investigated the impact of outlier detection methods when analysing bio-
logical variability data. Again, simulated data were used to show the effect of using different
methods to identify outliers and removing these prior to analysis. The effect of these methods,
and the validity of results, was investigated and guidance provided.
The seventh Chapter reviewed the literature in the area and related areas of developing and
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evaluating monitoring strategies. This review discussed modelling methods, signal and noise,
screening, and health economic approaches.
The eighth Chapter developed a model allowing monitoring data to be simulated and mon-
itoring strategies to be compared, with optimal strategies selected. This Chapter used the
ELUCIDATE study as a case study. The model simulated trial data and this was compared
with the actual trial data. This analysis allowed the performance of monitoring strategies to
be compared.
9.1.2 What are the current methods for assessment of biological variabil-
ity?
To understand the current methods used to assess the biological variability of tests (design,
analysis and reporting) a review of the literature was undertook in Chapter 2, a review of
studies of biological variability in Chapter 3 and a case study analysis using these methods
in Chapter 4.
There was little identified literature regarding the design of biological variability studies in
the review in Chapter 2. For laboratory based studies there appeared to be one main source
of design advice, the Fraser-Harris framework published in 1989. This design guidance was
evident in the studies of biological variability identified and reviewed in Chapter 3. The
Fraser-Harris framework offered limited information regarding sample size but there have
been recent publications commenting on this issue.
The review of the literature (Chapter 2) identified the methods for the analysis of biological
variability studies. The terminology of results differed across disciplines and the area of clin-
ical chemistry had the most well defined methods. The primary method of evaluating data
was ANOVA or a random effects model. In the laboratory setting there was additional guid-
ance regarding transforming data and outlier removal, again stemming from the Fraser-Harris
framework. When biological variability data are log-transformed prior to analysis, methods
can be used to provide ‘exact’ results (see Chapter 2). The identified literature demonstrated
the estimates of variability were different across areas, with laboratories favouring the calcu-
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lation of coefficients of variation and reference change values; whereas, in the medical setting
intra-cluster correlation coefficients were commonly referred to. Methods for similar set-
tings to biological variability include inter-intra reader analysis and Bland-Altman analysis
(comparison of methods for measuring the same thing). Chapter 3 highlighted how biologi-
cal variability analysis methods were used in the identified studies and Chapter 4 provided
examples of the use of these analyses.
Chapter 2 identified literature calling for the standardisation of terminology and notation and
a checklist for reporting. The infrequent use of confidence intervals to display uncertainty of
estimates in laboratory studies of biological variability was also identified as a concern, as
the meaning and interpretation of estimates may be affected by lack of clear reporting of the
range of likely values for estimates of variability.
9.1.3 How well are biological variability studies designed, analysed and
reported?
The main finding from the review of biological variability studies (Chapter 3) was the lack
of these studies, particularly considering their importance in identifying the optimal use of
a test in monitoring. The majority of the studies identified were for laboratory tests, rather
than physiological and imaging tests, although this may be due to the search criteria used.
There is a need to educate researchers to understand the key importance of these studies and
the vital information they provide to tailor the use of tests.
The review (Chapter 3) identified the design of biological variability studies as suboptimal,
often recruiting very few participants (particularly studies of laboratory tests) and rarely
providing any justification for the sample size chosen. Participants in biological variability
studies are often healthy participants and do not reflect the population that would receive
the test to monitor progressive or recurrent disease; estimates of variability from studies of
healthy populations may be very different to disease populations. Some studies of biological
variability did not assess analytical, within-individual and between-individual variability in
the same study and instead relied on external estimates; this practice is not appropriate and
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has the potential to result in incorrect estimates of variability.
The review of biological variability studies (Chapter 3) showed the analysis was in most cases
appropriately performed by ANOVA or random effects modelling. In the studies of biological
variability of laboratory tests additional methods were used prior to this analysis to assess
the normality of data and identify outliers, leading to transformation and deletion of outliers.
The process of assessing normality and transforming data may be performed to ensure the
methods of analysis are appropriate but may also be due to the beneficial impact on analysis
when log-transformed biological variability data are used (coefficients of variation can easily
be derived), with exact estimates produced for log-normal data.
The purpose of outlier detection and removal methods is less obvious and more concern-
ing. The purpose of these studies is to evaluate variability, with the removal of variability
prior to analysis potentially introducing bias (removing outliers generally removes variabil-
ity). Chapter 4 further investigated the impact of transformation and outlier detection us-
ing a case study, showing the results vary when these methods are employed. The use of
log-transformation needs to be complemented with the calculation of ‘exact’ results and be
clearly specified when reporting methods and results. The analysis with and without outlier
exclusion showed the impact of outlier removal often led to a reduction in the estimated
variability.
The review of studies of biological variability identified reporting was poor often due to lack
of detail regarding: sample size rationale, number of measurements, timing of repeats and
the method of analysis. Confidence intervals were rarely used to indicate the uncertainty of
estimates. It was also likely that outlier detection and deletion and normality assessment and
transformation may have been performed in some studies but the methods were not explicitly
stated.
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9.1.4 Can the design and analysis of biological variability studies be im-
proved, specifically sample size planning and outlier detection meth-
ods? Are the current methods for analysis of biological variability
studies valid, considering sample size planning and outlier detection
methods?
The review of biological variability studies (Chapter 3) highlighted the need for improvements
in areas of design, analysis and reporting. Subsequent work in Chapter 5 was developed to
provide guidance to researchers when planning biological variability studies by investigating
the impact of sample size (number of participants, observations of participants, and assess-
ments of observations of participants) on the precision of results. Chapter 6 focussed on
understanding the impact of different methods for outlier detection on the standard analysis
of biological variability data and the results obtained. The empirical analysis of a biological
variability study conducted in Chapter 4 further uncovered the issues with analysis and how
this should be reported.
Chapter 3 identified issues with the design of biological variability studies. One of the main
issues identified was sample size and this was further investigated in Chapter 5. A simulation
model was developed allowing biological variability data to be simulated and evaluated, and
using multiple simulations the bias and precision of estimates of biological variability were as-
sessed. The results showed estimates may not be valid in some test scenarios with small sam-
ple sizes, due to the bias of variability estimates. The results identified where to focus resource
to gain precision. Increasing the number of participants appeared to be most beneficial as
this increased the precision of analytical, within-individual and between-individual variability
which impacts on the precision of all measures of coefficient of variation, the reference change
value and the index of individuality. An application was developed to carry out the simulation
and guide researchers, https://alicesitch.shinyapps.io/bvs_simulation/.
Chapter 6 investigated one of the concerns regarding analysis of biological variability data,
which was the use of outlier detection methods and deletion of the measures identified. The
results of this simulation study showed, with log-normally distributed data, outlier detection
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methods generally led to underestimation of the variability. Outlier detection methods in-
volving the Cochran C test and Tukey IQR rule were particularly poor. With outlying data
present the best performing outlier detection strategies were identified.
The review work in Chapter 3 and empirical analysis in Chapter 4 concluded and recom-
mended reporting of biological variability studies needs to be transparent. The Bartlett
Checklist has been developed which should improve reporting, and particularly enabling
studies of biological variability in laboratory medicine to be identified. This checklist could
be further enhanced to include the issues identified the methods for: checking normality of
data, transformation leading to the methods used to produce results, as well as whether any
methods have been used to identify and remove outliers, and any potential bias resulting
from using these methods. When outliers are detected and removed this should be fully re-
ported and it would be good practice for this analysis to be presented as a sensitivity analysis
alongside the analysis of the full data set.
The review identified confidence intervals were rarely given for estimates of biological variabil-
ity; Chapter 2 provides the formulas for these confidence intervals and an application was de-
veloped alongside the simulation work in Chapter 5 allowing researchers to easily calculate and
visualise these for a range of sample sizes (https://alicesitch.shinyapps.io/bvs_cis).
Reporting of confidence intervals indicates the uncertainty of estimates and allows results
from separate studies to be compared.
9.1.5 What are the current methods for the design and analysis of moni-
toring strategies?
The review of monitoring and monitoring related literature (Chapter 7) identified a paucity
of research, with the few relevant studies reporting an analysis or simulation of a particu-
lar monitoring situation; most studies simply offered a standard method for designing and
analysing a monitoring strategy. The review identified a general model of monitoring data,
with the observed values comprising of the true (unobserved) value and the measurement
error.
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In the published literature on screening tests, methods focussed on identifying the optimal
frequency of screening. The review identified thresholds are often developed using variability
data, especially in the area of treatment titration. Whilst variability information is necessary
when developing a monitoring strategy, it is important to include considerations such as
impact on patient health for monitoring progressive and recurrent disease. The literature
review also highlighted the potential biases in monitoring data.
9.1.6 Can modelling methods be used to predict the performance of mon-
itoring strategies, to identify optimal strategies to be evaluated in
an RCT?
Chapter 8 introduced a model for monitoring data allowing observed test data and ‘true’
underlying and unobserved data to be generated. Monitoring data were generated using
knowledge of disease progression, accuracy of the monitoring test and variability of the mon-
itoring test. Monitoring strategies were then evaluated using the observed data to give a
test outcome and the underlying ‘true’ value to indicate the true disease state. Monitoring
strategies were defined specifying the decision rule, test threshold, frequency and duration of
monitoring. Decision rules using a simple threshold for all participants, relative and absolute
increase from last and first measure for each individual, including a retest component and
using predictions from a linear regression model were compared. For the ELUCIDATE case
study, the best performing strategy was the linear regression strategy with similar results for
the simple threshold strategy. Comparing the simulated data with the ELUCIDATE data
showed the results were similar and the simulation model may have been able to identify
a preferable monitoring strategy for the trial, with a higher threshold used to reduce false
positive results.
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9.2 Strengths and Limitations
9.2.1 Strengths
The work presented in this thesis looks at an under researched area where non evidence based
practice is a common occurrence. The importance of understanding biological variability and
the impact of this information on how tests are used for monitoring is under-acknowledged,
thus under-utilised.
Biological variability studies are often small niche projects in laboratories. This thesis offers a
coherent statistical review of methods which will help researchers in this field understand why
they are using these methods and challenge the specific ways these methods are employed.
Guidance and understanding will improve the design, analysis and reporting of biological
variability studies.
The sample size simulation work allows researchers to plan biological variability studies ac-
cording to the precision of all estimates of biological variability, adding to the previous knowl-
edge in this area. Also the application for calculating confidence intervals may help with the
reporting of estimates. Guidance on the issues associated with outlier detection will help
understanding of the potential problems when using these methods and enable researchers
to use these approaches when necessary and with appropriate caution.
The further simulation work focusses on the whole monitoring strategy and evaluates mon-
itoring test performance. This approach allows all aspects of a monitoring strategy to be
evaluated rather than each component in isolation. Optimal strategies can then be selected
for further evaluation.
9.2.2 Limitations
Chapters 2, 3 and 7 provide reviews of the literature for assessing biological variability, bio-
logical variability studies and monitoring and monitoring-related methodology respectively.
These reviews were not systematic reviews. The purpose of the literature reviews (Chapters 2
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and 7) was to understand the main methods available and a systematic review would not have
been an efficient way to locate this information. The purpose of Chapter 3 was to understand
the current state of the field of biological variability studies. These studies were difficult to
identify, especially studies of physiological and imaging tests. It may be laboratory studies
are over represented in the review of biological variability studies as these were the studies
easily located due to the recorded and updated Westgard QC database. A systematic review
may have identified more biological variability studies to enhance this review.
Chapter 4 used a single case study for empirical analysis. This case study had multiple
outcomes but all of these were related to kidney function. This case study also focussed on
laboratory tests and analyses of physiological and imaging tests were not performed. The
sample size for the eGFR-C study was small with only 20 participants, four observations
of each participant and analysis in duplicate; however, this is reflective of these studies in
practice.
Chapters 5 and 6 presented simulation studies to understand the precision of estimates of
results using simulated data which are normally or log-normally distributed. These distri-
butions were used so the estimated result from the simulation could be compared with the
expected result. However, it is unlikely real biological variability data will perfectly follow
these distributions. Use of the sample size application requires researchers to input estimates
for each level of variability, which may not be known.
Chapter 8 produced a model which was dependent on many data sources and assumptions.
Data required for this model included natural progression of disease (case mix at study
entry and an estimate of the rate of progression), the performance of the test (accuracy,
specifically the link between biomarker and disease stage) and the measurement error of the
test (biological variability estimates). Limited data sources were available to contribute these
data. It is unlikely such an array of data would be available in many clinical areas for many
tests. The model assumed linear progression between stages of disease, which may not be
fully appropriate.
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9.3 Implications for practice
The work presented in this thesis emphasises the importance of estimating biological vari-
ability and the potential studies of biological variability have to impact on development of
evidence based approaches to monitoring disease progression and recurrence. Highlighting
the importance of these studies will not just increase the quality of the design, analysis and
reporting but also the number of these studies conducted and the variety of settings these
studies are conducted in. Researchers need to understand the importance of having good es-
timates of biological variability particularly for monitoring purposes, as do funders, as this is
an area that can be vastly improved for limited resource. The results of biological variability
studies may also show a test is not fit for monitoring prior to full scale evaluation limiting
further cost.
This thesis allows better planning of biological variability studies. The issues identified in the
review of biological variability studies and the empirical analyses need to be communicated
to researchers in this area. The application developed to help researchers plan the sample size
of biological variability studies considering the precision of estimates gives usable guidance
which has the potential to greatly improve these studies. The application for confidence
intervals for some biological variability estimates provides a tool for improving the reporting
of uncertainty for these studies.
This thesis also provides recommendations to improve the analysis of biological variability
studies with researchers empowered by further understanding of the methods and the issues
related to outlier detection. The work on outlier detection also highlights the need for caution
when interpreting results from studies that have used outlier detection methods.
The methods for planning and evaluating monitoring strategies prior to a trial, in terms
of performance, need refining and tailoring to the specific situations they are applied to.
However, this work shows the data required to undertake such an evaluation prior to a trial,
the small preliminary studies that should be performed when developing a strategy and the
possibilities if this information is available.
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The work presented in this thesis has provided a cohesive and complete pathway for develop-
ing an evidence-based monitoring strategy to be fully evaluated in a monitoring RCT. Figure
9.1 demonstrates the necessary evidence required to design a monitoring strategy; from proof
of principle, biological variability and accuracy studies, and using results from these studies
with natural history data to model strategies allowing selection of optimal strategies and
further evaluation using a monitoring RCT.
As monitoring RCTs are typically very expensive, following this pathway of studies can
identify monitoring tests that are not fit for purpose (due to lack of proof of principle,
high variability, poor accuracy or substandard monitoring strategy performance) early in the
process using small-scale studies and modelling. Using this pathway also ensures only optimal
tests are evaluated using monitoring RCTs.
9.4 Future research
Searches for biological variability studies indicated the need for clear labelling of these studies
and the development of search terms.
A checklist for planning studies of biological variability would be beneficial. This would
highlight the importance of sample size, choosing an appropriate population, specifying the
measures of variability to be assessed and pre-specifying the methods for analysis. The
Bartlett Checklist requires updating to reflect the additional points identified for transparent
reporting; namely the methods for outlier detection and removal. Reporting of exactly how
this has been conducted, the number of observations removed and the recommendation the
analysis of the complete data set be reported also need to be included. A risk of bias tool
could be developed to assess these studies also.
The impact of using of healthy populations to measure variability and using external sources
to obtain some measures of variability require further investigation. These issues stem from
a lack of understanding and indicated researchers in this area require further guidance when
planning biological variability studies.
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Proof of principle study
Decision
to progress
Biological variability study
to estimate analytical, within-
individual and between-
individual variability in
appropriate population
Decision
to progress
Improve test or
identify new test
–Investigate causes
of variability and
limit variability
–Improve test, identify
new test, or consider
a different population
Test accuracy study
to estimate test accuracy
in appropriate population –Investigate causes
of poor accuracy and
improve accuracy
–Improve test, identify
new test, or consider
a different population
Decision
to progress
Natural history study
to gain disease progres-
sion estimates for ap-
propriate population
Modelling study
to identify optimal
monitoring strategies
Decision
to progress
–Investigate causes
of poor strategy
performance and
modify appropriately
–Improve test, identify
new test, or consider
a different population
Monitoring RCT
to evaluate the ben-
efit of monitoring
Figure 9.1: Pathway of designing monitoring studies.
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9.5. Conclusions
The work concerning biological variability studies could be developed to further understand
the impact of outlier detection and removal. This may be through additional empirical
analyses to understand the impact of this practice or via a simulation study, using data that
do not perfectly follow a distribution and is closer to real data.
The monitoring simulation work needs to be developed further to provide a generic case
which can be modified by researchers to develop an idea of the performance of a strategy.
The simulations performed can then have a greater degree of flexibility of strategies (changing
more than one component at a time).
When the final results of the ELUCIDATE study (long-term follow up) are obtained anal-
ysis can be undertaken to further compare the simulation model with the ELUCIDATE
data.
The monitoring simulation models can be further developed to consider the potential patient
outcomes and cost-effectiveness of monitoring strategies. Also, given the need for data from
a variety of sources, value of information analysis may be useful to understand where to focus
resource.
9.5 Conclusions
This thesis has identified key information and methods that can be used to develop moni-
toring strategies allowing monitoring of disease progression and recurrence to be evidence-
based.
In addition to the biological variability of the monitoring test, other key information for
evaluating the use of monitoring of progressive or recurrence disease is the natural history
of the disease and the accuracy of the monitoring test. Incorporating all this knowledge and
using modelling techniques allows observed monitoring data and the underlying disease state
to be simulated. These data can then be used to compare monitoring strategies in terms
of strategy performance. This approach was validated by comparing the modelled data to
observed study data.
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Chapter 9. Discussion and Conclusions
This thesis has highlighted the importance of biological variability studies and the estimates
obtained from them. Work needs to be done to ensure these studies are performed more often
and in a variety of clinical areas, and researchers need to understand how to design these
studies using the correct population, using the correct methods for analysis, and reporting the
methods and results in a transparent manner. Tools have been developed allowing researchers
to easily calculate confidence intervals for variance estimates and to plan studies with ap-
propriate sample sizes to understand the likely precision of key estimates. Recommendations
have also been made regarding the use of outlier detection methods when analysing biological
variability studies and the interpretation from studies that have used these methods.
Using the pathway identified in this thesis, poor monitoring tests (for example, the ELF test to
monitor progression of liver fibrosis and prostate specific antigen for monitoring recurrence of
prostate cancer) can be identified early using small-scale studies (proof of principle, biological
variability studies, test accuracy and modelling). Use of this pathway also ensures monitoring
strategies are optimised prior to full evaluation in a monitoring RCT.
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Appendix A
Biological variability studies:
review of design, analysis, and
reporting
A.1 Studies identified for review of biological variability stud-
ies
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Table A.1: Studies identified for review of biological variability studies.
ID Search Authors Year Title Journal
1 A Curtis et al184 2014 Evaluation of dried blood spots with a multiplex assay for measuring recent
HIV-1 infection
PLoS One
2 A Gabriele et al185 2014 Reproducibility of the Carpet View system: a novel technical solution for
display and off line analysis of OCT images
Int J Cardiovasc
Imaging
3 A Jimmerson et al87 2014 Development and validation of a dried blood spot assay for the
quantification of ribavirin using liquid chromatography coupled to mass
spectrometry
J Chromatogr B
Analyt Technol
Biomed Life Sci
4 A Manley et al186 2014 Comparison of IFCC-calibrated HbA(1c) from laboratory and point of care
testing systems
Diabetes Res Clin
Pract
5 A & B1 Saez-Benito Godino et al187 2014 Multicentre evaluation of glycated haemoglobin (HbA1c) of Roche
Diagnostics in Andalusia
Clin Biochem
6 B1 Wu et al188 2014 Biological variation of the osmolality and the osmolal gap Clin Biochem
7 B2 Alizai et al189 2014 Cartilage lesion score: comparison of a quantitative assessment score with
established semiquantitative MR scoring systems
Radiology
8 B2 Donati et al86 2014 Diffusion-weighted MR imaging of upper abdominal organs: field strength
and intervendor variability of apparent diffusion coefficients
Radiology
9 B2 Frings et al190 2014 Repeatability of metabolically active tumor volume measurements with
FDG PET/CT in advanced gastrointestinal malignancies: a multicenter
study
Radiology
10 B2 Giles et al191 2014 Whole-body diffusion-weighted MR imaging for assessment of treatment
response in myeloma
Radiology
11 B2 Knobloch et al192 2014 Arterial, venous, and cerebrospinal fluid flow: simultaneous assessment with
Bayesian multipoint velocity-encoded MR imaging
Radiology
See §3.3.1 for detail of searches.
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ID Search Authors Year Title Journal
12 B2 Roujol et al193 2014 Accuracy, precision, and reproducibility of four T1 mapping sequences: a
head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE
Radiology
13 B2 Suh et al194 2014 Atypical imaging features of primary central nervous system lymphoma that
mimics glioblastoma: utility of intravoxel incoherent motion MR imaging
Radiology
14 B2 Thevenot et al195 2014 Assessment of risk of femoral neck fracture with radiographic texture
parameters: a retrospective study
Radiology
15 B3 Aakre et al85 2014 Weekly and 90-minute biological variations in cardiac troponin T and
cardiac troponin I in hemodialysis patients and healthy controls
Clin Chem
16 B3 Bailey et al82 2014 Pediatric within-day biological variation and quality specifications for 38
biochemical markers in the CALIPER cohort
Clin Chem
17 B3 Karon et al196 2014 Precision and reliability of 5 platelet function tests in healthy volunteers and
donors on daily antiplatelet agent therapy
Clin Chem
18 B3 Noceti et al197 2014 Tacrolimus pharmacodynamics and pharmacogenetics along the calcineurin
pathway in human lymphocytes
Clin Chem
19 B3 Simpson et al90 2014 Use of observed within-person variation of cardiac troponin in emergency
department patients for determination of biological variation and percentage
and absolute reference change values
Clin Chem
20 C1 Beco et al198 1998 Study of the female urethra’s submucous vascular plexus by color Doppler World Journal of
Urology
21 C1 Chen et al83 2011 The assessment of voluntary pelvic floor muscle contraction by
three-dimensional transperineal ultrasonography
Archives of
Gynecology &
Obstetrics
22 C1 Heit199 2002 Intraurethral sonography and the test-retest reliability of urethral sphincter
measurements in women
Journal of Clinical
Ultrasound
23 C1 Oelke et al200 2009 Manual versus automatic bladder wall thickness measurements: a method
comparison study
World Journal of
Urology
See §3.3.1 for detail of searches.
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ID Search Authors Year Title Journal
24 C1 Oliveira et al84 2007 Ultrasonographic and Doppler velocimetric evaluation of the levator ani
muscle in premenopausal women with and without urinary stress
incontinence
European Journal of
Obstetrics,
Gynecology, &
Reproductive Biology
25 C1 Otcenasek et al201 2002 New approach to the urogynecological ultrasound examination European Journal of
Obstetrics,
Gynecology, &
Reproductive Biology
26 C2 Naresh et al202 2013 Day-to-day variability in spot urine albumin-creatinine ratio American Journal of
Kidney Diseases
27 C2 Ristiniemi et al203 2012 Evaluation of a new immunoassay for cystatin C, based on a double
monoclonal principle, in men with normal and impaired renal function
Nephrology Dialysis
Transplantation
28 C2 Rule et al204 2013 Estimating the glomerular filtration rate from serum creatinine is better
than from cystatin C for evaluating risk factors associated with chronic
kidney disease.
Kidney International
29 C2 Sjostrom et al205 2009 Cystatin C as a filtration marker–haemodialysis patients expose its
strengths and limitations
Scandinavian Journal
of Clinical &
Laboratory
Investigation
30 C2 Walser et al206 1993 Prediction of glomerular filtration rate from serum creatinine concentration
in advanced chronic renal failure
Kidney International
31 C3 Beeh et al207 2003 Long-term repeatability of induced sputum cells and inflammatory markers
in stable, moderately severe COPD
Chest
32 C3 Herpel et al89 2006 Variability of spirometry in chronic obstructive pulmonary disease: results
from two clinical trials
American Journal of
Respiratory & Critical
Care Medicine
See §3.3.1 for detail of searches.
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33 C3 Liistro et al208 2006 Technical and functional assessment of 10 office spirometers: A multicenter
comparative study
Chest
34 C3 Madsen et al209 1996 Patient-administered sequential spirometry in healthy volunteers and
patients with alpha 1-antitrypsin deficiency
Respiratory Medicine
35 C3 McCarley et al210 2007 A pilot home study of temporal variations of symptoms in chronic
obstructive lung disease
Biological Research for
Nursing
36 C3 Timmins et al211 2013 Day-to-day variability of oscillatory impedance and spirometry in asthma
and COPD
Respiratory
Physiology &
Neurobiology
37 D Alexander et al58 2013 Prognostic utility of biochemical markers of cardiovascular risk: impact of
biological variability
Clin Chem Lab Med
38 D Alvarez et al212 2000 Components of biological variation of biochemical markers of bone turnover
in Paget’s bone disease
Bone
39 D Alvarez et al91 2003 Biological variation of seminal parameters in healthy subjects Human Reproduction
40 D Andersen et al213 2010 Comparison of within- and between-subject variation of serum cystatin C
and serum creatinine in children aged 2-13 years
Scand J Clin Lab
Invest
41 D Andersson et al214 2003 Variation in levels of serum inhibin B, testosterone, estradiol, luteinizing
hormone, follicle-stimulating hormone, and sex hormone-binding globulin in
monthly samples from healthy men during a 17-month period: possible
effects of seasons
J Clin Endocrinol
Metab
42 D Ankrah-Tetteh et al215 2008 Intraindividual variation in serum thyroid hormones, parathyroid hormone
and insulin-like growth factor-1
Ann Clin Biochem
43 D Braga et al216 2011 Revaluation of biological variation of glycated hemoglobin (HbA(1c)) using
an accurately designed protocol and an assay traceable to the IFCC
reference system
Clin Chim Acta
See §3.3.1 for detail of searches.
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44 D Brown et al217 2008 Assay validation and biological variation of serum receptor for advanced
glycation end-products
Ann Clin Biochem
45 D Browne et al218 2007 Accuracy and biological variation of human serum paraoxonase 1 activity
and polymorphism (Q192R) by kinetic enzyme assay
Clin Chem
46 D Carlsen et al95 2011 Within-subject biological variation of glucose and HbA(1c) in healthy
persons and in type 1 diabetes patients
Clin Chem Lab Med
47 D Cembrowski et al94 2010 The use of serial patient blood gas, electrolyte and glucose results to derive
biologic variation: a new tool to assess the acceptability of intensive care
unit testing
Clin Chem Lab Med
48 D Cheuvront et al219 2010 Biological variation and diagnostic accuracy of dehydration assessment
markers
Am J Clin Nutr
49 D Cho et al220 2005 The biological variation of C-reactive protein in polycystic ovarian syndrome Clin Chem
50 D Corte et al221 2010 Biological variation of free plasma amino acids in healthy individuals Clin Chem Lab Med
51 D Dednam et al93 2008 Biological variation of myeloperoxidase Clin Chem
52 D Desmeules et al222 2010 Biological variation of glycated haemoglobin in a paediatric population and
its application to calculation of significant change between results
Ann Clin Biochem
53 D Dittadi et al223 2004 Biological variation of plasma chromogranin A Clin Chemistry Lab
Med
54 D Dittadi et al224 2008 Biological variability evaluation and comparison of three different methods
for C-peptide measurement
Clin Chem Lab Med
55 D Dittadi et al225 2008 Within-subject biological variation in disease: the case of tumour markers Ann Clin Biochem
56 D Frankenstein et al62 2011 Biological variation and reference change value of high-sensitivity troponin
T in healthy individuals during short and intermediate follow-up periods
Clin Chem
57 D Garde et al226 2000 Seasonal and biological variation of blood concentrations of total cholesterol,
dehydroepiandrosterone sulfate, hemoglobin A(1c), IgA, prolactin, and free
testosterone in healthy women
Clin Chem
See §3.3.1 for detail of searches.
274
A
.1.
S
tu
d
ies
id
en
tifi
ed
for
rev
iew
of
b
iological
variab
ility
stu
d
ies
ID Search Authors Year Title Journal
58 D Gonza´lez et al227 2001 Biological Variation of Interleukin-1β, Interleukin-8 and Tumor Necrosis
Factor-α in Serum of Healthy Individuals
Clin Chemistry Lab
Med
59 D Jensen et al228 2007 Biological variation of thyroid autoantibodies and thyroglobulin Clin Chem Lab Med
60 D Kristoffersen et al229 2012 A model for calculating the within-subject biological variation and
likelihood ratios for analytes with a time-dependent change in
concentrations; exemplified with the use of D-dimer in suspected venous
thromboembolism in healthy pregnant women
Ann Clin Biochem
61 D Lara-Riegos et al230 2013 Short-term estimation and application of biological variation of small dense
low-density lipoproteins in healthy individuals
Clin Chem Lab Med
62 D Martinez-Morillo et al88 2012 Reference intervals and biological variation for kallikrein 6: influence of age
and renal failure
Clin Chem Lab Med
63 D McKinley et al231 2001 Plasma homocysteine is not subject to seasonal variation Clin Chem
64 D Melzi d’Eril Aet al232 2001 Biological variation of serum amyloid A in healthy subjects Clin Chem
65 D Melzi d’Eril et al233 2003 Biological variation of N-terminal pro-brain natriuretic peptide in healthy
individuals
Clin Chem
66 D Meo et al234 2005 Biological variation of vascular endothelial growth factor Clin Chem Lab Med
67 D Moller et al235 2003 Biological variation of soluble CD163 Scand J Clin Lab
Invest
68 D Mosca et al236 2013 Analytical goals for the determination of HbA(2) Clin Chem Lab Med
69 D Nguyen et al237 2008 Within-subject variability and analytic imprecision of insulinlike growth
factor axis and collagen markers: implications for clinical diagnosis and
doping tests
Clin Chem
70 D Pagani et al238 2001 Biological variation in serum activities of three hepatic enzymes Clin Chem
71 D Pineda-Tenor et al239 2013 Biological variation and reference change values of common clinical
chemistry and haematologic laboratory analytes in the elderly population
Clin Chem Lab Med
See §3.3.1 for detail of searches.
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72 D Reclos et al240 2006 Estimation of the biological variation of glucose-6-phosphate dehydrogenase
in dried blood spots
Accreditation and
Quality Assurance
73 D Reinhard et al241 2009 Biological variation of cystatin C and creatinine Scand J Clin Lab
Invest
74 D Rohlfing et al242 2002 Biological variation of glycohemoglobin Clin Chem
75 D Rossi et al243 2013 High biological variation of serum hyaluronic acid and Hepascore, a
biochemical marker model for the prediction of liver fibrosis
Clin Chem Lab Med
76 D Serteser et al244 2012 Biological variation in pregnancy-associated plasma protein-A in healthy
men and non-pregnant healthy women
Clin Chem Lab Med
77 D Shand et al245 2006 Biovariability of plasma adiponectin Clin Chem Lab Med
78 D Talwar et al246 2005 Biological variation of vitamins in blood of healthy individuals Clin Chem
79 D Trape´ et al247 2000 Reference Change Value for HbA1c in Patients with Type 2 Diabetes
Mellitus
Clin Chemistry Lab
Med
80 D Trape´ et al248 2003 Reference change value for alpha-fetoprotein and its application in early
detection of hepatocellular carcinoma in patients with hepatic disease
Clin Chem
81 D Trape´ et al249 2005 Biological variation of tumor markers and its application in the detection of
disease progression in patients with non-small cell lung cancer
Clin Chem
82 D Trape´ et al250 2010 Determination of biological variation of alpha-fetoprotein and
choriogonadotropin (beta chain) in disease-free patients with testicular
cancer
Clin Chem Lab Med
83 D Valero-Politi et al251 2001 Annual Rhythmic and Non-Rhythmic Biological Variation of Magnesium
and Ionized Calcium Concentrations
Clin Chemistry Lab
Med
84 D van der Merwe et al252 2002 Biological variation in sweat sodium chloride conductivity Ann Clin Biochem
85 D van Hoydonck et al253 2003 Reproducibility of blood markers of oxidative status and endothelial
function in healthy individuals
Clin Chem
See §3.3.1 for detail of searches.
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86 D Vasile et al254 2010 Biological and analytical variability of a novel high-sensitivity cardiac
troponin T assay
Clin Chem
87 D Vasile et al255 2011 Biologic variation of a novel cardiac troponin I assay Clin Chem
88 D Viljoen et al256 2008 Analytical quality goals for parathyroid hormone based on biological
variation
Clin Chem Lab Med
89 D Wu et al257 2009 Short- and long-term biological variation in cardiac troponin I measured
with a high-sensitivity assay: implications for clinical practice
Clin Chem
90 D Wu et al258 2012 Long-term biological variation in cardiac troponin I Clin Biochem
91 D & E Bandaranayake et al92 2007 Intra-individual variation in creatinine and cystatin C Clin Chem Lab Med
92 D & E Delanaye et al259 2008 New data on the intraindividual variation of cystatin C Nephron Clin Pract
93 D & E Toffaletti et al260 2008 Variation of serum creatinine, cystatin C, and creatinine clearance tests in
persons with normal renal function
Clin Chim Acta
94 E Gaspari et al261 1998 Precision of plasma clearance of iohexol for estimation of GFR in patients
with renal disease
J Am Soc Nephrol
95 E Gowans et al262 1988 Biological Variation of Serum and Urine Creatinine and Creatinine
Clearance: Ramifications for Interpretation of Results and Patient Care
Annals of Clinical
Biochemistry: An
international journal
of biochemistry and
laboratory medicine
96 E Keevil et al263 1998 Biological variation of cystatin C: implications for the assessment of
glomerular filtration rate
Clin Chem
97 E Khullar et al24 1994 A novel technique for measuring bladder wall thickness in women using
transvaginal ultrasound
Ultrasound Obstet
Gynecol
98 E Kuo264 2009 Measurement of detrusor wall thickness in women with overactive bladder
by transvaginal and transabdominal sonography
Int Urogynecol J
Pelvic Floor Dysfunct
See §3.3.1 for detail of searches.
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99 E Lekskulchai et al265 2008 Detrusor wall thickness as a test for detrusor overactivity in women Ultrasound Obstet
Gynecol
100 E Panayi et al266 2010 Ultrasound measurement of vaginal wall thickness: a novel and reliable
technique
Int Urogynecol J
101 E Tubaro et al267 2013 Intra- and inter-reader variability of transvaginal ultrasound bladder wall
thickness measurements: results from the shrink study
Neurology and
Urodynamics
See §3.3.1 for detail of searches.
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Table A.2: Details of studies identified for review of biological variability studies.
Study details Study design Analysis Reporting
ID Test type Measure Tests (n) Situations (n) Participants Participants (n) Analysis CVA CVI CVG RCV II ICC
1 Laboratory Antibody
reactivity
(blood spot
assay HIV)
6 6 Non-healthy
participants
51 ANOVA/RE
(assumed)
Yes No No No No No
2 Imaging Stents (angina) 2 6 Non-healthy
participants
21 Other No No No No No Yes
3 Laboratory Ribavirin
(hepatitis C)
1 1 Unknown 4 ANOVA/RE
(assumed)
Yes No No No No No
4 Laboratory HbA1c 3 3 Non-healthy
participants
23 Other No No No No No No
5 Laboratory HbA1c 1 4 Non-healthy
participants
35 ANOVA/RE
(assumed)
Yes No No No No No
6 Laboratory Osmolal gap,
sodium,
glucose
6 6 Healthy
participants
20 ANOVA/RE
(assumed)
Yes Yes Yes Yes Yes No
7 Imaging Cartilage
legion score
3 3 Mixed
participants
77 ANOVA/RE
(assumed)
No No No No No Yes
8 Imaging Abdominal
diffusion
6 6 Healthy
participants
10 ANOVA/RE Yes No No No No Yes
9 Imaging Tumour size 19 19 Non-healthy
participants
34 ANOVA/RE No No No No No Yes
See §3.3.1 for detail of searches.
279
A
p
p
en
d
ix
A
.
B
iological
variab
ility
stu
d
ies:
rev
iew
of
d
esign
,
an
aly
sis,
an
d
rep
ortin
g
ID Test type Measure Tests Situations Participants Sample size Analysis CVA CVI CVG RCV II ICC
10 Imaging Myeloma
treatment
response
1 1 Mixed
participants
15 ANOVA/RE
(assumed)
No Yes No No No No
11 Imaging Blood and
CSF flow
1 1 Healthy
participants
10 ANOVA/RE
(assumed)
No No No No No Yes
12 Imaging Extra cellular
volume
fraction
4 8 Healthy
participants
7 ANOVA/RE No No No No No No
13 Imaging Tumour
parameters
and blood
volume
4 8 Non-healthy
participants
60 ANOVA/RE
(assumed)
No No No No No Yes
14 Imaging Bone texture 4 4 Unknown 53 ANOVA/RE
(assumed)
No No No No No Yes
15 Laboratory Cardiac
troponin
2 8 Mixed
participants
39 ANOVA/RE Yes Yes Yes Yes Yes No
16 Laboratory Biochemical
markers
38 53 Healthy
participants
29 ANOVA/RE No Yes Yes Yes Yes No
17 Laboratory Platelet
function
5 10 Mixed
participants
53 ANOVA/RE Yes Yes No No No Yes
18 Laboratory Lymphocytes 4 4 Healthy
participants
5 ANOVA/RE
(assumed)
Yes Yes No No Yes No
19 Laboratory Cardiac
troponin
1 1 Non-healthy
participants
283 ANOVA/RE No Yes Yes Yes Yes No
See §3.3.1 for detail of searches.
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ID Test type Measure Tests Situations Participants Sample size Analysis CVA CVI CVG RCV II ICC
20 Imaging Length and
thicknesss of
sheath and
distance
3 3 Mixed
participants
27 ANOVA/RE
(assumed)
No No No No No No
21 Imaging US pelvic floor 8 8 Mixed
participants
20 ANOVA/RE No No No No No Yes
22 Imaging US urethral
spincter
measurements
8 8 Healthy
participants
29 ANOVA/RE No No No No No Yes
23 Imaging US bladder
wall thickness
4 4 Non-healthy
participants
50 Other No No No No No No
24 Imaging US and
Doppler area
measures
8 8 Mixed
participants
63 Other No No No No No No
25 Imaging US 6 6 Non-healthy
participants
10 Other No No No No No No
26 Laboratory Albumin
creatinine ratio
1 1 Non-healthy
participants
157 Other No No No No No No
27 Laboratory Cystatin C 1 1 Healthy
participants
170 ANOVA/RE
(assumed)
No Yes No No No No
28 Laboratory eGFR 5 5 Unknown 40 ANOVA/RE
(assumed)
No Yes No No No No
29 Laboratory Serum
Cystatin C
1 1 Non-healthy
participants
134 ANOVA/RE
(assumed)
No Yes Yes No No No
30 Laboratory GFR and
creatinine
2 2 Non-healthy
participants
85 ANOVA/RE
(assumed)
No Yes No No No No
See §3.3.1 for detail of searches.
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ID Test type Measure Tests Situations Participants Sample size Analysis CVA CVI CVG RCV II ICC
31 Physiological Sputum and
FEV
14 14 Non-healthy
participants
12 ANOVA/RE
(assumed)
No No No No No Yes
32 Physiological Spirometry 4 4 Non-healthy
participants
7101 Other No No No No No No
33 Physiological Pulmonary
function tests
11 11 Healthy
participants
9 Other No No No No No No
34 Physiological Spirometry 1 2 Mixed
participants
20 Other No No No No No No
35 Physiological Peak flow 1 1 Non-healthy
participants
10 ANOVA/RE No No No No No No
36 Physiological Respiratory
measures
5 30 Mixed
participants
30 ANOVA/RE No Yes No No No Yes
37 Laboratory Cholesterol 9 18 Healthy
participants
15 ANOVA/RE No Yes Yes No Yes Yes
38 Laboratory Bone turnover 7 14 Mixed
participants
29 ANOVA/RE No Yes Yes Yes Yes No
39 Laboratory Seminal
parameters
6 6 Healthy
participants
20 ANOVA/RE No Yes Yes Yes Yes No
40 Laboratory Cystatin C 2 2 Unknown 30 ANOVA/RE
(assumed)
Yes Yes Yes Yes Yes No
41 Laboratory Male hormone 7 7 Healthy
participants
27 ANOVA/RE No Yes Yes No No No
42 Laboratory Hormone 5 5 Healthy
participants
10 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
43 Laboratory HbA1c 1 3 Healthy
participants
18 ANOVA/RE Yes Yes Yes Yes Yes No
See §3.3.1 for detail of searches.
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ID Test type Measure Tests Situations Participants Sample size Analysis CVA CVI CVG RCV II ICC
44 Laboratory Blood (RAGE) 1 1 Healthy
participants
21 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
45 Laboratory CHD risk
markers
9 9 Unknown 17 ANOVA/RE Yes Yes Yes No No No
46 Laboratory HbA1c 3 6 Mixed
participants
30 ANOVA/RE Yes Yes Yes Yes No No
47 Laboratory Electrolytes
(ICU testing)
9 9 Non-healthy
participants
ANOVA/RE
(assumed)
Yes Yes No No No No
48 Laboratory Dehydration
markers
6 6 Healthy
participants
18 ANOVA/RE
(assumed)
Yes Yes Yes Yes Yes No
49 Laboratory CRP 1 1 Mixed
participants
23 ANOVA/RE
(assumed)
Yes Yes Yes Yes No Yes
50 Laboratory Plasma blood 25 25 Healthy
participants
11 ANOVA/RE No Yes Yes Yes No No
51 Laboratory MPO 1 1 Healthy
participants
12 ANOVA/RE Yes Yes Yes No Yes No
52 Laboratory HbA1c 1 1 Non-healthy
participants
38 ANOVA/RE No Yes Yes Yes No No
53 Laboratory Plasma 1 1 Healthy
participants
22 ANOVA/RE Yes Yes Yes Yes Yes No
54 Laboratory C-peptide 1 1 Healthy
participants
15 ANOVA/RE No Yes Yes Yes No No
55 Laboratory Tumour
markers
2 4 Mixed
participants
43 ANOVA/RE No Yes No No No No
56 Laboratory Troponin T 2 4 Healthy
participants
37 ANOVA/RE Yes Yes No Yes No No
See §3.3.1 for detail of searches.
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ID Test type Measure Tests Situations Participants Sample size Analysis CVA CVI CVG RCV II ICC
57 Laboratory Blood markers 6 18 Healthy
participants
21 ANOVA/RE No Yes Yes No Yes No
58 Laboratory Cytokines 3 9 Healthy
participants
15 ANOVA/RE No Yes Yes Yes Yes Yes
59 Laboratory Thyroid
markers
3 4 Healthy
participants
24 ANOVA/RE No Yes Yes No No No
60 Laboratory D-dimer 1 3 Mixed
participants
36 ANOVA/RE Yes Yes Yes Yes Yes No
61 Laboratory LDL 1 3 Healthy
participants
24 ANOVA/RE Yes Yes Yes Yes Yes No
62 Laboratory klk6 CKD 1 1 Healthy
participants
4 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
63 Laboratory Vitamin B
intake
6 6 Healthy
participants
22 ANOVA/RE Yes Yes Yes No No Yes
64 Laboratory Serum amyloid
A (SSA) and
CRP
2 6 Healthy
participants
24 ANOVA/RE Yes Yes Yes Yes Yes No
65 Laboratory Brain
prohormone
1 3 Healthy
participants
16 ANOVA/RE Yes Yes Yes Yes Yes No
66 Laboratory Growth factor 3 12 Healthy
participants
28 ANOVA/RE Yes Yes Yes Yes Yes No
67 Laboratory CD163 1 2 Healthy
participants
12 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
68 Laboratory HbA(2) 1 1 Healthy
participants
17 ANOVA/RE No Yes Yes No No No
See §3.3.1 for detail of searches.
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69 Laboratory Growth factor 6 6 Healthy
participants
1103 ANOVA/RE No Yes Yes Yes Yes No
70 Laboratory Hepatic
enzymes
3 9 Healthy
participants
10 ANOVA/RE Yes Yes Yes Yes Yes No
71 Laboratory Biochemical
and
haematological
analytes
(elderly
population)
26 52 Healthy
participants
253 ANOVA/RE No Yes Yes Yes Yes No
72 Laboratory glucose-6-
phosphate
(dried blood
spots newborn
screening)
1 1 Healthy
participants
20 ANOVA/RE Yes Yes Yes No Yes No
73 Laboratory Cystatin C 2 4 Mixed
participants
39 ANOVA/RE Yes Yes Yes Yes Yes No
74 Laboratory Glycohemoglobin 2 2 Unknown 48 ANOVA/RE No Yes Yes No No No
75 Laboratory Liver fibrosis
markers
3 12 Mixed
participants
80 ANOVA/RE
(assumed)
No Yes Yes Yes No No
76 Laboratory Plasma protein 1 1 Healthy
participants
11 ANOVA/RE No Yes Yes Yes Yes No
77 Laboratory Plasma
adiponectin
3 3 Mixed
participants
20 ANOVA/RE No Yes Yes Yes Yes No
78 Laboratory Vitamins 15 15 Healthy
participants
14 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
See §3.3.1 for detail of searches.
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79 Laboratory HbA1c 1 4 Non-healthy
participants
47 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
80 Laboratory AFP 1 7 Mixed
participants
115 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
81 Laboratory Tumour
markers
3 6 Mixed
participants
40 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
82 Laboratory AFP 2 2 Non-healthy
participants
28 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
83 Laboratory Magnesium
and calcium
2 2 Healthy
participants
51 ANOVA/RE
(assumed)
No Yes Yes Yes No No
84 Laboratory Sweat sodium
chloride
conductivity
1 3 Mixed
participants
55 ANOVA/RE
(assumed)
No Yes Yes No Yes No
85 Laboratory Oxidative
status
7 7 Healthy
participants
25 ANOVA/RE
(assumed)
Yes Yes Yes No No No
86 Laboratory Cardiac
troponin
1 2 Healthy
participants
20 ANOVA/RE Yes Yes Yes Yes Yes No
87 Laboratory Cardiac
troponin
1 2 Healthy
participants
ANOVA/RE Yes Yes Yes Yes Yes No
88 Laboratory Parathyroid
hormone
1 1 Healthy
participants
20 ANOVA/RE
(assumed)
Yes Yes Yes Yes Yes No
89 Laboratory Cardiac
troponin
1 2 Mixed
participants
29 ANOVA/RE Yes Yes Yes Yes Yes No
90 Laboratory Cardiac
troponin
1 1 Unknown 19 ANOVA/RE No Yes Yes Yes Yes No
See §3.3.1 for detail of searches.
286
A
.1.
S
tu
d
ies
id
en
tifi
ed
for
rev
iew
of
b
iological
variab
ility
stu
d
ies
ID Test type Measure Tests Situations Participants Sample size Analysis CVA CVI CVG RCV II ICC
91 Laboratory Creatinine and
cystatin C
2 2 Healthy
participants
10 ANOVA/RE
(assumed)
No Yes Yes Yes Yes No
92 Laboratory Cystatin C 3 3 Healthy
participants
13 ANOVA/RE
(assumed)
Yes Yes No Yes No No
93 Laboratory Serum
creatinine,
cystatin C,
and creatinine
clearance
4 4 Healthy
participants
31 ANOVA/RE
(assumed)
No Yes Yes No No No
94 Laboratory Plasma
clearance of
iohexol (GFR)
1 6 Non-healthy
participants
24 ANOVA/RE
(assumed)
No Yes No No No No
95 Laboratory Creatinine 5 11 Healthy
participants
15 ANOVA/RE
(assumed)
Yes Yes Yes Yes Yes No
96 Laboratory Cystatin c 2 2 Healthy
participants
12 ANOVA/RE
(assumed)
Yes Yes Yes Yes No Yes
97 Imaging US bladder
wall thickness
1 1 Non-healthy
participants
10 Other No No No No No No
98 Imaging Sonography
detrusor wall
thickness
1 1 Mixed
participants
10 Other No No No No No No
99 Imaging US detrusor
wall thickness
1 1 Unknown 67 ANOVA/RE No No No No No Yes
100 Imaging US vaginal
wall thickness
6 6 Unknown 25 Other No No No No No No
See §3.3.1 for detail of searches.
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101 Imaging US bladder
wall thickness
1 1 Unknown 40 Other No No No No No No
See §3.3.1 for detail of searches.
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case study evaluating glomerular
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B.1 Detailed results of analyses
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variation
C.1 Results of the normally distributed data simulation; vary-
ing sample size
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C.1. Results of the normally distributed data simulation; varying sample size
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Appendix C. Sample size guidance and justification for studies of biological variation
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C.2. Results for log-normal data simulation; varying sample size
C.2 Results for log-normal data simulation; varying sample
size
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Figure C.1: Log-normal biological variability sample size simulation: SD estimates from
biological variability data simulations varying sample size: SDA (left column), SDI (middle
column) and SDG (right column) estimates when varying number of participants (n1, top
row), number of observations per participant (n2, middle row), and number of replicate
assessments per observation per participant (n3, bottom row). Median is shown by horizontal
line, Q1 and Q3 shown by extremes of box; and minimum and maximum values shown by
arrows. Estimates shown in red are for the baseline strategy. The dashed line reflects the
true SD and the dotted lines are the 95% confidence intervals around the true value of the
estimate for the given sample size, using the methods of Burdick and Graybill.34
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Figure C.2: Log-normal biological variability sample size simulation: II and RCV estimates
from biological variability data simulations varying sample size: II (left column) and RCV
(right column) estimates when varying number of participants (n1, top row), number of obser-
vations per participant (n2, middle row), and number of replicate assessments per observation
per participant (n3, bottom row). Median is shown by horizontal line, Q1 and Q3 shown by
extremes of box; and minimum and maximum values shown by arrows. Estimates shown in
red are for the baseline strategy. The dashed line reflects the true II or RCV.
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Figure C.3: Log-normal biological variability sample size simulation: asymmetric RCV es-
timates from biological variability data simulations varying sample size: RCV lower bound
(left column) and RCV upper bound (right column) estimates when varying number of par-
ticipants (n1, top row), number of observations per participant (n2, middle row), and number
of replicate assessments per observation per participant (n3, bottom row). Median is shown
by horizontal line, Q1 and Q3 shown by extremes of box; and minimum and maximum values
shown by arrows. Estimates shown in red are for the baseline strategy. The dashed line
reflects the true RCV bound.
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C.2. Results for log-normal data simulation; varying sample size
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Appendix C. Sample size guidance and justification for studies of biological variation
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C.3. Results of the normally distributed data simulation; varying variability
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C.3. Results of the normally distributed data simulation; varying variability
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C.4 Results of the log-normal data simulation; varying vari-
ability
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Figure C.4: Log-normal biological variability sample size simulation: SD estimates from bio-
logical variability data simulations varying test variability: SDA (left column), SDI (middle
column) and SDG (right column) estimates when varying value of SDA (top row), value of
SDI (middle row), and value of SDG (bottom row). Median is shown by horizontal line, Q1
and Q3 shown by extremes of box; and minimum and maximum values shown by arrows.
Estimates shown in red are for the baseline strategy. The dashed line reflects the true SD
and the dotted lines are the 95% confidence intervals around the true value of the estimate
for the given sample size, using the methods of Burdick and Graybill.34
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Figure C.5: Log-normal biological variability sample size simulation: CV estimates from bio-
logical variability data simulations varying test variability: CVA (left column), CVI (middle
column) and CVG (right column) estimates when varying value of CVA (top row), value of
CVI (middle row), and value of CVG (bottom row). Median is shown by horizontal line, Q1
and Q3 shown by extremes of box; and minimum and maximum values shown by arrows.
Estimates shown in red are for the baseline strategy. The dashed line reflects the true CV
and the dotted lines are the 95% confidence intervals around the true value of the estimate
for the given sample size, using the methods of Burdick and Graybill.34
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Figure C.6: Log-normal biological variability sample size simulation: II and RCV estimates
from biological variability data simulations varying test variability: II (left column) and RCV
(right column) estimates when varying value of CVA (top row), value of CVI (middle row),
and value of CVG (bottom row). Median is shown by horizontal line, Q1 and Q3 shown by
extremes of box; and minimum and maximum values shown by arrows. Estimates shown in
red are for the baseline strategy. The dashed line reflects the true II or RCV.
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Figure C.7: Log-normal biological variability sample size simulation: asymmetric RCV esti-
mates from biological variability data simulations varying test variability: RCV lower bound
(left column) and RCV upper bound (right column) estimates when varying value of CVA
(top row), value of CVI (middle row), and value of CVG (bottom row). Median is shown by
horizontal line, Q1 and Q3 shown by extremes of box; and minimum and maximum values
shown by arrows. Estimates shown in red are for the baseline strategy. The dashed line
reflects the true RCV bound.
313
Appendix C. Sample size guidance and justification for studies of biological variation
T
a
b
le
C
.1
3
:
L
o
g
n
o
rm
a
l
sim
u
la
tion
:
b
ias
p
erform
an
ce
m
easu
res
vary
in
g
C
V
A
,
C
V
I
an
d
C
V
G
.
B
ia
s
In
p
u
ts
B
ia
s
(×
1
0 −
4)
P
e
rc
e
n
ta
g
e
b
ia
s
S
ta
n
d
a
rd
ise
d
b
ia
s
n
1
n
2
n
3
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
2
0
4
2
0
.0
1
0
.1
0
0
.2
0
-0
.2
1
9
-2
.7
8
9
-3
0
.6
8
6
-0
.1
7
5
-0
.2
8
0
-1
.5
4
9
-2
.2
7
4
-3
.0
9
2
-9
.0
2
5
2
0
4
2
0
.0
2
0
.1
0
0
.2
0
-0
.4
3
7
-2
.8
2
4
-3
0
.5
0
6
-0
.1
7
5
-0
.2
8
3
-1
.5
4
0
-2
.2
7
1
-3
.0
7
3
-8
.9
6
1
2
0
4
2
0
.0
4
0
.1
0
0
.2
0
-0
.6
5
5
-2
.9
8
9
-3
0
.3
9
9
-0
.1
7
5
-0
.3
0
0
-1
.5
3
5
-2
.2
6
9
-3
.1
3
9
-8
.9
0
9
2
0
4
2
0
.0
5
0
.1
0
0
.2
0
-0
.8
7
4
-3
.3
1
6
-3
0
.3
6
4
-0
.1
7
5
-0
.3
3
2
-1
.5
3
3
-2
.2
6
9
-3
.3
0
4
-8
.8
6
8
2
0
4
2
0
.0
6
0
.1
0
0
.2
0
-1
.0
9
2
-3
.8
4
6
-3
0
.4
0
1
-0
.1
7
5
-0
.3
8
6
-1
.5
3
5
-2
.2
7
0
-3
.5
8
0
-8
.8
3
8
2
0
4
2
0
.0
7
0
.1
0
0
.2
0
-1
.3
1
0
-4
.6
3
8
-3
0
.5
1
3
-0
.1
7
5
-0
.4
6
5
-1
.5
4
1
-2
.2
7
1
-3
.9
7
9
-8
.8
2
1
2
0
4
2
0
.0
9
0
.1
0
0
.2
0
-1
.5
2
7
-5
.7
6
6
-3
0
.7
0
1
-0
.1
7
5
-0
.5
7
8
-1
.5
5
0
-2
.2
7
0
-4
.5
1
0
-8
.8
1
7
2
0
4
2
0
.1
0
0
.1
0
0
.2
0
-1
.7
4
4
-7
.3
2
9
-3
0
.9
6
7
-0
.1
7
5
-0
.7
3
5
-1
.5
6
4
-2
.2
7
0
-5
.1
7
9
-8
.8
2
4
2
0
4
2
0
.0
5
0
.0
5
0
.2
0
-0
.8
7
4
-3
.6
7
1
-2
5
.2
2
3
-0
.1
7
5
-0
.7
3
5
-1
.2
7
4
-2
.2
7
0
-5
.1
7
9
-7
.6
6
7
2
0
4
2
0
.0
5
0
.0
7
0
.2
0
-0
.8
7
4
-3
.0
6
0
-2
7
.4
8
5
-0
.1
7
5
-0
.4
0
9
-1
.3
8
8
-2
.2
7
0
-3
.6
9
8
-8
.2
2
1
2
0
4
2
0
.0
5
0
.1
0
0
.2
0
-0
.8
7
4
-3
.3
1
6
-3
0
.3
6
4
-0
.1
7
5
-0
.3
3
2
-1
.5
3
3
-2
.2
6
9
-3
.3
0
4
-8
.8
6
8
2
0
4
2
0
.0
5
0
.1
2
0
.2
0
-0
.8
7
3
-3
.7
9
7
-3
3
.9
1
2
-0
.1
7
5
-0
.3
0
5
-1
.7
1
2
-2
.2
6
9
-3
.1
6
4
-9
.5
9
8
2
0
4
2
0
.0
5
0
.1
5
0
.2
0
-0
.8
7
4
-4
.3
6
5
-3
8
.2
0
2
-0
.1
7
5
-0
.2
9
3
-1
.9
2
9
-2
.2
7
0
-3
.1
0
7
-1
0
.4
0
3
2
0
4
2
0
.0
5
0
.1
7
0
.2
0
-0
.8
7
4
-4
.9
7
7
-4
3
.3
3
5
-0
.1
7
5
-0
.2
8
7
-2
.1
8
8
-2
.2
7
0
-3
.0
8
4
-1
1
.2
7
8
2
0
4
2
0
.0
5
0
.2
0
0
.2
0
-0
.8
7
4
-5
.6
1
2
-4
9
.4
5
1
-0
.1
7
5
-0
.2
8
3
-2
.4
9
7
-2
.2
7
0
-3
.0
7
5
-1
2
.2
1
9
2
0
4
2
0
.0
5
0
.1
0
0
.1
0
-0
.8
7
4
-3
.3
1
5
-2
5
.2
3
8
-0
.1
7
5
-0
.3
3
2
-2
.5
3
0
-2
.2
7
0
-3
.3
0
3
-1
2
.1
3
3
2
0
4
2
0
.0
5
0
.1
0
0
.1
5
-0
.8
7
4
-3
.3
1
5
-2
6
.5
5
2
-0
.1
7
5
-0
.3
3
2
-1
.7
8
0
-2
.2
7
0
-3
.3
0
3
-9
.8
0
6
2
0
4
2
0
.0
5
0
.1
0
0
.2
0
-0
.8
7
4
-3
.3
1
6
-3
0
.3
6
4
-0
.1
7
5
-0
.3
3
2
-1
.5
3
3
-2
.2
6
9
-3
.3
0
4
-8
.8
6
8
2
0
4
2
0
.0
5
0
.1
0
0
.2
5
-0
.8
7
3
-3
.3
1
6
-3
4
.8
8
9
-0
.1
7
5
-0
.3
3
2
-1
.4
1
7
-2
.2
6
9
-3
.3
0
4
-8
.3
8
1
2
0
4
2
0
.0
5
0
.1
0
0
.2
9
-0
.8
7
3
-3
.3
1
6
-3
9
.6
7
7
-0
.1
7
5
-0
.3
3
2
-1
.3
5
2
-2
.2
6
9
-3
.3
0
5
-8
.0
9
0
2
0
4
2
0
.0
5
0
.1
0
0
.3
4
-0
.8
7
3
-3
.3
1
7
-4
4
.5
4
9
-0
.1
7
5
-0
.3
3
3
-1
.3
1
1
-2
.2
6
8
-3
.3
0
5
-7
.9
0
0
2
0
4
2
0
.0
5
0
.1
0
0
.3
9
-0
.8
7
3
-3
.3
1
7
-4
9
.4
1
7
-0
.1
7
5
-0
.3
3
3
-1
.2
8
3
-2
.2
6
8
-3
.3
0
5
-7
.7
6
7
2
0
4
2
0
.0
5
0
.1
0
0
.4
3
-0
.8
7
3
-3
.3
1
7
-5
4
.2
2
9
-0
.1
7
5
-0
.3
3
3
-1
.2
6
3
-2
.2
6
8
-3
.3
0
5
-7
.6
6
9
2
0
4
2
0
.0
5
0
.1
0
0
.4
7
-0
.8
7
3
-3
.3
1
7
-5
8
.9
5
6
-0
.1
7
5
-0
.3
3
3
-1
.2
4
8
-2
.2
6
9
-3
.3
0
5
-7
.5
9
6
314
C.4. Results of the log-normal data simulation; varying variability
T
ab
le
C
.1
4:
L
og
n
or
m
al
si
m
u
la
ti
on
:
ac
cu
ra
cy
an
d
co
v
er
ag
e
p
er
fo
rm
an
ce
m
ea
su
re
s
va
ry
in
g
C
V
A
,
C
V
I
a
n
d
C
V
G
.
A
c
c
u
ra
c
y
a
n
d
c
o
v
e
ra
g
e
In
p
u
ts
M
e
a
n
sq
u
a
re
d
e
rr
o
r
(×
1
0
−
4
)
C
o
v
e
ra
g
e
M
e
a
n
9
5
%
C
I
w
id
th
n
1
n
2
n
3
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
2
0
4
2
0
.0
1
0
.1
0
0
.2
0
0
.0
0
9
0
.8
1
5
1
1
.6
5
5
0
.9
5
2
0
.9
5
7
0
.9
5
1
0
.0
0
4
0
.0
3
7
0
.1
4
6
2
0
4
2
0
.0
2
0
.1
0
0
.2
0
0
.0
3
7
0
.8
4
5
1
1
.6
8
2
0
.9
5
2
0
.9
5
9
0
.9
5
2
0
.0
0
8
0
.0
3
8
0
.1
4
6
2
0
4
2
0
.0
4
0
.1
0
0
.2
0
0
.0
8
3
0
.9
0
7
1
1
.7
3
6
0
.9
5
2
0
.9
5
9
0
.9
5
4
0
.0
1
2
0
.0
3
9
0
.1
4
6
2
0
4
2
0
.0
5
0
.1
0
0
.2
0
0
.1
4
8
1
.0
0
9
1
1
.8
1
6
0
.9
5
2
0
.9
5
8
0
.9
5
3
0
.0
1
6
0
.0
4
2
0
.1
4
7
2
0
4
2
0
.0
6
0
.1
0
0
.2
0
0
.2
3
1
1
.1
5
6
1
1
.9
2
4
0
.9
5
2
0
.9
5
4
0
.9
5
5
0
.0
2
0
0
.0
4
5
0
.1
4
7
2
0
4
2
0
.0
7
0
.1
0
0
.2
0
0
.3
3
3
1
.3
6
1
1
2
.0
5
8
0
.9
5
2
0
.9
5
6
0
.9
5
4
0
.0
2
4
0
.0
4
8
0
.1
4
8
2
0
4
2
0
.0
9
0
.1
0
0
.2
0
0
.4
5
3
1
.6
3
8
1
2
.2
2
0
0
.9
5
2
0
.9
5
3
0
.9
5
4
0
.0
2
8
0
.0
5
3
0
.1
4
9
2
0
4
2
0
.1
0
0
.1
0
0
.2
0
0
.5
9
1
2
.0
0
8
1
2
.4
1
1
0
.9
5
2
0
.9
6
1
a
0
.9
5
4
0
.0
3
2
0
.0
5
9
a
0
.1
5
0
2
0
4
2
0
.0
5
0
.0
5
0
.2
0
0
.1
4
8
0
.5
0
4
1
0
.8
8
5
0
.9
5
2
0
.9
6
1
a
0
.9
4
9
0
.0
1
6
0
.0
3
0
a
0
.1
4
0
2
0
4
2
0
.0
5
0
.0
7
0
.2
0
0
.1
4
8
0
.6
8
6
1
1
.2
5
3
0
.9
5
2
0
.9
5
5
0
.9
5
1
0
.0
1
6
0
.0
3
4
0
.1
4
3
2
0
4
2
0
.0
5
0
.1
0
0
.2
0
0
.1
4
8
1
.0
0
9
1
1
.8
1
6
0
.9
5
2
0
.9
5
8
0
.9
5
3
0
.0
1
6
0
.0
4
2
0
.1
4
7
2
0
4
2
0
.0
5
0
.1
2
0
.2
0
0
.1
4
8
1
.4
4
1
1
2
.5
9
9
0
.9
5
2
0
.9
5
9
0
.9
5
9
0
.0
1
6
0
.0
5
0
0
.1
5
2
2
0
4
2
0
.0
5
0
.1
5
0
.2
0
0
.1
4
8
1
.9
7
5
1
3
.6
3
1
0
.9
5
2
0
.9
6
2
0
.9
6
0
0
.0
1
6
0
.0
5
8
0
.1
5
8
2
0
4
2
0
.0
5
0
.1
7
0
.2
0
0
.1
4
8
2
.6
0
7
1
4
.9
5
3
0
.9
5
2
0
.9
5
7
0
.9
6
3
b
0
.0
1
6
0
.0
6
7
0
.1
6
4
b
2
0
4
2
0
.0
5
0
.2
0
0
.2
0
0
.1
4
8
3
.3
3
3
1
6
.6
2
3
0
.9
5
2
0
.9
5
9
0
.9
7
1
c
0
.0
1
6
0
.0
7
5
0
.1
7
6
c
2
0
4
2
0
.0
5
0
.1
0
0
.1
0
0
.1
4
8
1
.0
0
8
4
.3
9
1
0
.9
5
2
0
.9
5
8
0
.9
7
1
d
0
.0
1
6
0
.0
4
2
0
.0
9
1
d
2
0
4
2
0
.0
5
0
.1
0
0
.1
5
0
.1
4
8
1
.0
0
8
7
.4
0
3
0
.9
5
2
0
.9
5
7
0
.9
5
8
0
.0
1
6
0
.0
4
2
0
.1
1
6
2
0
4
2
0
.0
5
0
.1
0
0
.2
0
0
.1
4
8
1
.0
0
9
1
1
.8
1
6
0
.9
5
2
0
.9
5
8
0
.9
5
3
0
.0
1
6
0
.0
4
2
0
.1
4
7
2
0
4
2
0
.0
5
0
.1
0
0
.2
5
0
.1
4
8
1
.0
0
8
1
7
.4
5
2
0
.9
5
2
0
.9
5
8
0
.9
5
4
0
.0
1
6
0
.0
4
2
0
.1
7
8
2
0
4
2
0
.0
5
0
.1
0
0
.2
9
0
.1
4
8
1
.0
0
8
2
4
.2
1
2
0
.9
5
2
0
.9
5
8
0
.9
5
2
0
.0
1
6
0
.0
4
2
0
.2
0
9
2
0
4
2
0
.0
5
0
.1
0
0
.3
4
0
.1
4
8
1
.0
0
8
3
2
.0
0
2
0
.9
5
2
0
.9
5
8
0
.9
5
0
0
.0
1
6
0
.0
4
2
0
.2
4
1
2
0
4
2
0
.0
5
0
.1
0
0
.3
9
0
.1
4
8
1
.0
0
8
4
0
.7
2
8
0
.9
5
2
0
.9
5
8
0
.9
5
2
0
.0
1
6
0
.0
4
2
0
.2
7
1
2
0
4
2
0
.0
5
0
.1
0
0
.4
3
0
.1
4
8
1
.0
0
8
5
0
.2
9
1
0
.9
5
2
0
.9
5
8
0
.9
5
2
0
.0
1
6
0
.0
4
2
0
.3
0
1
2
0
4
2
0
.0
5
0
.1
0
0
.4
7
0
.1
4
8
1
.0
0
8
6
0
.5
9
6
0
.9
5
2
0
.9
5
8
0
.9
5
2
0
.0
1
6
0
.0
4
2
0
.3
3
1
a
8
C
Is
co
u
ld
n
o
t
b
e
ca
lc
u
la
te
d
;
b
2
C
Is
co
u
ld
n
o
t
b
e
ca
lc
u
la
te
d
;
c
1
0
C
Is
co
u
ld
n
o
t
b
e
ca
lc
u
la
te
d
;
d
1
8
C
Is
co
u
ld
n
o
t
b
e
ca
lc
u
la
te
d
.
315
Appendix C. Sample size guidance and justification for studies of biological variation
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C.4. Results of the log-normal data simulation; varying variability
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Appendix C. Sample size guidance and justification for studies of biological variation
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C.4. Results of the log-normal data simulation; varying variability
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C.5. Sensitivity analyses
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Appendix C. Sample size guidance and justification for studies of biological variation
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C.5. Sensitivity analyses
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Appendix C. Sample size guidance and justification for studies of biological variation
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C.5. Sensitivity analyses
T
ab
le
C
.2
5:
In
cr
ea
se
d
b
as
e
n
1
,
n
2
an
d
n
3
:
II
,
R
C
V
an
d
m
ea
n
es
ti
m
at
es
,
m
ed
ia
n
(Q
1
,
Q
3
)[
m
in
im
u
m
,
m
a
x
im
u
m
]
fr
o
m
b
io
lo
g
ic
a
l
va
ri
a
b
il
it
y
d
at
a
si
m
u
la
ti
on
s
va
ry
in
g
n
u
m
b
er
of
p
ar
ti
ci
p
an
ts
,
ob
se
rv
at
io
n
s
an
d
as
se
ss
m
en
ts
.
C
V
s
a
n
d
R
C
V
s
a
re
d
is
p
la
ye
d
a
s
p
er
ce
n
ta
g
es
.
In
p
u
ts
M
e
d
ia
n
(Q
1
,
Q
3
)[
m
in
im
u
m
,
m
a
x
im
u
m
]
n
1
n
2
n
3
C
V
A
C
V
I
C
V
G
I
I
R
C
V
I
I
R
C
V
M
ea
n
5
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.6
0
(0
.4
6
,
0
.8
2
)[
0
.2
4
,
1
3
7
3
2
.6
7
]
3
1
.0
0
(2
8
.4
5
,
3
3
.7
3
)[
1
9
.4
1
,
5
2
.0
9
]
9
.9
9
(9
.4
0
,
1
0
.6
3
)[
7
.2
6
,
1
2
.8
5
]
1
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
7
(0
.4
9
,
0
.6
9
)[
0
.2
9
,
1
.7
5
]
3
1
.0
3
(2
9
.1
7
,
3
3
.1
1
)[
2
3
.4
8
,
4
3
.5
4
]
9
.9
7
(9
.5
3
,
1
0
.4
1
)[
7
.8
9
,
1
1
.9
6
]
2
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
7
(0
.5
0
,
0
.6
4
)[
0
.3
4
,
1
.2
0
]
3
0
.9
4
(2
9
.6
8
,
3
2
.2
7
)[
2
4
.9
5
,
3
8
.4
8
]
1
0
.0
1
(9
.7
3
,
1
0
.2
9
)[
8
.2
7
,
1
1
.3
4
]
3
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
1
,
0
.6
2
)[
0
.3
7
,
0
.9
3
]
3
1
.0
3
(2
9
.8
1
,
3
2
.1
5
)[
2
5
.8
4
,
3
7
.2
9
]
1
0
.0
0
(9
.7
5
,
1
0
.2
7
)[
8
.8
9
,
1
1
.1
3
]
4
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
0
,
0
.8
4
]
3
1
.0
1
(3
0
.0
6
,
3
1
.9
0
)[
2
7
.3
3
,
3
5
.2
6
]
1
0
.0
0
(9
.8
0
,
1
0
.2
0
)[
8
.8
4
,
1
0
.9
2
]
6
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
3
,
0
.6
0
)[
0
.4
2
,
0
.8
0
]
3
0
.9
7
(3
0
.2
0
,
3
1
.7
2
)[
2
7
.5
1
,
3
5
.3
0
]
1
0
.0
1
(9
.8
5
,
1
0
.1
8
)[
9
.1
7
,
1
0
.8
9
]
1
0
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
4
,
0
.5
9
)[
0
.4
4
,
0
.7
2
]
3
0
.9
8
(3
0
.3
5
,
3
1
.5
9
)[
2
8
.3
6
,
3
3
.8
8
]
1
0
.0
1
(9
.8
6
,
1
0
.1
6
)[
9
.2
5
,
1
0
.6
8
]
4
0
2
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
0
,
0
.6
3
)[
0
.3
6
,
1
.1
8
]
3
1
.1
3
(2
9
.0
6
,
3
3
.1
3
)[
2
1
.3
2
,
4
0
.5
7
]
9
.9
9
(9
.7
7
,
1
0
.2
2
)[
8
.9
6
,
1
1
.1
8
]
4
0
4
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
1
,
0
.6
2
)[
0
.4
0
,
0
.8
5
]
3
0
.9
2
(2
9
.5
4
,
3
2
.2
8
)[
2
5
.1
2
,
4
0
.3
8
]
1
0
.0
0
(9
.7
8
,
1
0
.2
5
)[
8
.9
5
,
1
1
.0
3
]
4
0
6
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
2
)[
0
.3
9
,
0
.9
1
]
3
1
.0
2
(2
9
.8
5
,
3
2
.1
4
)[
2
5
.8
6
,
3
7
.0
3
]
1
0
.0
1
(9
.7
8
,
1
0
.2
3
)[
9
.0
1
,
1
0
.9
1
]
4
0
8
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.3
9
,
0
.8
6
]
3
1
.0
1
(3
0
.0
1
,
3
1
.9
9
)[
2
6
.1
8
,
3
6
.2
3
]
1
0
.0
2
(9
.8
0
,
1
0
.2
4
)[
8
.9
4
,
1
0
.9
6
]
4
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
0
,
0
.8
4
]
3
1
.0
1
(3
0
.0
6
,
3
1
.9
0
)[
2
7
.3
3
,
3
5
.2
6
]
1
0
.0
0
(9
.8
0
,
1
0
.2
0
)[
8
.8
4
,
1
0
.9
2
]
4
0
1
2
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
1
,
0
.9
1
]
3
1
.0
2
(3
0
.1
6
,
3
1
.9
3
)[
2
7
.0
8
,
3
5
.9
0
]
1
0
.0
0
(9
.7
9
,
1
0
.2
2
)[
8
.8
9
,
1
0
.9
6
]
4
0
2
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
3
,
0
.6
1
)[
0
.4
2
,
0
.8
8
]
3
0
.9
3
(3
0
.2
2
,
3
1
.8
4
)[
2
7
.2
7
,
3
5
.7
4
]
1
0
.0
2
(9
.7
9
,
1
0
.2
3
)[
8
.8
8
,
1
1
.0
8
]
4
0
1
0
2
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
0
,
0
.8
6
]
3
1
.0
4
(3
0
.0
0
,
3
1
.9
9
)[
2
6
.7
5
,
3
6
.4
4
]
1
0
.0
0
(9
.7
9
,
1
0
.2
2
)[
9
.0
5
,
1
1
.1
9
]
4
0
1
0
3
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
0
,
0
.8
4
]
3
1
.0
1
(3
0
.0
6
,
3
1
.9
0
)[
2
7
.3
3
,
3
5
.2
6
]
1
0
.0
0
(9
.8
0
,
1
0
.2
0
)[
8
.8
4
,
1
0
.9
2
]
4
0
1
0
4
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
2
)[
0
.3
9
,
0
.8
4
]
3
0
.9
4
(3
0
.0
4
,
3
1
.9
6
)[
2
6
.4
8
,
3
6
.7
8
]
1
0
.0
1
(9
.7
9
,
1
0
.2
4
)[
9
.0
5
,
1
0
.8
3
]
4
0
1
0
6
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
2
,
0
.8
5
]
3
0
.9
3
(3
0
.1
0
,
3
1
.9
3
)[
2
6
.7
2
,
3
5
.2
8
]
1
0
.0
0
(9
.7
9
,
1
0
.2
0
)[
9
.0
1
,
1
1
.0
6
]
4
0
1
0
1
0
5
1
0
2
0
0
.5
6
3
0
.9
9
0
.5
6
(0
.5
2
,
0
.6
1
)[
0
.4
1
,
0
.9
7
]
3
0
.9
4
(3
0
.1
3
,
3
1
.8
8
)[
2
7
.0
8
,
3
5
.9
4
]
1
0
.0
0
(9
.7
9
,
1
0
.2
1
)[
8
.9
2
,
1
1
.2
0
]
327
Appendix C. Sample size guidance and justification for studies of biological variation
T
a
b
le
C
.2
6
:
In
crea
sed
b
a
se
n
1 ,
n
2
a
n
d
n
3 :
S
D
estim
a
tes,
m
ed
ian
(Q
1,
Q
3)[m
in
im
u
m
,
m
ax
im
u
m
]
from
b
iological
variab
ility
d
ata
sim
u
lation
s
va
ry
in
g
σ
A
,
σ
I
a
n
d
σ
G
.
In
p
u
ts
M
e
d
ia
n
(Q
1
,
Q
3
)[m
in
im
u
m
,
m
a
x
im
u
m
]
n
1
n
2
n
3
σ
A
σ
I
σ
G
σ
A
σ
I
σ
G
4
0
1
0
3
0
.1
2
5
1
2
0
.1
3
(0
.1
2
,
0
.1
3
)[0
.1
1
,
0
.1
4
]
1
.0
0
(0
.9
8
,
1
.0
3
)[0
.8
7
,
1
.1
3
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.2
5
1
2
0
.2
5
(0
.2
5
,
0
.2
5
)[0
.2
3
,
0
.2
7
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
7
,
1
.1
3
]
1
.9
9
(1
.8
3
,
2
.1
5
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.3
7
5
1
2
0
.3
8
(0
.3
7
,
0
.3
8
)[0
.3
4
,
0
.4
1
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
7
,
1
.1
4
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.5
1
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.6
2
5
1
2
0
.6
3
(0
.6
2
,
0
.6
4
)[0
.5
7
,
0
.6
8
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
6
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.7
5
1
2
0
.7
5
(0
.7
4
,
0
.7
6
)[0
.6
8
,
0
.8
2
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
7
]
1
.9
8
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.8
7
5
1
2
0
.8
8
(0
.8
6
,
0
.8
9
)[0
.8
0
,
0
.9
5
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
8
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
1
1
2
1
.0
0
(0
.9
8
,
1
.0
2
)[0
.9
1
,
1
.0
9
]
1
.0
0
(0
.9
7
,
1
.0
4
)[0
.8
5
,
1
.2
0
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.5
0
.5
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
0
.5
0
(0
.4
8
,
0
.5
2
)[0
.4
2
,
0
.6
0
]
1
.9
9
(1
.8
3
,
2
.1
4
)[1
.3
7
,
2
.6
8
]
4
0
1
0
3
0
.5
0
.7
5
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
0
.7
5
(0
.7
3
,
0
.7
7
)[0
.6
5
,
0
.8
7
]
1
.9
9
(1
.8
3
,
2
.1
5
)[1
.3
6
,
2
.6
9
]
4
0
1
0
3
0
.5
1
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.5
1
.2
5
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.2
5
(1
.2
2
,
1
.2
9
)[1
.0
8
,
1
.4
2
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
4
,
2
.7
1
]
4
0
1
0
3
0
.5
1
.5
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.5
0
(1
.4
6
,
1
.5
4
)[1
.3
0
,
1
.7
0
]
1
.9
9
(1
.8
3
,
2
.1
7
)[1
.3
2
,
2
.7
2
]
4
0
1
0
3
0
.5
1
.7
5
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.7
5
(1
.7
1
,
1
.8
0
)[1
.5
2
,
1
.9
7
]
1
.9
8
(1
.8
3
,
2
.1
7
)[1
.3
0
,
2
.7
3
]
4
0
1
0
3
0
.5
2
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
2
.0
0
(1
.9
5
,
2
.0
5
)[1
.7
3
,
2
.2
5
]
1
.9
9
(1
.8
2
,
2
.1
7
)[1
.2
7
,
2
.7
4
]
4
0
1
0
3
0
.5
1
1
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
0
.9
9
(0
.9
1
,
1
.0
9
)[0
.6
3
,
1
.3
7
]
4
0
1
0
3
0
.5
1
1
.5
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
1
.4
9
(1
.3
7
,
1
.6
2
)[1
.0
0
,
2
.0
4
]
4
0
1
0
3
0
.5
1
2
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
1
.9
9
(1
.8
3
,
2
.1
6
)[1
.3
5
,
2
.7
0
]
4
0
1
0
3
0
.5
1
2
.5
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
2
.4
8
(2
.2
9
,
2
.6
9
)[1
.7
0
,
3
.3
7
]
4
0
1
0
3
0
.5
1
3
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
2
.9
8
(2
.7
5
,
3
.2
2
)[2
.0
4
,
4
.0
4
]
4
0
1
0
3
0
.5
1
3
.5
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
3
.4
8
(3
.2
0
,
3
.7
5
)[2
.3
9
,
4
.7
0
]
4
0
1
0
3
0
.5
1
4
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
3
.9
8
(3
.6
6
,
4
.2
8
)[2
.7
3
,
5
.3
7
]
4
0
1
0
3
0
.5
1
4
.5
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
4
.4
8
(4
.1
2
,
4
.8
2
)[3
.0
8
,
6
.0
3
]
4
0
1
0
3
0
.5
1
5
0
.5
0
(0
.4
9
,
0
.5
1
)[0
.4
6
,
0
.5
4
]
1
.0
0
(0
.9
7
,
1
.0
3
)[0
.8
6
,
1
.1
5
]
4
.9
7
(4
.5
7
,
5
.3
5
)[3
.4
3
,
6
.7
0
]
328
C.5. Sensitivity analyses
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Appendix C. Sample size guidance and justification for studies of biological variation
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C.5. Sensitivity analyses
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Appendix C. Sample size guidance and justification for studies of biological variation
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Appendix F. Simulating monitoring data and evaluating monitoring strategies
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F.1. Detailed simulation results
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F.2 Detailed simulation results–sensitivity analyses
A BC
D
E
F
G
H
0 5 10 15
0
5
10
15
Mean number of tests per person
D
el
ay
 to
 d
ia
gn
os
is 
of
 m
or
e 
th
an
 1
2 
m
on
th
s 
(%
)
Trade−off
mean number of tests decreased
but increased % delay
Trade−off
mean number of tests increased
but decreased % delay
Inferior
mean number of tests increased
and increased % delay
Superior
mean number of tests decreased
and decreased % delay
Figure F.1: Adjusted fibrosis progression rate–performance of various monitoring strategies
on simulated monitoring data with PPV of 25%. A is the simple threshold strategy; B is the
retest strategy; C is the decreased monitoring frequency strategy; D is the absolute increase
from initial value strategy; E is the absolute increase from last value strategy; F is the relative
increase from initial value strategy; G is the relative increase from last value strategy; H is
the linear regression strategy.
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Appendix F. Simulating monitoring data and evaluating monitoring strategies
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F.2. Detailed simulation results–sensitivity analyses
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F.2. Detailed simulation results–sensitivity analyses
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F.2. Detailed simulation results–sensitivity analyses
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Appendix F. Simulating monitoring data and evaluating monitoring strategies
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Appendix F. Simulating monitoring data and evaluating monitoring strategies
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F.2. Detailed simulation results–sensitivity analyses
T
ab
le
F
.3
6:
M
on
it
or
in
g
si
m
u
la
ti
on
ad
ju
st
ed
fi
b
ro
si
s
p
ro
gr
es
si
on
se
n
si
ti
v
it
y
an
al
y
se
s–
re
su
lt
s
u
si
n
g
re
fe
re
n
ce
st
ra
te
g
y
w
it
h
in
cr
ea
se
d
b
et
w
ee
n
-
in
d
iv
id
u
al
va
ri
ab
il
it
y
b
y
ob
se
rv
at
io
n
p
oi
n
t.
O
b
se
rv
a
ti
o
n
T
e
st
s
T
P
re
su
lt
s
F
P
re
su
lt
s
F
N
re
su
lt
s
T
N
re
su
lt
s
P
o
si
ti
v
e
re
su
lt
s
D
is
e
a
se
d
a
P
P
V
S
e
n
si
ti
v
it
y
m
o
n
th
(n
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
(%
)
(%
)
0
2
0
0
0
0
1
7
7
9
(8
.9
)
6
9
1
6
(3
4
.6
)
6
7
9
(3
.4
)
1
0
6
2
6
(5
3
.1
)
8
6
9
5
(4
3
.5
)
2
4
5
8
(1
2
.3
)
2
0
.5
7
2
.4
6
1
1
3
0
5
1
7
1
(1
.5
)
1
2
9
9
(1
1
.5
)
6
8
3
(6
.0
)
9
1
5
2
(8
1
.0
)
1
4
7
0
(1
3
.0
)
8
5
4
(7
.6
)
1
1
.6
2
0
.0
1
2
9
8
3
5
1
0
9
(1
.1
)
8
0
8
(8
.2
)
7
4
1
(7
.5
)
8
1
7
7
(8
3
.1
)
9
1
7
(9
.3
)
8
5
0
(8
.6
)
1
1
.9
1
2
.8
1
8
8
9
1
8
1
1
9
(1
.3
)
6
3
1
(7
.1
)
7
4
6
(8
.4
)
7
4
2
2
(8
3
.2
)
7
5
0
(8
.4
)
8
6
5
(9
.7
)
1
5
.9
1
3
.8
2
4
8
1
6
8
9
9
(1
.2
)
5
4
4
(6
.7
)
7
5
7
(9
.3
)
6
7
6
8
(8
2
.9
)
6
4
3
(7
.9
)
8
5
6
(1
0
.5
)
1
5
.4
1
1
.6
3
0
7
5
2
5
1
1
1
(1
.5
)
4
4
6
(5
.9
)
7
6
5
(1
0
.2
)
6
2
0
3
(8
2
.4
)
5
5
7
(7
.4
)
8
7
6
(1
1
.6
)
1
9
.9
1
2
.7
3
6
6
9
6
8
1
2
4
(1
.8
)
3
9
0
(5
.6
)
7
5
2
(1
0
.8
)
5
7
0
2
(8
1
.8
)
5
1
4
(7
.4
)
8
7
6
(1
2
.6
)
2
4
.1
1
4
.2
4
2
6
4
5
4
1
2
9
(2
.0
)
4
1
2
(6
.4
)
7
4
7
(1
1
.6
)
5
1
6
6
(8
0
.0
)
5
4
1
(8
.4
)
8
7
6
(1
3
.6
)
2
3
.8
1
4
.7
4
8
5
9
1
3
1
4
3
(2
.4
)
3
4
6
(5
.9
)
7
1
8
(1
2
.1
)
4
7
0
6
(7
9
.6
)
4
8
9
(8
.3
)
8
6
1
(1
4
.6
)
2
9
.2
1
6
.6
5
4
5
4
2
4
1
2
2
(2
.2
)
3
0
5
(5
.6
)
7
2
7
(1
3
.4
)
4
2
7
0
(7
8
.7
)
4
2
7
(7
.9
)
8
4
9
(1
5
.7
)
2
8
.6
1
4
.4
6
0
4
9
9
7
1
3
0
(2
.6
)
2
8
6
(5
.7
)
7
1
7
(1
4
.3
)
3
8
6
4
(7
7
.3
)
4
1
6
(8
.3
)
8
4
7
(1
7
.0
)
3
1
.2
1
5
.3
A
ll
9
5
5
0
7
3
0
3
6
(3
.2
)
1
2
3
8
3
(1
3
.0
)
8
0
3
2
(8
.4
)
7
2
0
5
6
(7
5
.4
)
1
5
4
1
9
(1
6
.1
)
1
1
0
6
8
(1
1
.6
)
1
9
.7
2
7
.4
a
T
es
ts
p
er
fo
rm
ed
w
h
en
th
e
p
a
ti
en
t
w
a
s
d
is
ea
se
d
.
T
ab
le
F
.3
7:
M
on
it
or
in
g
si
m
u
la
ti
on
ad
ju
st
ed
fi
b
ro
si
s
p
ro
gr
es
si
on
se
n
si
ti
v
it
y
an
al
y
se
s–
re
su
lt
s
u
si
n
g
re
fe
re
n
ce
st
ra
te
g
y
w
it
h
in
cr
ea
se
d
b
et
w
ee
n
-
in
d
iv
id
u
al
va
ri
ab
il
it
y
b
y
ob
se
rv
at
io
n
p
oi
n
t
an
d
P
P
V
at
25
%
.
O
b
se
rv
a
ti
o
n
T
e
st
s
T
P
re
su
lt
s
F
P
re
su
lt
s
F
N
re
su
lt
s
T
N
re
su
lt
s
P
o
si
ti
v
e
re
su
lt
s
D
is
e
a
se
d
a
P
P
V
S
e
n
si
ti
v
it
y
m
o
n
th
(n
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
n
(%
)
(%
)
(%
)
0
2
0
0
0
0
1
4
0
6
(7
.0
)
3
8
7
6
(1
9
.4
)
1
0
5
2
(5
.3
)
1
3
6
6
6
(6
8
.3
)
5
2
8
2
(2
6
.4
)
2
4
5
8
(1
2
.3
)
2
6
.6
5
7
.2
6
1
4
7
1
8
1
9
0
(1
.3
)
1
0
0
2
(6
.8
)
1
1
0
9
(7
.5
)
1
2
4
1
7
(8
4
.4
)
1
1
9
2
(8
.1
)
1
2
9
9
(8
.8
)
1
5
.9
1
4
.6
1
2
1
3
5
2
6
1
4
1
(1
.0
)
6
6
7
(4
.9
)
1
2
1
5
(9
.0
)
1
1
5
0
3
(8
5
.0
)
8
0
8
(6
.0
)
1
3
5
6
(1
0
.0
)
1
7
.5
1
0
.4
1
8
1
2
7
1
8
1
2
5
(1
.0
)
5
2
3
(4
.1
)
1
2
7
2
(1
0
.0
)
1
0
7
9
8
(8
4
.9
)
6
4
8
(5
.1
)
1
3
9
7
(1
1
.0
)
1
9
.3
8
.9
2
4
1
2
0
7
0
1
1
7
(1
.0
)
4
6
1
(3
.8
)
1
3
4
9
(1
1
.2
)
1
0
1
4
3
(8
4
.0
)
5
7
8
(4
.8
)
1
4
6
6
(1
2
.1
)
2
0
.2
8
.0
3
0
1
1
4
9
2
1
3
2
(1
.1
)
4
2
3
(3
.7
)
1
4
1
8
(1
2
.3
)
9
5
1
9
(8
2
.8
)
5
5
5
(4
.8
)
1
5
5
0
(1
3
.5
)
2
3
.8
8
.5
3
6
1
0
9
3
7
1
5
9
(1
.5
)
4
4
1
(4
.0
)
1
4
3
7
(1
3
.1
)
8
9
0
0
(8
1
.4
)
6
0
0
(5
.5
)
1
5
9
6
(1
4
.6
)
2
6
.5
1
0
.0
4
2
1
0
3
3
7
1
3
0
(1
.3
)
3
9
2
(3
.8
)
1
5
0
9
(1
4
.6
)
8
3
0
6
(8
0
.4
)
5
2
2
(5
.0
)
1
6
3
9
(1
5
.9
)
2
4
.9
7
.9
4
8
9
8
1
5
1
6
1
(1
.6
)
3
6
3
(3
.7
)
1
5
8
7
(1
6
.2
)
7
7
0
4
(7
8
.5
)
5
2
4
(5
.3
)
1
7
4
8
(1
7
.8
)
3
0
.7
9
.2
5
4
9
2
9
1
1
9
6
(2
.1
)
3
4
2
(3
.7
)
1
6
2
7
(1
7
.5
)
7
1
2
6
(7
6
.7
)
5
3
8
(5
.8
)
1
8
2
3
(1
9
.6
)
3
6
.4
1
0
.8
6
0
8
7
5
3
1
8
3
(2
.1
)
3
1
7
(3
.6
)
1
6
5
1
(1
8
.9
)
6
6
0
2
(7
5
.4
)
5
0
0
(5
.7
)
1
8
3
4
(2
1
.0
)
3
6
.6
1
0
.0
A
ll
1
3
3
6
5
7
2
9
4
0
(2
.2
)
8
8
0
7
(6
.6
)
1
5
2
2
6
(1
1
.4
)
1
0
6
6
8
4
(7
9
.8
)
1
1
7
4
7
(8
.8
)
1
8
1
6
6
(1
3
.6
)
2
5
.0
1
6
.2
a
T
es
ts
p
er
fo
rm
ed
w
h
en
th
e
p
a
ti
en
t
w
a
s
d
is
ea
se
d
.
413
Appendix F. Simulating monitoring data and evaluating monitoring strategies
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F.2. Detailed simulation results–sensitivity analyses
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